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Abstract (200 words) 
Peritoneal metastasis, (CPM) develop in 15% of colorectal cancers. Cytoreductive 
surgery and heated intraperitoneal chemotherapy (CRS & HIPEC) aims to achieve 
macroscopic tumour resection and ablation of microscopic disease.  However, 5-year 
survival varies widely and morbidity and mortality are relatively high. There is a need 
to improve patient selection and a paucity of research concerning CPM disease 
biology. Prognostic classifiers have been developed in a number of cancers, though 
none in CPM. I aimed to identify a multi-dimensional classifier to improve patient 
selection for CRS & HIPEC and to further the understanding of CPM disease biology. 
 
Firstly, clinical prognostic factors for patients with CPM undergoing CRS & HIPEC were 
identified by systematic review. Secondly, comprehensive molecular profiling of the 
transcriptome, epigenome and genome of CPM was performed to develop a prognostic 
multidimensional classifier. Finally, a potential biomarker of tumour recurrence 
following CRS & HIPEC was examined using circulating tumour DNA. 
 
This study has identified clinical and molecular features capable of predicting poor 
prognosis CPM and has potential applications in improved patient selection for 
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1.1 The epidemiology of colorectal cancer  
Colorectal cancer (CRC) is the fourth most common cancer in the UK with 41,804 new 
cases in 2015 and 16,384 deaths in 2016 (1, 2). Rates of CRC are higher in males 
than females.  The incidence of CRC has increased by 4% since the 1990s (1, 2). This 
may be attributable to an increased prevalence of risk factors in previous years and 
improved detection with the introduction of bowel cancer screening in 2006 (3). 
There is wide variation in incidence globally with high rates in Australia, New Zealand, 
Europe and America compared to Africa and Asia. This global variation is likely to 
represent the effects of environmental exposures including red meat, dietary fat and 
reduced fibre. Migrants from low to high-risk areas adopt the incidence of the country 
they migrate to implicating environmental and lifestyle risk factors in the development 
of CRC (4). Low socioeconomic status is associated with a 14% increase in CRC (3).  
Several studies have established environmental risk factors, which may explain the 
socioeconomic disparity in the development of CRC. The European Prospective 
Investigation into Cancer (EPIC) was a large multicentre prospective cohort, which 
recruited over half a million participants and followed them for 15 years to investigate 
the relationship between diet, nutritional status, lifestyle, environmental factors and the 
incidence of disease. EPIC established a protective effect of a high fibre and fish diet 
for CRC and an increased risk associated with a high intake of processed and red meat 
(5, 6). The United States nurses’ health study was a multicentre prospective cohort 
study of over 280,000 participants followed for 24 years investigating risk factors for 
several diseases. The study established risk factors associated with CRC: obesity, low 





1.2 The aetiology of colorectal cancer 
The aetiology of CRC is multifactorial with a complex interplay between environmental 
factors, hereditable components and spontaneous genetic mutations.  
The majority of CRC is sporadic. There is a wide variation in cancer incidence 
according to the tissue of origin from 4.82% for cancers of the large intestine to 0.003% 
for cancers of the brain (8). Some of this variation can be explained by environmental 
factors known to increase the risk of CRC: obesity, intake of red and processed meat, 
Tobacco, alcohol intake (5-7), inflammatory bowel disease (9, 10) and abdominal 
irradiation (11). Variation in tissue-specific cancer incidence persists despite 
adjustment for environmental exposure, meaning environmental factors account for 
only a small proportion of the cases of CRC. In 2015 Vogelstein et al established a 
correlation between the number of stem cell divisions and the risk of cancers in a given 
tissue, suggesting that random mutations which occur during deoxyribonucleic acid 
(DNA) replication of normal tissues are a significant causative factor in the 
development of CRC (8).   
Familial association studies suggest up to 30% of CRC cases have a heritable 
component. Only 5%, however, are the result of well-defined CRC syndromes with 
known genetic mutations.  Hereditary non-polyposis colorectal cancer (HNPCC) also 
known as Lynch syndrome, is an autosomal dominant condition associated with an 
80% lifetime risk of CRC. HNPCC results from an autosomal dominant germline 
mutation of the mismatch repair genes (MMR) MLH1, MSH2, PMS2 or MSH6. Familial 
adenomatous polyposis (FAP) is characterised by numerous adenomatous polyps in 
the colon and rectum resulting in CRC if untreated. FAP results from a dominantly 
inherited germline mutation of the adenomatous polyposis coli (APC) gene. HNPCC 
and FAP account for the majority of inherited CRC. Other less common CRC 
syndromes associated with known heritable mutations include; MUTYH-associated 
polyposis (MAP), an autosomal recessive condition resulting from mutation of the 
MUTYH gene. Peutz-Jeghers syndrome (PJS), an autosomal dominant polyposis 
syndrome resulting from mutation of the STK11 gene. Juvenile polyposis syndrome 




BMPR1A or SMAD4 genes (12), and autosomal dominant proofreading polyposis 
syndromes, characterised by a mutation in the POLE1 or POLD1 genes respectively. 
1.3 Tumorigenesis  
In CRC arising outside of such inherited syndromes, multiple sequential genetic events 
accumulate leading to the inactivation of tumour suppressor genes, the activation of 
oncogene pathways and tumorigenesis.  
A gene mutation is a permanent DNA sequence alteration. Mutations range in size 
from a single nucleotide base pair (SNV) to the insertion or deletion of a sequence of 
nucleotides (indel), to structural variants greater than 1kb pairs such as inversions or 
translocations. The size, type and location of the mutation dictates the effect on its 
gene protein product. This can range from no effect (synonymous) to alterations in 
protein structure, function or production (non-synonymous). Germline DNA mutations 
inherited from a parent are present in every cell in the body. Acquired or somatic 
mutations occur at a time point after conception, result from environmental factors or 
errors in cell replication and are only present in certain cells. Somatic mutations directly 
affecting the potential of the cell to become cancerous, to progress and to metastasise 
are cancer driver mutations. These mutations confer a clonal growth advantage and 
are selected as the tumour cell population increases. Passenger mutations are those 
that do not confer a growth advantage and do not contribute to tumorigenesis. Cancer 
driver mutations are uncommon in the general population, other genetic mutations 
occur more frequently. Genetic changes common to more than 1% of the population 
are known as polymorphisms, these are considered normal DNA variants. 
Tumour suppressor genes suppress inappropriate cell growth and division and 
stimulate cell death as well as maintaining DNA repair pathways. These functions 
prevent mutation accumulation and abnormal tissue growth. Loss of function mutations 
in tumour suppressor genes is commonly recessive. For cancer to develop both gene 
alleles must acquire mutations. This is known as the “two-hit” hypothesis and was first 
proposed by Alfred Knudson in 1971 (13). The common genetic events leading to CRC 




1.3.1 Mismatch repair inactivation and microsatellite instability  
The fidelity of DNA replication is a very reliable process, incorrect base incorporation 
or the failure of the DNA polymerases proofreading function result in an error rate of 
around 10-7 base pairs per genome (14). The DNA mismatch repair pathway (MMR) 
ensures stable cell replication by targeting base substitution mismatches and insertion-
deletion mismatches, which have escaped proofreading by DNA polymerases (Figure 
1.1). Following DNA replication, the mismatch proofreading system is signalled to the 
daughter strand.  A series of mismatch repair proteins (MutS, MutH and MutL) 
recognise and repair errors in the daughter strand. MutS recognises the mismatched 
base and binds to it; MutL binds and activates MutH, which nicks the daughter strand. 
A DNA Helicase separates the DNA strand and allows MutSHL complex to excise it. 
The strand is digested by an exonuclease. The gap is repaired by a DNA polymerase 
using the other strand as a template (15). 
The MMR pathway contributes up to 1000-fold to the fidelity of cell replication. 
Inactivation of the MMR pathway, therefore, results in a high rate of spontaneous 
mutations. The hallmark of MMR-deficient cells is microsatellite instability (MSI) 
characterised by single-base mismatches and small insertion and deletion loops of 
unpaired bases, between 12–17 % of colorectal cancers are MSI (16), around 4-5% of 
metastatic colorectal cancers are MSI (17). 
Kim et al examined the association of MSI status with recurrence patterns, DFS, OS 
in 2940 patients with CRC. MSI high (MSI-H)  tumours recurred more frequently with 
local or peritoneal recurrence and less frequently in the lung or liver, additionally 
patients with recurrent MSI tumours had reduced OS compared with patients with 
microsatellite stable (MSS) tumours (18). 
MSI-H tumours have a high tumour mutational burden (TMB) ≥ 20 mut/Mb, This results 








Figure 1-1 The DNA mismatch repair pathway. 
A) A single nucleotide mismatch is formed during mitosis. B) Mismatch repair proteins 
identify the error in the newly synthesised DNA and clamp onto its location. C) The 
sliding clamp can migrate in either direction of the mismatch, recruitment of MutSα 
clamps ensure movement in the 5’ to 3’ direction encountering the PCNA-DNA 
polymerase complex. D) Exo1 excises the daughter strand back to the site of the 
mismatch. E) The error is corrected by resynthesis This figure is reprinted from Jascur 




1.3.2 The Wnt signalling pathway  
The Wnt signalling pathway regulates intestinal cell proliferation, differentiation and cell 
fate decisions (Figure 1.2). Wild type Wnt is a signalling molecule which binds to cell 
receptor complexes (Frizzled, FZD) initiating the recruitment of scaffold proteins and 
disruption of the β-catenin destruction complex (AXIN, APC, CK1, GSK3β) inhibiting 
its nuclear localisation. In the absence of the destruction complex, β-catenin 
accumulates and translocates into the nucleus where it associates with TCF 
transcription factors to drive the transcription of target genes. Wnt activation maintains 
crypt stem cell compartments in the healthy colon by promoting proliferation and stem-
cell-like phenotypes. When persistently activated by mutation it leads to the 
development of CRC (21, 22). The Wnt signalling pathway is activated in over 90% of 
CRC due to mutations in either the β-catenin gene (CTNNB1) or APC. Inactivation of 
the APC tumour suppressor gene results in inappropriate and consistent activation of 
the Wnt signalling pathway and cell clonal expansion. APC is mutated in the majority 
of sporadic CRC as well as in FAP. In both FAP and sporadic mutations of the APC 
gene, a bi-allelic or ‘two-hit’ mutation must occur for tumorigenesis to occur. In a small 
group with wild type APC, mutations of the β-catenin gene (CTNNB1) located on exon-
3, inappropriately activate the Wnt signalling pathway driving the transcription of Wnt 














The Wnt signalling pathway. Off state: in the abscesnce of Wnt ligands, β-catenin is 
phosphorylated by a destruction complex which marks it for proteasomal degradation. 
Wnt signalling is inhibited by multiple negative Wnt regulators (LGR4, ZNRF3, RNF43). 
On state: Binding of a Wnt ligand to its receptor Frizzled induces phosphorylation of 
co-receptor LRP5/6, forming a docking site for AXIN which disrupts the destruction 
complex allowing stabilisation and nuclear translocation of β-catenin. This results in 
transcription of Wnt target genes. This figure is reprinted from Van Andel et al, 2019, 
figure 1 (24). 
  




1.3.3 Chromosomal instability (CIN) 
Chromosomal instability (CIN) is characterised by widespread imbalances in 
chromosome number (aneuploidy), loss of heterozygosity or the formation of 
structurally abnormal chromosomes. CIN can result from several aberrant processes: 
The spindle assembly or mitotic checkpoint ensures fidelity of chromosome 
segregation by delaying anaphase until all pairs of chromatids are properly aligned. 
Defects here lead to mis-segregation and aneuploidy. Similarly, extra centrosomes 
lead to multiple spindle poles and the unequal distribution of chromosomes. Telomeres 
are DNA-protein complexes, which protect the chromosome from fusing or breaking 
during replication. When the telomere becomes shortened, apoptosis is triggered. 
Where this is compromised, chromosome ends enter breakage, fusion, bridge cycles 
leading to genome reorganisation and tumour formation. DNA damage response 
machinery protects cells from genotoxic stress by initiating cell cycle arrest and repair 
or apoptosis. p53 is a DNA repair protein implicated in CRC and predisposing to CIN  
(25). 
Loss of heterozygosity is a hallmark of CIN; 25–75% of alleles are lost in tumours. This 
is thought to be a consequence of interchromosomal recombination and deletions. CIN 
is present in 70–85% of CRC and is associated with drug resistance and poor 
outcomes with a reduction in both disease-free survival (DFS) and overall survival  
(OS) (26). 
1.3.4 p53 
Wild type TP53 encodes a transcription factor inducing cell cycle arrest, senescence, 
and apoptosis in response to cellular stress or DNA damage. p53 binds to DNA, 
stimulating the production of p21 protein, which interacts with a cell division stimulating 
protein cdk2. The p21/cdk2 complex inhibits cell cycle transition resulting in cell cycle 
arrest or senescence. p53 induces the expression of pro-apoptotic proteins (BCL-2, 
BAX) triggering apoptosis (27). p53 levels are tightly regulated by interaction with the 
E3 ubiquitin ligase MDM2, itself induced by p53, which targets p53 for ubiquitination 




Mutant TP53 is unable to bind to DNA, the stop signal is switched off and cells continue 
to divide unchecked. Autosomal dominant mutations of TP53 result in Li-Fraumeni 
syndrome, characterised by the early onset of multiple cancers of various types. p53 
mutations occur in up to 70% of CRC and are associated with lymphatic and vascular 
invasion, chemotherapy resistance and poor prognosis (12, 27).  
1.3.5 Transforming growth factor Beta  
TGF-β is a multifunctional cytokine, which regulates proliferation, cell death, 
differentiation, adhesions, motility and epithelial to mesenchymal transition (EMT)  
(29). TGF-β ligands are activated by extracellular proteases (matrix metalloproteinase) 
and bind to its receptors (TGFR1 and TGFR2). Activated TGFR1 phosphorylates 
downstream SMAD transcription factors. The resulting complex translocates to the 
nucleus initiating the transcription of TGF-β responsive genes, which suppress cell 
proliferation or induce apoptosis (29). 
TGF-β mutation can occur at all points of the pathway (TGF-β ligands, TGFR1/2, 
SMAD). TGF-β signalling inactivation is not able to induce tumorigenesis alone but is 
dependent on convergent signalling pathway dysregulation. A TGF-β activated 
microenvironment suppresses the differentiation and activity of lymphocytes excluding 
T-cells and allowing tumours to escape from immune surveillance. This 
immunosuppressive effect is associated with poor outcomes (30). Alterations in the 
TGF-β pathway affect 40%–50% of all CRCs and are associated with a high risk of 
disease recurrence (29). 
1.3.6 The MAPK pathway 
The mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation and 
differentiation. It receives divergent stimuli from metabolic stress, DNA damage, 
altered protein concentrations and communications from other cells  (22, 31). The 
MAPK pathway is triggered by the binding of a ligand (growth factor, cytokine or 
hormone) to a receptor tyrosine kinase (RTK) a transmembrane protein. Activated RTK 
is bound by cytoplasmic proteins. Guanine–nucleotide exchange factors (GEFs) then 
activate RAS, a GTPase protein at the plasma membrane.  RAS is inactive when 




RAS then activates BRAF (MAPK). Activated BRAF facilitates the phosphorylation of 
a MEK (MAPK). MEK, in turn, activates the final MAPK in the cascade ERK. ERK 
translocates to the nucleus, activating transcription factors that result in gene 
expression (Figure 1.3) (22). 
Several mutations resulting in upregulation of the MAPK pathway have been identified.  
Epithelial growth factor receptor (EGFR) is a receptor tyrosine kinase transmembrane 
protein mutated or over-amplified in up to 77% of CRC (31). Mutation of the KRAS 
signal transducer (mutated in 50% of CRC) activates BRAF kinases (mutated in 5-15% 
CRC), which in turn upregulates transcription factors and drives the MAPK signalling 
cascade (22, 31). KRAS mutation in CRC is associated with an increased risk of 
recurrence and death (32). KRAS mutation leads to the continued activation of the 
MAPK pathway in the absence of its upstream regulators. It is therefore associated 
with poor response to anti-EGFR targeted therapy commonly used in CRC such as 
Cetuximab and Panitumumab (33). BRAF mutations result in continuous activation of 
MEK and ERK and the transcription of factors involved in cell proliferation and survival. 
They are associated with reduced OS in both the early and the metastatic setting (34). 
In malignant melanoma treatment with the BRAF inhibitor Vemurafenib is associated 
with improved response and progression-free survival. In CRC however, treatment with 
BRAF inhibitors is associated with no significant survival gains (35). In CRC single-
agent BRAF inhibition provides inadequate suppression of the MAPK pathway and can 
trigger an increase in upstream EGFR activation, downstream CRAF activation and 
signaling through the MAPK or PI3K pathways (36, 37). 
Up to one-third of CRC bears a phosphatidylinositol 3-kinase gene (PI3KCA) mutation 
or loss of the Phosphate and tensin homolog tumour suppressor gene (PTEN), both of 
which increase PI3K pathway signalling which in turn affects cell growth, differentiation 
and proliferation (22). Mutations in PI3KCA are associated with resistance to anti 
EGFR therapies in the absence of EGFR mutation suggesting they may drive aberrant 








Figure 1-3 The RAS/RAF/MEK pathway and the PI3K/AKT/mTOR pathways. 
Ligand binding activates the receptor tyrosine kinase (RTK) transmembrane protein, 
which is bound by cytoplasmic proteins. GTPase proteins and Guanine–nucleotide 
exchange factors (GEFs) then activate the RAS oncogene. RAS then activates BRAF, 
a mitogen-activated protein kinase (MAPK). Activated BRAF facilitates the 
phosphorylation of a MEK (MAPK). MEK, in turn, activates the final MAPK in the 
cascade, ERK. ERK translocates to the nucleus, activating transcription factors that 
result in gene expression responsible for cell growth, protein synthesis and 
angiogenesis (39). The RAS/RAF/MEK/MAPK pathway converges with the PI3K/AKT 
pathway, Phosphoinositide 3-kinase (PI3K) is recruited to the membrane by activated 
growth factor receptors. PI3K phosphorylates phosphoinositides producing 
phosphatidylinositol-3,4,5-triphosphate (PIP3) which signals to AKT through enzymes, 
kinases and transcription factors. The activated PI3K/AKT pathway promotes 
metabolism, proliferation, cell survival, growth and angiogenesis. This figure is 




1.3.7 The role of aberrant methylation in colorectal cancer 
In health DNA methylation allows cells to acquire and maintain a specialised state, 
suppresses the expression of viral and non-host DNA and facilitates the cell response 
to environmental stimuli and ageing. Aberrant DNA methylation (hyper or hypo) is 
implicated in many disease processes including ageing, neurological disorders, 
metabolic disorders and cancer.  
1.3.7.1 Transcriptional silencing of tumour suppressor and DNA repair genes 
In health, the majority (70-80%) of CpG sites are methylated resulting in epigenetic 
silencing. CpG islands conversely, located in promoter regions of genes are usually 
un-methylated (40). In cancer cells, there is a loss of global methylation and a gain of 
methylation at the promotors of selected CpG islands. This results in the transcriptional 
silencing of specific genes including tumour suppressor genes (41). Methylation 
inhibits transcription directly by inhibiting transcription factor binding and indirectly by 
recruiting methyl CpG binding proteins and their associated repressive chromatin 
remodelling (42). 
Up to 50% of genes mutated in hereditary forms of cancer undergo methylation 
associated transcriptional silencing in sporadic cancers (43). Loss of gene function 
arising from aberrant promoter methylation can provide a survival advantage to 
neoplastic cells similar to that resulting from mutations (43). Genes regulating the cell 
cycle, tumour cell invasion, DNA repair, chromatin remodelling, cell signalling, 
transcription and apoptosis become aberrantly methylated and silenced in nearly every 
tumour type (42). 
The impact of global hypomethylation of non-promotor regions and structural elements 
such as centromeric DNA in cancer is less well understood but may result in genomic 
instability such as those resulting from germline mutations of DNMT3 which results in 
a loss of methylation at centromeric regions and profound chromosomal structural 
changes (43). Embryonic stem cells deficient in DNMTs are viable but die when 




Whilst a modest increase in DNMT activity and protein expression has been noted in 
some cancers, this has not been able to explain the patterns of aberrant methylation 
in CRC (41). 
1.3.7.2 The CpG island methylator phenotype 
A group of cancers display a 3-5 fold elevation in methylation compared to age-
matched controls, these are known as CpG Island Methylator Phenotype (CIMP) (41). 
Up to 70-80% of sporadic MSI colorectal cancers display CIMP and specifically are 
attributable to the methylation associated silencing of the MLH1 mismatch repair gene 
(44). 
CIMP positive tumours commonly occur in older, female patients and the proximal 
colon. On a molecular level, CIMP tumours display high levels of KRAS and BRAF 
mutation and low levels of TP53 mutation (44). Histologically, CIMP tumours are poorly 
differentiated. CIMP status has additional prognostic implications; CIMP+MSI+ 
tumours are associated with good prognosis whereas CIMP+MSI- tumours a poor 
prognosis (44). 
1.3.7.3 Mutability of methylcytosines 
Cytosine methylation can influence tumorigenicity. Methylated cytosines are 
themselves mutagenic and can undergo spontaneous hydrolytic deamination causing 
C–T transitions. This enhanced mutagenesis is seen in mutations of the TP53 tumour 
suppressor gene, up to 50% of inactivating point mutations in the coding region of 
TP53 occur at methylated cytosines (43).  
1.3.7.4 Methylation inhibition 
DNA methylation inhibitors such as 5-azacytidine can restore the function of genes 
transcriptionally silenced by methylation (43). These drugs have been trialled with 
promise in vitro and animal studies. Clinical trials of DNA methylation inhibitors in 
patients with metastatic CRC have demonstrated that they are generally well tolerated 
at low doses and are capable of reversing hypermethylation. They are, however, 




DNA methylation inhibitors result in genome-wide methylation changes and this global 
effect may reduce their efficacy. Whilst reversal of methylation at one gene site may 
result in drug sensitisation at another it may reduce drug sensitivity. Clinical 
effectiveness of methylation inhibitors is limited by low bioavailability and dependence 
on nucleoside transporters for cellular uptake (48). Ongoing and future clinical trials 
focus on the use of methylation inhibitors as a priming agent to minimise resistance 
preceding further cytotoxic or immunotherapy (49).  
1.3.8 Tumour immune recognition and evasion 
Genetic and epigenetic alterations allow the immune system to distinguish tumour cells 
from host tissue. Tumour cells display antigenic peptides (epitopes) on major 
histocompatibility complex (MHC) molecules on the cell surface. These are recognised 
as ‘non-self’ by CD8 T-lymphocytes triggering their destruction. 
Tumours, however, can evade immune recognition and elimination via several 
mechanisms. Constant tumour cell division produces new tumour cell variants. Loss of 
MHC antigen expression, loss of surface antigen expression and the secretion of 
immunosuppressive cytokines such as VEGF and TGF-β result in decreased immune 
visibility (50). 
Tumour antigen epitopes can be shared between different tumours or encoded by 
unique somatic mutations private to an individual tumour (neoepitopes). 
Immunotherapies can be targeted towards shared epitopes or personalised to an 
individual tumours neoepitope (51). 
1.3.9 The adenoma-carcinoma sequence 
Tumorigenesis is a multistep process arising from a combination of mutations or 
epigenetic changes (Figure 1.4). Vogelstein et al hypothesised a genetic model for 
CRC in which the sequential accumulation of known genetic mutations in APC, KRAS 
and TP53 drive the transition from healthy colonic epithelium to dysplasia to CRC (52). 
It is accepted that tumorigenesis is a sequential process arising from a combination of 
mutations. Sequencing of a large cohort of CRC, however, demonstrated only a small 




carcinoma sequence and more than one-third of tumours contained mutations in only 
one of APC, KRAS or P53 (53).  The model proposed by Vogelstein is an 
oversimplification, whilst tumorigenesis occurs as a sequential process, the genetic 








Figure 1-4 The adenoma-carcinoma sequence 
The adenoma-carcinoma sequence describes the sequential accumulation of known 
genetic mutations, associated with recognisable stages of tumorigenesis, which drive 
the transition from healthy colonic epithelium to dysplasia to colorectal cancer (CRC 
(55)). Loss of adenomatous polyposis coli (APC) is the first step transforming normal 
colorectal epithelium to adenoma. Larger adenomas and early carcinomas acquire 
mutations in the small GTPase KRAS, followed by loss of chromosome 18q with 
SMAD4, which is downstream of transforming growth factor-β (TGFβ), and mutations 
in TP53 in frank carcinoma. The accumulation of sequential mutations lead to 
chromosomal instability (CIN), mismatch repair gene inactivation leads to microsatellite 






1.3.10 Copy number alteration 
Copy number alterations (CNAs) are somatic changes resulting in gain or loss of DNA 
sections from the genome (56). CNAs contribute to the onset and the progression of 
cancer by the activation of proto-oncogenes and the inactivation of tumour suppressor 
genes (56). The initiation and progression of CRC involve the stepwise accumulation 
of CNAs. Adenomas have comparable levels of CNAs to carcinomas, metastatic CRC 
has increased CNAs when compared with invasive CRC (57). CNAs frequently 
identified in CRC are gains at chromosomes 1q, 7p, 7q, 8p, 8q, 12q, 13q, 19q, 20p, 
20q and losses at chromosomes 8p, 17p, 18p and 18q (58). These common CNAs 
identify several oncogenes commonly amplified or deleted in CRC. Commonly 
amplified oncogenes include EGFR, ERBB2, CND1, IGF2, NET and MYC (58). 
Amplification of these genes through CNA results in tumour developments and 
progression and confers resistance to some drugs such as Cetuximab. Commonly 
deleted tumour suppressor genes include TP53, APC, PTEN and SMAD4 (58). 
Deletion of these genes through CNA results in cell growth with no regulatory 
mechanisms such as apoptosis or cell cycle arrest. These CNA result in dysregulation 






1.4 The molecular classification of colorectal cancer 
1.4.1 Consensus molecular subtypes 
Gene expression profiles in use in CRC include the Consensus Molecular Subtypes 
(CMS) and the colorectal cancer intrinsic subtypes (CRIS). The colorectal cancer 
subtype consortium (CRCSC) used gene expression profiles of approximately 4000 
largely early stage primary CRCs (8% stage IV) to define four biologically distinct 
Consensus Molecular Subtypes (CMS) (Table 1.1). CMS1 comprises most tumours 
with MSI and is characterised by the infiltration of activated immune cells, CMS2 and 
CMS3 show epithelial characteristics with oncogene amplification, high Wnt and Myc 
signalling in CMS2 and metabolic reprogramming in CMS3. CMS4 comprises 
mesenchymal-like cancers with high stromal infiltration and poor prognosis (59). The 
CMS classifiers have a number of clinical associations. CMS1 tumours are common in 
females with right-sided CRC and high histopathological grade, they are associated 
with poor survival following relapse  (59). CMS2 tumours are commonly left-sided and 
associated with high survival following relapse (59). CMS4 tumours are commonly 
diagnosed at an advanced stage and display worse OS and relapse-free survival, 
(RFS) despite adjustment for clinicopathological variables, MSI status, BRAF and 
KRAS mutations (59). CMS classifiers can be used to deliver targeted therapy, for 
example in CMS4 there is evidence that stromal cells mediate resistance to 
chemotherapies and targeted therapy (60). TGFβ signalling inhibitors have been 
trialled with success in pre-clinical models to block cross-talk between the tumour 
microenvironment and halt disease progression of stromal rich CMS4 CRC (61). TGFβ 
receptor inhibitors are currently being trialled in combination with chemotherapy in this 
patient subgroup (60). 
CMS are classified according to the gene expression of all heterogeneous components 
which make up a tumour, cancer cells, vessels, fibroblasts and immune cells (62). Non-
neoplastic cells within the extracellular matrix send extrinsic signals which dictate the 
prognosis of tumours such as the CMS4 mesenchymal subtype (62). Stromal traits in 
CRC influence prognosis, which is a weakness of the CMS classifier as it is a stroma 




proportion of non-cancerous cells may mask the subtle but biologically relevant gene 
expression profiles of neoplastic cells (62). 
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1.4.2 Colorectal intrinsic subtypes 
An alternative classification system, the colorectal cancer intrinsic subtypes (CRIS) 
aims to classify tumours according to the gene expression of neoplastic cells alone 
excluding the heterogeneous stroma (62). CRIS categorises CRC into five novel 
transcriptional classes. CRIS-A tumours are commonly BRAF-mutated, MSI, KRAS-
mutated and MSS, a group for which no targeted treatment is currently available (62).  
CRIS-A tumours exhibit strong glycolytic/hypoxic signatures suggesting they may 
respond to anti-metabolic therapy (62). CRIS-B tumours are invasive, associated with 
poor prognosis and high TGFβ signalling (62). CRIS-B tumours may respond to 
treatments targeting TGFβ stromal signals (62). CRIS-C tumours are dependent on 
EGFR signals and sensitive to treatment with EGFR antibodies (62). CRIS-D tumours 
display high expression of IGF2 associated with resistance to EGFR blockade in KRAS 
wild type tumours (62). The final subtype, CRIS-E includes KRAS-mutated, paneth 
cell-like CIN tumours with high WNT pathway activity which are commonly resistant to 
treatment with anti-EGFR antibodies. Wnt inhibitors may be a useful treatment option 
in this group (62). 
The CRIS subtypes can be used in conjunction with the extent of stromal infiltration to 
predict prognosis and treatment response (62). Patients with high levels of cancer-
associated fibroblasts in CRIS-B tumours have a poorer prognosis than those with low 
cancer-associated fibroblasts and are likely to benefit from adjuvant therapy (62). 
1.4.3 Molecular prognostic classifiers 
Only a small fraction of features identified through next generation sequencing (NGS) 
techniques have established clinical effects which can be used to predict clinical 
outcomes. A group of such features can be defined as a biomolecular classifier. The 
development of NGS classifiers has some inherent problems, sample sizes are 
commonly small, datasets have high dimensionality, the number of features is orders 
of magnitude greater than the number of samples. Genes are connected via pathways 
resulting in multicollinearity of features (63). Extracting the features capable of 
predicting a phenotype in subsequent patient cohorts from such complex data is 




significant features from high-dimensional molecular data, three models are discussed 
below. Partial least squares discriminatory analysis (PLS-DA) models, find features 
which maximise sample co-variance for a given phenotype (64). PLS-DA is well suited 
to the dimensionality and multicollinearity of NGS data (64). PLS-DA is a linear model 
which requires normally distributed data. Support vector machine (SVM) models find a 
linear or non-linear hyperplane which maximises the separation between phenotypes 
(64). Random forest (RF) models are formed of an ensemble of classification trees, 
the dataset is repeatedly sampled and the trees aggregated into a predictive ensemble 
(64). Although these models achieve good prediction accuracies they do however tend 
to produce an excess of features increasing the risk of overfitting and prediction 
variability (63). To make clinical predictions these models require a restricted list of 
features before entering the verification phase of classifier development. The analysis 
of the thousands to millions of combinations of features identified by NGS is not 
computationally feasible for large datasets. Several statistical methods of feature 
selection have been described to extract a restricted set of variables reducing the 
dimensionality of the dataset. One strategy is to filter the features before building the 
classifier. In filter feature selection features are ranked according to a univariate or 
multivariate metric (63). Filter feature selection is fast, however as it is performed 
before model construction features may not be optimal for classifier performance, 
additionally, the resulting classifier is large (63). A second method combines feature 
selection and model construction into a single step by including a penalisation 
constraint into the building of the classifier, the embedded approach limits the number 
of features with non-zero coefficients in the model (63). Embedded methods are fast, 
but the resulting classifier is large and unstable on repetition. Embedded feature 
selection uses one type of classifier. Several studies suggest optimal classifier 
performance results from the application of distinct classifier models depending on the 
dataset structure (63). Wrapper feature selection can be applied to any classifier and 
iteratively selects features based upon the classifier performance. With wrapper 
feature selection each new subset is used to train the model which is tested on a 





1.5 The presentation of colorectal cancer 
CRC may be asymptomatic, with 10% of cases detected by routine screening in the 
UK (3). The introduction of a UK National screening program for CRC has led to a shift 
in the mode of presentation from symptomatic to screening, with resulting earlier stage 
at diagnosis and a reduction in emergency and metastatic presentations (65). The UK 
CRC screening program began in 2006 and targets men and women aged between 
60 and 74 years. Screening comprises biennial faecal occult blood testing (FOBT) plus 
or minus colonoscopy or CT colonoscopy as appropriate for those with positive FOBT  
(66). 
Symptomatic CRC commonly presents with bleeding per rectum, abdominal pain, iron 
deficiency anaemia and or change in bowel habit. Emergency presentations resulting 
from advanced disease include bowel obstruction or perforation (67). 
1.6 The diagnosis of colorectal cancer 
A diagnosis of CRC is made by clinical history and examination. Diagnosis is confirmed 
with colonoscopy to visualise the tumour extent and its anatomical location. At the time 
of colonoscopy, the tumour is marked with tattoo dye to aid in its localisation during 
subsequent surgery. Tumour biopsies allow histological confirmation and 
categorisation.  
1.7 The staging and grading of colorectal cancer 
Computed tomography (CT) imaging of the chest, abdomen and pelvis is used to 
estimate the stage of disease pre-operatively (68). The pathological grade from 1–3 is 
established with endoscopic biopsy. Three pathological staging systems are used in 
the UK to describe the spread and extent of CRC. The Dukes system (69), the tumour 
node metastasis system (TNM) (70), and a numbered staging system from I-IV. 
Staging systems describe the extent of local tumour invasion, the presence, location 
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1.8 Mechanism and routes of metastasis in CRC 
Up to 26% of CRC patients present with metastasis, 5-year survival for such patients 
is just 7% (3). Metastasis is the spread, survival and growth of tumour cells in organs 
distant to their primary tissue of origin. CRC commonly metastasises in order of 
frequency: to the liver, regional lymph nodes, peritoneum and lungs (71).  
Paget in 1889 described the ‘seed and soil’ hypothesis of metastasis. Neoplasms are 
biologically heterogeneous, diverse cell populations (72). Metastasis selects for cells  
‘seeds’, able to succeed in invasion, embolization, survival and multiplication (72). 
Different organ microenvironments ‘soil’ are biologically unique, expressing different 
cell receptors and growth factors which influence the phenotype of tumours which grow 
there (72). Metastasis depends on cross-talk between the metastasising cell and 
micro-environment in which they grow. 
CRC metastasis occurs via several mechanisms: Haematogenous, tumour cells 
detach and invade the circulation, cell arrest occurs via attachment to endothelial cells 
or decreased vessel luminal size. Extravasation and transmigration are followed by 
growth or dormancy (73). Lymphatic, tumour cell invasion of lymphatic channels results 
in regional lymph node metastasis (73). Direct invasion, tumour growth breaches the 
bowel’s serosal surface and further growth is contiguous through adjacent organs and 
peritoneum (74). Cell seeding, tumour rupture or capsular breach (iatrogenic or 
spontaneous) allows tumour cells to seed and grow throughout the abdominal cavity 
(Figure 1.5) (74).  
1.9 Peritoneal metastasis 
Colorectal peritoneal metastasis (CPM) develop in up to 15% of CRC. CPM occurs in 
10% of CRC at diagnosis (synchronous) and in 25% of patients with recurrent disease 
(metachronous) (75-77). CPM is increased in patients with advanced tumour stage, 
nodal metastasis, vascular invasion, tumour obstruction or perforation  (75-77). CPM 
is isolated in 3-10% of all cases of CRC, presenting in the absence of distant 







Figure 1-5 Routes of CRC metastasis 
 
Colorectal cancer metastasis occurs via common mechanisms. Haematogenous, 
lymphatic, direct invasion or cell seeding by tumour rupture or capsular breach. This 





1.10 The treatment of peritoneal metastasis 
1.10.1 Palliative chemotherapy 
With palliation survival with CPM is limited to just 6 months (79). Traditionally, CPM 
was considered a terminal stage of CRC. Treatment was focused on palliation and 
included palliative surgery (tumour de-bulking or a de-functioning stoma) and palliative 
Fluoropyrimidine based chemotherapy. Overall survival with palliative treatment 
ranged from between 8–12 months (80, 81). In truth, outcomes were likely to be 
improved for isolated CPM as study populations were mixed to include patients with 
distant metastasis (81). This treatment rationale was challenged by a surgeon from the 
USA, Dr Paul Sugarbaker who defined CPM as locoregional disease suitable for 
aggressive treatment (82). 
Current cytotoxic treatment of metastatic CRC remains Fluoropyrimidine based 
intravenous 5-fluorouracil (5-FU) or its oral equivalent Capecitabine. Combination 
therapy, when tolerated, produces improved response rates, progression-free and 
overall survival (83). Two combinations with similar activity are commonly used, 5-
Fu/Leucovorin/Oxaliplatin (FOLFOX) or 5-Fu/Leucovorin/ Irinotecan (FOLFIRI) (83). 
Patients progressing on primary treatment can be switched to secondary 
chemotherapy, progression on FOLFOX would be followed by FOLFIRI and vice versa 
(83).  
Biologically targeted agents can be used in combination with intravenous 
chemotherapy. Biologics include monoclonal antibodies (Bevacizumab) active against 
vascular endothelial growth factor receptor (VEGF) or Cetuximab, active against 
epidermal growth factor receptor (EGFR). 
Cytotoxic combination treatments have improved survival for CPM. A retrospective 
analysis in patients with metachronous CPM treated with biological targeted agents 
and systemic chemotherapy revealed significant improvements in OS compared with 
systemic chemotherapy alone (13 months vs. 20.3 months) (84).  
Despite optimal cytotoxic and biological treatments the survival of patients with CPM 
is reduced when compared with patients with other sites of distant metastasis 




et al performed a subgroup analysis of two, phase 3 chemotherapy trials. Whilst overall 
survival was improved for patients with CPM with Oxaliplatin based chemotherapy as 
compared to Irinotecan, (15.7 months vs. 12.7 months) their survival was significantly 
reduced compared with patients with metastatic CRC and no PM (15.7 months vs. 
20.9) (85).  The CAIRO II trial added Bevacizumab (a monoclonal antibody agent active 
against vascular endothelial growth factor (VEGF)) and or Cetuximab (a monoclonal 
antibody agent active against EGFR) to Capecitabine and Oxaliplatin based 
chemotherapy. The addition of monoclonal antibodies improved OS from 10.4 to 15.2 
months for patients with CPM. Survival for patients without CPM and with other sites 
of distant metastasis, however, was significantly greater (20.9 months vs. 15.2) (86). 
Whilst systemic cytotoxic and biologic therapies improve outcomes for patients with 
CPM, survival with peritoneal metastasis remains significantly lower than for patients 
with other sites of metastasis. Systemic cytotoxic and biologic therapy remains the 
standard of care in some cases: to downstage disease potentially converting 
unresectable to resectable, to prolong survival, improve symptoms and maintain 
quality of life for patients with unresectable disease (83). 
1.10.2 Cytoreductive surgery and heated intraperitoneal chemotherapy, history 
Surgical tumour de-bulking was first described in the 1930s for patients with advanced 
ovarian cancer and subsequently pseudomyxoma peritonei. In the 1970s de-bulking 
surgery became more radical with the aim of removal of all tumour deposits greater 
than 1cm in diameter. This was termed cytoreductive surgery (CRS) (87, 88).  
In the 1980s several trials demonstrated the pharmacokinetic advantages of 
intraperitoneal vs. systemic chemotherapy for peritoneal disease allowing the 
administration of higher dose delivery locally with reduced systemic side effects (89). 
Ovarian cancer patients undergoing IP chemotherapy for low volume peritoneal 
disease (<2cm deposits) showed significantly improved OS when compared with high 
volume disease (>2cm deposits), (49 months vs. 8 months) (90).  Hyperthermia works 
synergistically with cytotoxic drugs increasing their efficacy via increased tissue 
perfusion and drug delivery as well as causing direct tumour cell damage (91). 
Intraperitoneal chemotherapy is therefore heated to improve its efficacy, heated 




CRS & HIPEC was first applied to gastrointestinal cancers and specifically CRC by Dr 
Paul Sugarbaker in the 1980s (92). Several phase I and II studies followed which 
showed good tolerability of intraperitoneal chemotherapy, with encouraging 
improvements in survival but relatively high post-operative morbidity (93, 94).  
1.10.3 Cytoreductive surgery and heated intraperitoneal chemotherapy, 
technique 
The technique for CRS & HIPEC includes a methodical laparotomy, peritonectomy, 
omentectomy and multi-visceral resections, as required depending on the spread of 
peritoneal metastasis (95).  
The extent of peritoneal tumour burden at surgery is described by the peritoneal 
carcinomatosis index (PCI) (Figure 1.6) (96). This is an additive score from 0-39. The 
peritoneal cavity is divided into 13 regions and in each region, the largest tumour 
nodule is measured. Tumour deposits > 5cm score 3, tumour deposits 0.5-5cm score 
2, tumours <0.5cm score 1 and where no tumour is visible tumour the score is 0. The 
scores from each region are added with a final score ranging from 0-39. Increased PCI 
is a poor prognostic indicator for CPM (97). Other scoring systems in use internationally 
describing the extent of tumour burden include the Gilly peritoneal carcinomatosis 
staging and Dutch simplified peritoneal cancer index. The Peritoneal Surface Disease 
Severity Score (PSDSS) incorporates PCI, clinical symptoms and histological grade to 
predict response to CRS & HIPEC (98).  
The completeness of cytoreduction score (CC score) describes the degree of 
macroscopic tumour remaining after CRS and the likelihood of benefit from 
intraperitoneal chemotherapy (99). Patients with no residual tumour score CC0, 
residual tumour of <0.25cm CC1, residual tumour 0.25-2.5cm CC2 and >2.5cm CC3. 
CC scores of CC0 and CC1 are termed complete cytoreduction and gain the greatest 
benefit from HIPEC which can penetrate the peritoneum to a depth of between 3-5mm 








Figure 1-6 The peritoneal carcinomatosis index (PCI) 
 
The extent of peritoneal metastasis is described by the peritoneal carcinomatosis index 
(PCI). The peritoneal cavity is divided into 13 regions and in each region, the largest 
tumour nodule is measured. Tumour deposits > 5cm score 3, tumour deposits 0.5-5cm 
score 2, tumours <0.5cm score 1 and where no tumour is visible tumour the score is 
0. The scores from each region are added with a final score ranging from 0-39 (101). 







Table 1-3 The completeness of cytoreduction, (CC) score. 
Residual peritoneal disease after CRS CC score 
No visible disease CC0 
Residual disease <0.25cm CC1 
Residual disease 0.25-2.5cm CC2 
Residual disease >2.5cm CC3 
 
The completeness of cytoreduction score (CC score) describes the degree of 
macroscopic tumour remaining after CRS and the likelihood of benefit from IP 





1.10.4 Heated intraperitoneal chemotherapy, technique 
HIPEC is delivered via a variety of techniques. The open or coliseum technique 
suspends the skin edges from a Thompson® or Omni-tract® retractor using a running 
suture. A plastic sheet is sewn between the skin edges. Fixed-flow rate pumps placed 
inside the abdomen maintain a flow rate of 1L/minute, a heat exchanger and 
temperature probes ensures the perfusate is maintained at between 41-43°C (102).  
An alternative closed technique involves the same pumps and probes with the closure 
of the laparotomy giving a closed perfusion circuit. Following both techniques the 
abdomen is opened, perfusate washed away anastomoses formed and the abdomen 
closed.  
The coliseum technique allows improved access to the abdomen for the operating 
surgeon, uniform exposure of all abdominal areas to heat and chemotherapy and 
protection to theatre staff from direct chemotherapy contact. The closed technique 
rapidly achieves and maintains hyperthermia, there is reduced risk of chemotherapy 
contact for theatre staff, both as direct and aerosolized. The distribution of 
chemotherapy and heat is however less uniform, pooling of heat and chemotherapy 
may result in undertreatment of some areas and increased risks of morbidity such as 
ileus, perforation and fistula formation (103). No randomised controlled trials exist to 
compare the two techniques, and the method used varies according to departmental 
preference and experience (104).  
Chemotherapy drugs used in HIPEC are varied. Desirable features of HIPEC drugs 
include slow clearance from the peritoneal cavity, synergy with hyperthermia as well 
as rapid hepatic metabolism and renal clearance to avoid systemic effects (105). 
Commonly used agents include Mitomycin C (an alkylating antibiotic) or Oxaliplatin (a 
platinum derivative) which is given simultaneously with intravenous 5-fluorouracil and 
Leucovorin. No prospective or randomised studies exist comparing HIPEC 
chemotherapy drugs in CRC, superiority has not been demonstrated in retrospective 




1.10.5 Adjuvant intraperitoneal chemotherapy 
CRS & HIPEC may be followed by adjuvant intraperitoneal chemotherapy. Early 
postoperative intraperitoneal chemotherapy (EPIC) is given in the immediate post-
operative period (days 1-5) via abdominal drains. Retrospective cohorts including 
patients undergoing a variety of intraperitoneal chemotherapy, CRS & HIPEC, CRS & 
EPIC or CRS & HIPEC & EPIC found no significant difference in oncological outcome 
despite the addition of EPIC (108-110). Sequential postoperative intraperitoneal 
chemotherapy (SPIC) is given over a prolonged postoperative period, in six, 6-day 
cycles. Two retrospective cohorts comparing CRS & HIPEC and CRS & SPIC, both 
demonstrated improved oncological outcomes with HIPEC (111, 112). One 
randomised trial, (ICARuS), comparing CRS & HIPEC with CRS & EPIC is ongoing 
and due to complete in 2019 (113). 
1.10.6 Cytoreductive surgery and heated intraperitoneal chemotherapy, 
oncological outcomes 
To date, one randomised controlled trial (RCT) exists comparing CRS & HIPEC to 
systemic intravenous chemotherapy for CPM (114). CRS & HIPEC was associated 
with significant improvements in DFS (22.2 months vs. 12.6 months) and a 5-year OS 
of 45% for those patients with complete cytoreduction. (115) One further RCT was 
attempted in 2016 comparing CRS & HIPEC to systemic chemotherapy, however, it 
terminated with just 24 patients in each arm due to recruitment difficulties, median OS 
was 25 months with CRS & HIPEC vs. 18 months with systemic chemotherapy (116). 
Four case-controlled studies compared CRS & HIPEC to systemic IV chemotherapy. 
CRS & HIPEC resulted in a median OS of 34–62.7 months compared to 16.8–23.9 
months for systemic IV chemotherapy (111, 112, 117, 118). The remainder of studies 
concerning the use of CRS & HIPEC for CPM are case series reporting OS ranging 
from 3.7-35 months and 5-year OS of between 0-55% (108-110, 119-139). 
Following CRS & HIPEC OS is improved for patients with a low PCI, in whom complete 
cytoreduction is achieved. None the less the oncological outcomes for CRS & HIPEC 
vary widely across the literature with limited consensus on patient suitability for 




1.10.7 Cytoreductive surgery and heated intraperitoneal chemotherapy, 
morbidity and mortality 
CRS & HIPEC can last up to 12 hours in duration and necessitates a high dependency 
or intensive care stay and up to a 2-week length of stay. CRS & HIPEC is associated 
with high postoperative mortality of 0-12% and morbidity of 7–63% (110-112, 120, 121, 
123-131, 133, 135, 138, 141-145). Common postoperative complications include 
fistula formation 2-10% (108, 110, 125-130, 142), abscess formation 1.8-21% (110, 
121, 125, 128, 130, 142), and anastomotic leak in 5-10.4% (124-126, 130). Re-
operation, as a result, is necessary in between 4–20.8% of cases (111, 121, 125, 128-
130). 
1.11 Biomarkers of colorectal peritoneal metastasis, circulating tumour DNA 
A cancer biomarker is secreted by a tumour or by the body as a reaction to the 
presence of a tumour. Biomarkers can be used in cancer diagnosis, to guide treatment 
or as markers of tumour recurrence.  
 
Fragments of circulating tumour DNA (ctDNA) circulate in the bloodstream. The 
mechanisms by which these fragments enter the circulation remains unclear but three 
potential origins have been proposed, apoptosis or necrosis of tumour cells, release 
from viable tumour cells and from circulating tumour cells (146). ctDNA represents a 
proportion of ccfDNA normally present at low levels in healthy individuals  (146). In 
health, ccfDNA is thought to originate from haematopoietic cells through apoptosis, 
necrosis, secretion or inefficient phagocytosis (146). ccfDNA increases in response to 
several conditions including myocardial infarction, serious infections, inflammation and 
pregnancy (146).  
 
ctDNA is an attractive option as a tumour marker. As it is composed of tumour DNA it 
has potential as a non-invasive, liquid biopsy, which can determine genomic and 
epigenetic markers allowing the delivery of targeted personalised treatments without 
the need for surgical resection or biopsy. Although ctDNA fragments are short (150 – 




as they are released from multiple tumour regions or foci, in some cases, they have 
been able to detect mutations missed in corresponding tumour samples (147).  
1.12 The biology of colorectal peritoneal metastasis 
There is a paucity of research regarding the biology of CPM and in particular the 
biology of the subset of patients with isolated and limited CPM suitable for treatment 
with CRS & HIPEC.  
Sequencing of a variety of tumours has determined high intratumor heterogeneity in 
primary tumours with gene expression signatures of good and poor prognosis detected 
within the same tumour (148). It is hypothesised that metastasis develop from 
heterogenous primary tumour clones selected through competitive selection and late 
clonal expansion (148). Clonal cells may acquire differential organ specific metastatic 
traits (148). Comparison of genetic variations by WGS reveal disparity between 
primary tumour and metastasis suggesting additional mutations are acquired after 
metastasis (148). 
Several retrospective cohort studies have examined the biology of advanced or 
recurrent primary CRC. In these studies, genes commonly mutated in CRC are 
correlated with clinicopathological features such as advanced tumour size, the 
presence of lymph node, distant or peritoneal metastasis and survival outcomes.  
1.12.1 MAPK pathway mutations 
Four retrospective cohort studies examined the prevalence of KRAS mutation in 
patients with advanced and recurrent CRC and reported the proportion with 
synchronous or metachronous PM. Three studies found no increased prevalence of 
PM in patients with KRAS mutation (149-151). One study found an increased 
frequency of PM in patients with KRAS mutation, 11.1% vs. 6% wild type (152). 
Four retrospective cohort studies examined the prevalence of mutation of the Raf-
kinase BRAF in advanced or recurrent CRC and found high rates of synchronous or 
metachronous PM in patients with a BRAF mutation of between 30-60% vs. 7-18% in 
BRAF wild type tumours (149-151, 153). BRAF mutation was a marker of reduced OS 




or signet ring histology and greater than three sites of distant metastasis (149-151, 
153).  
1.12.2 PI3K pathway mutations 
Three retrospective cohorts examined mutation of the PI3K pathway in patients with 
advanced or recurrent CRC and found no relationship with PM (150-152). 
1.11.3 Metastasis-associated colon cancer 1 gene (MACC1)  
MACC1 is a key regulator of hepatocyte growth factor. MACC1 is involved in cellular 
growth, epithelial-mesenchymal transition, angiogenesis, cell motility, invasiveness, 
and metastasis. Shirahata et al examined the expression of MACC1 in a retrospective 
cohort of patients with advanced and recurrent primary CRCs (154). They found 
MACC1 was upregulated in patients with CPM and advanced tumour stage (154).  
These were primary CPM making it difficult to determine whether MACC1 was a 
marker of advanced stage, PM or both. 
1.12.4 Histone acetyltransferase (Tip60) 
The Tip60 gene regulates DNA repair and apoptosis. Sakuraba et al examined the 
expression of Tip60 in a cohort of advanced and recurrent primary CRCs (155). They 
demonstrated that Tip60 was downregulated in patients with large tumour size, poor 
differentiation and the presence of peritoneal or distant metastasis making it difficult to 
determine whether Tip60 was a marker of advanced stage, PM or both. 
1.12.5 Neurone glial-related cell adhesion molecule (Nr-CAM) 
Nr-CAM is involved in the development and function of the nervous system, it is also 
overexpressed in CRC and has been shown to enhance cell motility and invasiveness. 
Chan et al examined the expression of Nr-CAM in a retrospective cohort of advanced 
and recurrent primary CRCs (156). Nr-CAM expression was increased in patients with 
lymph node and distant metastasis including PM, vascular invasion and p53 
expression, Nr-CAM expression was not related to tumour size (156). Patients with 




chemotherapy, however, given the retrospective study design, this may be a result of 
selection bias  (156). 
1.12.6 Collagen Triple Helix Repeat Containing 1 (CTHRC1)  
CTHRC1 is a protein-coding gene associated with digestive tract tumours which may 
contribute to cell invasion and metastasis. Tan et al examined the expression of 
CTHRC1 in patients with advanced and recurrent CRC. Patients with CPM had 
increased expression of CTHRC1 which was associated with reduced OS, 31.36 +/- 
5.63 months vs. 57.84 +/- 3.69 months (157). However, no information was provided 
about the surgical or systemic treatment of either the primary CRC or the PM meaning 
that the difference in OS may be due to un-reported treatment differences. 
1.12.7 Increased TOPO1, Cox2, ERCC1 and reduced RRM1 protein expression 
in CPM 
El-Deiry at al performed next-generation sequencing using a panel of 45 known 
biomarkers with therapeutic targets. This large cohort included 6892 metastatic CRC 
of which 465 were CPM with unmatched controls (158). The TOPO1 gene was 
upregulated in CPM. TOPO1 is the target of Irinotecan based chemotherapy and it has 
been hypothesised increased expression predicts increased benefit from Irinotecan 
(158). ERCC1 expression was upregulated in CPM. ERCC1 gene expression is 
predictive of resistance to Oxalaplatin based chemotherapy (158). RRM1 expression 
was reduced in CPM. Reduced expression of RRM1 suggests an improved benefit to 
gemcitabine-based chemotherapy, an agent not commonly in use in CPM (158). 
Whilst these studies demonstrate the prevalence of known mutations in subgroups of 
patients with CPM, some problems exist which mean we cannot extrapolate the 
findings to a population with isolated CPM. All retrospective patient cohorts included 
were undergoing palliative chemotherapy for advanced or recurrent CRC, there was 
poor reporting of treatment detail (surgical or adjuvant) or it’s intent as palliative or 
curative. Mutation analysis was performed most commonly on primary CRC resection 




The cohorts included large proportions of patients with PM in addition to numerous 
distant sites of metastasis. Whilst this suggests mutation status may be a risk factor 







CPM occurs in a small but significant number of patients with CRC. With palliation few 
patients survive greater than 6 months, systemic chemotherapy can increase survival 
to between 12–20 months depending upon patient selection, tumour biology and 
chemotherapy choice, however peritoneal metastasis show relative resistance to 
systemic chemotherapy when compared with other metastasis.  
Selected patients can be treated with curative intent using CRS & HIPEC (117). 
Following NICE guidance on CRS & HIPEC for peritoneal carcinomatosis, the 
technique has been commissioned for CPM in England since 2013.  Despite this, 
ongoing controversy exists regarding the role of CRS & HIPEC for CPM.  
There is a paucity of research regarding the biology of CPM and in particular the 
biology of the subset of patients with isolated and limited CPM suitable for treatment 
with CRS & HIPEC. Given the significant morbidity and mortality associated with CRS 
& HIPEC and wide variation in oncological outcomes reported in the available 
literature, there is significant room for improvement in the identification of prognostic 






1. Metachronous CPM is will acquire biological changes distinct from 
matched primary CRC in keeping with evolutionary adaptation, disease 
progression and the development of metastatic disease. 
2. A clinical and molecular classifier can be developed to predict prognosis 
and response to the best available treatment for CPM, CRS & HIPEC. 
3. Circulating tumour DNA can be used as a liquid biopsy prior to surgery, 
guiding treatment, and following surgery to determine residual disease 
and the need for further treatment. 
 
1.15 Aims 
1. For patients with CPM undergoing treatment with CRS & HIPEC, to 
define the significant clinical prognostic factors via systematic review 
and meta-analysis of the existing literature. 
2. To determine the gene expression methylation and somatic mutation 
profile associated with the development of CPM and conferring ‘poor 
prognosis’ in patients with CPM following CRS & HIPEC (DFS equivalent 
to palliative chemotherapy treatment, <12 months). 
3. To develop a biomolecular classifier (gene expression and methylation) 
for use with known clinical factors, capable of predicting prognosis for 
patients with CPM. 
4. To determine whether ctDNA mutations correlate with those found in 
CPM specimens and can be used to predict poor prognosis and 












2.1 List of reagents and suppliers 
2.1.1 General consumables and equipment common to all techniques 
DNA LoBind tube, 1.5ml, Eppendorf AG, Hamburg, Germany  
 
Conical tube, 15ml, Corning, New York, USA 
 
FALCON conical tube, 15ml, Corning, New York, USA 
 
8-Strip 'Non-Flex' PCR Tubes with Individual Attached Caps, 0.2ml, Starlab, 
Milton Keynes, UK     
 
Cryotube, 1.8ml, Thermo Fisher Scientific, Northumberland, UK     
 
Hard-Shell PCR Plates, 96-well 0.8mL, BIO-RAD, Vienna, Austria 
 
Abgene™ Polypropylene Deepwell Storage Plate, 96-well 0.8mL, 
 
Thermo Fisher Scientific, Northumberland, UK  
 
Adhesive PCR Plate Foils, Thermo Fisher Scientific, Northumberland, UK 
 
Nunc™ 96-Well Cap Mats, Thermo Fisher Scientific, Northumberland, UK     
 
Magnetic stand- 96, Ambion, Northumberland, UK 
 
MagnaRack™, Invitrogen, California, United States 
 
Trough, Thermo Fisher Scientific, Northumberland, UK         
 





Nuclease free water, Omega-Bio-tek, Georgia, USA 
 
Isopropanol, Thermo Fisher Scientific, Northumberland, UK 
 
Ethanol absolute, Thermo Fisher Scientific, Northumberland, UK 
 
Tris(hydroxymethyl)aminomethane, Sigma-Aldrich, Missouri, United States 
 
C1000 Touch Thermal Cycler, Bio-Rad, California, USA 
 
Plate centrifuge, Greiner bio-one, Kremsmünster, Austria 
 
Hereaus Megafuge 16R Centrifuge, Thermo Fisher, Northumberland, UK 
 
2.1.2 Tissue collection and storage 
PAXgene Blood ccfDNA tube, Qiagen, Manchester UK 
 
Vacutainer™ Hemogard Closure Plastic K2-EDTA Tube, Thermo Fisher  
Scientific, Northumberland, UK 
 
RNA later stabilisation solution, Thermo Fisher Scientific, Northumberland, UK 
 
2.1.3 Extraction of RNA and DNA 
TruXTRAC FFPE total NA Kit, Covaris, Brighton, UK 
 
E220 evolution focused-ultrasonicator, Covaris, Brighton, UK 
 
TURBO DNA-free kit, Thermo Fisher Scientific, Northumberland, UK 
 





QIAamp DNA FFPE kit, Qiagen, Manchester, UK 
 
AllPrep DNA/RNA Mini Kit, Qiagen, Manchester, UK 
 
TissueLyser II, Qiagen, Manchester, UK 
 
TissueLyser Adapter Set 2 x 24, Qiagen, Manchester, UK 
 
Stainless steel beads, 5mm, Qiagen, Manchester, UK 
 
Maxwell® RSC instrument, Promega, Wisconsin, USA  
 
Maxwell® RSC Buffy Coat DNA Kit, Promega, Wisconsin, USA 
 
Cell3TM Xtract, Nonacus, Birmingham, UK 
 
2.1.4 Quantification of DNA and RNA  
QubitTM 3.0 Fluorometer, Thermo Fisher Scientific, Northumberland, UK 
 
QubitTM dsDNA HS (high sensitivity assay kit) and QubitTM RNA HS (high 
sensitivity) assay kit, Thermo Fisher Scientific, Northumberland, UK 
 
2200 TapeStation Nucleic Acid System and the 2200 TapeStation Software 
A.01.05, Agilent, Santa Clara, USA 
 
Genomic DNA ScreenTape and the Genomic DNA Reagents, Agilent, Santa 
Clara, USA 
 





High Sensitivity RNA ScreenTape and the RNA High sensitivity reagents, 
Agilent, Santa Clara, USA 
 
Loading tips, Agilent, Santa Clara, USA 
 
Optical Tube 8x Strip, Agilent, Santa Clara, USA 
 
2100 Bio-analyser, Agilent, Santa Clara, USA 
 
High sensitivity DNA chips, Agilent, Santa Clara, USA 
 
2.1.5 RNA library preparation 
Quant Seq 3’ MRNA-Seq Library Prep kit, Lexogen, Vienna, Austria 
 
TruSeq stranded total RNA kit, Illumina, California, USA 
 
SuperScript II Reverse Transcriptase, Thermo Fisher, Northumberland, UK 
 
Agencourt RNAClean XP beads, Beckman Coulter, California, USA        
 
2.1.6 DNA sequencing 
NextSeq500, Illumina, San Diego, California, United States 
 
75-cycle High Output flow cell, Illumina, San Diego, California, United States 
 
150-cycle High Output flow cell, Illumina, San Diego, California, United States 
 
PhiX, Illumina, San Diego, California, United States 
 






2.1.7 Methylation arrays 
EZ DNA Methylation Kit, Zymo, California, USA     
 
ZR-96 DNA Clean & Concentrator-5 Kit (2 x 96 Preps), Zymo, California, USA 
 
Infinium HD FFPE Restore, Illumina, California, USA 
 
Infinium MethylationEPIC BeadChip Kit (32 samples), Illumina, California, USA 
 
Multi-Sample BeadChip Alignment Fixture, Illumina, California, USA    
 
Infinium BeadChip Expansion Package, Illumina, California, USA 
 
Infinium BeadChip Wash rack, Illumina, California, USA 
 
Infinium BeadChip Glass tray, Illumina, California, USA  
 
Te-Flow 48 position rack chamber, Tecan, Männedorf, Switzerland 
 
Infinium Hybridization Chamber, Illumina, California, USA  
  
Infinium Hybridization Chamber Inserts (8), Illumina, California, USA             
 
ALPS 25 Manual Heat Sealer, Thermo Fisher, Northumberland, UK         
 
Illumina Hybridization Oven (220V), Illumina, California, USA 
 
High-Speed Microplate Shaker, Illumina, California, USA              
 






Hybex Micro sample Incubator, SciGene, California, USA, 
 
I-Scan®, 110 V/220 V, Illumina, California, USA           
 
GenomeStudio 2.0.4, Illumina, California, USA          
 
RStudio desktop (2015), Massachusetts, USA 
 
2.1.8 Exome sequencing 
8-microTUBE-50 AFA Fibre Strip V2 (12), Covaris, Brighton, UK        
 
E220 evolution focused-ultrasonicator, Covaris, Brighton, UK 
 
TruSeq® Exome Kit (96 Samples), Illumina, California, USA           
 
2.1.9 DNA panel sequencing 









This study obtained ethical approval from the North West Haydock Research Ethics 
Committee (15/NW/0079), project ID (171283). Participants gave informed consent. 
2.2.2 Clinical sample preparation 
Retrospective patients were recruited from an internally held database of all patients 
undergoing CRS & HIPEC at Good Hope hospital from 2011–2017. Patients with CPM 
(adenocarcinoma), no extra-abdominal metastasis, a CC0 resection and a PCI of < 12 
were eligible for inclusion. Patients were divided into two groups. With palliative 
chemotherapy, DFS is 11-13 months and therefore patients, post-treatment (CRS & 
HIPEC) with DFS <12 months were defined as the “poor prognosis” cohort (114, 115). 
Patients undergoing therapy with DFS > 12 months were defined as a “good prognosis” 
cohort.  For each patient tissue was sourced from the colorectal primary tumour, the 
metachronous colorectal peritoneal metastasis and normal tumour free tissue. 
Formalin-fixed, paraffin-embedded (FFPE) tumour blocks were sectioned into triplicate 
and further divided into 5x 8-micron scrolls. Tissue was sourced through the Human 
Biomaterials Resource Centre (HBRC) at the University of Birmingham. Histologically 
confirmed, tumour free tissue samples for paired analysis were taken from the 
cytoreductive specimen.  
Prospective patients were recruited from the peritoneal malignancy clinic, given an 
information sheet to take away and were consented on the day of surgery. Samples 
were sectioned immediately, preserved in RNAlater solution (Thermo Fisher, 
AM7021), refrigerated overnight and frozen at -20 °C.  
Demographics, tumour and treatment details were collated from the patient electronic 
record and anonymised via the HBRC. The cohorts were compared, for continuous 
variables, the student's T-test was applied to normally distributed data and Mann 
Whitney-U to non-normally distributed data. Categorical variables were compared with 
the Chi-squared test or Fisher's exact test, a P-value of < 0.5 was considered 




compared using the Kaplan Meier method in IBM SPSS Statistics for Windows, Version 
24.0 (159). 
At the induction of anaesthesia matched normal whole blood samples were collected 
in 5 ml EDTA tubes (Thermo Fisher, 367525), centrifuged at 900 xg for 10 minutes, 
the lymphocyte rich buffy coat collected and stored at -20 °C. Blood samples for 
circulating tumour DNA (ctDNA) were collected into 10ml PAXgene tubes (Qiagen, 
768115) at the induction of anaesthesia, postoperatively and at 3, 6, 9 and 12 months 
follow up appointments.  The PAXgene tube was centrifuged for 15 minutes at 1900xg, 
plasma pipetted into a 15 ml falcon tube and centrifuged for a further 10 minutes at 
1900xg. Plasma was stored in Cryotubes (Thermo Fisher, 374500TS) at -20 °C. 
2.2.3 Nucleic acid extraction  
2.2.3.1 DNA & RNA extraction from retrospective FFPE tissue samples 
DNA and RNA were extracted from FFPE scrolls using Adaptive Focused Acoustics 
(AFA), the truTRAC® FFPE total NA Kit (Covaris, 520220) and the E220 evolution 
focused-ultrasonicator (Covaris, 500429) as per the manufacturer’s instructions.  
Briefly, 2x 5 μm FFPE scrolls were loaded into a Covaris microtube with 120 μl of tissue 
lysis buffer and proteinase-K. The focused-ultrasonicator dissociates the paraffin and 
re-hydrates the sample. Tissue lysis is achieved by incubation at 56 °C for 15 minutes 
and centrifuged at 5,000 xg for 15 minutes.  
To reverse formalin crosslinking the RNA containing supernatant was collected and 
heated to 80 °C for 15 minutes. RNA was precipitated and purified using a silica spin 
column and collection tube, isopropanol, buffers and series of centrifuge and wash 
steps as per the manufacturer's instructions. In-solution DNase digestion was 
performed using the TURBO DNA-free kit to remove DNA contaminants (Thermo 
Fisher, AM1907). RNA columns were incubated with a TURBO DNase mixture for 25 
minutes, purified with wash buffer steps and centrifuged as per the manufacturer's 
instructions. RNA was eluted into a DNA LoBind tube using 30 μl of elution buffer (EB) 
and stored at -80 °C. 
Tissue lysis buffer and proteinase-K mix were added to the DNA pellet, tissues lysis 




digestion was performed at 56 °C for one hour, followed by incubation at 80 °C for one 
hour to achieve formalin de-crosslinking. Samples were processed once again in the 
focussed-ultrasonicator. DNA was precipitated and purified using a silica spin column, 
collection tube, ethanol and buffers and a series of centrifuge and wash steps as per 
the manufacturer's instructions. DNA was eluted in buffer warmed to 70 °C and stored 
at -20°C until further processing.  
Samples resulting in low concentrations of RNA were extracted again using the second 
set of scrolls. The two samples were combined and concentrated using the RNA Clean 
& Concentrator-5 kit (Zymo, R1015). Samples were combined with RNA binding buffer 
and a 1x volume of 95% (v/v) ethanol, transferred to a Zymo-Spin Column and 
centrifuged at 11,000xg for 30 seconds. Two further wash and centrifuge steps were 
performed with RNA Prep buffer and RNA wash buffer as per the manufacturer's 
instructions. RNA was eluted into a DNA LoBind tube in 15 μl of EB and stored at -80 
°C. 
Samples resulting in low concentrations of DNA were extracted again using the second 
set of scrolls. The two samples were combined and concentrated using the Genomic 
DNA Clean & Concentrator kit (Zymo, D4066). Briefly, samples were combined with 
DNA binding buffer, transferred to a Zymo-Spin Column, and centrifuged at 11,000xg 
for 30 seconds. Two further wash and centrifuge steps were performed with DNA wash 
buffer as per the manufacturer's instructions. Finally, DNA was eluted into a clean DNA 
LoBind tube using 50 μl of EB and stored at -20 °C.  
For some samples, this did not provide adequate concentrations of DNA for both 
exome sequencing and methylation arrays. For these, a repeat extraction was 
performed using an alternative method allowing a higher input of DNA material, the 
QIAamp DNA FFPE kit (Qiagen, 56404). In brief, up to 8 scrolls were added to a 1.5 
ml Eppendorf with 1 ml of xylene and vortexed for 10 seconds to dissociate the paraffin. 
The samples were centrifuged at full speed and the supernatant discarded. The pellet 
was lysed by incubation in lysis buffer ATL and proteinase K for one hour at 56°C. 
Further incubation at 90 °C for one-hour reverses formalin crosslinking. DNA was 
precipitated using a QIAamp MinElute silica spin column, collection tube, buffer AL, 




a series of buffer wash and centrifuge steps as per the manufacturer's instructions. 
DNA was eluted from the column using 50 μl of buffer ATE and stored at -20 °C. 
2.2.3.2 DNA & RNA extraction from prospective fresh tissue preserved in RNA 
later 
DNA and RNA were extracted from fresh tissue which had been preserved in RNA 
later solution (Thermo Fisher, AM7021) using the Qiagen AllPrep DNA/RNA mini kit 
(Qiagen, 80204). In brief, tissues were removed from RNA later, to a 2 ml Eppendorf 
no more than 30 mg of tissue was added with 600 μl of Lysis buffer (RLT) / B-
mercaptoethanol (1 ml / 10 μl). One 5 mm stainless steel bead was added (Qiagen, 
69989) and tissue homogenization performed with the Qiagen TissueLyser II (Qiagen, 
85300). Following homogenization, the lysate was centrifuged for 3 minutes at 
maximum speed. The supernatant was transferred to an AllPrep DNA spin column and 
centrifuged for 30 seconds at ≥ 8000 x g. The dry DNA spin column was placed into a 
new collection tube until further processing. The flow-through continued to RNA 
purification. 
2.2.3.2.1 RNA purification 
One volume of 70% (v/v) ethanol was added to the RNA containing flow-through, mixed 
by pipette, transferred to an RNeasy silica spin column and centrifuged ≥ 8000 x g for 
15 seconds. A series of three wash and centrifuge steps of the RNeasy spin column 
was performed to purify the RNA using RW1 and RPE wash buffers as per 
manufacturer's instructions. RNA was eluted into a DNA LoBind tube in 50 μl of NFW 
by centrifuge and stored at -80 °C. 
2.2.3.2.2 DNA purification 
A series of two wash and centrifuge steps of the AllPrep DNA spin column was 
performed to purify the DNA using AW1 and AW2 wash buffers as per manufacturer's 
instructions, centrifuged at ≥ 8000 x g and the flow-through discarded. DNA was eluted 
from the spin column with 50 μl of EB by centrifuge. To achieve a higher DNA 




2.2.3.3 DNA extraction from prospective matched normal blood samples 
DNA was extracted from 250 μl of the buffy coat using the Maxwell® RSC Buffy Coat 
DNA Kit, a cartridge-based magnetic bead extraction method (Promega, AS1540) and 
the Maxwell® RSCI instrument (Promega, AS4500). In brief, DNA extraction occurs 
within the pre-filled cartridge, which is split into wells containing lysis buffer, 
MagneSil™ Paramagnetic Particles (PMPs) and wash buffers. DNA is bound to and 
moved between wells by the PMPs and the application of a magnetic force to 
disposable plungers. Cells are lysed in a guanidine-based lysis buffer and mechanical 
lysis from the disposable plungers. DNA is moved through a series of wash wells to 
remove impurities. Purified DNA is then eluted from the beads in a 
tris(hydroxymethyl)aminomethane (TRIS), Ethylenediaminetetraacetic acid (EDTA) 
based lysis buffer heated to 56 °C. 
2.2.3.4 Cell-free DNA extraction from plasma samples 
A variety of methods are available for the collection of ctDNA. The proportion of ctDNA 
in total circulating cell free DNA (ccfDNA) is greater in the plasma than serum, higher 
ctDNA levels in serum are due to leakage from leucocytes as clotting occurs, therefore 
plasma separation is recommended as soon as possible following blood collection 
(160). 
 
DNA was extracted from the full volume of plasma taken from each patient at each 
time point (3-7 ml), using the Cell3TMXtract kit (Nonacus, C3048LK). Plasma was 
thawed and mixed with the 5x digestion buffer (250 μl) and Proteinase-K (100 μl) per 
ml of plasma. Samples were incubated for 30 minutes at 55 °C. Two volumes of DNA 
binding buffer were added to the digested sample, placed into a silica spin column 
assembly and centrifuged at 1,000 xg for 2 minutes. DNA Equilibrium buffer (400 μl) 
was added to the column and centrifuged at >10,000 xg for 1 minute. The DNA was 
purified using two wash buffer and centrifuge steps. DNA was eluted from the spin 




2.2.4 Fluorometric Quantification of RNA and DNA  
The quantification of nucleic acid concentration allows standardisation or normalisation 
in experiments. Fluorometric quantification uses fluorescent dyes, specific to DNA, 
RNA or protein. The dyes have low fluorescence until they bind to their target. Once 
bound they become intensely fluorescent. At a given volume of dye, the fluorescence 
signal, read by a Fluorometer is directly proportional to the concentration of target in 
solution. The concentration is calculated by comparison to known standards of DNA 
concentration. 
2.2.4.1 QubitTM quantification 
DNA and RNA concentrations were quantified using the QubitTM 3.0 Fluorometer 
(Invitrogen, Q33216). The QubitTM measures the fluorescence intensity of fluorescent 
dye bound to nucleic acids. A QubitTM double-stranded DNA (dsDNA), HS (high 
sensitivity) assay kit and QubitTM RNA HS assay kit were used with the QubitTM 3.0 
Fluorometer. Standards were prepared with 10 μl of each standard and 190 μl of 
QubitTM working solution. Samples were prepared by adding 1 μl of sample to 199 μl 
of QubitTM working solution and read using the Fluorometer. The nucleic acid 
concentration was recorded in ng/μl.  
2.2.5 DNA & RNA electrophoresis 
Electrophoresis separates charged macromolecules such as DNA, RNA and proteins 
based on size according to their response to an electric current. An electrical current 
is placed across a gel and the molecules move towards the opposite charge with the 
smallest fragments moving more rapidly than the largest. To visualise the fragments 
the gel is pre-stained with a dye, which binds the molecule and fluoresces when 
exposed to ultraviolet (UV) light.  
Electrophoresis was performed using either the Agilent 2200 TapeStation Nucleic Acid 
System (Agilent, G2965AA), Agilent 2200 TapeStation Software A.01.05 or the Agilent  
2100 Bio-analyser (Agilent, G2939BA).  
The TapeStation uses a ready-made three-layer polymer gel (ScreenTape) containing 




mini-robot directly from a 96-well plate or strip tubes. Up to 16 samples are run 
simultaneously and imaged. Dye within the chip allows the migrating fragments to be 
detected. A computer records fragment sizes and concentrations. 
The Bio-analyser uses a ready-made chip with 16 sample channels etched into the 
chip. Sample and ladder are mixed with a dye-containing buffer and loaded onto a 1% 
(v/v) agarose precast gel. Separation of samples through these channels when an 
electric voltage is applied occurs according to fragment mass. Dye within the chip 
allows the migrating fragments to be detected a connected computer records fragment 
sizes and concentrations. 
2.2.5.1 TapeStation 
Genomic DNA was analysed using the Genomic DNA ScreenTape (Agilent, 5067–
5365) and the Genomic DNA Reagents (Agilent, 5067–5366) with samples drawn from 
sample tube strips.  RNA was analysed using the High Sensitivity RNA ScreenTape 
(Agilent, 5067-5579) and the RNA High sensitivity reagents (Agilent, 5067-5580, 5067-
5581) with samples drawn from sample tube strips. dsDNA was analysed using the 
D1000 High Sensitivity ScreenTape (Agilent, 5067-5584) and the D1000 High 






Figure 2-1 Tape station electropherogram 
 
A representative tape station electropherogram. Markers indicate lower marker, upper 
marker and the average size of the nucleic acid sample in base pairs. This figure has 







During RNA library preparation amplification products were checked on the Agilent 
2100 Bio-analyser (Agilent, G2939BA). Briefly, a gel dye mix was prepared by mixing 
the high sensitivity DNA dye concentrate and gel matrix (Agilent, 5067-4627). Gel-dye 
mix (9 μl) was then loaded into the High sensitivity DNA chip to cast a gel (Agilent, 
5067-4626). DNA marker (5 μl) and 1 μl of ladder or sample were loaded into each 
well, the chip incubated for 1 minute at room temperature and read using the Agilent 
2100 Bio-analyser. 
2.2.6 Polymerase chain reaction, an introduction 
Polymerase chain reaction (PCR) is an in-vitro technique commonly used to amplify 
specific DNA regions of interest, identified by a primer. PCR uses thermal cycling, 
repeated cycles of heating and cooling to allow temperature-dependent reactions. High 
temperatures first separate the dsDNA (94-96 °C). PCR primers anneal to the region 
of interest at 50-65 °C. The temperature is increased to the optimal temperature of a 
DNA polymerase (75-80 °C) and primers are extended with the addition of 
deoxyribonucleoside triphosphates (dNTP). As each PCR cycle progresses DNA is 
exponentially doubled. Amplified sections of DNA produced via PCR are described as 
amplicons. 
2.2.7 RNA sequencing 
The genome comprises all the genetic material present in an organism. Expression of 
the genome relies on transcription, messenger Ribonucleic Acid (mRNA) acts as a 
transient copy or transcript of the genomic DNA, which is translated into encoded 
proteins. 
Transcription occurs in the following steps: RNA polymerase and transcription factors 
bind to promoter regions of DNA. RNA polymerase separates ds-DNA and 
complementary RNA nucleotides bind to a single strand of complementary DNA 
(cDNA). The precursor messenger RNA (mRNA) strand is released, further processing 
in the nucleus transforms it from precursor mRNA to mature mRNA. Polyadenylation 




Capping describes the addition of a five-prime cap, a specially altered nucleotide at 
the 5’ ends of mRNA. Splicing describes the removal of introns and the joining of exons 
before translation (Figure 2.2). 
The sum of RNA transcripts is known as the transcriptome. Measuring gene expression 
in different tissues or conditions creates a snapshot of which cellular processes are 
active and which are dormant in a cell at a particular point in time. 
The transcriptome is composed of many species of RNA; in addition to protein-coding 
mRNAs, the genome encodes various non-coding RNAs.  Some RNA species play an 
essential role in protein synthesis. Transfer RNAs (tRNA) deliver amino acids to the 
ribosome, where ribosomal RNA (rRNA) links amino acids to form proteins (161). Small 
nuclear RNAs are less than 200 nucleotides in length. They comprise several non-
coding RNA molecules that often function to silence RNA. MicroRNA (miRNA) or small 
interfering RNA (siRNA) are both types of small RNA able to degrade mRNA and 
repress translation (161). Other species of small RNA included piwi-interacting RNA 
(piRNA) which also participates in RNA silencing. Small nucleolar RNAs (snoRNA) 
participate in post-transcriptional modification of gene expression levels known as RNA 
interference (161). In RNA interference miRNAs attenuate gene expression by 
promoting the degradation of mRNA or repressing translation (161). Small nuclear 
RNAs (snRNA), participate in RNA splicing, forming a large protein complex known as 
the spliceosome which recognises splice sites in the precursor mRNA (161). Long non-
coding RNAs (lncRNA) act to regulate gene expression through many diverse 
functions including the modification of chromatin, direct transcriptional regulation, the 
regulation of precursor RNA processing, modification of miRNA, the production of 
siRNA and the regulation of genomic imprinting (161). Here, we primarily address the 






















Gene expression is the manufacture of its protein product. DNA serves as a template 
for complementary base pairing, a polymerase enzyme catalyses the formation of an 
mRNA precursor which is further processed by polyadenylation, capping and splicing 
before translation into a protein molecule. This figure is reprinted from Clancy et al, 
2008, Figure 1 (162). 
  




2.2.7.1 Contemporary RNA sequencing techniques 
2.2.7.1.1 Microarray  
Microarrays quantify a set of predetermined RNA transcripts. The array consists of 
short nucleotide probes designed to match known transcripts, arrayed on a solid 
substrate (Figure 2.3) (163).  
The transcriptome is prepared from an experimental condition, cDNA reverse 
transcripts are prepared and labelled with a red fluorescent dye (163). A control library 
is constructed from a non-experimental condition and labelled with a green fluorescent 
dye (163). Experimental and control libraries are hybridised to the microarray probes 
(163). A dual-channel laser excites the dye and the fluorescence indicates the degree 
of hybridisation (163). Gene expression is measured as the ratio of the two 
fluorescence wavelengths (163). Increased expression is visualised as red and 
decreased expression as green, constitutive expression shows as black (163). 








Figure 2-3 Microarray technology 
 
The transcriptome is prepared from an experimental condition, cDNA reverse 
transcripts are prepared and labelled with a red fluorescent dye. A control library is 
constructed from a non-experimental condition and labelled with a green fluorescent 
dye. Experimental and control libraries are hybridised to the microarray probes. A dual-
channel laser excites the dye and the fluorescence indicates the degree of 
hybridisation. Gene expression is measured as the ratio of the two fluorescence 
wavelengths. Increased expression is visualised as red and decreased expression as 
green. The constitutive expression is shown as black. The figure is reprinted from Afzal 






Microarrays have several limitations. Arrays are limited to interrogating for the genes 
for which probes are designed (165). Background hybridisation describes the non-
specific attachment of the probe to the membrane background (165). Cross 
hybridisation described signal produced by transcripts with non-perfect but significant 
sequence similarity with the probe (165). Because of background and cross 
hybridisation microarrays have difficulty detecting transcripts in low abundance (165). 
Conversely, microarrays are prone to hybridisation saturation for highly abundant 
genes meaning they cannot give reliable measures of subtle changes of genes with 
high expression levels (165). Microarray probe intensity depends upon the affinity to 
the probe under given hybridisation conditions. In microarray multiple probes 
interrogate different regions of the same gene, expression level changes are not 
always consistent across all probe sets for the same gene (165). Exon specific probes 
mean splice variants of the same gene can be missed (165). These factors can lead 
to incorrect conclusions regarding expression (165). 
2.2.7.1.2 RNA-seq 
RNA-seq combines high-throughput sequencing with bioinformatics to quantify gene 
expression. Reads of many short fragments are computationally reconstructed and 
aligned to a reference genome allowing deep sequencing of the entire transcriptome  
(166). 
RNA-seq avoids hybridisation based limitations such as background noise or with 
probe issues such as the limited detection range of individual probes, cross-
hybridisation and non-specific hybridisation (165). RNA-seq can detect novel 
transcripts, discover sequence variations and splice variants and accurately quantify 
the expression of low and high abundance genes (165). Input RNA requirements are 
low allowing examination of small samples down to the single-cell level. The high 
sensitivity of RNA-seq allows quantification of gene expression within infrequent cell 
populations from a sample (166). 
RNA-seq involves enrichment of the transcriptome of interest (via enrichment for poly-
adenylated mRNA), fragmentation, amplification followed by single or paired-end 




sensitivity: Oligonucleotide probes separate mRNA molecules by binding to their 
poly(A) tails, alternatively, ribo-depletion removes abundant ribosomal RNAs (167). 
mRNAs are longer than typical sequencing read lengths so transcripts are fragmented 
before sequencing (167). The cDNA transcript copy is then amplified, this allows input 
of very-low amounts of RNA with enrichment of fragments containing the expected 5’ 
and 3’ adaptor sequences (167). The addition of spike-in controls provides quality 
control of library preparation and sequencing in terms of fragment length and bias due 
to the fragment position in a transcript (168). 
Sequencing of the transcript in one direction (single-end) is rapid, cheap and sufficient 
for quantification of gene expression levels. Sequencing in both directions (paired-end) 
improves alignment and transcript isoform discovery (166, 167). 
RNA-seq sensitivity depends on the number of reads per sample. Large numbers of 
reads are needed to ensure sufficient coverage of the transcriptome and detection of 
low abundance transcripts (167). The current benchmark is 70-fold coverage for 
standard RNA-seq and 500-fold coverage to detect rare transcripts or isoforms (167). 
Analysis of gene expression relies on counting sequencing read alignments to the 
reference genome while compensating for transcript size variation. Longer genes 
therefore potentially have higher counts at the same expression level (168). A solution 
to this is limiting the sequencing read to the 3’ region of the transcript, counts are then 
based on the same region of each gene. Other benefits of 3’ sequencing include a 
reduction in the depth of sequencing required and allowing for a higher degree of 
sample degradation such as that found in FFPE samples. 
In 3’ sequencing normalised total RNA is added to an oligodT primer, which binds to 
the poly(A) tail of mRNA. Following cDNA first-strand synthesis the RNA is removed 
and second-strand synthesis initiated by binding of a DNA polymerase. The library is 
cleaned using a magnetic bead-based purification step, indexed by the addition of 








Figure 2-4 3'Prime RNA sequencing 
 
An oligodT primer binds to the polyA tail of mRNA. Following cDNA first-strand 
synthesis the RNA template is removed, DNA polymerase binding initiates second 
strand synthesis. Magnetic bead-based purification is followed by indexing and PCR 
amplification before sequencing. This figure is reprinted from the Lexogen Quantseq 








2.2.7.2 RNA library preparation, 3’ mRNA-seq method 
Library preparation was performed using the Quant Seq 3’ mRNA-Seq Library Prep kit 
(Lexogen, SKU:015.96). RNA samples were defrosted on ice, normalised to 2 ng in 5 
μl of NFW in a 96 well plate. Following each thermocycler step samples were pulse 
centrifuged. Following the addition of each reagent, samples were pipette mixed and 
pulse centrifuged.  
2.2.7.2.1 First-strand synthesis:  
An oligo-dT primer selectively binds the poly(A) tail of mRNA, the cleaved RNA 
fragments are then reverse transcribed into the first-strand cDNA. A master mix at 42 
°C, (0.95 μl first-strand cDNA synthesis mix 2 / 0.5 μl enzyme mix 1) was mixed with 
the normalised samples. The plate was incubated on the thermal cycler for 1 hour at 
42 °C (Bio-Rad, 184-1100). 
2.2.7.2.2 RNA removal:  
RNA removal solution (5 μl) was added and incubated at 95 °C for one hour, then 
cooled to 25 °C on the thermal cycler to degrade the RNA template, (Bio-Rad, 184-
1100). 
2.2.7.2.3 Second strand synthesis:  
This process synthesises a replacement strand to generate ds-cDNA. Second strand 
synthesis one (10 μl) was added, incubated at 98 °C on the thermal cycler, (Bio-Rad, 
184-1100) then cooled slowly to 25 °C for 30 minutes. A second master mix, (4 μl 
second strand synthesis two / 1 μl enzyme 2) was added and incubated for a further 
15 minutes. 
2.2.7.2.4 Purification:  
Purification beads, (16 μl) were mixed with each sample, incubated for 5 minutes, 
placed onto a magnetic stand, (Thermo Fisher, AM10027) until the liquid cleared. The 




Purification solution (48 μL) was added, incubated at room temperature for 5 minutes, 
placed onto a magnetic stand (Thermo Fisher, AM10027) until the liquid cleared and 
the supernatant discarded. Two 120 μL ethanol washes were performed and the pellet 
air-dried for up to 10 minutes. The pellet was resuspended in 20 μl of EB, incubated 
for 2 minutes, placed on a magnetic stand (Thermo Fisher, AM10027) and 17 μl of 
supernatant transferred to a new midi plate (Abgene, AB0859). 
2.2.7.2.5 Library amplification and indexing:  
The dsDNA library was amplified to add the complete adaptor sequences required for 
cluster generation and provide sufficient material for QC and sequencing. Seven 
microliters of a third master-mix (7 μl PCR mix / 1 μl Enzyme mix 3) was added with 5 
μl of the respective index in a 96 well plate. Twenty-six cycles of PCR were performed 
on the thermal cycler, (Bio-Rad, 184-1100) (initial denaturation 98 °C for 30 seconds, 
26 cycles of PCR at 98 °C for 10x seconds, 65 °C for 20x seconds, 72 °C for 30x 
seconds, 72 °C for 1 minute and hold at 10 °C. Amplification products were checked 
on the bio-analyser. 
2.2.7.2.6 Purification:  
A purification step was repeated as before with 27 μl of SPB, 30 μl of EB, 30 μl of 
purification solution, 2x ethanol washes and resuspension in 20 μl of EB resulting in a 
final volume of 17 μl of the sample in a new 8-strip PCR tube (Starlab, I1402-3700). 
2.2.7.2.7 Quantification:  
The DNA concentration was quantified using the QubitTM 3.0 Fluorometer using 
methods described previously. DNA Library size was checked by electrophoresis using 
the 2200 TapeStation Nucleic Acid System (Agilent, G2965AA), 2200 TapeStation 
Software A.01.05 and D1000 High Sensitivity ScreenTape (Agilent, 5067-5584) and 
the D1000 High sensitivity reagents (Agilent, 5067-5585). Libraries were frozen at -20 




2.2.7.3 RNAseq bioinformatics  
Unaligned RNA-seq data was uploaded into the Partek® Flow® genomics suite 
software package (Partek, St Louis, MI, USA). Pre-alignment quality assurance/quality 
control (QA/QC) was performed to check the total number of reads per sample, read 
length and quality. Trimming was performed to remove any low-quality reads and the 
data aligned to the reference genome (NCBI build 37, hg19). Following alignment, a 
further QA/QC step removed any unaligned reads. 
Gene Specific Analysis (GSA) Modelling was performed using the Partek® flow®. GSA 
identifies the optimum statistical model for a specific transcript and then uses that 
model to test for differential expression. GSA produces P-values, fold change 
estimates and other measures of importance for the factor of interest. A false discovery 
rate (FDR) filter of <0.1 was applied to the data meaning no more than 10% of 
differential gene expression is type 1 error. 
CMS and CRIS classifications were performed using ‘CMScaller’ (v0.99.1) in the R 
/Bioconductor statistics package, (by Dr Andrew Beggs). With CMScaller, prediction 
confidence is estimated from gene resampling (n = 1000) and samples with false 
discovery rate adjusted, P-value > 0.05 were “not assigned” (NA) (170). Fisher's exact 
test was used to compare contingency between primary and CPM or good and poor 
prognosis CPM test in IBM SPSS Statistics for Windows, Version 24.0 (159). A P- 
value of < 0.05 was considered significant.  
2.2.8 DNA sequencing 
Next-generation sequencing is based on the chain/dye-terminator method described 
by Sanger et al in the 1970s (171). Sequencing is based on the selective incorporation 
of fluorescently labelled nucleotides by DNA polymerase in a PCR reaction (Figure 
2.5) (172). 
 
Samples are prepared, fragmented and bound to adaptors, complementary to 
oligonucleotides bound to the flow cell, as well as indices which identify the sample  
(172). When applied to the flow cell, each fragment binds to an oligonucleotide 




of DNA. The dsDNA is denatured and the template washed away (172). Fragments 
are amplified via bridge amplification, the strand bends and the opposite adaptor binds 
to a second complementary adaptor, further PCR reaction creates an identical strand 
of DNA (172). This reaction is performed in parallel for each fragment of DNA resulting 
in clonal amplification of fragments and clusters of identical DNA (172). 
 
During each cycle, a mixture of all four fluorescently tagged nucleotides and 3’-blocked 
dNTPs are added and compete for addition to the DNA primer (172). After the addition 
of each nucleotide, the unbound dNTPs are removed, the clusters are excited by a 
light source, a fluorescent signal is emitted specific to the base type and the surface 
imaged to identify which dNTP was incorporated (172). The fluorophore and blocking 
group are removed and a new cycle can begin (172). Each cluster and DNA fragment 







Figure 2-5 Next generation sequencing 
(a) A library is composed of fragments of double-stranded DNA flanked by adapter 
sequences and indices, correctly ligated libraries are amplified. (b) Cluster 
generation on the surface of the flow cell. (1) Fragments bind complementary 
oligonucleotides. (2) Bridging amplification generates clusters. (3) One strand from 
the double-strand DNA is cleaved and washed away (c) In each sequencing cycle, 
3’-blocked deoxynucleotides (dNTPs) and fluorescently labelled A, T, G and C bases 
are applied. After the addition of each nucleotide, the sequencing reaction is 
stopped, and the image is taken. (d) In paired-end sequencing when the first-strand 
sequencing reaction is finished, the synthesized strand is removed and the process 
is repeated for the opposite strand. This figure is reprinted from Shin et al 2014, 





2.2.8.1 DNA sequencing method 
The 75, 150 or 300-cycle mid or high Output flow cell and reagents (Illumina, FC-404-
2005, FC-404-2002, 20024905) were thawed and allowed to equilibrate to room 
temperature.  
PhiX (Illumina, FC-110-3001) is a concentrated bacteriophage genomic library with an 
average size of 500bp, this acts as a biological control for the sequencing run. DNA 
libraries were normalised to a 0.5 nm concentration and pooled. The DNA library and 
PhiX control were denatured by combining with equal volumes of a 0.2M sodium 
hydroxide (NaOH) solution (SigmaAldrich, 221465-500G) vortexed briefly, centrifuged 
at 280 xg for 1 minute and incubated at room temperature for 5 minutes. An equal 
volume of Tris-HCL was added, (Sigma-Aldrich, 77-86-1) vortexed briefly and 
centrifuged at 280 xg for 1 minute. The denatured library and Illumina PhiX sequencing 
control were then diluted to a 20 pm concentration with the addition of HT1 
hybridisation buffer to a final loading concentration of 1.6 pm in 1.3 ml before addition 
to the Illumina reagent cartridge. 
 
The reagent cartridge buffer cartridge and flow cell were loaded into the NextSeq500. 
Indices were assigned to sample IDs in base space and run parameter assigned 




Epigenetics refers to several bio-molecular mechanisms that modify gene expression 
and the resulting phenotype, without alteration of the DNA sequence or genotype (40). 
In health, DNA methylation allows cells to acquire and maintain a specialised state and 
function, silence the expression of non-host genomic DNA and facilitates the cellular 
response to environmental stimuli (40). 
An example of epigenetics in health is the random inactivation of one X-chromosome 




(40). As males only possess one copy of the X-chromosome, x-linked disorders have 
a classical phenotype, heterozygous females, however, have increased phenotypic 
variation depending on which chromosome is silenced (40). Three mechanisms 
comprise the main drivers of epigenetic modification; 
2.2.9.1 Histone modification  
Histones are alkaline proteins which DNA bases are wound around allowing them to 
be packaged and organised into Chromatin. A variety of post-translational histone 
modifications are possible, resulting in a multiplicity of possible combinations and 
modifications (40). Histone acetylation marks transcriptionally active regions whereas 
hypo-acetylation marks transcriptionally inactive regions (40). In contrast, histone 
methylation can be a marker for both active and inactive regions (40). Other post-
transcriptional modifications include phosphorylation and ubiquitination (40). 
2.2.9.2 Non-coding RNA associated gene silencing 
Non-coding RNA such as anti-sense transcripts, non-coding RNA or the RNA 
interference pathway (RNAi) can lead to enzymatic degradation of mRNA, the 
formation of heterochromatin (tightly packaged, inactive DNA) and mitotically heritable 
transcriptional silencing.  
2.2.9.3 DNA methylation  
Methyl groups (CH3) can be added to cytosine or adenine DNA bases by DNA 
methyltransferases enzymes (DNMTs) to give 5-methylcytosine (5Mc) (Figure 2.6) 
(40). There are three types of DNMT. DNMT1 is the most abundant, it binds to 
hemimethylated DNA at CpG sites, after replication, it methylates cytosine in the new 
strand maintaining the CpG methylation pattern through mitosis (174). DNMT3A and 
DNMT3B are responsible for de-novo methylation and show an affinity for 
hemimethylated and none methylated DNA, they are required for genome-wide 
methylation of DNA occurring after embryo implantation. 
CpG sites are DNA regions where a cytosine nucleotide is followed by a guanine 
nucleotide in a 5’ to 3’ direction. Cytosines in CpG dinucleotide sequences can be 




methylated which results in epigenetic silencing (40).  CpG islands are short regions 
of between 0.5-4 kbp with a GC content greater than 55%. They are located in 
promoter regions of genes, usually un-methylated and conserved during evolution (40).  
CpG island methylation causes stable heritable transcriptional silencing. Aberrant de 
novo methylation of CpG islands is a hallmark of human cancer found early in 
carcinogenesis. DNA methylation allows cells to acquire and maintain a specialised 
state, suppresses the expression of viral and non-host DNA and facilitates the cell 
response to environmental stimuli and ageing. Aberrant DNA methylation (hyper or 
hypo) is implicated in many disease processes including ageing, neurological 








Figure 2-6 DNA methylation 
The addition of methyl groups (CH3) to cytosine DNA bases by DNA methyltransferase 
(DNMT) to give 5-methylcytosine (5Mc). S-adenosylmethionine  (SAM) is a co-
substrate in methyl transfers, S-adenosylhomocysteine (SAH) is formed by the 





2.2.9.4 Methylation analysis 
2.2.9.4.1 Methylation dependent DNA treatment   
5MC is not distinguishable from unmethylated cytosine by hybridisation and as DNMTs 
are not present during PCR this information is erased during amplification. Therefore, 
all sequence-specific DNA methylation analysis relies on a type of methylation-
dependent DNA treatment before amplification or hybridisation. Several treatments 
exist and are discussed below. 
2.2.9.4.2 Endonuclease digestion  
Isoschizomers of bacterial restriction endonucleases with different sensitivities to 5MC 
methylation-sensitive restriction enzymes (MSREs) are used to determine the 
methylation status of cytosine at specific sites (176). One enzyme of isoschizomer pair 
is insensitive to 5MC, the other will not cut DNA if the cleavage site contains 5MC  
(176). 
Endonucleases provide information only about CpGs within the cleavage sites of the 
specific enzymes. In addition, this technique is prone to false-positive results due to 
incomplete endonuclease digestion, they should therefore not be used for the detection 
of low-abundance methylated molecules (176). 
2.2.9.4.3 Affinity enrichment  
Affinity enrichment isolates methylated DNA from the rest by antibody 
immunoprecipitation with methyl CpG binding proteins (176). Antibodies specific for 
5MC are combined with denatured genomic DNA allowing the enrichment of 
methylated regions (176). 
Affinity based methods do not reveal information of individual CpG dinucleotides and 
require significant bioinformatics adjustment for varying CpG density at different 




2.2.9.4.4 Bisulphite conversion  
The treatment of genomic DNA with sodium bisulphite deaminates unmethylated 
cytosine residues to uracil much more rapidly than methylated cytosines (176).  
Preferential deamination of cytosine by bisulfite occurs by sequential sulfonation, 
hydrolytic deamination and alkaline desulfonation reactions (176). The DNA double 
helix is converted into two single strands (176). DNA is fragmented by incubation at 
high temperature, sodium bisulphite deaminates cytosine and incubation at high pH 
removes the sulphite generating uracil (176). 5MC is not susceptible to bisulfite 
conversion and remains intact (Figure 2.7) (176). The bisulphate induced sequence 
differences in DNA template, (conversion of cytosine to thymine, by uracil) form the 
basis for discriminating between methylated and unmethylated DNA (176). Methylation 
of any CpG in the genome can be determined – for total cell population and individual 
DNA molecules (176). 
Bisulphite conversion is prone to several issues. Bisulphite conversion relies on the 
conversion of every unmethylated cytosine to uracil. Incomplete conversion may if 
dsDNA is not completely denatured or if it is not maintained in single-stranded 
conformation during the process due to variations in parameters such as temperature 
or salt concentration (176). In PCR amplification, the primers may not amplify the 

















1) DNA is denatured by incubation at high temperature 2) Incubation with sodium 
bisulphite deaminates cytosine 3) Incubation at high pH removes the sulphite 
generating uracil. 5-methylcytosine is not susceptible to bisulphite conversion and 
remain intact. (This figure was drawn in PowerPoint, Microsoft office) 
 
  




2.2.9.5 Methylation analysis techniques 
A variety of methods exist to analyse methylation. These can be divided into those that 
determine the methylation status of a single CpG locus of a short sequence and those 
that determine methylation at a global or genome-wide level. 
Single CpG loci or short sequence methylation analysis techniques 
2.2.9.5.1 Methylation-specific PCR (MS-PCR) / quantitative MS-PCR 
Bisulphite treatment of DNA converts unmethylated cytosine to uracil whilst 5MC is 
preserved (177). During PCR uracil is amplified as thymidine which 5Mc is unchanged  
(177). Primers for both methylated and unmethylated DNA are designed to determine 
the methylation status of a locus of interest and gel electrophoresis is used to 
discriminate between the two (177). Methylated specific PCR is qualitative and can be 
used as an initial screen for methylation of specific genes but requires subsequent 
validation using a quantitative method (177).  
Quantitative MS-PCR is possible with technology such as MethyLight. Bisulphite 
converted DNA is amplified using PCR with 3x oligonucleotides, a dual labelled 
fluorescent probe flanked by a forward and reverse primer (177). After annealing to the 
PCR product, the probe is cleaved by a Taq DNA polymerase triggering a fluorescent 
signal (177). Fluorescence is measured in each cycle and is proportional to the PCR 
product generated (177).  
2.2.9.5.2 Methylation-sensitive single-nucleotide primer extension (Ms-SnuPE) 
Methylation-sensitive single-nucleotide primer extension (Ms-SnuPE) uses sodium 
bisulphite treated DNA amplified with PCR to give a template of the target sequence 
(177). An oligonucleotide primer anneals to a PCR generated template immediately 5’ 
to the nucleotide of interest (177). The primer is then extended in the presence of DNA 
polymerase and a labelled deoxyribonuclease (177). The relative amount of 
incorporated label is proportional to the relative amount of that base at that site in the 
DNA template (177). Ms-SnuPE is quantitative and allows the analysis of small 





2.2.9.5.3 Bisulphite pyrosequencing  
Bisulphite pyrosequencing quantifies methylation in bisulphite treated DNA via the 
detection and quantification of pyrophosphate released from incorporated nucleotides 
by DNA polymerase during amplification. Pyrophosphate undergoes an enzymatic 
process and emits a light signal which is recorded by a camera. This method does not 
rely on primer sequencing for specificity and can quantify multiple CpG sites in a single 
run. It is however limited to a sequence length of 100-150bp. 
 
2.2.9.5.4 Combined bisulphite restriction analysis (COBRA)  
Bisulphite treated DNA is amplified using PCR primers which do not discriminate 
between methylated and unmethylated sites (177). PCR products are a mixed 
population which have retained or lost their CpG restriction enzyme sites (177). 
Products are treated with a restriction enzyme which cleaves sites which were 
originally methylated (177). Digested fragments are separated by electrophoresis, 
large bands correspond to undigested fragments and small bands to digested 
methylated fragments (177). The bands can be imaged quantifying the methylation 
percentage of the sample. COBRA is quantitative and allows the analysis of small 
amounts of DNA (177). 
 
2.2.9.5.5 High resolution melting analysis  
Bisulphite treated DNA is amplified using PCR. Precise warming of the PCR product 
results in melting of the DNA strands (177). This is monitored in real-time using a 
fluorescent dye which fluoresces when bound to double-stranded DNA and at a low 
level when the DNA denatures (177). This is captured by a camera and plotted in a 
melting curve showing the fluorescence vs. the temperature (177). Methylation-specific 
denaturing high-performance liquid chromatography (MS-DHPLC) is an in-tube high 
resolution melting analysis assay (177).  Methylation-specific denaturing gradient gel 
electrophoresis (MS-DGGE) separates differentially methylated melted molecules in 





2.2.9.5.6 Methylation-specific microarray  
Bisulphite treated DNA is amplified using non-discriminatory PCR with fluorescently 
labelled primers and hybridised to a glass slide with oligonucleotides which 
discriminate between methylated and unmethylated cytosines (177). This method 
allows the analysis of multiple genes on one array, however closely spaced CpGs may 
not be accurately analysed if the gene is heterogeneously methylated (177). 
Genome-wide methylation analysis techniques 
High throughput methods make it possible to simultaneously analyse the status of 
thousands of CpG islands across the genome. Some of the technologies in use 
currently are discussed below. 
2.2.9.5.7 Affinity enrichment Chromatin immunoprecipitation  
This technique uses an antibody or protein with an affinity for 5MC to isolate methylated 
DNA (176). The enriched and input DNA are labelled with fluorescent dyes and 
hybridised to a microarray with probes specific for CpG islands or promotor regions  
(176). Bioinformatics analysis is performed to reveal methylation using the relative 
signal intensities of the enriched and input DNA (176). Affinity based methods allow 
genome-wide assessment of DNA methylation but are not able to yield information on 
individual CpG dinucleotides (176). 
2.2.9.5.8 Beadchip Microarray  
This technique from Illumina analyses methylation sites quantitatively across the 
genome at single-nucleotide resolution allowing genome-wide profiling of human DNA 
methylation (176). Following bisulfite conversion DNA is fragmented and hybridised to 
methylation-specific oligomers linked to individual bead types (176). Each bead 
corresponds to a specific DNA CpG site and methylation state (176). The current assay 
interrogates 850,000 methylation sites (176). The Illumina BeadChip microarray has 
relatively low DNA input requirements, is adapted to allow the use of degraded FFPE 








The U bead type matches the unmethylated CpG site; the M bead type matches the 
methylated site. In the top figure, the unmethylated CpG target site matches with the 
U probe, enabling single-base extension and detection. It has a single-base mismatch 
to the M probe, which inhibits extension. If the CpG locus of interest is methylated 
(bottom figure), the reverse occurs. This figure is reprinted from the Infinium 
methylation assay product literature, 2019 (178). 
 
 




2.2.9.6 Next-generation sequencing 
Sequence-based analysis allows allele-specific methylation analysis, does not require 
a designed microarray and can cover a larger proportion of the genome with less DNA 
input. Bisulphite treated DNA is fragmented, ligated to adaptors and sequenced using 
next-generation sequencing allowing visualisation of differentially methylated sites at 
single-nucleotide resolution. Next-generation sequencing is relatively expensive and 
complex in terms of bioinformatics analysis. 
Methylation analysis methods used in this thesis were selected to allow genome-wide 
differential methylation analysis, at an affordable cost per sample, using techniques 
which have been successfully performed within our laboratory. As the Illumina Infinium 
EPIC array is essentially an SNP array this method of methylation analysis allow the 
analysis of CNA within the genomic regions targeted by the methylation probes with 
similar sensitivity to SNP platforms (71%) (179).  
2.2.9.7 Methylation analysis Infinium MethylationEPIC array, methods 
Following the addition of each reagent, samples were mixed by pipette or vortex and 
pulse centrifuged. Following each thermal cycler step samples were pulse 
centrifuged. 
2.2.9.7.1 Bisulphite treatment of FFPE DNA 
Bisulphite conversion was performed using the Zymo EZ-DNA methylation kit (D5004). 
CT conversion reagent is prepared by mixing with 7.5 ml of NFW and 1.85 ml of dilution 
buffer. In a midi plate (Abgene, AB0859) 350 ng of normalised DNA in 42.5 μl of NFW 
(Omega BIO-TEK PD092) was mixed with 1 μl of dilution buffer. The plate was then 
incubated at 42 °C for 30 minutes on a thermal cycler (Bio-Rad, 184-1100). CT 
conversion reagent (97.5 μl) was mixed with each sample and the plate incubated, in 
the dark, on the thermal cycler (Bio-Rad, 184-1100) for 16 cycles of (95 °C for 30 
seconds, then 50 °C for 60 minutes).  
 
Binding buffer (400 μl) was combined with samples in a Zymo-SpinTm I-96 plate. A 
wash was performed with wash buffer, centrifuged at > 3,000 xg for 5 minutes and the 




room temperature for 20 minutes, centrifuged at >3,000xg for 5 minutes and the flow-
through discarded. Two further washes were performed with 500 μl of wash buffer and 
centrifuged at >3,000 xg for 5 minutes then 10 minutes. DNA was eluted in a final 
volume of 8 μl of EB. 
2.2.9.7.2 FFPE DNA restoration 
Bisulphite converted, degraded FFPE was restored using the Infinium HD FFPE 
restore kit (Illumina, WQ-901-2004). Bisulphite treated DNA was added to a midi plate 
and denatured with 0.1N (4 μl) sodium hydroxide. Primer restore reagent (34 μl) and 
amplification mix restore reagent (38 μl) were added, sealed, mixed by inversion and 
incubated at 37 °C for one hour. 
 
DNA was cleaned using the ZR-96 DNA clean and concentrator-5 kit (Zymo, D4023). 
Samples were mixed with binding buffer (560 μl), added to a Zymo-spin column, 
centrifuged at 2250 xg for 2 minutes and the flow-through discarded. A wash step was 
performed using Zymo-wash buffer, (600 μl) centrifuged at 2250 xg for 2 minutes and 
the flow though discarded. DNA was eluted in a final volume of 10 μl of EB. 
 
DNA was incubated at 95 °C for 2 minutes and placed on ice. Convert master mix 
reagent (10 μl) was added, then incubated at 37 °C for 1 hour. DNA was cleaned again 
using the ZR-96 DNA clean and concentrator-5 kit, (Zymo, D4023) as described 
previously. DNA was eluted in 10 μl of deionised water. Eluted DNA was used as input 
for the Infinium MethylationEPIC BeadChip Kit (Illumina, WG-317-1002). 
 
2.2.9.7.3 Amplify bisulphite converted DNA 
DNA (8 μl) was added to a midi plate, (Abgene, AB0859) with multi-sample 
amplification mix 1 (20 μl) and 4 μl of 0.1N sodium hydroxide to denature and neutralise 
the samples. The plate was sealed with a cap mat (Thermo Fisher, 276000) and 
incubated at room temperature for 10 minutes. Random primer mix (68 μl) and multi-
sample amplification master mix (75 μl) were mixed, the plate sealed and incubated in 




2.2.9.7.4 Fragment DNA 
Fragmentation solution (50 μl) was mixed with each sample containing well of the midi 
plate (Abgene, AB0859) sealed with a cap mat and incubated for 1 hour at 37 °C. 
2.2.9.7.5 Precipitate DNA 
Precipitation solution (100 μl) was mixed with each sample, sealed with a cap mat and 
incubated at 37 °C for 5 minutes. Isopropanol 100% (v/v) (300 μl) (Thermo Fisher, 
10674732) was added to each sample, sealed and inverted 10x to mix. The plate as 
then incubated at 4 °C for 30 minutes and centrifuged at 3000 xg, 4 °C for 20 minutes. 
The plate was inverted on to an absorbent pad, smacked down and tapped firmly for 1 
minute until all wells were dry. The plate was left for 1 hour to air dry the DNA pellet. 
2.2.9.7.6 Re-suspend DNA 
RSB (46 μl) was added to each sample. A foil seal was applied and firmly sealed using 
a heat sealer (Thermo Fisher, 11590314) The plate was then incubated in the Illumina 
Hybridisation oven for 1 hour at 48 °C. 
2.2.9.7.8 Hybridize to bead chip 
Samples were placed on a heat block at 95 °C for 20 minutes to denature and allowed 
to cool to room temperature. The hybridisation chambers were assembled (Illumina, 
BD-60-402, WG-15-301). Humidifying buffer (400 μl) was added to the reservoirs. 
Each BeadChip was placed into its Hybridisation chamber insert. The DNA samples 
were loaded onto the BeadChip (26 μl) and the BeadChips placed into the hybridisation 
chamber. The chamber was transferred into the Hybridisation oven at 48 °C for 16 
hours. 
2.2.9.7.9 Wash bead chip 
The hybridisation chamber was removed from the oven and cooled to room 
temperature for 30 minutes. Wash dishes (Illumina, BD-60-460) were filled with a 
reagent used to prepare BeadChips for hybridization (PB1) (200 ml). The BeadChips 
were removed from their inserts, the covers removed then placed into wash racks 




for 1 minute. This was repeated once in fresh PB1. Flow-through chambers were 
assembled (Illumina, WG-10-201). 
2.2.9.7.10 Extend and stain bead chip 
The chamber rack (TECAN, 3002329) was warmed to 44 °C and each flow-through 
chamber assembly placed into the chamber rack. Into the reservoir of each flow-
through chamber, the following reagents were dispensed:  
 
• Wash solution (150 μl) incubated for 30 seconds and repeated 5x. 
• XStain BeadChip solution 1 (450 μl) incubated for 10 minutes. 
• XStain BeadChip solution 2 (450 μl) incubated for 10 minutes.  
• Two-Color Extension Master Mix (200 μl) incubated for 15 minutes.  
• 95% (v/v)  formamide 1 mM EDTA incubated for 1 minute and repeated once.  
• Incubate for 5 minutes then ramp the chamber rack temperature to 39.2 °C. 
• XStain BeadChip solution 3 (450 μl) incubate for 1 minute and repeated once. 
 
Into each reservoir of the flow-through chamber, the following were dispensed:  
 
• Superior Two-Color Master Mix (250 μl), incubated for 10 minutes, XStain 
BeadChip solution 3, incubated for 1-minute repeated once, wait for 5 minutes.  
• Anti-Stain Two-Colour Master Mix (250 μl) and incubate for 10 minutes, XStain 
BeadChip solution 3, incubate for 1 minute and repeat once, wait for 5 minutes.  
• Superior Two-Colour Master Mix (250 μl) and incubate for 10 minutes, XStain 
BeadChip solution 3, incubate for 1 minute and repeat once, wait for 5 minutes.  
• Anti-Stain Two-Colour Master Mix (250 μl) and incubate for 10 minutes, XStain 
BeadChip solution 3, incubate for 1 minute and repeat once, wait for 5 minutes.  
• Superior Two-Colour Master Mix (250 μl) and incubate for 10 minutes, XStain 
BeadChip solution 3, incubate for 1 minute and repeat once, wait for 5 minutes.  
 
The flow-through chambers were removed from the chamber rack. A wash was 
repeated with 310 ml of PB1 in a wash rack for 5 minutes. A final wash dish was 




submerged 10x in the dish and allowed to soak for 5 minutes. BeadChips were 
removed from the rack and dried in a vacuum desiccator for 50-55 minutes at 675 mm 
Hg (SICCO, V 1821-07). 
2.2.9.7.11 Image bead chip 
Bead chips were imaged using the iScan system (Illumina, SY-101-1001). Data was 
exported as raw image files and proprietary iDAT files.  
2.2.9.8 Methylation bioinformatics 
Raw data in the form of IDAT files were loaded into the RStudio version 3.5.0 software 
using the minifi package and Bioinformatics analysis performed using the Chip 
Analysis Methylation Pipeline (ChAMP) R package, version 2.10.2 (180, 181). In brief, 
red/green intensity levels were captured from the Illumina IDAT files, background 
corrected and SWAN-normalised to produce beta-values. The beta-value is an 
estimate of methylation level using the raw intensities between methylated and 
unmethylated alleles. Beta-values are between 0-1, where 0 is unmethylated and 1 is 
fully methylated. Raw methylation data were filtered to exclude: inconsistent probes 
which fail to detect a signal with high confidence, (a detection value > 0.01), failed 
probes with <3 beads, non-CpG probes, SNP related probes that would give genetic 
rather than epigenetic observations (182), multi-hit probes and probes on chromosome 
X and Y chromosome to exclude gender bias. To check the dataset was suitable for 
analysis a quality check was performed. A shift in the distribution of methylation beta-
values results from the different chemistry of array probes across the Infinium assays. 
This requires a correction strategy of normalisation using the BMIQ strategy (183, 184). 
To identify unwanted types of variation not of biological origins, such as batch effects 
a singular value decomposition (SVD) was performed (185). Batch effects may arise 
due to an experiment being performed on different days. As batch effects were not 
identified, a normalisation method to correct for this was not required.  
 
Differential methylation was analysed via identification of differentially methylated 
probes (DMPs). DMP implements the limma package to calculate the P-value for 
differential methylation between groups using a linear regression model (186). DMPs 




extracted. The methylation fold change was obtained by calculating the difference 
between the mean beta-value for each probe. The threshold for statistical significance 
was set at a Bayes factor (BF) of 4. 
Differentially methylated regions (DMRs) are extended segments of the genome which 
show a qualitative alteration in DNA methylation levels between two groups. DMR 
analysis was performed using the Bumphunter algorithm (187). Bumphunter groups all 
probes into small clusters then applies random permutation methods to estimate 
candidate DMRs. Bumphunter output includes all detected DMRs, their length, clusters 
and the number of CpGs annotated. The threshold for statistical significance was set 
at a P-value of <0.05. Copy number alteration calling was performed using the CHAMP 
CNA function, a P-value of < x10-10 was considered to be significant (179). The R code 
used to complete the methylation bioinformatics is displayed in appendices, table S1. 
 
2.2.10 Exome sequencing 
A more comprehensive analysis of the genome is required to identify the somatic 
mutations associated with the development of CPM and conferring a poor prognosis. 
Whole-genome sequencing, (WGS) determines the complete DNA sequence of the 
cells within a sample. WGS was first performed in humans in 2007, it was initially 
prohibitively expensive. The cost of WGS reduced substantially in the following 
decade. The price per sample, however, still sits at between £1500-2000. This in 
addition to associated start-up costs for sequencers capable of providing the depth and 
breadth of coverage required. An alternative is to sequence a targeted area of the 
genome. The exome comprises the protein-coding portion of the genome. Although 
exons comprise just 1% of the genome they are thought to harbour up to 85% of 
mutations associated with disease (188). In WES DNA is fragmented before library 
preparation, this results in a reduced uniformity of coverage compared to WGS. WES, 
therefore, requires a higher depth to give adequate coverage, (100X vs. 30X). The 
probes used for target enrichment vary in length, sequence and overlap, this can lead 
to variability in target specificity between WES kits (the Illumina TruSeq exome kits are 
designed to give ≥80% on target reads). As reads are focussed on a small subset of 




smaller data output which is faster and easier to analyse than WGS. It is difficult to 
perform WGS on FFPE samples due to sample degradation and reduced DNA yields, 
WES, however, is feasible due to an in-house protocol developed in our laboratory. 
To allow exome sequencing the DNA is fragmented and the exon sequences captured 
using a variety of methods. Solid-phase hybridisation use probes complementary to 
the exon sequences fixed to a microarray. DNA is applied to the microarray and the 
exons hybridise to the probes, non-targeted fragments are washed away and enriched 
DNA eluted for sequencing. Liquid-phase hybridisation uses liquid phase biotinylated 
probes bound to magnetic streptavidin beads. The exons hybridise to the probes and 
the non-targeted fragments are washed away on a magnetic plate, enriched DNA is 








Blue bars represent the desired exon sequence, red the unwanted intron sequence. 
A) Solid-phase hybridisation. Exons bind to complementary probes on the microarray 
surface, the array is washed and DNA eluted. B) Liquid phase capture. Biotinylated 
probes are mixed with fragmented DNA, the exons hybridise to the probes in solution. 
The bead-DNA complex is washed and the desired DNA eluted. This figure is reprinted 
from Teer et al, 2010, figure 1 (189). 
  




2.2.10.1 Exome sequencing, method 
Following the addition of each reagent, samples were pipette mixed and pulse 
centrifuged. Following each thermal cycler step samples were pulse centrifuged. 
2.2.10.1.1 Fragment DNA 
In an 8-strip PCR tube (Starlab, I1402-3700) 300ng of normalised DNA in 49 μL of 
RSB was added to 1 μl of 50 mM EDTA. Samples were transferred to microTUBEs 
(Covaris, 520174) and fragmented to 150 bp using the E220 evolution focused-
ultrasonicator (Covaris, 500429) with the following settings: Duty factor 10%, peak 
power 175, cycles/burst 200, duration 150 seconds, temperature 7 °C, water level 5. 
Fragment length was checked by electrophoresis using the 2200 TapeStation Nucleic 
Acid System (Agilent, G2965AA), Agilent 2200 TapeStation Software A.01.05 and 
D1000 High Sensitivity ScreenTape (Agilent, 5067-5584) and the D1000 High 
sensitivity reagents (Agilent, 5067-5585). 
2.2.10.1.2 Clean-up fragmented DNA 
In a midi plate (Abgene, AB0859) DNA samples (50 μl) were mixed with sample 
purification beads (SPB) (100 μl), incubated at room temperature for 5 minutes, then 
placed on a magnetic stand (Thermo Fisher, AM10027) until the liquid cleared. Two 
80% (v/v) ethanol washes were performed (200 μl) of 80% (v/v) ethanol on a magnetic 
stand (Thermo Fisher, AM10027). DNA was then re-suspended in RSB (62.5 μl) 
incubated at room temperature for 2 minutes, placed on a magnetic stand (Thermo 
Fisher, AM10027) until the liquid cleared, then 60 μl of sample transferred to a new 8-
strip PCR tube (Starlab, I1402-3700). 
 
2.2.10.1.3 Repair ends and select library size 
End repair mix (40 μl) was mixed with each sample then placed on the thermal cycler, 
(Bio-Rad, 184-1100) for 30 minutes at 30 °C. A clean-up step was repeated as before 
with 250 μl of SPB, 2x 80% (v/v) ethanol washes and resuspension in 20 μl of RSB 




2.2.10.1.4 Adenylate 3’ Ends 
A-Tailing mix (12.5 μl) was added to each sample and incubated on a thermal cycler, 
thermal cycler, (Bio-Rad, 184-1100) at 37 °C for 30 minutes, 70 °C for 5 minutes and 
held at 4 °C. 
2.2.10.1.5 Ligate adaptors 
The following reagents (2.5 μl) were added to each tube, RSB, ligation mix, DNA index 
adaptors, incubated on the thermal cycler, (Bio-Rad, 184-1100) at 30 °C for 10 minutes 
then held at 4 °C. The reaction was stopped by the addition of stop ligation buffer (5 
μl). 
2.2.10.1.6 Clean up Ligated fragments 
A clean-up step was repeated as before with 42.5 μl of SPB, 2x 80% (v/v) ethanol 
washes and resuspension in 52.5 μl of RSB resulting in a final volume of 50 μl of the 
sample in a new 8-strip PCR tube (Starlab, I1402-3700). 
2.2.10.1.7 Enrich DNA fragments 
PCR primer cocktail (5 μl) and enhanced PCR mix (20 μl) was added to each sample. 
Samples were placed on the thermal cycler (Bio-Rad, 184-1100) for 95 °C for 3 
minutes, 12x cycles of 98 °C for 20 seconds, 60 °C for 15 seconds, 72 °C for 5 minutes 
and held at 4 °C. 
2.2.10.1.8 Clean up amplified DNA 
SPB (40 μl) was mixed with each sample, transferred to a midi plate, (Abgene, 
AB0859) incubated for 5 minutes at room temperature, placed onto a magnetic stand 
until the liquid cleared and 82 μl of supernatant transferred to a new midi plate, 
(Abgene, AB0859).  
A clean-up step was repeated as before with 82 μl of SPB, 2x ethanol washes and 
resuspension in 17.5 μl of RSB resulting in a final volume of 15 μl of the sample in a 




2.2.10.1.9 Validate and quantify libraries 
The DNA concentration was quantified using the QubitTM 3.0 Fluorometer using 
methods described previously. DNA Library size was checked by electrophoresis using 
the Agilent 2200 TapeStation Nucleic Acid System (Agilent, G2965AA), Agilent 2200 
TapeStation Software A.01.05 and D1000 High Sensitivity ScreenTape (Agilent, 5067-
5584) and the D1000 High sensitivity reagents (Agilent, 5067-5585). 
2.2.10.1.10 Hybridise probes 
Libraries were pooled in groups of three using 500ng of each library and a final volume 
of 40 μl of RSB. To each library pool capture target buffer, (50 μl) and coding exome 
oligo’s (10 μl) were mixed and placed on the thermal cycler (Bio-Rad, 184-1100) for 95 
°C for 10 minutes, 10x cycles of 1 minute at 94 °C, decreasing by 2 °C per cycle and 
held at 58 °C for at least 90 minutes. 
2.2.10.1.11 Capture hybridised Probes 
Streptavidin magnetic beads, SMB (250 μl) were mixed with the sample in a 1.5ml 
DNALoBind tube, incubated for 25 minutes, placed onto a magnetic stand until the 
liquid cleared and the supernatant discarded. Streptavidin wash solution (200 μl) was 
mixed with each sample, placed on a heat block at 50 °C for 30 minutes then onto the 
magnetic stand until the liquid clears and the supernatant discarded. This wash was 
repeated as above once.  
Elution pre-mix (23 μl) was mixed with the SMB to re-suspend the sample, incubated 
at room temperature for 2 minutes and placed on a magnetic stand until the liquid 
cleared. The supernatant (21 μl) was transferred to a new 8-strip PCR tube (Starlab, 
I1402-3700). 
2.2.10.1.12 Perform second hybridisation 
To each library pool capture target buffer (50 μl) and coding exome oligo’s (10 μl) were 
mixed, and placed on the thermal cycler, (Bio-Rad, 184-1100) for 95 °C for 10 minutes, 
10x cycles of 1 minute at 94 °C, decreasing by 2 °C per cycle and held at 58 °C for at 




2.2.10.1.13 Perform the second capture 
An identical ‘Capture hybridised probes’ step was performed as before. The resulting 
supernatant (21 μl) was transferred to a new 8-strip PCR tube (Starlab, I1402-3700). 
2.2.10.1.14 Clean up captured library 
A clean-up step was repeated as before with 45 μl of SPB, 2x ethanol washes and 
resuspension in 27.5 μl of RSB resulting in a final volume of 25 μl of the sample in a 
new 8-strip PCR tube (Starlab, I1402-3700). 
2.2.10.1.15 Amplify enriched library 
PCR primer cocktail (5 μl) and enrichment amplification mix (20 μl) were mixed with 
each sample and placed on the thermal cycler (Bio-Rad, 184-1100) at 98 °C for 30 
seconds, 10x cycles of 98 °C for 10 seconds, 60 °C for 30 seconds, 72 °C for 5 minutes 
and held at 4 °C. 
2.2.10.1.16 Clean up the amplified enriched library 
A clean-up step was repeated as before with 45 μl of SPB, 2x ethanol washes and 
resuspension in 22 μl of RSB resulting in a final volume of 20 μl of the sample in a new 
8-strip PCR tube (Starlab, I1402-3700). 
2.2.10.1.17 Validate enriched library 
The DNA concentration was quantified using the QubitTM 3.0 Fluorometer using 
methods described previously. DNA Library size was checked by electrophoresis using 
the Agilent 2200 TapeStation Nucleic Acid System (G2965AA), Agilent 2200 
TapeStation Software A.01.05 and D1000 High Sensitivity ScreenTape (Agilent t, 
5067-5584) and the D1000 High sensitivity reagents (Agilent, 5067-5585). Libraries 
were frozen at -20 °C until sequenced before sequencing on the Next seq 500 with a 
150-cycle high Output flow cell (in batches of 12 samples). 
2.2.10.2 Exome sequencing bioinformatics 
Sequencing reads were assessed using FastQC. The Phred quality scores are 




Phred score of <30 were removed giving a base call accuracy of 99.9%. In accordance 
with Illumina sequencing coverage recommendations, 12 samples were multiplexed 
on a high output flow cell to give 50X coverage and a minimum of 33.3 million reads. 
Sequence reads were aligned to the human reference genome, (NCBI build 37 (hg19)) 
using the Burrows-Wheeler Aligner (BWA) package (190). SAMTools was used to 
generate chromosomal coordinate-sorted BAM files and Picard was used to remove 
sequence duplicates which suggest PCR duplication (191). Somatic variants were 
called from matched tumour-normal samples using Strelka2 in tumour/normal mode 
(192). Dr Andrew Beggs performed the initial QC, alignment and somatic variant calling 
discussed above. The subsequent mutation filtering, annotation and analysis were 
performed by me. 
 
Somatic variants were viewed, filtered and annotated in Genomics Workbench (193). 
Variants which are present with greater than 1% of the population are unlikely to result 
in disease. Therefore mutations with a MAF of >1% in known variant databases, 
(dbSNP and 100,000 genomes) were filtered. Variants were compared to known 
variant databases, (dbSNP and 100,000 genomes) to annotate experimental variants 
with information from known variants and to identify novel rare variants. Significant 
somatic mutations are likely to be clonally selected for and conserved during evolution. 
Therefore, to add information to novel variants the conservation score was added, 
(PhastCons). The PhastCons ranges from 0-1 with a score of 1 indicating the mutation 
is highly conserved. Mutations were further annotated to include genomic information, 
exon number and functional consequences such as amino acid change. The 
prognostic CPM groups were compared in genomics workbench using Fischer exact 
test, (applied to the number of occurrences of each allele of the variant in the case and 
control cohorts) to identify potential candidate driver mutations for poor prognosis 
CPM.  
 
Somatic mutations for each tumour cohort, (primary minus normal, CPM minus normal 
and CPM minus primary) were entered into the IntOGen platform for further analysis 
(194). The IntOGen-mutation platform incorporates several pipelines to determine the 




The OncodriveFM pipeline receives as input the list of synonymous, nonsynonymous 
and frameshift-indel mutations. It adds to this three scores which describe the 
functional impact of mutations on amino acid structure and function, (Sorting Intolerant 
From Tolerant, (SIFT) (195), PolyPhen2 (196) and Mutation Assessor scores) (194, 
197). OncodriveFM then assesses whether any gene shows a trend towards the 
accumulation of mutations with a high functional impact, as compared to the 
background distribution of these functional impact scores in all mutations detected 
across the cohort of tumour samples (194). The resulting P-values are combined using 
Fisher’s approach to produce an integrated P-value, (to allow for possible non-
dependence of the 3 values an FDR of <0.05 is applied) and a Q-value, (multiple 
testing corrected P-value) (194). These scores are transformed using transFIC to 
compensate for the tolerance of different proteins to functional variants, to assess the 
likelihood that a specific somatic mutation is a cancer driver (194). The 
OncodriveCLUST pipeline receives nonsynonymous and silent mutations as input. It 
then assesses the clustering of protein affecting mutations to identify relevant activated 
pathways (194). 
 
Tumour mutational burden was calculated by dividing the number of non-synonymous 
mutations by the exome panel size (45 Mb). 
 
Microsatellite instability was determined using the Microsatellite instability classifier in 
R studio (by Dr Andrew Beggs) (198, 199). 
2.2.11 DNA panel sequencing 
Target enrichment allows the targeting of specific DNA regions of interest, for example, 
a panel of selected genes. This allows increased sequencing depth whilst minimising 
cost. The Qiagen QIAseqTM panel integrates unique molecular indices or barcodes 
(UMIs) which are integrated into a single gene-specific, primer based targeted 
enrichment process. Each unique DNA molecule is barcoded before amplification, 
sequence reads with different barcodes represent original molecules whilst sequences 
with the same barcode are results of PCR duplication. The kit contains 1197 primers 





Table 2-1 Genes targeted by the QIAseqTM targeted panel CDHS-14542Z-1197 
ACVR2A APC ARID1A ATM B2M BCL9L BMPR2 BRAF 
FBXW7 GNAS KRAS MLH1 MSH2 MSH6 NRAS PIK3CA 
PTEN RNF43 RPL22 SMAD2 SMAD4 SOX9 TCF7L2 TGIF1 









Schematic representation of the QIAseqTM targeted DNA panel workflow. The DNA 
sample undergoes enzymatic fragmentation, adaptors are ligatied including unique 
molecular indices and sample indices, target enrichment is performed with primer 
extension, sample indexing and amplification prior to sequencing. Figure reprinted 
from the Qiagen targeted DNA panel handbook, Figure 2 (200).  
  




2.2.11.1 DNA panel sequencing method  
Following the addition of each reagent, samples were pipette mixed and pulse 
centrifuged. Following each thermal cycler step samples were pulse centrifuged. Text 
in italics indicates the modifications made for the sequencing of ctDNA. 
2.2.11.1.1 Enzymatic fragmentation  
In an 8-strip PCR tube (Starlab, I1402-3700) 40 ng of normalised DNA in 16.75 μL of 
NFW was added to 2.5 μl of fragmentation buffer, 0.75 μl FERA solution and 1.25 μl of 
FG solution. On ice 5 μl of Fragmentation enzyme was added and the reaction 
incubated on a thermal cycler, (Bio-Rad, 184-1100) for 32 °C for 24 minutes, 72 °C for 
30 minutes and held at 4 °C. 
2.2.11.1.2 Adaptor ligation 
Ligation buffer (10 μl), an IL-N7 index (2.8 μl, 0.5 μl) DNA ligase 5 μl, ligation solution 
7.2 μl and 2.3 μl of NFW was added to the reaction and incubated at 20 °C on a 
thermal cycler for 15 minutes, (Bio-Rad, 184-1100). 
2.2.11.1.3 Clean-up of adaptor-ligated DNA 
NFW was added to bring the sample to a volume of 100 μl, (80 μl) and transferred to 
a midi plate (Abgene, AB0859). The samples were incubated with 100 μl, (112 μl) of 
QIAseq magnetic beads for 5 minutes, placed onto a magnetic stand until the liquid 
cleared and the supernatant discarded. The bead pellet was washed with 2x 200 μl 
80% (v/v) ethanol washes and resuspended in 52 μl of NFW, 50 μl was transferred to 
a new midi plate  
A clean-up step was repeated as before with 50 μl, (70 μl) of QIAseq beads, 2x 200 μl 
80% (v/v) ethanol washes and resuspension in 12 μl of NFW resulting in a final volume 
of 9.4 μl of the sample in a new 8-strip PCR tube (Starlab, I1402-3700). 
2.2.11.1.5 Target enrichment 
TEPCR buffer (4 μl), the QIAseq DNA panel (5 μl), Illumina forward primer (0.8 μl) and 




thermal cycler  (Bio-Rad, 184-1100) at 95 °C for 13 minutes, 98 °C for 2 minutes, 8x 
cycles of 98 °C for 15 seconds, 68 °C for 10 minutes, 72 °C for 5 minutes and held at 
4 °C. 
2.2.11.1.6 Clean-up of target enrichment 
NFW was added to result in a volume of 100 μl, (90 μl) and transferred to a midi plate, 
(Abgene, AB0859). The samples were mixed with 100 μl, (108 μl) of QIAseq magnetic 
beads and incubated for 5 minutes at room temperature, placed onto a magnetic stand 
until the liquid cleared and the supernatant discarded. The bead pellet was washed 
with 2x 200 μl 80% (v/v) ethanol washes and re-suspended in 16 μl of NFW, 13.4 μl 
was transferred to a new 8-strip PCR tube (Starlab, I1402-3700). 
2.2.11.1.7 Universal PCR 
UPCR buffer (4 μl), HotStarTaq DNA polymerase (1 μl) and NFW (1.6 μl) were added 
to the sample and mixed with a dry unique index, IL-S502-S511. The reaction was 
incubated on a thermal cycler (Bio-Rad, 184-1100) with the following settings. (95 °C 
for 13 minutes, 98 °C for 2 minutes, 8x cycles of 98 °C for 15 seconds, 68 °C for 10 
minutes, 72 °C for 5 minutes and held at 4 °C). 
2.2.11.1.8 Clean-up of universal PCR 
NFW was added to result in a volume of 100 μl, (90 μl) and transferred to a midi plate, 
(Abgene, AB0859). The samples were mixed with 100 μl, (108 μl) of QIAseq magnetic 
beads and incubated for 5 minutes at room temperature, placed onto a magnetic stand 
until the liquid cleared and the supernatant discarded. The bead pellet was washed 
with 2x 200 μl 80% (v/v) ethanol washes and re-suspended in 30 μl of NFW, 28 μl was 
transferred to a new 8-strip PCR tube (Starlab, I1402-3700). 
2.2.11.1.9 Validate enriched library 
The DNA concentration was quantified using the QubitTM 3.0 Fluorometer using 
methods described previously. DNA Library size was checked by electrophoresis using 
the 2200 TapeStation Nucleic Acid System (Agilent, G2965AA), Agilent 2200 




5584) and the D1000 High sensitivity reagents (Agilent, 5067-5585). Libraries were 
frozen at -20 °C until sequenced on the Nextseq 500 with a 300-cycle mid Output flow 
cell. 
2.2.12 Biosigner classifier development 
For both the retrospective and prospective patient cohorts unaligned RNA-seq data 
was uploaded into the Partek® Flow® genomics suite software package (Partek, St 
Louis, MI, USA). Pre-alignment quality assurance/quality control (QA/QC) was 
performed to check the total number of reads per sample, read length and quality. 
Trimming was performed to remove any low-quality reads and the data aligned to the 
reference genome hg19. Following alignment, a further QA/QC step removed any 
unaligned reads. Gene counts for both the retrospective and prospective cohorts were 
downloaded and labelled with Entrez numerical gene IDs. Normalised methylation beta 
values for both the retrospective and prospective cohorts were downloaded. 
Gene counts or beta values were loaded into RStudio version 3.5.0 software and 
Bioinformatics analysis performed using the Biosigner R package, version 2.10.2 (63). 
The Biosigner package generates test subsets of variables by random bootstrapping. 
As the dataset has a small number of samples the recommended number of bootstraps 
of 50 was doubled to 100 to increase the stability of the resulting classifier. Biosigner 
selects variables, which significantly contribute to the prediction performance of a 
binary classifier, in this case, prognosis. The procedure is repeated by applying the 
algorithm to the dataset restricted to the significant variables until for a given round all 
candidate variables are found significant if there is no variable left to be tested. The 
Biosigner algorithm returns stable signature (S), in addition to several tiers form A – E 
corresponding to variables discarded during previous iterations. Signatures from three 
distinct classifiers are run in parallel (PLS-DA, RF and SVM) as the performance of 
each classifier varies depending upon the dataset structure. The Biosigner classifier R 





2.2.13 Circulating tumour DNA sequencing techniques 
ctDNA analysis can focus on several targets, simple quantification of DNA levels, 
analysis of single or panels of mutations, methylation and clonality. A variety of 
methods are available for the analysis of ctDNA. Digital PCR methods detect ctDNA 
mutations by partitioning DNA fragments in an emulsion (201). BEAMing is a digital 
PCR method which utilises beads, emulsion, amplification, and magnetics (201). Water 
droplets in an oil emulsion act as reaction vessels containing a mixture of template, 
primers, PCR reagents, and magnetic beads (201). Fluorescently labelled 
dideoxynucleotide terminators discriminate wild type and mutant DNA sequences and 
are analysed by flow cytometry (201).  Droplet-digital PCR is based on water-oil 
emulsion droplet technology by the distributes the DNA sample into thousands to 
millions of droplets containing a single mutated or wild type strand that can be 
distinguished by flow cytometry using fluorescent TaqMan-based probes (201). Real-
time PCR is a rapid, cheap method to detect ctDNA mutations at an allele frequency 
of 10-20% (201). Several modifications improve sensitivity. Most of these are based 
on either using a blocking oligo at the 3′-end to block the amplification of the normal 
allele and allowing the amplification of the mutant allele or they make use of a 
modification step in the PCR protocol that enriches variant alleles from a mixture of 
wild-type and mutation-containing DNA (201). NGS analyses millions of short ctDNA 
sequences in parallel, these are then aligned to the reference genome (201). NGS in 
ctDNA analysis can focus on specific target regions of known mutation panels or 
analyse novel mutations via WES or WGS (201). 
 
2.2.13.1 Circulating tumour DNA, bioinformatics 
ctDNA levels in ng/ μL were examined at each time point. The DFS for patients with 
undetectable ctDNA post-CRS & HIPEC was compared to those with detectable ctDNA 
using the Kaplan Meier method. Median mutation number and levels of ctDNA in ng/ 
μL were compared to that detected in the tumour and at subsequent time points using 
Mann-Whitney U. The correlation between tumour and baseline ctDNA mutation 
number was examined using Pearson’s coefficient correlation. All statistical tests were 





Sequencing reads in FastQC format were uploaded to the Qiagen Biomedical 
Genomics Workbench. Reads were trimmed to remove adaptors and primer-dimer 
artefacts (<40bp). Sequence reads were aligned to the human reference genome, 
(NCBI build 37 (hg19)) using the Burrows-Wheeler Aligner (BWA-MEM). Poorly 
mapped reads were filtered, and gene-specific primer sequences trimmed and 
annotated with UMI. Variant calling was performed using smCounter2. SmCounter2 
determines whether the allele frequency of the variant is significantly above the 
background error rate.  
Lollipop plots were produced to determine the distribution and frequency of mutations 
as well as the associated amino acid changes for the most frequent variants. VCF files 
were converted to mutation annotation format using vcf2maf and then merged into a 
single file stratified by sample identifier (202). The MAF file was then loaded into 





Chapter 3 A meta-analysis of prognostic factors for 
patients with colorectal peritoneal metastasis 






Some of the work in this chapter has been previously published in Hallam et al 2019 
(203). In this publication I was responsible for the writing of the text, collection of the 
data and also production any of the figures used in this thesis. 
3.1 Introduction 
CPM occurs in up to 15 per cent of cases of CRC (75-77). The prognosis for CPM is 
poor, untreated median OS is 6 just months (79). With systemic chemotherapy, the 
median OS is improved to up to 20 months (84-86). The standard for CPM is CRS & 
HIPEC which may improve median OS by 20 – 63 months (108, 109, 112, 115, 117, 
118, 124, 130, 137).  
CRS & HIPEC is a long, high-cost operation associated with a protracted inpatient and 
high dependency (HDU) or intensive care (ITU) stay, an associated mortality rate of 1-
12 per cent and morbidity rate of 7-63 per cent (112, 121, 123, 124, 127, 130, 135, 
138, 144, 145). Improving patient selection is therefore crucial to maximising patient 
outcomes whilst minimising morbidity and mortality. 
Variation in outcomes for CRS & HIPEC can be explained in part by patient selection, 
for example necessitating the ability to achieve complete cytoreduction at CRS, the 
exclusion of patients with extensive CPM as assessed by Sugarbaker’s peritoneal 
carcinomatosis index (PCI), and selection of patients with minimal co-morbidity and 
good performance status.  
Several clinicopathological variables which impact on survival have been identified in 
the literature including lymph node status, tumour differentiation and histological 
findings, the completeness of cytoreduction (CC score) and PCI. There is wide 
variation however in the variables reported by studies and selection criteria for centres 
performing CRS & HIPEC worldwide and in turn in their outcomes.  
Studies reporting prognostic factors in CRS & HIPEC are cohort in design with small 
samples. Each examines numerous and varying prognostic factors on different scales 
of measurement. No consensus exists as to which prognostic factors contraindicate 
CRS & HIPEC or predict a good outcome. Comprehensive evidence synthesis is 




The aim of this systematic review and meta-analysis was to analyse all prognostic 
factors affecting OS in patients with CPM undergoing CRS & HIPEC. 
3.2 Method 
3.2.1 Literature search 
A comprehensive literature search was conducted in accordance with the Preferred 
Reporting Items for Systematic Review and Meta-Analysis (PRISMA) (204). MEDLINE, 
Embase and Cochrane Library electronic databases, registers of clinical trials 
(ClinicalTrials.gov and the WHO International Clinical Trials Registry) and the 
Conference Proceedings Citation Index, Zetoc, were searched from inception to the 
present. The search strategy captured terms for colorectal cancer, peritoneal 
metastasis and CRS & HIPEC techniques, separated by the Boolean operator ‘AND’. 
Searches were supplemented by a hand search of selected journals and the reference 
lists of all included studies. 
Example Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Colorectal Neoplasms/  
2     ((colon* or colorectal) adj2 (cancer or carcinoma or tumo$r or malignan*)).ti,ab.  
3     exp Peritoneal Neoplasms/  
4     ((peritoneal or peritoneum) adj2 (cancer or carcinoma* or malignan$ or spread* 
or neoplasm*)).ti,ab.  
5     1 or 2  
6     3 or 4  
7     cytoreductive surgery.ti,ab.  
8     ((intraperitoneal or intra-peritoneal) adj2 chemotherapy).ti,ab.  
9     CRS.ti,ab.  
10     HIPEC.ti,ab.  
11     7 or 8 or 9 or 10  
12     5 and 6  





3.2.2 Study selection 
English-language studies were eligible for inclusion if they reported on the impact of 
prognostic factors on OS for patients with CPM undergoing CRS & HIPEC. Where 
multiple studies describe the same cohort of patients, the largest and most complete 
dataset was included. Review articles, case reports or case series of fewer than 10 
patients were excluded. Additional exclusion criteria included studies involving patients 
with primary tumours other than CRC and studies where a proportion of the cohort did 
not receive both CRS & HIPEC. 
After screening the titles and abstracts, articles fulfilling the eligibility criteria were 
identified and their full-text publications reviewed. Literature search and study selection 
were done independently by two researchers, and any disagreements were resolved 
by discussion with senior reviewers. After a qualitative assessment, articles were 
screened to ensure they presented adequate statistical information to be included in 
the meta-analysis: hazard ratios (HRs) with confidence intervals or Kaplan–Meier 
curves with the number of events and patients at risk.  
3.2.3 Assessment of risk of bias 
The quality and risk of bias of individual studies were assessed using the Quality in 
Prognosis Studies tool (QUIPS) tool (205).  This tool reviews each study in six criteria: 
study participation, attrition, prognostic factor measurement, outcome measurement, 
confounding factors and the statistical analysis and reporting. Two authors scored all 
articles independently (SH & RT).  
3.2.4 Data Extraction 
Data were independently extracted by two reviewers (SH & RT) using a piloted data 
extraction form. The number of patients, study design, patient demographics, tumour 
characteristics, use of adjuvant and neoadjuvant regimens, CRS & HIPEC techniques, 
survival and prognostic factors were recorded. 
The unadjusted hazard ratio (HR) and its 95% confidence interval (c.i.) and P-value 
were extracted. When adjusted HRs (with confidence intervals and P-values) were 
reported, these were extracted along with the set of adjustment factors. If HRs, 




al were used to estimate them indirectly from Kaplan Meier curves, when presented in 
adequate detail with the numbers of events and patients at risk (206, 207).  
Prognostic factors reported on a continuous scale were extracted. If results were 
categorised into three or more categories, results for each comparison were extracted 
and when clinically relevant these were grouped to form a binary comparison.  
3.2.5 Prognostic factor selection 
All prognostic factors adequately described and reported by two or more independent 
studies were included.  
3.2.6 Statistical analysis 
Owing to clinical and methodological heterogeneity, a random-effects meta-analysis 
was used (on the log(HR) scale) using the method of DerSimonian and Laird (208). 
The combined effect size was described by the pooled HR, its confidence interval and 
P-value, with P < 0.050 considered significant. For prognostic factors reported by more 
than two studies, a 95 per cent prediction interval (a measure of the variation in 
treatment effects) is presented (209). Heterogeneity was also described by the I2 
statistic (210). All analyses were performed in STATA® version 15 (StataCorp, College 
Station, Texas, USA). 
3.3 Results  
The final literature search was performed on the 3rd of April 2018. Literature searches 
(after removal of duplicates) identified 1052 records. Titles and abstract screening 
identified 158 abstracts for full-text review. Of these, fifty-one studies met the inclusion 
criteria. Twenty-four unique studies reporting on 3128 patients with CPM presented 
adequate data to be included in the meta-analysis (112, 123, 135, 139, 141, 211-229) 
(Figure 3.1).  Of the 24 cohort studies six were prospective (123, 214, 217, 219, 223, 
226), and the remaining 18 retrospective (112, 135, 139, 141, 211-213, 215, 216, 218, 
220-222, 224, 225, 227-229) (Table 3.1).  
Several studies presented both an unadjusted and adjusted hazard ratio. As 
adjustment factors varied widely between studies (table 3.2) meta-analysis was 





There was a low risk of bias from study participation. The moderate risk of bias due to 
study attrition reflects the poor reporting of loss to follow-up. There was a low risk of 
bias due to prognostic factor measurement. Prognostic factors were objective, clearly 
defined and clinically relevant. Reporting of all prognostic factors and treatment 
variations was incomplete in the majority of studies, resulting in a moderate risk of bias. 
The presentation of results and analytical strategy was sufficient in the majority of 
studies resulting in a low risk of bias (Table 3.3). 
Pooled median overall survival across all studies was 32 months (12.2 – 51 range) 


















Age, years (range) Gender 
(M:F) 










Italy  RC 101 60 (29-79) 40:61 44.9 (24.1-
65.7 95%CI) 
Charlston 






France RC 49 52.7 x̅ +/-SD 11  19:30 27 x̅ +/-8 NS ECOG<2 (100) 
Cashin  
(2012) 
Sweden RC 126 55 x̅ (14-79) 76:75 49 (0.5-200) NS WHO <2 (100) 
Da Silva 
(2006) 
USA RC 70 45.5 x̅ (18-71) 27:43 46.5 x̅ (6-241) NS NS 
Duraj  
(2013) 
Sweden PC 11 
LM+PM  




















France RC 114 50 +/-SD 10 49:65 46.8 (0-140.4) NS NS 
Elias  
(2014) 










France RC 173 48.9 (20-74) 71:102 48 (41.2-56.3) NS NS 
Franko  
(2008) 
USA RC 65 51.6+/- SD 13.2  
 
 
18:47 NS NS NS 
Froysnes 
(2016) 




China PC 60 < 60 46 (77) 
> 60 14 (23) 
26:34 NS NS NS 
Huang  
(2016) 






USA RC 318 50.6 x̅ (18-86) 171:147 15 (3-264) NS NS 
Lorimer 
(2017) 
France RC 22 
PM+LM  
36 PM   
60 (21-77) median 
NS 0.82 





















Singapore RC 50 50 (14-71) 18:32 13.3 (0.8 – 
87.1) 













Netherlands RC 445 69.3+/-SD 11.6 AC 
68.5+/-SD 12.1 
MC 
65.3+/-SD 14.2 SR 
 



















ASA 1 4:5 
ASA 2 22:45 
ASA 3 3:5 
Sluiter (2016 
Netherlands RC 65 62 (31-78) 25:40 21 (2-50) NS NS 
Teo (2015) Singapore RC 35 51 (14-71) 11:24 24.7 (0.6-81.8) NS ECOG ≤1 
35(100) 
Ung (2013) Australia RC 125 58.9 (NS) 50:75 23.3 (1-156) NS NS 
Winer 
(2014) 
USA RC 30 54.9 x̅ +/-SD 14.5 22:8 52 (IQR 1.04-
11.5) 
NS NS 
(NS not specified, RC retrospective cohort, PC prospective cohort, LM liver metastasis, 
PM peritoneal metastasis, AC adenocarcinoma, MC mucinous, SR signet ring,  ECOG 
Eastern Cooperative Oncology Group performance status score, ASA American 
Society of anaesthesiologists score, SB small bowel, NSB not small bowel, NS not 
specified, x̅ mean, IQR inter-quartile range, CI confidence interval, SD standard 









































































































































































   X   X  X X X       X  
Benziri  
(2012) 




        
Cashin  
(2012) 
 X        X     X X X  X 
Da Silva  
(2006) 
X    X X    X 
 
         
Duraj  
(2013) 
X X X  X  X   X  X  X   X  X 
Elias  
(2010) 
    X     X X     X    
Elias 
(2013) 
X X X    X   X          
Elias  
(2014) 
X X   X  X   X          
Faron  
(2016) 
    X     X 
 
         
Franko  
(2008) 
           X X       
Froysnes  
(2016) 
X X X  X     X 
 
         
Huang  
(2014) 
         X X         
Huang  
(2016) 
X    X   X  X 
 
         
Ihemalndu  
(2017) 
X X      X   X        x 
Lorimer 
(2017) 
  X  X  X X  X X X X     X  
Maggiori  
(2013) 
X X X  X  X   X      X X   
Ng  
(2016) 
         X         X 
Shen  
(2004) 
X X  X X X X     X  X      
Sluiter  
(2016) 









  X                 
Ung  
(2013) 
X    X     X          
Winer  
(2014) 
X X         X       X  
(ECOG, PM peritoneal metastasis, PCI Peritoneal carcinomatosis index, CC score 
completeness of cytoreduction, GI gastrointestinal, MVR multi-visceral resection, R status 
resection status, HIPEC heated intraperitoneal chemotherapy, EPIC Early post-operative 
chemotherapy, SPIC Sequential postoperative intraperitoneal chemotherapy ASA American 
society of anaesthesiologists score VEGF, Vascular endothelial growth factor, VCAN 






PRISMA flow diagram detailing the records identified, included and excluded and the 
reasons for this. This figure is reprinted from Hallam et al, 2019, figure 1 (203). 
  




Table 3-3 Risk of bias assessment results for each study using the Quality in 
Prognostic Studies (QUIPS) tool 
 
Study ID Study 
participation 










Baratti (2014) Moderate Moderate Low  Low Moderate Low 
Benziri (2012) Low Moderate Low Moderate High Low 
Cashin (2012) Low Moderate Low Low Moderate Moderate 
Da Silva (2006) Moderate High High Moderate Moderate Low 
Duraj (2013) Low Moderate Low Low Moderate Low 
Elias (2010) Low Moderate Low Moderate Moderate Low 
Elias (2013) Moderate Low High Low Moderate Low 
Elias (2014) Low Moderate Low Moderate High Low 
Faron (2016) Low Moderate Low Low Moderate Moderate 
Franko (2008) Moderate Moderate Low Moderate Moderate Low 
Froysnes 
(2016) 
Low Moderate Low Low Moderate Low 
Huang (2014) Low Low Low Low Moderate Low 
Huang (2016) Low Moderate Low Moderate Moderate Low 
Ihemalndu 
(2017) 
Low Moderate Low Moderate Moderate Low 
Lorimer (2017) Low Moderate Low Low Moderate Low 
Maggiori 
(2013) 
Low Low Low Low Moderate Low 
Ng (2016) High High Low Moderate Moderate Low 
Shen (2004) Low Moderate Low Moderate Moderate Low 









Low Moderate Moderate Moderate Moderate Low 
Teo (2015) Low Low Low Low Moderate Low 
Ung (2013) Low Moderate Low Moderate Moderate Low 






Table 3-4 Survival outcomes 
Author (year) Deaths Median OS (95% CI) 5-year OS (95% CI) 
Baratti  
(2014) 
n=37 (31 disease related) 32 (16.2-55.9) 11.7% (9.5-24.5) 
Beniziri (2012) NS 51 (NS) NS 
Cashin (2012) NS 34 (2-77) CRS&HIPEC 
25 (2-188) CRS&SPIC, P=0.047 
40% CRS&HIPEC 
18% CRS&SPIC, P=0.047 
Da Silva (2006) NS 33 (NS) 32% (NS) 
Duraj (2013) NS 15 (6-46) PM+LM 
34 (19-37) PM, P=0.2 
NS 
Elias (2010) NS 30.1 (NS) 27% (21-33%) 
Elias (2013) n=47 (41) NS NS 
Elias (2014)  SB 30.9 x̃ (0.23-113) 
NSB 45.5 x̃ (0.79-144) 
39% (NS) 
Faron (2016) NS 41 (32-50) 42% (NS) 
Franko (2008) NS 15.3 (NS) 
20.2 R0/1 
MVR 32.8 (NS) / Controls 20 = 0.787 
NS 
Froysnes (2016) NS 47 (42-52) NS 
Huang (2014) NS 16 (12.2-19.8) 22% 
Huang (2016) NS 42.1 (33.7-50.4) 34% (NS) 
Ihemelandu 
(2017) 
NS 21.5 (NS) 25% (NS) 
Lorimer (2017) NS PM 25.2 (14.8-82.6) 
PM+LM 36.1 (19.6-113.7), P =0.3 
PM: 40.7% (23.4-77.3) 
PM+LM: 42.1% (19.7-63) 
Maggiori (2013) NS NS PM+LM: 26% (18-35) 
PM: 43% (35-51) 
Ng (2016) n=18 (36) x̃ 28.8 (18.3-39.1) NS 












NS 26 (22.2-29.9) rectal 
35.1 (22.8-47.3) colon 
32% (NS) rectal 
24% (NS) colon 
Sluiter (2016) NS 34.4 (29.4-39.2)  NS 
Teo (2015) n=13 (37) 27.1 (15.3-39.1) 19.1 (NS) 
Ung (2013) NS 37.1 (NS) colon 
29.6 (NS) rectum 
33% (NS) colon 
20% (NS) rectum 
Winer  
(2014) 
n=25 (83) 12.2 (7.5-17.2) NS 
 (NS not specified, NK not known, x ̃median with (range), PM: Peritoneal metastasis, 
LM liver metastasis, SB small bowel, NSB none small bowel, CRS cytoreductive 
surgery, HIPEC heated intraperitoneal chemotherapy, EPIC Early postoperative 
intraperitoneal chemotherapy, SPIC sequential postoperative intraperitoneal 






Figure 3-2 Prognostic factor effect on overall survival, (Hazard ratio and 95% 
confidence interval) 
Hazard ratios are shown with 95 per cent confidence intervals. Values in parentheses 
after each factor indicate the numbers of studies providing unadjusted and adjusted 
hazard ratios respectively. ECOG, Eastern Cooperative Oncology Group; PM, 
peritoneal metastasis; GI, gastrointestinal; PCI, Peritoneal Carcinomatosis Index; CC, 





3.3.1 Prognostic factors 
Individual forest plots and funnel plots for each prognostic factor are presented in 
appendices, figure S1. 
 
3.3.1.1 Patient factors 
 
3.3.1.1.1 Age 
The pooled median age of patients was 54 years (range 45.5–69.3). Eleven studies 
reported on age as a prognostic factor (123, 126, 135, 139, 213, 214, 217, 219, 221, 
227, 228). Ten studies reported adequate data to be included in the meta-analysis. 
Five studies categorised age into binary outcomes which we were unable to 
meaningfully combine (123, 139, 213, 219, 228).  The pooled unadjusted HR was 1 
(0.98 – 1.03), I^2 = 38.5%, and adjusted HR 1 (0.96 – 1.04), I^2 = 69.3%, for an 
increase in age of one year. These data provide no evidence that age is a useful 
predictor of OS (Figure 3.2). 
3.3.1.1.2 Sex  
Nine studies reported the effect of sex on OS (123, 126, 135, 214, 216, 217, 219, 221, 
229). Eight studies presented adequate data to be included in the meta-analysis. The 
pooled unadjusted HR was 1.20 (0.83 – 1.71), I^2 = 33.8% and adjusted HR 1.73 (1.20 
– 2.48), I^2 = 11.6%. It is unclear therefore whether sex is a useful predictor of OS. 
3.3.1.1.3 ECOG performance status 
Five studies reported the influence of ECOG on OS (123, 126, 211, 222, 230). Three 
studies presented adequate data to be included in the meta-analysis. The pooled 
unadjusted HR for an ECOG score of at least 2 was 0.78 (0.57 – 1.07), I^2 = 0%. These 
data provide no evidence that ECOG is a useful predictor of OS. 





3.3.1.2.1 Adverse primary tumour features 
Three studies reported the influence of adverse features of the primary tumour 
(obstruction/perforation) on OS (123, 126, 213). Two studies presented adequate date 
to be included in the meta-analysis. The pooled adjusted HR was 2.91 (1.5 – 5.69) I^2 











































































































































48:54 NS 92:7 RS 
n=1 NS 
n=1 

















NS 20 x̅ 
+/- 
SD 9 
8:41 NS N+ n=22  
N- n=27 















102:48 NS 135:15 NS NS Excluded NS MC n=89 
SR   n=18 
1-10   
n=49     
11-20 

















22:34 NS NS NS N1/2 
n=22 
NS 15:22:8 SR 8 <10     
n=23     
10-20 
n=28      
>20       
n=5 



















NS N0     
n=14 
N1/2 




MC n=36    











































PM       
N+ n=14, 
N0 n=6, 






NS R1 n=10 R2   
n=1 PM+HM 
R1 n=20     

































































NS NS 94:23 NS NS LM n=24 
Ovarian 
n=46 
NS NS 9.2 x̅ 
(0-27) 

































SB     MC 
n=28, SR 
n=10 






















NS NS 135:38 
 
NS NS LM n=52 NS NS 10.2 x̅ 
+/-6.8 





































































24:36 NS 35:25 NS NS NS AC, well / mod diff. n=26 























NS NS NS RPLN 
n=102  
Excluded 3:97:27  
Benign 
n=22 
SR n=11 9.5 x̅ 
+/- SD 
6.6 










NS NS NS NS NS NS NS NS NS 0/1 n=164  





































NA 54:4 T>2 
n=55   
























NA 50:11 PM  
32:5 
PM+LM  
























































74:3 NS NS LM n=10 
None n=65 
NS n=2 
NS MC n=43 
(56)    SR 
n=7 (9)      
NS n=27 
(35) 
NS R0/1 n=37 



























NA NS NS NS NS NS AC n=246 
(55)     
MC 
n=156 

































































































n=17    




AC  n=39 
MC n=22   
SC     n=4 
*SPCI      
<2 n=1    
2-4 
n=42  5 
n=14    
>5 n=8 




































































8:85:32 MC n=56 
(45) 
1-6     
n=43        
7-12   
n=46      
13-19 
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NS n=3   
(Synch synchronous, metach metachronous, RS rectosigmoid, RPLN retroperitoneal 
lymph node, DFI disease-free interval, NS not specified, NA not applicable, LM liver 
metastasis, PM peritoneal metastasis, AC adenocarcinoma, MC mucinous, SR signet 
ring, PCI peritoneal carcinomatosis index, sPCI short peritoneal carcinomatosis index, 
LM liver metastasis, CC completeness of cytoreduction score, R0-2 completeness of 
resection, CRS cytoreductive surgery, HIPEC heated intraperitoneal chemotherapy, 
SB small bowel, NSB not small bowel , NS not specified, x̅ mean, x median, CI 
confidence interval, SD standard deviation, P= P-value, n=number followed by value 





3.3.1.2.2 Rectal or colonic primary 
Eight studies reported the influence of a rectal or colonic primary on OS (135, 214, 
216, 219, 222, 226, 230, 231). Six studies presented adequate data to be included in 
the meta-analysis. The pooled unadjusted HR was 1.48 (0.71 – 3.09), I^2 = 68.5%. 
These data provide no evidence that a rectal primary is a useful predictor of OS. 
3.3.1.2.3 Lymph node metastasis 
Eleven studies reported on the effect of lymph node status on OS (112, 123, 139, 213-
215, 217, 227, 228, 230, 231). Nine studies presented adequate data to be included in 
the meta-analysis. The pooled unadjusted HR was 1.42 (1.06 – 1.92) I^2 = 0% and 
adjusted HR 1.08 (0.6 – 1.95) I^2 = 68.6%. It is unclear therefore whether lymph nodes 
are a useful predictor of OS. 
3.3.1.2.4 Tumour differentiation 
Two studies reported the effect of primary tumour differentiation on OS (214, 219). The 
pooled unadjusted HR was 0.9 (0.18–4.40), I^2 = 72.4%. These data provide no 
evidence that primary tumour differentiation is a useful predictor of OS. 
3.3.1.2.5 Timing of CPM (Synchronous or metachronous) 
Three studies reported on the effect of the timing of CPM (synchronous or 
metachronous) on OS (112, 219, 231). Two presented adequate data to be included 
in the meta-analysis. The pooled unadjusted HR was 1.13 (0.56 – 2.28), I^2 = 57.1%, 
indicating that the timing of CPM is not a useful predictor of OS. 
3.3.1.2.6 Ascites  
Two studies reported on the effect of malignant ascites on OS (123, 219). One paper 
presented an unadjusted HR (1.50, 95 per cent c.i. 0.70 to 3.21) (219) and one an 
adjusted HR (3.23,1.56 to 6.69) (123) meaning it was not possible to provide a pooled 
effect estimate.  
3.3.1.2.7 Hepatic metastasis 
Eleven studies included patients with hepatic metastasis (HM) (123, 211, 214-218, 
222, 223, 226, 228), two studies did not specify that HM were resected (123, 218) 




on OS (123, 126, 211, 214, 216, 217, 222, 223).  Seven presented adequate data to 
be included in the meta-analysis. The pooled unadjusted HR was 1.36 (0.85 – 2.16)) 
I^2 = 43.6% and the adjusted HR 2.49 (0.74 – 8.41) I^2 = 85.3%. These data provide 
no evidence that the presence of surgically treated hepatic metastasis are a useful 
predictor of OS. 
3.3.1.2.8 Signet ring histology 
Three studies reported on the effect of signet ring histology on OS (112, 221, 225). 
Two included adequate data to be included in the meta-analysis. The pooled adjusted 
HR was 1.65 (0.68–4.03), I^2 = 0% (p=0.926) suggesting signet ring histology is not a 
useful predictor of OS.  
3.3.1.2.9 Mucinous histology  
Four studies reported in the influence of mucinous histology on OS (112, 139, 222, 
225). Three studies presented adequate data to be included in the meta-analysis. The 
pooled unadjusted HR was 1.10 (0.70–1.72), I^2 = 0% (p=0.456) suggesting mucinous 
histology is not a useful predictor of OS. 
3.3.1.2.10 Gastrointestinal anastomosis  
Two studies reported on the effect of one or more gastrointestinal (GI) anastomosis on 
OS (123, 222). One paper presented an unadjusted HR and one an adjusted meaning 
it was not possible to provide a pooled effect estimate. 
3.3.1.2.11 PCI 
Eighteen studies reported on the effect of the extent of CPM as described by the PCI  
(112, 135, 139, 211-220, 222, 224, 228, 231, 232). PCI was reported as a continuous 
variable or condensed into categorical variables. Sixteen studies presented adequate 
data to be included in the meta-analysis.  
A PCI of greater than the following levels was predictive of reduced OS:  >20, 
unadjusted HR 2.9 (1.95–4.31), I^2 = 0, adjusted HR 5.04 (2.74– 9.29), I^2 = 0, > 15, 
unadjusted HR 3.12 (2.02-4.80), I^2 = 0% (p=0.515), adjusted HR 2.09 (1.39 – 3.15), 
I^2 = 0% (p=0.570).  PCI as a continuous variable was predictive of reduced OS: 




– 1.11), I^2 = 67.1%. Lower PCI levels were not predictive of OS: PCI > 10, unadjusted 
pooled HR 2.57 (0.69–9.67), I^2 = 90%. PCI > 6, adjusted pooled HR 3.28 (0.77 – 
13.94), I^2 = 92%.  
3.3.1.3 Treatment factors 
3.3.1.3.1 Prior surgical score 
Three studies reported on the influence of the prior surgical score (PSS) on OS (112, 
214, 221).  The pooled unadjusted HR was 1.23 (0.78 – 1.95) I^2 = 0%. These data 
provide no evidence that PSS is a useful predictor of OS. 
3.3.1.3.2 Post-operative morbidity 
Three studies reported the association between postoperative morbidity and OS  
(219, 222, 228). The pooled unadjusted HR was 1.56 (0.74–3.31) I^2 = 48.7%. 
These data provide no evidence that postoperative morbidity is a useful predictor of 
OS. 
3.3.1.3.3 Neo-adjuvant and adjuvant chemotherapy  
Neo-adjuvant and adjuvant treatment of the primary tumour was poorly reported (Table 
3.6). None of the studies reported response to treatment or whether it was completed 
as planned. 
Two studies reported the effect of neoadjuvant chemotherapy prior to CRS & HIPEC 
on OS (112, 222). The pooled unadjusted HR was 1.00 (0.63 – 1.58), I^2 = 0% 
(p=0.425). These data provide no evidence that neoadjuvant chemotherapy is a useful 
predictor of OS. 
Four studies reported on the effect of adjuvant chemotherapy, following CRS & HIPEC 
on OS (112, 215, 222, 228). The pooled unadjusted HR suggested that there is no 
evidence that the use of adjuvant chemotherapy is predictive of OS 0.6 (0.29–1.21), 
I^2 = 68.1%.  
3.3.1.3.4 Completeness of cytoreduction 
Eight studies reported on the effect of the completeness of cytoreduction on OS (112, 
212, 215, 219, 221, 222, 229, 232).  Seven studies presented adequate data to be 




in OS, unadjusted HR 1.75 (1.18-2.59), I^2 = 79.5% and adjusted HR 1.61 (1.31–1.97), 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HIPEC n=161, EPIC n=7, HIPEC+EPIC n=48 





















































































































































































































































































































































































































































































































































PM: n=49 HIPEC alone, n=11 EPIC alone, n=1 HIPEC+EPIC 

























































































































































































































































































































































































































































































































































































































































































































































(MMC Mitomycin C, OXA Oxalaplatin, LV Leucovorin, 5-FU 5 Fluorouracil, CIS 
Cisplatin, DOX Doxorubicin, DOC docetaxel, CBDCA carboplatin, IRI Irinotecan, CAP 
Capecitabine, mg milligrams, m2 metres squared, Min minute, C centigrade, EPIC 
Early postoperative intraperitoneal chemotherapy, SPIC sequential postoperative 




intraperitoneal chemotherapy, NA not applicable, NS not specified, deviation, 
n=number followed by value in parenthesis, percentage) 
3.4 Discussion 
This systematic review and meta-analysis examined the effect of prognostic factors on 
OS following CRS & HIPEC for CPM. Emergency presentation with obstruction or 
perforation of the primary tumour as well as the extent of CPM and the completeness 
of resection, as described by the PCI and the CC score respectively, were the only 
significant prognostic factors. 
An emergency presentation of the primary tumour with obstruction or perforation was 
predictive of reduced OS (for both synchronous and metachronous CPM). Several 
factors may contribute to this. In the primary setting, colorectal cancers presenting with 
obstruction or perforation are associated with decreased cancer-specific survival and 
increased postoperative mortality (233). Obstructed or perforated colorectal cancer is, 
by definition, advanced in stage and increases the risk of metastasis; additionally, 
emergency presentation limits the possibility of neoadjuvant treatment and may delay 
adjuvant treatment owing to postoperative morbidity. The extent of peritoneal 
metastasis as described by the PCI was predictive of reduced OS as a continuous 
variable and when the PCI score was 15 or above. A complete cytoreduction (CC0) 
was predictive of improved OS. Improving patient selection is therefore reliant on the 
ability to predict accurately the extent of peritoneal metastasis and the ability to resect 
it completely. Specialist radiologists have demonstrated good concordance between 
radiological and surgical PCI estimations, particularly when combining modalities; 
however, these tend to be most accurate in patients with high PCI scores (234, 235). 
In some centers, this is used in combination with diagnostic laparoscopy before CRS 
& HIPEC. This is feasible in the majority of patients and may help to reduce the 
laparotomy rate in patients for whom CRS & HIPEC may not be possible (236). 
Included patients were relatively young at 54 (range 45–69) years compared with the 
incident age of colorectal cancer (80-90 years) (1). In addition, performance status was 
not reported by the majority of studies in the review and limited to an ECOG <2 by a 




Details of neoadjuvant and adjuvant treatments were reported poorly in the included 
studies. Within these limits, the use of neoadjuvant or adjuvant chemotherapy was not 
predictive of OS after CRS & HIPEC. One meta-analysis, by Kwakman and colleagues 
from 2016 (237), examined the effect of clinicopathological variables only on OS 
following CRS & HIPEC. Significant prognostic factors identified in the present review 
(adverse features of the primary tumour, PCI, CC score) were not comparable with 
those from Kwakman et al as they were not examined (237). In contrast to the present 
study, Kwakman and co-workers found performance status, the presence of lymph 
node or hepatic metastasis, tumour differentiation, signet ring histology, a rectal 
primary and the use of neoadjuvant chemotherapy to be predictive prognostic factors 
(237). A number of differences may explain this variation in findings: the exclusion of 
73 papers described as unavailable in full text may introduce a potential selection bias 
(237). In addition, a number of studies included by Kwakman and colleagues were 
excluded in the present study for the following reasons: presentation of inadequate 
data to estimate the HR accurately (118, 126, 231, 238), the inclusion of mixed primary 
tumours (227, 239, 240) and the inclusion of patients having repeat CRS & HIPEC 
procedures. Finally, the meta-analysis combined all studies regardless of the 
presentation of unadjusted or adjusted HR  (237). The strengths of the present study 
include the comprehensive and systematic literature search including 3128 patients 
with CPM undergoing CRS & HIPEC, all potential prognostic factors were included, 
and a consistent association was found between predictive prognostic factors across 
different studies. The low heterogeneity associated with these factors adds to the 
strength and generalizability of the findings. The application of strict inclusion criteria 
limits the potential impact of factors such as mixed primary tumour origin. The present 
analysis takes into account the adjustment factors used in primary studies to ensure 
meta-analysis of time to event data was performed only when data were comparable. 
Some limitations must, however, be acknowledged. This review is limited by the quality 
of primary studies and the heterogeneity of the population. Prognostic factor 
systematic reviews, by their nature, represent one of the most difficult categories due 
to their retrospective and observational nature. As CRS & HIPEC is performed at 
tertiary centres, data concerning the primary tumour and its treatment may not have 




of data necessary for accurate meta-analysis varied widely across primary studies, 
which may introduce a degree of inclusion bias. 
There was a lack of molecular and genetic data concerning patients with CPM 
undergoing CRS & HIPEC in comparison with studies of primary colorectal cancer, and 
this is an area for future research. Discordance between primary genetic mutations 
and those in peritoneal metastases may identify novel therapeutic targets and 
prognostic markers in this metastatic group. Recent research by Schneider and 
colleagues found that RAS/RAF mutations impair survival after CRS/HIPEC (241), 
although this is the only study that has considered this prognostic factor and validation 
is required. Further large-scale research is needed to account for these factors; this 
would require collaboration between CRS & HIPEC centres, standardization of the 




Chapter 4 : Describing the biology of colorectal 
peritoneal malignancy - an investigation of the gene 
expression, methylation and somatic mutation 
alterations associated with the development of 






Some of the work in this chapter has been previously published in Hallam et al 2020 
(242). In this publication I was responsible for the writing of the text, collection of the 
data and also production any of the figures used in this thesis. 
 
4.1 Introduction 
In the preceding chapters, we established the known clinical prognostic factors for 
patients with CPM. Obstruction or perforation of the primary tumour, the extent of PM 
as described by the PCI score and the completeness of cytoreduction as described by 
the CC score. Despite optimal selection for CRS & HIPEC using these known 
prognostic factors, there is still significant variation in survival for these patients. Little 
is known about the biology of isolated CPM. Understanding tumour biology may 
identify which patients with primary CRC are at risk of developing CPM, and which are 
suitable for treatment with CRS & HIPEC or alternative existing or novel treatment 
strategies. 
Gene expression profiling studies in primary CRC have identified genetic signatures 
associated with the development of lymph node metastasis (243), systemic metastasis 
(243), and predicting prognosis (243). One small study of CPM identified a gene 
expression profile predictive of reduced OS following CRS & HIPEC (244). This study, 
however, combined small numbers of CPM with a larger cohort of appendix 
adenocarcinoma, a biologically distinct tumour with a significantly improved prognosis.  
Methylation profiling studies in primary CRC have identified changes associated with 
the development of metastasis and predicting prognosis. The methylation of markers 
of CIMP appear to be stable between matched primary CRC and hepatic metastasis 
suggesting the global hypermethylation of CIMP is established before the development 
of metastasis (245, 246). In support of this Murata et al examined the methylation levels 
of long interspersed nuclear elements (LINEs). LINES comprise 17% of the genome 
and act as a surrogate marker of global DNA methylation (247). They found equivalent 
LINE-1 methylation in primary CRC and matched liver metastasis (247). Zhang et al 
found CIMP was associated with an unfavourable response to chemotherapy and a 




(248). This may relate to a higher mutation frequency of EGFR related genes such as 
BRAF, NRAS and PIK3CA, (74.1%) (248). Given the 70-80% correlation between 
CIMP and MSI high tumours, it is difficult to know whether the reduced chemotherapy 
response is a reflection of MSI high or CIMP status (18, 44). A number of studies 
examined the methylation status of individual genes of known importance in CRC and 
found hypermethylation of genes including KRAS, the miR-34 and CDKN2A tumour 
suppressors and hypomethylation of the MYC oncogene in metastatic CRC which was 
associated with reduced OS (249-252). Hypermethylation of Wnt modulators and the 
resulting Wnt pathway dysregulation are associated with recurrence in primary CRC 
and reduced OS (252, 253).  
Copy number alterations result in the activation of oncogene or deactivation of proto-
oncogenes. To our knowledge, no group have analysed the difference in CNA primary 
CRC vs. CPM. Lee et al compared CNA in primary CRC and matched liver metastasis 
(254). Forty-seven per cent of patients showed significant differences in CNA between 
primary and metastasis (254). 
The sequentially accumulated somatic mutations driving the development of primary 
CRC tumorigenesis have been described in detail in the literature. The mutations 
associated with the development of metastasis are less clearly defined. Whilst a 
number of studies have examined the association between mutations, (known CRC 
drivers or potential) and the development of metastasis their results have been 
contradictory. Goryca et al performed WES exome sequencing in 7 primary CRC and 
matched liver metastasis. Using the Cancer-Specific High-throughput Annotation of 
Somatic Mutations (CHASM) method, they identified potential drivers which were 
exclusive to metastatic sites, (BAHD1, PLXND1) (255). Mlecnik et al examined primary 
CRC samples from 212 patients, (with and without distant metastasis) for a panel of 
48 commonly mutated CRC genes and found similar patterns of genomic alterations 
in both groups (256). Huang et al performed a meta-analysis to investigate the 
association between key CRC driver mutations and the development of metastasis  
(257). They found KRAS, p53, SMAD4 and BRAF mutations were associated with 
lymph node and distant metastasis (257). In all studies samples were taken from 




development of metastasis were not captured, additionally, the site of metastasis was 
not specified and included lymph node which is an earlier stage of metastasis than 
distant CPM. 
Few studies have examined the somatic mutations found in CPM and their prognostic 
implications. These studies, however, are limited to individual or small panels of 
mutations routinely tested for in clinical practice, there is limited evidence to suggest 
which genes should be included in panel sequencing in CPM. Schneider et al 
examined the KRAS and BRAF mutation status of patients with CPM who underwent 
CRS & HIPEC (241). They found mutations of RAS/RAF were associated with reduced 
OS and that this association was independent of the use of targeted anti-EGFR 
treatment (241). Sasaki et al examined the KRAS, BRAF and PIKCA mutation status 
of 526 patients with metastatic CRC, with or without CPM (150). They found the 
incidence of BRAF mutation was significantly associated with the presence of CPM but 
not with prognosis  (150).  
There is a need to improve the outcomes for patients with CPM and significant variation 
in survival despite optimal patient selection for treatment using currently known 
prognostic factors. There is a paucity of knowledge concerning CPM tumour biology. 
Understanding the transcriptome, epigenome and genome of CPM will form the basis 
to identify which patients with primary CRC are at risk of developing CPM, those 
suitable for treatment with CRS & HIPEC or alternative existing or novel treatment 
strategies.  
Aim: to determine the gene expression methylation and somatic mutation profile 
associated with the development of CPM and conferring ‘poor prognosis’ in patients 










4.2.1 Retrospective patient cohort 
From 2011-2017 a total of 161 patients underwent CRS & HIPEC at University 
Hospitals Birmingham, 88 patients for metachronous CPM. 
Patients were excluded for the following reasons: rectal primary, 5, incomplete CC2 
resection, 8, PCI of ≥ 12 20, follow up ≤ 12 months 27 leaving 28 patients. Complete 
information regarding the primary CRC pathology and treatment was available for 26 
patients who form the basis of this study. Each patient had matched normal, primary 
CRC and CPM samples. 
Thirteen patients had a DFS of 24 months (15–72 range) following CRS & HIPEC and 
formed the ‘good prognosis’ cohort, thirteen patients had a DFS of 6 months (2-11 
range) and formed the poor prognosis cohort (Figure 4.1). There were no significant 
differences in patient demographics, primary CRC or CPM tumour, treatment or follow 
up between cohorts, (table 4.1).  
Following nucleic acid extraction all, 26 patients had adequate CPM RNA for RNAseq 
(13 good, 13 poor prognosis), 25 had matched primary CRC samples. For methylation 
array 24 patients (12 good, 12 poor prognosis) had adequate DNA. As the Infinium 
methylation array comes in a 32-prep kit, 4 good and 4 poor prognosis primary tumours 
were matched to these. For exome sequencing 24 patients (12 good, 12 poor 
prognosis) had adequate DNA from both the primary and CPM samples, extraction of 







Table 4-1 Comparison of good and poor prognosis patient cohorts 
 Good 
Prognosis 
Poor prognosis P-value 
Age, mean +/- SD 58 +/-13 58 +/-9 0.97 











































DFI months, mean +/- SD 25 +/-9 24 +/-12 0.83 
PCI score, median (range) 5 (3-12) 8 (2-12) 0.019 










Follow up, months,                
median (range)  










DFS, median (range) 24 (15-72) 6 (2-11) <0.0001 
OS, median (range) 29 (19-72) 16 (5-55) 0.12 
 (n= number, value in parenthesis, percentage, DFI, disease free interval, PCI, 
peritoneal carcinomatosis index, CC score, completeness of cytoreduction, DFS, 






Figure 4-1 Kaplan-Meier disease-free survival analysis, good vs. poor 
prognosis patient cohorts 
Kaplan-Meier curve showing disease free survival in patients in the retrospective 
patient cohort with good and poor prognosis following CRS & HIPEC for CPM. Log-












4.2.2 RNA sequencing, differential gene expression 
 
4.2.2.1 Differential gene expression, primary CRC vs. matched metachronous 
CPM 
A Kyoto Encyclopaedia of Genes and Genomes, (KEGG) pathway analysis was 
performed to identify the enriched biological functions among the differentially 
expressed genes. Differentially expressed genes participated in a variety of functions. 
Pathways identified are detailed in table 4.2. The most enriched pathways include 






Table 4-2 KEGG pathway enrichment analysis, primary CRC vs. matched 
metachronous CPM 













































Primary CRC and matched CPM showed differential expression of 65 genes with an 
FDR <0.1 (Figure 4.2 and Figure 4.3). Sixteen genes showed decreased expression 
in CPM compared with primary CRC. The full list can be seen in appendices, table S3. 
The 10 genes with the highest fold change of known significance are discussed below 
(Table 4.3).  
In the literature FABP6, DEFA6, DMBT1, OLFM4 and MUC2 are highly expressed in 
adenoma or early CRC with reduced expression in metastasis suggesting a role in 
early tumorigenesis which is not required for metastasis. The expression of FABP6, an 
intercellular bile acid transporter, was decreased 34.30-fold in CPM. Elevated bile acid 
concentrations associated with high-fat diets are detrimental to the colonic epithelial 
architecture through mechanisms of oxidative DNA  damage, inflammation and 
increased cell proliferation (258).  Omachi et al found high expression of FABP6 in 
primary CRC compared with low levels in lymph node metastasis (259).  
 
DEFA6 expression, part of a cytotoxic peptide family involved in host defence of the 
bowel and a downstream Wnt target, was decreased 8.15-fold in CPM. Radeva et al 
found high expression of DEFA6 in colorectal adenomas compared to CRC (260). 
Decreased DEFA6 expression in CPM suggests the development of Wnt pathway 
dysregulation and immune system evasion in the transition from primary to CPM (261). 
DMBT1 expression was decreased 6.06-fold in CPM. DMBT1 controls the interaction 
between tumour cells and the immune system as well as epithelial differentiation (261). 
No studies have described DMBT1 expression in colorectal metastasis, however, Du 
et al demonstrated high expression in benign prostatic tissue, weak expression in early 
primary prostatic cancer and no expression in advanced prostatic cancer. Given the 
role of DMBT1 in immune surveillance of tumour cells its downregulation may reflect 
tumour cell immune evasion in metastasis (262). IGHA1 is an immune receptor (261), 
its expression was reduced 3.66-fold in CPM. Fehlker et al found reduced expression 
of IGHA1 along with other immune response genes in metastatic CRC (263). Taken 
together decreased expression of these immune regulators suggests an immune 





OLFM4 is a target of the Wnt/β-catenin pathway and marker of colorectal stem cells 
(264), its expression was reduced 3.77-fold in CPM. OLFM4 downregulates β-catenin 
signalling by binding to Frizzled receptors in place of Wnt ligands, OLFM4 deletion 
promotes colon tumorigenesis (265). High expression of OLFM4 is associated with 
early tumour stage, and improved survival and is downregulated in poorly 
differentiated, advanced primary tumours and metastasis resulting in unchecked Wnt 
pathway activation (265, 266). 
 
Mucin 2, (MUC2) encodes a mucinous coating which forms a protective intestinal 
barrier, expression was reduced 2.34-fold in CPM (261). Reduced expression of MUC2 
is associated with progression and metastasis of CRC (267). In vitro MUC2 suppresses 
the migration of CRC cells, its downregulation results in upregulation of interleukins 
and E-cadherins promoting EMT, invasion and metastasis (267).  
 
The expression of CES2  was reduced 3.2-fold in CPM, CES2 encodes an intestinal 
enzyme involved in the intestinal clearance of drugs and activation of ester-containing 
prodrugs such as capecitabine and irinotecan, commonly used chemotherapy agents 
in  CRC (261). The decreased expression may suggest resistance in this cohort of 
patients, Shaojun et al demonstrated the expression of CES2 predicts Irinotecan 






Table 4-3 The top 10 genes with significantly reduced expression (FDR<0.1) in 







1 FABP6 -34.30 1.74 x 10-06 
2 DEFA6 -8.15 8.55 x 10-06 
3 DMBT1 -6.06 2.43 x 10-04 
4 TTC38 -4.56 5.80 x 10-05 
5 OLFM4 -3.77 1.01 x 10-04 
6 IGHA1 -3.66 4.23 x 10-05 
7 CES2 -3.20 6.84 x 10-05 
8 NDUFS6 -2.70 7.74 x 10-05 
9 P2RY11 -2.53 6.37 x 10-04 







Forty-nine genes showed increased expression in CPM compared with primary CRC. 
The full list can be seen in appendices, table S4. The 10 genes with the highest fold 
change of known significance are discussed below (Table 4.4).  
CD53 a tetraspanin and TSC22D3 an anti-inflammatory protein glucocorticoid (GC)-
induced leucine zipper both have a mechanistic role in cell survival and the inhibition 
of apoptosis, a cellular process essential for metastasis (261, 269, 270). Their 
expression was increased 7.29 and 3.36-fold respectively suggesting downregulation 
of apoptotic pathways in CPM.  
Increased expression of CYR61, CXCL12, CTGF and CSTB suggest an invasive, 
epithelial-mesenchymal phenotype. CYR61 promotes migration, invasion a loss of 
polarity and adhesion (261, 271), increased expression correlates with EMT, 
metastasis and poor prognosis (271, 272). CXCL12 triggers proliferation, migration, 
angiogenesis, invasion and metastasis in vitro (273) and correlates with distant 
recurrence and poor OS (274). CTGF encodes a matricellular protein with a role in 
fibrosis, inflammation and connective tissue remodelling, high expression is noted in 
the CMS4 subtype suggesting a role in EMT (261, 275). CSTB encodes a cystatin 
which participates in the dissolution and remodelling of connective tissue and 
basement membrane in tumour invasion and metastasis, high expression is found in 
metastatic CRC and correlates with decreased OS (276). Their expression of CYR61, 
CXCL12, CTGF and CSTB were increased 4.24, 3.64 and 3.49 and 3.41-fold 
respectively suggesting EMT in the development of CPM.  
NR2F1 expression was increased 3.53-fold in CPM (261). NR2F1 is upregulated in 
dormant cancer cells, blocking NR2F1 in vivo results in a rapid switch from dormancy 
to proliferation and systemic recurrence (277). Cancer cell dormancy may be an 
important mechanism in the recurrence of CPM from dormant cell populations following 
CRS & HIPEC. 
DCN can initiate several signalling pathways including ERK and EGFR leading to 
growth suppression, its expression was increased 3.3-fold in CPM, this was 
unexpected and in contrast to the literature  (278). In vitro reduced DCN expression 




motility, proliferation and invasion (278). Clinically reduced expression of DCN is 
associated with the development of metastasis in both breast and lung cancer (278). 
Phosphatase And Tensin Homolog (PTEN) is a tumour suppressor gene capable of 
inactivating the PI3K-dependent signalling pathway (261). PTEN expression was 
increased 3.25-fold in CPM, this was unexpected and in contrast to the literature. There 
is a gradual decline in the levels of PTEN in the sequence of transition from normal to 
polyp to carcinoma to distant metastasis. PTEN levels are inversely correlated with 
clinical severity (TNM stage, reduced survival) in CRC (279). 
NF-κB Inhibitor Alpha, (NF-κBIA) encodes a protein which inhibits the NF-κB 
transcription factor by masking nuclear localisation signals keeping NF-κB sequestered 
in the cytoplasm and blocking transcription factor binding (261). NF-κBIA expression 
was increased 3.24-fold in CPM, its upregulation may reflect increased NF- κB activity 
in the development of CPM. NF-κB activity in cancer cells can be thought of as a 
malignant reflection of its normal behaviour in protecting the organism from danger, 







Table 4-4 The top 10 genes with significantly increased expression (FDR<0.1 in 
CPM samples compared with primary CRC samples 
Rank Gene ID Fold 
change 
FDR P-value 
1 CD53 7.29 5.87 x 10-05 
2 CYR61 4.24 3.12 x 10-04 
3 CXCL12 3.64 9.25 x 10-04 
4 NR2F1 3.53 7.09 x 10-04 
5 CTGF 3.49 1.55 x 10-04 
6 CSTB 3.41 6.13 x 10-04 
7 TSC22D3 3.36 3.94 x 10-04 
8 DCN 3.30 6.19 x 10-05 
9 PTEN 3.25 9.28 x 10-04 




























Heatmap depicting differential genes expression in CPM and matched primary CRC. 
Sample type is indicated at the upper border of the heatmap, CRS blue = CPM, P red 
= primary. This figure is reprinted from Hallam et al, 2020, figure 2 (242). 







Principle component analysis depicting differential genes expression in CPM and 
matched primary CRC.  
  
       Primary 
       CPM 
Figure 4-3 Principal component analysis, differential gene expression CPM 




4.2.2.2 Differential gene expression profile Poor vs. Good prognosis CPM 
KEGG pathway analysis was performed to identify the enriched biological functions 
among the differentially expressed genes. Differentially expressed genes participated 
in a variety of functions. Pathways identified are detailed in table 4.5. The most 
enriched pathways include those involved in endocytosis, metabolism, phagocytosis, 
cell movement and architecture, bacterial and viral cell infection, transcription and the 






Table 4-5 KEGG pathway enrichment analysis, poor vs. good prognosis CPM, 
p= <0.05 
Gene set Class KEGG pathway Enrichment 
score 
P-value 
has04144  Cellular Processes; 
Transport and 
catabolism 
Endocytosis 11.67 8.56 x10-6 
hsa00130 Metabolism; 
Metabolism of 





5.07 6.28 x10-3 




of epithelial cells 4.76 8.56 x10-3 




infection 4.14 0.02 

















hsa04966 Organismal Systems; 
Excretory system 


















Citrate cycle (TCA 
cycle) 3.20 0.04 
hsa01230  Biosynthesis of 
amino acids 
3.20 0.04 
hsa04520 Cellular Processes; 
















One hundred and fifty-nine genes showed increased expression in poor prognosis 
CPM compared with good prognosis (Figure 4.6 and Figure 4.7). The full list can be 
seen in appendices, table S5. The 10 genes with the highest fold change of known 
significance are discussed below, (table 4.6).  
The expression of CEACAM1, a member of the carcinoembryonic antigen (CEA) 
immunoglobulin family was increased 8.27-fold in poor prognosis CPM (261). Cellular 
activities of CEACAM1 include adhesion, the inhibition of differentiation, apoptosis, 
disruption of tissue architecture and the inhibition of NK cell immune-mediated death 
(281). CEACAM1 expression correlates with metastasis and reduced survival in CRC 
(281). CEA levels are not routinely measured in patients with CPM, and it would be 
interesting to see whether this is reflected in serum CEA levels of patients with 
colorectal cancer. Novel therapies in the form of CEA TCB IgG-based T-cell bispecific 
antibodies result in immune-mediated tumour lysis in tumours overexpressing CEA, a 
potential therapeutic target in patients with CPM given the high expression of 
CEACAM1 (282).  
Genes regulating cell survival and inhibiting apoptosis were upregulated in poor 
prognosis CPM suggesting rapid and unchecked tumour cell growth. BCYRN1, a small 
non-messenger RNA and RELB Proto-Oncogene, (RELB) promote cell proliferation, 
survival, inhibit apoptosis and correlate with tumour stage and size (280, 283). Their 
expression was increased 7.96 and 6.17-fold respectively in poor prognosis CPM. 
DCAF12 is an apoptosis regulator (261), expression was increased 6.17-fold in poor 
prognosis CPM (284).  
Genes regulating transcription, cell growth and angiogenesis were upregulated in poor 
prognosis CPM suggesting a rapid growth. VEZF1 is an endothelial cell-specific 
transcription factor involved in angiogenesis and lymph-angiogenesis (261, 285). 
VEZF1 expression was increased 10.4-fold in poor prognosis CPM suggesting a rapid 
rate of angiogenesis, lymph-angiogenesis in keeping with metastatic growth in the poor 
prognosis cohort. POLR3GL encodes an RNA polymerase (261), its expression was 
increased 6.05-fold in poor prognosis CPM suggesting an increased rate of 
transcriptional activity. FEM1C expression was increased 5.69-fold in poor prognosis 




the cell cycle from G2 – S phase, perhaps indicating an increased rate of cell growth 
(286). KHDRBS3 activities include pre-mRNA splicing and cell cycle control. 
KHDRBS3 expression was increased 5.42-fold in poor prognosis CPM. Its function has 
only been studied in vitro where it is downregulated as cancer cell lines become 
immortalised.  
AXIN1 encodes a cytoplasmic protein which forms the ß-Catenin destruction complex, 
a negative regulator of the WNT signalling pathway (23). AXIN1 expression was 
increased 5.42-fold in poor prognosis CPM which suggests increased activity of the 












Table 4-6 The top 10 genes with significantly increased expression (FDR<0.1) 
in poor prognosis CPM 
 




VEZF1 -10.40 3.76 x10-05 
2 CEACAM1 -8.27 1.83 x10-03 
3 BCYRN1 -7.96 7.50 x10-05 
4 RP11-192H23.5 -6.22 2.38 x10-04 
5 RELB -6.17 9.50 x10-04 
6 DCAF12 -6.17 1.36 x10-05 
7 POLR3GL -6.05 1.48 x10-03 
8 FEM1C -5.69 1.87 x10-03 
9 AXIN1 -5.42 1.67 x10-04 






Five genes showed decreased expression in poor prognosis CPM compared with good 
prognosis, however, none had a fold change ≥ 1.5 suggesting a minimal difference in 






Table 4-7 The five genes with significantly reduced expression (FDR<0.1) in 








1 KIAA0319L 1.30 2.89 x10-03 
2 CORO7 1.16 7.36 x10-04 
3 DIP2C 1.13 1.90 x10-04 
4 STK38 1.05 6.38 x10-05 






4.2.2.3 Correlation between metastasis development, prognosis and CMS and 
CRIS subtypes 
Amongst the 51 primary CRC and CPM samples, 35 were representative of each CMS 
subtype, the remaining 16 samples did not have a consistent pattern within one of the 
four CMS subtypes, (Table 4.8, Figure 4.4). Comparison of the CMS subtypes in 
primary or CPM groups and prognostic groups within CPM revealed the following 
patterns. Firstly, there appeared to be a transition from primary CRC between CMS 
subtypes. No primary CRC samples were classified as CMS4 (mesenchymal subtype 
characterized by prominent transforming growth factor activation, stromal invasion and 
angiogenesis) compared to 31% of CPM, P-value 0.085. Secondly, patients with poor 
prognosis CPM were more commonly CMS4, 46% vs. 15%, P-value 0.005, (table 
4.10). Whilst CMS were identified from a largely early stage cohort of primary CRC 
(59), they have subsequently been validated as prognostic in the setting of metastatic 


















Table 4-8 CMS classification primary vs. CPM 
 Non-
consensus 
CMS1 CMS2 CMS3 CMS4 Total 
Primary 10 (40) 4 (16) 6 (24) 5 (20) 0 (0) 25 
CPM 12 (46) 1 (4) 3 (12) 2 (7) 8 (31) 26 
Fishers exact P-value 0.085, values in parenthesis percentages 
 
Figure 4-4 Sankey diagram of the CMS transition from primary to CPM 
Sankey diagram showing the transition in CMS type from primary CRC to matched 





Amongst the 51 primary CRC and CPM samples, 42 were representative of each CRIS 
subtype, the remaining nine samples did not have a consistent pattern within one of 
the four CMS subtypes, (Table 4.9, Figure 4.5). There was no significant difference in 
CRIS classification between primary and CPM, P-value 0.365, or between good and 
poor prognosis CPM, P-value 0.148, (table 4.11). The non-concordance with CMS 
subtypes may be a reflection of the increased stromal mesenchymal tissue present in 
patients with CPM. As CRIS classification is based only on tumour cells such changes 













Table 4-9 CRIS classification primary vs. CPM 
 Non-
consensus 
CRISA CRISB CRISC CRISD CRISE Total 
Primary 4 (16) 6 (24) 4 (16) 8 (32) 0 (0) 3 (12) 25 
CPM 5 (19) 4 (16) 7 (30) 5 (19) 3 (12) 1 (4) 26 
















Samkey diagram showing the transition in CRIS type from primary CRC to matched 
CPM.  




Table 4-10 CMS classification good vs. poor prognosis CPM 
 Non-
consensus 








2 (15) 1 (8) 3 (23) 1 (8) 6 (46) 13 
Fishers exact P-value 0.005, values in parenthesis percentages 
 
Table 4-11 CRIS classification good vs. poor prognosis CPM 
 Non-
consensus 








1 (8) 2 (15) 5 (39) 2 (15) 3 (23) 0 (0) 13 































Heatmap depicting differential genes expression in good and poor prognosis CPM. 
Sample type is indicated at the upper border of the heatmap, CRS blue = CPM, P red 
= primary. This figure is reprinted from Hallam et al, 2020, figure 2 (242). 







Principle component analysis depicting differential genes expression in good and poor 
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       CPM 




4.2.3 Methylation  
4.2.3.1 Methylation Microarray Analysis, primary CRC vs. matched 
metachronous CPM 
Assay performance was assessed initially using the Illumina GenomeStudio 
Methylation Module. Thirty-two samples in total were hybridised successfully to the 
Illumina HumanMethylation EPIC microarrays. All arrays passed the manufacturers 
quality control metrics for DNP, Biotin staining, extension, hybridisation, target 
removal, specificity, negative, non-polymorphic controls and bisulphite conversion. 
Data pre-processing and quality control was carried out using the ChAMP pipeline in 
R studio.  All probes were detected as expected in the dataset, 411 control, 865918 
methylated and 865918 unmethylated probes. The following probes were removed 
during filtering: probes with a detection P-value above 0.01, (20139) probes with a 
bead count of <3 in at least 5% of samples, (8424), non-CpG probes, (2788) SNP 
probes, (77224), multi-hit probes (49), and probes located on the X and Y 
chromosome, (16650). The final number of probes included in the analysis was 
740644. Quality control can be seen in appendices figure S1 and table S6. 
4.2.3.2 Differential methylation at the probe level, primary CRC vs. matched 
metachronous CPM 
DMPs were called between the primary CRC and CPM with a BF of 4, (Table 4.12). 
Two probes were significantly differentially methylated The top-ranked differentially 
methylated probe was cg04146982 (chr8:144,943,810-144,943,810, hg19 
coordinates), which tags a CpG dinucleotide 3651 bp upstream of the transcription 
start site of gene Epiplakin 1 (EPPK1) (290). Review of RNAseq data revealed the 
expression of EPPK1 was decreased in CPM vs. matched primary CRC (Figure 4.8). 
EPPK1 is part of the Plakin family an important component of the cell cytoskeleton. 
Plakins are critical in the regulation of cell adhesion, migration and proliferation as well 
as playing a key role in mediating signalling transduction such as Wnt and ERK1/2 
signalling (261). The expression of EPPK1 is increased in CRC (291). Whilst plakins 
have no therapeutic agents which specifically target them several anticancer drugs are 





The other DMP was cg12209861 (chr4:37,459,078-37,459,078, hg19 coordinates), 
this CpG dinucleotide 3526 bp upstream of the transcription start site of gene 
Chromosome 4 Open Reading Frame 19, (C4orf19). C4orf19 is a protein-coding gene 




Table 4-12 Differentially methylated CpG sites, CPM vs. primary CRC 
Probe ID Beta value BF Adj. P Gene name 
cg04146982 0.79 34.5 5.67 x 10-16 EPPK1 
cg12209861 0.13 7.1 0.059 C4orf19 
Beta value, the proportion of methylation at a given locus ranges from 0 for 
unmethylated to 1 fully methylated. BF Bayes factor, adjusted P, the P-value 








Figure 4-8 Box plot of Epiplakin expression CPM vs. primary CRC 
Gene expression of EPPK1 in the retrospective patient cohort. The median expression 
of EPPK1 was 3.5 (IQR 156.25) in CPM and 58 (IQR 135) in primary CRC (Wilcoxon 






4.2.3.3 Differential methylated regions, primary CRC vs. matched 
metachronous CPM 
DMRs were called between primary CRC and CPM via the dmrLasso function of the 
CHAMP pipeline (Table 4.13). The top 10 most significant DMRs were located at 
chr11:2160904-2161586, which tags an intron of gene IGF2. Chr19:37157318-
37157945 which tags an exon of ZNF461. Chr15:79383167-79383980 which tags an 
exon of RASGFR1. Chr18:35145983-35147090 which tags an exon of CELF4. 
Chr19:58609269- 58609987 which tags an exon of ZSCAN18. Chr13:78493229-
78493712 which tags an exon of gene EDNRB. Chr6:28602543-28603027 located 
18,554 bp before gene ZBED9. Chr5:135415693-135416613 which tags an exon of 
gene VTRNA2-1. Chr19:58458572-58459358 which tags an exon of ZNF256 and 
chr5:38258007- 38259243 which tags an exon of EGFLAM. The complete list of DMR 
between primary CRC and CPM can be seen in appendices table S7. 
 
Insulin-Like Growth Factor 2 (IGF2) is a growth factor and commonly used marker of 
the CIMP phenotype (261). Methylation of IGF2 is associated with reduced OS in 
patients with metastatic CRC (292). The insulin/IGF system plays a key role in the 
development and progression of CRC. Hyperactivation of the insulin/IGF pathway 
establishes mitogenic and pro-angiogenic signals favouring neoplastic transformation 
of colonic epithelium. The insulin/IGF system contributes to resistance to 
chemotherapy and anti-EGFR antibodies by increasing PI3K/Akt signalling which 
hinders apoptotic signals desensitising CRC cells to the effects of these treatments 
(293). 
 
ZNF461, ZSCAN18 and ZNF256 are transcriptional regulators commonly methylated 
in CRC and overexpressed in metastatic CRC (261, 294). ZNF461 is associated with 
the progression of non-small cell lung cancer, its role in the development of colorectal 
metastasis is unknown but given their role in transcription regulation, this suggests an 
increased rate of cell growth in CPM (295). RASGRF1 is commonly methylated in 
CRC, its hypermethylation correlates with tumour stage, LN metastasis and reduced 




suggests dysregulation of the MAPK pathway and resulting increased cell proliferation 
and differentiation in CPM (22). 
 
EDNRB encodes a G protein-coupled receptor which regulates several processes 
including angiogenesis and the stimulation of cell growth and division (261). 
Hypermethylation of EDNRB and its decreased expression results in increased cell 
proliferation, angiogenesis and metastasises (297). EDNRB expression is reduced in 
several metastatic cancers though its exact role in the process has not been described 
(298).  
 
VTRNA2-1 is a tumour suppressing lncRNA, its hypermethylation abolishes its 






Table 4-13 The top 10 differentially methylated regions, (DMRs), CPM vs. 
primary CRC 












DMR1 chr11 2160904 2161586 682 0.002 IGF2 302 
DMR2 chr19 37157318 37157945 627 0.003 ZNF461 39 
DMR3 chr15 79383167 79383980 813 0.003 RASGRF1 195 
DMR4 chr18 35145983 35147090 1107 0.003 CELF4 196 
DMR5 chr19 58609269 58609987 718 0.003 ZSCAN18 61 
DMR6 chr13 78493229 78493712 483 0.003 EDNRB 70 
DMR7 chr6 28602543 28603027 484 0.004 ZBED9 32 
DMR8 chr5 135415693 135416613 920 0.005 VTRNA2-1 24 
DMR9 chr19 58458572 58459358 786 0.005 ZNF256 52 






4.2.3.4 Copy number alteration, primary CRC vs. matched metachronous CPM 
 
 
Comparison of CNA between primary and CPM did not identify any significant 
differences at a stringent P-value of < x10-10     however a number of CNA were identified 
at a lower significance threshold, p=2.78 x10-07 suggesting increase or decrease in the 
relevant genes activity, appendices table S8. The top 10 CNAs can be seen in table 
4.14. 
Genes showing CNA gains of known significance in patients with CPM included; 
TRIM3, 5, 6, 21 and 22, TRIM proteins are part of the E3 ubiquitin ligase family 
responsible of the post-translational modification of oncoproteins and tumour 
suppressor proteins (261). They have diverse roles in transcriptional regulation, cell 
growth, apoptosis, development and tumorigenesis (261, 300).  
MT1A, 2A, 3, 4 encode proteins of the metallothionein family, MT are oxidative stress-
induced proteins capable of transcription factor regulation. In oesophageal and CRC 
MT protein expression correlates with LN and distant metastasis, chemoresistance and 
reduced survival (301, 302).  
MMP26 encodes a matrix metalloproteinase a protein known to promote cell invasion 
and cancer progression in several cancer types (261). ILK is overexpressed in a 
diverse array of cancers including colorectal. ILK expression correlates with cell 
migration, invasion, EMT, metastasis and chemoresistance (303).  
POLR2C, APBB1 and TAF10 are transcriptional regulators (261).TAF10, APBB1, 
RRM1, CCKBR and UBQLN3 regulate cell cycle progression, proliferation and cellular 






Table 4-14 The top 10 CNAs, CPM vs. primary CRC 
Chr Start End Type Count Score GW_P Gene 
chr11 Gain 3817692 3818253 22 0.91 2.78 X10-07 NUP98 
chr11 Gain 3825449 4629195 22 0.91 2.78 X10-07 
RRM1 
TRIM21 




chr11 Gain 5705995 5705995 22 0.91 2.78 X10-07 TRIM5 
chr11 Gain 5712109 6518263 22 0.91 2.78 X10-07 












chr16 Gain 56635680 56645731 22 0.91 2.78 X10-07 
MT1A, 2A, 3, 
4 
chr16 Gain 57333722 57335017 22 0.91 2.78 X10-07 TRNALeu 
chr16 Gain 57495650 57503371 22 0.91 2.78 X10-07 POLR2C 
chr16 Gain 71842906 71843647 22 0.91 2.78 X10-07 AP1G1 
Located on chromosome 11 and 16, P-value of 2.78 x10-07 were gains located on 






4.2.3.5 Methylation Microarray Analysis, Poor vs. Good prognosis CPM  
 
Twenty-four samples in total were hybridised successfully to the Illumina Human 
Methylation EPIC microarrays. All arrays passed the manufacturers quality control 
metrics for DNP, Biotin staining, extension, hybridisation, target removal, specificity, 
negative, non-polymorphic controls and bisulphite conversion. 
Data pre-processing and quality control was carried out with the ChAMP pipeline in R 
studio.  All probes were detected as expected in the dataset, 411 control, 865918 
methylated and 865918 unmethylated probes. The following probes were removed 
during filtering: probes with a detection P-value above 0.01, (18586) probes with a 
bead count of <3 in at least 5% of samples, (6550) , non-CpG probes, (2806) SNP 
probes, (77592), multi-hit probes (49), and probes located on the X and Y 
chromosome, (16801). The final number of probes included in the analysis was 
743534. Quality control can be seen in appendices figure S1 and table S6. 
 
4.2.3.6 Differential methylation at the probe level, Poor vs. Good prognosis 
CPM 
 
DMPs were called between the good and poor prognosis CPM with a BF of 4, (Table 
4.15). Three probes were significantly differentially methylated. The top-ranked 
differentially methylated probe was cg07951355 (cr1:40123717) which tags an 
intergenic region 1076 bp before gene NT5C1A. Cg25909064 (chr11:120081487-
120082345) which tags an intron of gene OAF and cg12977942 (chr5:92839309-
92839309) which tags an intron of gene NR2F1-AS1 (290).  
 
NT5C1A helps to regulate adenosine in conditions of ischemia and hypoxia which are 
typical in a rapidly growing aggressive tumour such as poor prognosis CPM (290).  
NR2F1-AS1 is a lncRNA which regulates tumour cell growth and quiescence (304). 
NR2F1-AS1 is upregulated in oxaliplatin resistant hepatocellular carcinoma (HCC) in 




HCC cells (305). Oxaliplatin is a commonly used chemotherapy agent in primary CRC 
and CPM, both systemically and in HIPEC, if NR2F1‐AS1 is capable of mediating 
resistance in CRC this would contribute to the poor prognosis in this cohort of CPM. 
OAF encodes a poorly described protein whose overall function or prognostic 






Table 4-15 Differentially methylated CpG sites, good vs. poor prognosis CPM 
Probe ID T BF Adj. P Gene name 
cg07951355 -6.68 6 0.47 NT5C1A 
cg25909064 -5.72 4 0.47 OAF 
cg12977942 -5.63 4 0.47 
NR2F1-AS1  
T: the t value (the size of the difference relative to the variation in the sample) P the 







4.2.3.7 Differential methylated regions, Poor vs. Good prognosis CPM 
DMRs were called between primary CRC and CPM via the dmrLasso function of the 
CHAMP pipeline (Table 4.16). Six significant DMRs were located at chr10:134600295-
134600919, 758 bp following gene NKX6-2. Chr12:133464419-133464892 which tags 
an exon of gene CHFR. Chr10:8096305- 8096991 which tags an exon of gene GATA3. 
Chr16:54972078-54973579 located 3683 bp following gene IRX5. Chr20:30639816- 
30640256 tags an exon of gene HCK and chr11:2397201-2397655 which tags an 
intron of gene BC019904. 
  
NKX6-2, GATA3 and IRX5 encode transcription regulators, their hypermethylation 
suggests an increased rate of growth in poor prognosis CPM  (261). GATA3 regulates 
tumour angiogenesis, in vitro it represses the expression of chemokine CXCL1 
allowing the extravasation of proangiogenic monocytes (306). IRX5 is found in many 
cancers and regulates genes controlling apoptosis, it is also thought to reduce the 
sensitivity to the cytostatic effect of TGF- β (307). The expression of IRX5 is correlated 
with its neighbouring lncRNA CRNDE-h suggesting that the expression of both genes 
is under a level of coordinate control. In CRC high expression of CRNDE-h is 
associated with reduced OS (307).  
 
CHFR regulates cell cycle progression and entry into mitosis and functions as a 
negative regulator of NF-κB (308). CHFR is epigenetically silenced by 
hypermethylation resulting in angiogenesis, cell migration, cytokine production and cell 
survival in vitro, suggesting a loss of CHFR tumour suppressor function in CPM. 
Clinically in CRC hypermethylation of CHFR is associated with LN metastasis and 
reduced OS (309).  
 
Proto-Oncogene HCK is a member of the Src family of tyrosine kinases found in 
hematopoietic cells (261). HCK plays an important role in the regulation of innate 
immune responses (261). Pho et al found that high HCK levels correlate with reduced 
survival of patients with CRC and that in a mouse model HCK promotes the growth of 




and HCK oncogene activity. BC019904 encodes a poorly described gene, its 
significance is unknown in CRC (261). 
 
 
Table 4-16 Differentially methylated regions, (DMRs) good vs. poor prognosis 
CPM 












DMR_1 chr10 134600357 134600919 562 0.007 NKX6-2 569 
DMR_2 chr12 133464496 133464737 473 0.003 CHFR 91 
DMR_3 chr10 8096311 8096991 680 0.006 NA 509 
DMR_4 chr20 30639816 30640256 440 0.009 HCK 71 
DMR_5 chr16 54972078 54973579 1501 0.015 NA 179 







4.2.3.8 Copy number alteration, Poor vs. Good prognosis CPM 
Comparison of CNA between the CPM prognostic groups identified 34 gene losses at 
chromosomes 3, 4, 14, 15, 17 and 19, these are detailed in appendices table S9. 
CNA losses clustered in the RAS-MAPK-ERK signalling pathway suggesting 
dysregulation in poor prognosis CPM. The RAS oncogenes RAB8A and RAB34 are 
small GTPases capable of activating the expression of genes involved in cell growth, 
differentiation and survival (261). FGF5 regulates cell proliferation and differentiation, 
FGF5 interacts with ERK, FGF/ERK signalling is capable of maintaining pluripotency 
and driving differentiation  (261, 311). BMP3 hypermethylation is associated with the 
CIMP+ phenotype. Epigenetic inactivation of BMP3 is associated with the activation of 
the RAS-RAF-MEK-ERK signalling pathway (312).  
PTPN21 and VASH1 regulate cell growth and angiogenesis (261), PTPN21 and 
FAM32 regulate the cell cycle and apoptosis, ZKSCAN7 regulates transcription and 
IGFBP7 cell growth. CNA loss suggests increased rates of unchecked growth in poor 
prognosis CPM (261).  
RFTN1 regulates T and B-cell antigen receptor-mediated signalling, antibody 
production and cytokine secretion (261). CNA loss of RFTN1 suggests immune 
evasion in poor prognosis CPM. 
BMP3 is a ligand of the TGF- β protein family (261), CNA loss of a TGF- β ligand may 
suggest dysregulation of the TGF- β pathway in poor prognosis CPM. 
Comparison of CNA between the CPM prognostic groups identified 19 gene gains at 
chromosomes 9, 10 and 11 these are detailed in appendices table S9. 
Genes showing CNA gains in patients with poor prognosis CPM included; SIT1 a 
negative regulator of T-cell antigen mediated signalling (261). RNF38 a gene involved 
in oncogenesis and signal transduction (261). MELK a gene regulating the cell cycle, 
proliferation and carcinogenesis (261). PAX5 a transcription factor regulating tissue 
differentiation (261). SHB a gene regulating signal transduction and angiogenesis 
(261). ZEB1 a gene involved in EMT by the recruitment of SMARA4/BRG1 and in 
promoting tumorigenicity by repressing stemness inhibiting microRNAs (261). DEAF1 




adhesion  (261). EPS8L2 a gene regulating actin cytoskeleton remodelling (261). 




4.2.4 Exome sequencing 
 
4.2.4.1 Sequencing quality 
 
In Accordance with Illumina sequencing coverage recommendations, 12x samples 
were multiplexed on a high output flow cell to give 50X coverage and a minimum of 
33.3 million reads. Across all six sequencing runs, we obtained a median of 59.6X 
coverage (2.3-166.4) with a median uniformity of 88.1% (70.67-89.32). The median 
Q30 score obtained was 91.73% (85.23-93.68). Sequences with a Phred score of <30 
were removed giving a base call accuracy of 99.9%, appendices, table S10. 
 
4.2.4.2 Primary CRC, somatic variations 
 
In the primary CRC, there were 112,420 somatic SNV’s, (primary, normal subtraction). 
Variants present at >1% in the dbSNP common or 1000-Genomes databases were 
filtered leaving 38,366 variants. Of these SNVs, 7267 were classified as non-
synonymous. Eighty variants were found in the dbSNP or 1000 genome database, the 
remainder were novel. Of the novel variants, 3657 had a PhastCons score of 1 
suggesting they are highly conserved and likely functionally important mutations. Four 
samples have a TMB ≥ 20 mut/Mb, median 69.79 (26.62 – 203.53) (313). Additionally, 
12,727 indels were identified. Variants present at >1% in the dbSNP common or 1000 
Genomes databases were filtered leaving 7956 variants. Of these 736 variants were 
classified as non-synonymous. Sixty-seven variants were found in the dbSNP or 1000 
genome database, the remainder were novel, of these 228 variants had a PhastCons 
score of 1 suggesting they are highly conserved and likely functionally important 
mutations. The Somatic SNV and indel mutations in primary CRC were compared to 
known CRC driver mutations reported on the IntOGen database. Mutations were 






  Table 4-17 Known CRC driver mutations identified in the primary CRC cohort 
BRAF MED24 KRAS ASPM TRIO CHD4 CNOT1 TAF1 
MECOM MED12 ARID1A BMPR2 PIK3R1 NUP107 NF1 PTPRU 
EGFR DIS3 TP53 FN1 APC CEP290 AXIN2 DNMT3A 
NRAS PTGS1 CASP8 TGFBR2 RAD21 SOS2 SOX9 CAD 
CUL1 AKAP9 MAP3K4 ACSL6 ATRX CHD9 BPTF PPP2R1A 
NUP98 PTPN11 BRWD1 FXR1 PTEN TP53BP1 GNAS SF3B1 
NTN4 SMAD4 CLSPN POLR2B TCF7L2 TCF12 ITSN1 CTNNB1 






4.2.4.3 Primary CRC, candidate driver mutations 
 
Somatic mutations were entered into the IntOGen pipeline to determine their function 
and to identify candidate driver mutations. OncodriveFM identified 46 candidate driver 
genes with high levels of functional mutation, (Q-value<0.05) in the primary CRC 
cohort, appendices, table S11. The top 10 potential driver genes are discussed below 
(Table 4.18).  KRAS mutation was present in 69% of primary CRC samples. Mutation 
of the KRAS oncogene activates BRAF kinases, driving the MAPK signalling pathway 
leading to tumour proliferation and growth (31). KRAS mutation is associated with a 
high risk of recurrence in keeping with a cohort of primary CRC which have developed 
CPM (32). The high proportion of KRAS mutation in this cohort meant they would have 
had a poor response to anti-EGFR therapy (33). Tumour suppressor mutations of p53 
and ARHGEF12 were present in 62% and 23% of samples respectively. p53 induces 
cell cycle arrest, senescence and apoptosis in response to cellular stress of DNA 
damage. The loss of p53 through mutation allows tumour growth to establish, loss of 
checkpoint control enables continued cycling and the acquisition of additional 
mutations enabling cells to breach the basement membrane, acquire invasive and 
migratory potential and undergo EMT ultimately resulting in CPM (315). Wild type 
ARHGEF12 results in reduced cell proliferation and migration in vitro suggesting a 
tumour suppressor role in CRC which has most likely been lost in this cohort of primary 
CRC (261, 316).  CAD mutation was present in 40% of primary CRC samples. CAD 
controls pyrimidine nucleotide biosynthesis, an essential step in cell proliferation. CAD 
levels are regulated by the MAPK cascade (261). Wild type CAD is a negative regulator 
of the WNT/β-catenin signalling pathway in CRC inhibiting cell migration (317). Loss 
of CAD through mutation is likely to result in dysregulation of the MAPK and WNT/β-
catenin pathways with unchecked growth and metastasis.  
NME1-NME2 mutation was present in 30% of primary CRC, the function of NME1-
NME2 is poorly described though mutations are commonly found in highly metastatic 
cells such as neuroblastoma (261). NMD3 and SDHA are ribosome biogenesis factors 
present in 31% of primary CRC, and components of the mitochondrial respiratory chain 
present in 15% of primary CRC respectively, their mutation may reflect the increased 




present in 23% of primary CRC.  CDC42BPA is a member of the serine/threonine-
protein kinase family, a downstream effector of CDC42 which plays a role in 
cytoskeleton reorganisation, cell migration and cell cycle regulation (261) mechanisms 
essential for the growth and metastasis of primary CRC.  AP1S1 mutation was present 
in 23% of samples, AP1S1 encodes part of the clathrin coat assembly complex. RCN3 
mutation was present in 23% of primary CRC, RCN3 encodes a protein essential for 
biosynthesis and transport. The significance of these mutations is unknown (261). Of 
note in the remaining potential driver genes identified by the IntOGen pipeline, APC 
mutations were identified in 38% of primary CRC samples. Mutational inactivation of 
the APC tumour suppressor gene results in inappropriate and consistent activation of 





Table 4-18 The top 10 genes with a bias towards a high functional level of 
mutation in primary CRC 
 
P-value Q-value PPH2 P-
value 
MA P-value SIFT P-value 
KRAS 3.66E-15 
1.03E-11 
0.044 0.000 0.000 
TP53 3.90E-12 
5.46E-09 
0.000 0.000 0.002 
CAD 1.36E-11 
1.27E-08 
0.001 0.000 0.005 
NME1-NME2 1.35E-08 
9.47E-06 
0.081 0.000 0.054 
NMD3 1.46E-06 0.001 0.001 0.001 0.011 
RCN3 3.43E-05 0.014 0.010 0.002 0.011 
CDC42BPA 3.38E-05 0.014 0.004 0.007 0.011 
SDHA 5.17E-05 0.017 0.020 0.000 0.054 
AP1S1 5.71E-05 0.017 0.029 0.000 0.054 
ARHGEF12 6.22E-05 0.017 0.003 0.015 0.011 
Identified using OncodriveFM. Intogen, Q-value <0.05, potential drivers in primary CRC 







4.2.4.4 Primary CRC, pathways 
 
Somatic mutations were entered into the IntOGen pipeline to determine the KEGG 
pathways with multiple accumulated mutations. Ten cancer KEGG pathways were 
identified including the CRC pathway, 12 metabolic pathways and 4 associated with 
DNA replication and repair (Table 4.19). The complete list of KEGG pathways identified 






Table 4-19 The top 10 KEGG pathways with accumulated mutations of high 
functional impact in primary CRC 
Kegg ID Name Class Q-value 
hsa00280 Valine, leucine and 
isoleucine degradation 
Metabolism  7.54E-06 
hsa05217 Basal cell carcinoma Cancers: Specific types 2.13E-05 
hsa05210 Colorectal cancer Cancers: Specific types 0.000 
hsa04726 Serotonergic synapse Nervous system 0.000 
hsa03008 Ribosome biogenesis in 
eukaryotes 
Genetic; Translation 0.000 
hsa00240 Pyrimidine metabolism Metabolism 0.000 
hsa05216 Thyroid cancer Cancers: Specific types 0.000 
hsa04730 Long-term depression Nervous system 0.000 
hsa03430 Mismatch repair  Genetic Replication 
and repair 
0.001 






4.2.4.5 CPM, somatic variations 
 
In the CPM cohort 244,531 somatic SNV’s were identified, (CPM, primary subtraction). 
Variants present at >1% in the dbSNP common or 1000 Genomes databases were 
filtered leaving 33,652 variants. Six thousand and twenty-three variants were classified 
as non-synonymous, 28 mutations were present in three samples, 286 were present 
in 2 samples, the remainder were present in 1 sample. Ninety-three variants were 
found in the dbSNP or the 1000 genome database, the remainder were novel, of these 
3241 variants had a PhastCons score of 1 suggesting they are highly conserved and 
likely functionally important mutations. Seven samples had a TMB ≥ 20 mut/mb, 
median 198.76 (162.5-321.99) (313). Additionally, 19,979 indels were identified. 
Variants present at >1% in the dbSNP common or 1000 Genomes databases were 
filtered leaving 4812 variants. Of these 313 variants were classified as non-
synonymous, 2 mutations were present in three samples, 21 were present in 2 
samples, the remainder were present in 1 sample. Sixty-nine variants were found in 
the dbSNP or the 1000 genome database, the remainder were novel, of these 61 
variants had a PhastCons score of one suggesting they are highly conserved and likely 
functionally important mutations. The Somatic SNV and indel mutations in CPM were 
compared to known CRC driver mutations reported in the IntOGen database. 
Mutations were identified in 69 of 95 known CRC driver genes, 51 were shared 
between the primary and CPM, 13 were novel, (table 4.20) (314). Of the somatic 
variants identified in CPM, 58,958, (29%) were present in the primary CRC, 205,552 
variants occurred exclusively in the CPM suggesting a significant accumulation of 







Table 4-20 Known CRC driver gene mutations identified in the CPM cohort 
 
  
BRAF MED24 KRAS ASPM TRIO CHD4 CNOT1 TAF1 
MED12 ARID1A NUP107 NF1 PTPRU DIS3 TP53 FN1 
APC DNMT3A NRAS PTGS1 CASP8 RAD21 SOX9 CAD 
CUL1 AKAP9 MAP3K4 ACSL6 ATRX CHD9 BPTF NUP98 
PTPN11 BRWD1 FXR1 TP53BP1 GNAS SF3B1 NTN4 POLR2B 
TCF7L2 CTNNB1 CDC73 ATM BCOR PIK3CA TBX3 NR4A2 
FOXP1 WIPF1 ITSN1 SRGAP3 SOS2 WT1 GATA3 MGA 
GOLGA5 SMAD2 ELF3 CREBBP SMC1A ACO1 ZC3H11A PPP2R1A 








Venn diagram showing the proportion of mutations exclusive to and shared between 
primary CRC and matched CPM. This figure is adapted from Hallam et al, 2020, figure 
1 (242).  
Figure 4-9 Mutations exclusive to and shared between primary CRC 




4.2.4.6 CPM, candidate driver mutations 
 
Somatic mutations were entered into the IntOGen pipeline to determine their functional 
importance and to identify potential driver mutations. OncodriveFM identified 265 
potential driver genes with high levels of functional mutation, (Q-value<0.05) in the 
CPM cohort. The top 10 potential driver genes are discussed below (Table 4.21). The 
full list can be seen in appendices, table S13. 
 
FLNB, SPTB, PPL, and SVEP1 regulate cell adhesion, invasion and the induction of 
EMT, their mutation in CPM explain in part the process of metastasis from primary to 
CPM through the loss of cell adhesion and polarity typical of EMT. FLNB mutations 
were present in 46% of CPM samples. FLNB is an actin-binding protein which anchors 
the cell onto plasma adhesion receptors such as integrins regulating the dynamic 
changes of the actin cytoskeleton in response to extracellular signals (261). FLNB 
deficiency in a xenograft mouse model increases angiogenesis and promotes tumour 
growth and metastasis (318). Alternate splicing of FLNB is strongly associated with 
EMT signatures in breast cancer (319). SPTB mutations were present in 46% of CPM. 
SPTB encodes a spectrin protein involved in cell shape and membrane integrity, 
mutations likely reflect changes in cell adherence, a hallmark of metastatic cancer 
(261). PPL mutations were present in 38% of CPM samples. PPL encodes periplakin, 
AKT1/PKB interacts with PPL suggesting a role in cell growth and survival (261). The 
expression of wild type PPL is reduced in CRC vs. normal tissue. Knockdown of PPL 
in vitro promotes cell proliferation, migration, invasion and EMT transition (320).  
SVEP1 mutations were present in 54% of CPM samples. SVEP1 is a cell adhesion 
molecule. SVEP1 expression is stimulated by TNFα a pro-inflammatory cytokine able 
to affect cell adhesion, migration and induce EMT (261, 321). These mutations suggest 
a mechanism for the development of metastasis and the CMS4 mesenchymal 
phenotype seen more commonly in the CPM cohort.  
 
p53 tumour suppressor mutation was present in 38% of CPM, the loss of p53 through 
mutation allows tumours to establish, invade and metastasis as discussed in more 





PDE4DIP, RIOK2 and CDC16 are cell cycle regulators, their mutation suggests 
increased rates of cell growth and unchecked proliferation in CPM. PDE4DIP was 
mutated in 46% of CPM samples. PDE4DIP functions as an anchor, sequestering 
components of the cAMP-dependant pathway to Golgi and or centrosomes (261). This 
is a crucial process in cell migration, mitosis and cell-cycle progression (261). RIOK2 
mutations were present in 31% of CPM. ROIK2 is a serine/threonine biogenesis-
associated protein kinase regulating cell cycle progression (261). RIOK2 
overexpression promotes cell proliferation and loss to cell cycle exit and apoptosis in 
glioblastoma cells (322). CDC16 encodes a ubiquitin ligase component of the 
anaphase-promoting complex, APC/C a cyclin degradation system governing the exit 
from mitosis by the degradation of G1 and mitotic checkpoint regulators. In vitro 
overexpression of CDC16 suppresses invasion and metastasis of lung cancer cells  
(323).  
 
NUP98 and CDC16 are mitotic checkpoint regulators. Mutation of mitotic checkpoint 
regulators may result in the accumulation of additional mutations in CPM. NUP98 
mutations were present in 31% of CPM samples.  Nuclear pore complexes (NPCs) 
regulate the transport of macromolecules between the nucleus and cytoplasm. NUP98 
is known to form a complex with RAE1 preventing aneuploidy through the inhibition of 
premature securing degradation during mitosis (261). RAE1 and NUP98 play a critical 
role in regulating chromosomal segregation through the inhibition of securing 
ubiquitination mediated by the anaphase-promoting complex, (APC/C) (261). CDC16 
mutations were present in 23% of CPM samples. CDC16 encodes a ubiquitin ligase 
component of the anaphase-promoting complex, APC/C a cyclin degradation system 
governing the exit from mitosis by the degradation of G1 and mitotic checkpoint 
regulators. In vitro overexpression of CDC16 suppresses invasion and metastasis of 
lung cancer cells suggesting a potential role in CRC metastasis (323). RRP7A 
mutations were present in 38% of CPM. RRP7A encodes a protein involved in 





Of note in the remaining candidate driver genes identified by the IntOGen pipeline, the 
following known CRC driver mutations were identified.  
 
HLA-A mutations were present in 54% of CPM samples. HLA-A is one of 6 major 
histocompatibility complex antigen alleles responsible for presenting antigens to T-
cells, which triggers the apoptosis of non-self-cells (261). T-cell infiltration of CRC is 
inversely correlated with HLA-A expression and improved DFS. HLA antigen loss is 
common in MSI-H CRC where immune selective pressure leads to cell proliferation 
with defects in antigen presentation (324).  
 
MSH6 mutations were present in 38% of CPM samples. MSH6 encodes a mismatch 
repair protein, MutS involved in the repair of both single-base mismatches and 
insertion-deletion loops (261). Mutations of MSH6 are associated with hereditary non-
polyposis colon cancer, colorectal and endometrial cancer (261). No patient in the 
prospective cohort had a family history of CRC, which would be expected for an 
autosomal dominant germline mutation resulting in an up to 70% lifetime risk of CRC, 
suggesting these mutations were somatic. Such mutations may result in microsatellite 
instability and have been associated with the presence of isolated peritoneal 
metastasis (18). Microsatellite instability was found in 46% of CPM samples, all had 
associated high TMB median 195.59 (162-321.99). 
 
APC mutations were identified in 38% of CPM samples, the same proportion mutated 
in primary CRC, section 4.4.4.2.  
 
TET2 mutations were identified in 23% of CPM samples. TET2 is a dioxygenase that 
catalyses the conversion of 5MC into oxidative products, resulting in active DNA 
demethylation (261). TET2 has emerged as an important tumour suppressor in cancer 
is one of the most frequently mutated genes in a wide range of cancer types. The 
regulation of DNA methylation by TET enzymes protects malignant transformation 
(325). TET2 is expressed in CRC it does, however, show reduced nuclear localisation, 
particularly in patients with distant metastasis suggesting a loss of function (326). DNA 




methylation, reactivation of active DNA methylation may, therefore, result in re-
expression of tumour suppressors (326). In vitro-nuclear export inhibitor, Leptomycin-
B can increase levels of 5HMC and is a potential therapeutic option for these patients 
in addition to inhibitors of DNA methyltransferases (326). CHD7 mutations were 
identified in 15% of CPM samples, CHD7 is a transcriptional regulator and regulator of 
chromatin (261). Amongst tumours with CIMP and resulting global hypermethylation 
CDH7 is commonly mutated suggesting aberrant chromatin regulation resulting from 
CDH7 mutation may contribute to the development of CIMP CRC (327). 
 
Mutation of RNF43, FAM123B and TSC1 key components of the Wnt pathway suggest 
Wnt dysregulation in CPM. RNF43 mutations were present in 23% of CPM samples. 
RNF43 encodes an E3 ubiquitin-protein ligase, a negative regulator of Wnt signalling 
which promotes the turnover of frizzled and LRP6 (261). In vivo inhibition of RNF43 
enhances Wnt/β-catenin signalling in contrast to R-spondin, which enhances Wnt 
signalling by inhibiting RNF43 (328). RNF43 mutations exist upstream of the Wnt 
pathway making them an interesting therapeutic target as they would inhibit the Wnt 
pathway despite the presence of downstream pathway mutations (328). FAM123B 
mutations were identified in 15% of CPM samples. FAM123B is a regulator of the Wnt 
signalling pathway interacting with the beta-catenin destruction complex. FAM123B 
can act as a positive Wnt regulator by promoting LRP6 phosphorylation or as a 
negative regulator acting as a scaffold protein for the beta-catenin destruction complex 
(329). FAM123B is commonly mutated in CRC resulting in its inactivation, tumours with 
FAM123B mutations exhibit a mesenchymal phenotype characterised by inhibition of 
the Wnt pathway (329). TSC1 mutations were identified in 23% of CPM samples. TSC1 
and TSC2 encode hamartin and tuberin, which form a functional complex affecting cell 
growth, differentiation and proliferation. TSC1 is a negative regulator of the mTOR 
signalling pathway, a promotor of cell growth (261). Mutation of TSC1 results in 
reduced survival for patients with CRC (330). Wild type TSC1 negatively regulates β-






CCND2 mutations were identified in 15% of CPM samples. CCND2 encodes a cyclin 
which forms a complex with CDK4 or CDK6 regulating cell cycle transition at G1/S 
(261). CCND2 expression correlates with proliferation and increased metastatic 






Table 4-21The top 10 genes with a bias towards high functional levels of 
mutations in CPM 
 






FLNB 1.38E-13 7.53E-10 1.00E-08 0.0001 0.000 
TP53 1.10E-12 3.00E-09 0.000 1.00E-08 0.002 
RIOK2 2.33E-12 3.73E-09 0.000 1.00E-08 0.001 
PDE4DIP 3.42E-12 3.73E-09 0.001 1.00E-08 0.001 
RRP7A 2.88E-12 3.73E-09 0.001 1.00E-08 0.001 
SPTB 1.35E-11 1.22E-08 0.000 1.00E-08 0.009 
PPL 1.92E-10 1.49E-07 1.00E-08 0.007 0.007 
NUP98 2.49E-10 1.70E-07 1.00E-08 0.008 0.008 
SVEP1 2.16E-09 1.31E-06 0.000 0.000 0.000 
CDC16 1.75E-08 7.35E-06 0.000 0.000 0.003 
Identified using OncodriveFM, IntOGen, Q-value <0.05, potential drivers in CPM CRC 









4.2.4.7 CPM, pathways 
 
Somatic mutations were entered into the IntOGen pipeline to determine the KEGG 
pathways with multiple accumulated mutations. The top ten KEGG pathways included 
6 concerning the immune system, one signalling, one metabolic and one cancer, (table 








Table 4-22 The top 10 KEGG pathways with accumulated mutations of high 
functional impact in CPM 
KEGG Name Class Q-value 
hsa04512 ECM-receptor 
interaction  
Signalling molecules and 
interaction 
1.90E-07 
hsa04940 Type I diabetes 
mellitus 
Endocrine and metabolic disease 1.90E-07 
hsa05330 Allograft rejection Immune diseases 2.09E-07 
hsa05332 Graft-versus-host 
disease 
Immune diseases 3.06E-07 
hsa05145 Toxoplasmosis Infectious diseases 6.45E-07 
hsa05310 Asthma Immune diseases 6.45E-07 
hsa05320 Autoimmune thyroid 
disease 
Immune diseases 9.86E-07 
hsa04672 Intestinal immune 
network for IgA 
production 










4.2.5 Prognostic groups 
 
Patients with poor prognosis CPM had a higher proportion of somatic mutations than 
patients with good prognosis, 55% of all mutations in CPM cohort vs. 45%. Of the 
somatic mutations identified in poor prognosis CPM, 115,860 (45%) were present in 
patients with good prognosis CPM, 145,089 (55%) variants occurred exclusively in 
patients with poor prognosis CPM (Figure 4.10). Patients with poor prognosis CPM 








Figure 4-10 Mutations exclusive to and shared between good and poor 
prognosis CPM 
Venn diagram showing the proportion of mutations exclusive to and shared between 










Table 4-23 Potential candidate variants, poor prognosis CPM 








(control) Gene ID 
4 C G 0.007 0.53 62.5 0 FAM13A 
18 G C 0.023 0.53 50 0 PIEZO2 
CPM identified through Fisher exact test, genomics workbench (Chr, chromosome, 





4.2.5.1 Candidate driver mutations for poor prognosis CPM 
 
Comparison of somatic mutations, (Fisher exact test, genomics workbench) in patients 
with good and poor prognosis identified two potential candidate genes, we must, 
however, note the high FDR of 0.53 indicating that these results are at high risk of 
being false positives (Table 4.23).  
 
FAM13A is a protein-coding gene it is known to interact with several pathways 
important in CRC including Wnt/ β catenin and TGFβ. FAM13A can activate the Wnt/ 
β catenin pathway by increasing the stability of β catenin, which accumulates and 
translocates to the nucleus driving gene transcription (333, 334). Knockdown of 
FAM13A reduces Wnt signalling in human lung cancer cells. FAM13A is inversely 
correlated with TGFβ, TGFβ can act as a tumour suppressor and tumour promoter 
(335). In early-stage cancers it inhibits cell growth and proliferation, in advanced 
cancers it contributes to disease progression and the induction of cell migration and 
metastasis (335). In vitro, TGFβ induces apoptosis in lung cancer cell lines and 
downregulates both the RNA and protein levels of FAM13A (335). Silencing FAM13A 
with FAM13 siRNA results in a downregulation of FAM13A, promoting Rho protein 
activity which results in a decrease in cell number and proliferation but an increase 
in random cell migration (335). FAM13A mutation in poor prognosis CPM suggests 
dysregulation of the Wnt and TGFβ pathways.  
PIEZO2 encodes a transmembrane mechanically activated ion channel protein (336). 
The PIEZO2 generated calcium signal activates the downstream RhoA pathway 
necessary for the regulation of the actin cytoskeleton (336). In breast cancer brain 
metastasis, PIEZO2 plays a key role in the ability of cells to sense and transduce 
mechanical cues from the environment conferring an advantage in the cells ability to 
proliferate, invade and migrate within their secondary environment (336). In 
glioblastoma cells, PIEZO2 knockdown results in tumour growth inhibition, reduced 
vascular density and vascular hyperpermeability (337). This effect was thought to be 
mediated through the reduced secretion of Wnt/ β catenin protein Wnt11 in PIEZ02 
knockdown cells (337). PIEZO2 mutation may have a role in the process of invasion, 




4.3 Discussion  
This study determined the gene expression, CNA, methylation and somatic mutation 
profile of primary CRC and matched metachronous CPM to determine whether there 
was a change associated with the development of CPM or predicting prognosis for 
patients with CPM. To our knowledge, this is the first such analysis in a cohort of 
patients with isolated CPM suitable for treatment with CRS & HIPEC. 
Comparison of patients with primary CRC and metachronous CPM identified biological 
changes associated with the transition from primary CRC to CPM. There was 
downregulation of markers of early CRC tumorigenesis in CPM (FABP6, DEFA6, 
DMBT1, OLFM4 and MUC2). The expression of genes promoting cell survival and 
inhibiting apoptosis was upregulated (CD53, TSC72D3 and NF-κB). Genes regulating 
cell growth, proliferation, transcription and angiogenesis were hypermethylated or 
altered via CNA or somatic mutation (IGF2, EDNRB, ZNF461, ZSCAN256, ZSCAN18, 
POLR2C, APBB1, TAF10, MT proteins, PDE4DIP, RIOK2, CDC16, NUP98 and 
CCND2). Hypermethylation, CNA and somatic mutation resulted in the inactivation of 
tumour suppressors and oncogene activation in CPM (TP53, VTRA2-1, TRIM 
proteins). These changes suggest a rapid rate of tumour growth unchecked by tumour 
suppressor or apoptotic mechanisms in CPM.  
Increased MAPK and Wnt/β-catenin pathway activation were noted in CPM. Gene 
expression of markers of colon stem cells and negative regulators of the Wnt pathway 
was reduced (OLFM4, DEAFA6), negative Wnt regulators contained somatic 
mutations (APC, RNF43, FAM123B and TSC1). and hypermethylation of MAPK 
pathway marker (RASFGFR1) suggesting persistent activation of MAPK and Wnt 
pathways in CPM. Multiple mutations of negative Wnt signalling regulators make this 
an attractive therapeutic target. Numerous agents have been developed targeting the 
Wnt pathway the majority of which are still at the clinical trial stage. Porcupine inhibitors 
mediate the palmitoylation of Wnt ligands blocking Wnt signalling. The porcupine 
inhibitor LGK974 inhibits the upstream negative Wnt regulator mutant RNF43 and 
would be a potential therapeutic target in the CPM cohort (338). 
CPM contained a high proportion of MSH6 somatic mutations which suggests a 




high TMB median 195.59 (162-321.99). Of patients with poor prognosis 57% were 
MSI-H TMB-H. Of these 15% were BRAF mutant, it is thought that BRAF mutation 
drives the poor prognosis in MSI-H tumours. TMB-H tumours display an increased neo-
antigen load and dense immune cell infiltration, they respond well to treatment with 
immune checkpoint inhibitors such as nivolumab and  pembrolizumab (339-341). 
The expression of genes regulating innate immunity was downregulated (DEFA6, 
DMBT1, MUC2) or altered via somatic mutations, (HLA-A antigen) suggesting immune 
evasion in the transition to CPM.  
The expression of genes suppressing invasion, migration and EMT were 
downregulated or hypermethylated (MUC2, MMP26, ILK, FLNB, SPTB, PPL, and 
SVEP1) and those triggering these processes upregulated (CYR61, CXCL12, CTGF, 
and CSTB). These changes suggest a mechanism by which CPM cells metastasise 
from the primary CRC. In keeping with changes in EMT regulators there appeared to 
be a transition in CMS subtypes towards CMS4 from primary CRC to CPM. The CMS4 
subtype is an interesting therapeutic target, TGFβ signalling inhibitors and targeted 
immunotherapies have been trialled with success in pre-clinical models to block cross-
talk between the tumour microenvironment and halt disease progression of stromal 
rich CMS4 CRC (61, 342).  
Methylation appeared to be dysregulated in CPM with somatic mutation of the TET2 
tumour suppressor and CDH7 chromatin regulator. Active DNA demethylation by TET 
enzymes is an important tumour suppressor mechanism in a range of cancer types. 
The CDH7 gene is commonly associated with global hypermethylation and the CIMP 
phenotype. The presence of TET2 mutations in the CPM cohort in addition to mutations 
of the CDH7 gene suggests potential benefit from methylation inhibitors in addition to 
other cytotoxic or immunotherapy (43, 49, 327).  
There was downregulation of CES2, a gene known to activate the prodrug irinotecan, 
a commonly used chemotherapy in the adjuvant treatment of primary CRC and CPM, 
(CES2). Resistance to the treatment of primary CRC may in part explain the 




Biological changes were noted in poor prognosis CPM distinct to those found in good 
prognosis CPM which may confer poor prognosis in this cohort. The expression of 
genes promoting transcription, cell growth, cycle, angiogenesis and inhibition of 
apoptosis were upregulated, (VEZF1, POLR3GL, FEM1C, KHDRBS3, BCYRN1 and 
DCAF12). There was increased expression and hypermethylation of oncogenes, 
(RELB, HCK). There was hypermethylation and CNA of regulators of transcription, cell 
growth, cycle and angiogenesis, (NKX6-2, GATA3, IRX5, ZKSCAN7, PAX5, DEAF1A, 
CHFR, PTPN21, VASH1, IGFBP7, SHB, PTPN21, FAM32 and MELK) These changes 
suggest a rapid rate of unchecked tumour growth in poor prognosis CPM. 
The expression of genes regulating the innate immune evasion was upregulated, 
(CEACAM1) along with hypermethylation of genes regulating the innate immune 
response, (RFTN1, SIT1) suggesting immune evasion in poor prognosis CPM. Novel 
therapies in the form of CEA TCB IgG-based T-cell bispecific antibodies may, 
therefore, be of benefit in this patient cohort, they result in immune-mediated tumour 
lysis in tumours overexpressing CEA (282). 
There was downregulation of gene expression of negative regulators of the Wnt 
pathway (AXIN1) and somatic mutations of key Wnt regulators (FAM13A). There was 
hypermethylation of MAPK and TGF-β pathway markers (RAB8A, RAB34, FGF5 and 
BMP3) suggesting persistent activation of MAPK, TGF-β and Wnt in poor prognosis 
CPM.  
There were hypermethylation and somatic mutation of genes regulating invasion, 
migration and EMT (NR2F1-AS1, ZEB1, EPS8L2 and PIEZO) suggesting an increased 
invasive and migratory capacity and the development of EMT in poor prognosis CPM. 
There was a correlation between poor prognosis and the CMS4 mesenchymal subtype 
which can be targeted by several novel therapies including  TGFβ signalling inhibitors 
and targeted immunotherapies (61, 342).  
There was hypermethylation of a gene known to mediate resistance to oxaliplatin, a 
commonly used chemotherapy in the treatment of primary CRC and CPM (NR2F1-




A weakness of this study is the lack of validation of the findings. Publicly available 
genomic datasets were searched for comparable patient cohorts. The Cancer Genome 
Atlas (TCGA) contains one dataset from Yaeger et al which used MK-IMPACT, a 
hybridisation capture-based NGS assay targeting a limited panel of 486 genes, the 
dataset contains 1134 patients with metastatic CRC, 52 patients had peritoneal 
metastasis, the metastasis sample sequenced was peritoneal in 11, 5 of these were 
primary CRC and 6 metachronous (343-345).  Of the mutations, Yaeger et al identified, 
three were shared with this CPM cohort, TP53, APC and RNF43, given the difference 
in methods used these results are not directly comparable (343-345). The Gene 
Expression Omnibus (GEO) contained no suitable datasets with isolated peritoneal 
metastasis for comparison (346). To confirm the findings, results will need to be 
validated on a prospective patient cohort. The transcriptome is a snapshot of cellular 
activity at a moment in time. Pathway activity may not be identified if it were not active 
at the time the tumour was removed and sectioned. It is encouraging however that the 
biological changes identified in the transcriptome appear to be reflected by those found 
in methylation and somatic mutation profiles. We must acknowledge that this is a small 
cohort of patients, the biological changes identified here form a starting point in 
identifying the tumour biology associated with the development of CPM and predicting 
poor prognosis disease.  
 
In conclusion, we have identified biological changes in the transcriptome, epigenome 
and genome associated with the progression from primary CRC to CPM and with poor 
prognosis CPM. When validated and used with known clinical prognostic markers this 
can be used to predict patient outcome and to define new therapeutic targets for 









Chapter 5 Developing a bio-molecular classifier to 
predict response to treatment with cytoreductive 
surgery and heated intraperitoneal chemotherapy in 






The preceding chapter has identified changes in the transcriptome, genome and 
epigenome associated with the transition from primary to CPM and associated with 
poor prognosis following CRS & HIPEC using NGS. NGS techniques identify 
thousands to millions of differentially expressed features, only a small number of these 
have established clinical significance which can be used to predict a particular 
phenotype or outcome such as survival or disease recurrence, a group of such features 
can be defined as a biomolecular classifier. 
Due to the costs of NGS, sample sizes are commonly small. As a result, the number 
of features identified is much greater than the number of samples. Datasets are 
complex and features connected via pathways (63). Mathematical methods such as 
machine learning have been developed to overcome these challenges and extract the 
significant features from NGS datasets. Biomolecular classifiers have been developed 
and are in clinical use for prognostication and therapeutic stratification in breast cancer 
(347, 348). 
Several studies have used the Cox proportional hazards regression models to identify 
biomolecular features associated with a phenotype of interest such as poor survival or 
disease recurrence in primary CRC (349, 350). Due to the high dimensionality of NGS 
data, the Cox proportional hazards model requires large training cohorts which would 
be difficult to achieve given the small number of patients suitable with isolated CPM 
which have been resected allowing sampling. Additionally, many NGS techniques are 
relatively high cost meaning large cohorts require significant funding. These papers, 
therefore, used large datasets from The Cancer Genome Atlas (TCGA) or gene 
expression omnibus (GEO).  
Machine learning classification models have been used for a variety of purposes in 
CRC, these have been applied to and validated using datasets taken from GEO. 
Diagnostic classifiers have aimed to differentiate with greater certainty CRC from 
benign or other types of cancer. Long et al applied a random forest model to GEO 
differentially expressed gene (DEG) datasets comparing CRC to adenoma and normal 
tissue to improve the diagnostic accuracy of CRC (351). Sun et al applied an SVM 




types of cancer (352). Prognostic classifiers have aimed to identify patients with CRC 
at high risk of recurrence and in need of further adjuvant treatments. Zhi et al applied 
an SVM model to a filtered list of differentially expressed genes taken from GEO 
datasets in metastatic and primary CRC to identify patients at high risk of metastasis 
(353). Xu et al applied an SVM model to a filtered list of differentially expressed genes 
to identify a prognostic signature (354). The model was developed and validated using 
GEO and TCGA datasets, it resulted in an 15 gene signature with 77% accuracy for 
the prediction of disease recurrence (354). Yang applied a random forest classifier to 
GEO DEG datasets in patients with and without recurrence to extract a 4x gene 
signature capable of predicting recurrence in stage II CRC, on validation its AUC was 
0.943 (355). Zhi et al applied SVM methods to five DEG GEO datasets to develop a 
classifier 40 gene classifier capable of predicting the development of metastasis in 
CRC. Predictive classifiers have aimed to identify those patients likely to respond to a 
particular treatment. Gan et al applied a random forest classifier to GEO datasets in 
patients with and without FOLFOX treatment response to predict treatment response 
to FOLFOX in patients with advanced CRC (356). 
Public datasets containing patients with CPM are however limited with no datasets 
containing patients with isolated CPM in the absence of another site of metastasis. 
There is merit therefore in applying a machine learning classifier to the RNA and 
methylation datasets from chapter 4 to identify a prognostic signature capable of 
predicting response to CRS & HIPEC for patients with CPM.  
The Biosigner package in R uses wrapper feature selection to restrict the dataset 
reducing the risk of overfitting and prediction variability (63).  The Biosigner package 
combines three binary classifiers to optimise the classifier performance according to 
the dataset structure (PLS-DA, SVM and RF) (63). The dataset is split into training and 
testing subsets by bootstrapping (63). The model is trained on the training set and its 
accuracy determined on the holdout test set (63). Features are ranked according to 
their significance in the model (63). The dataset is restricted to the selected features 
and steps 1 – 4 are repeated until the selected list of features are stable (Figure 5.1) 
(63). As the training and testing subsets are not separated, (resampling between 
selection rounds) the performance may be over-optimistic. External validation on a new 




Aim: To develop a biomolecular classifier (gene expression and methylation) capable 








Figure 5-1 Description of the Biosigner algorithm for feature selection 
Figure showing the workflow of the Biosigner algorithm. The dataset is split into training 
and testing subsets by bootstrapping, features are ranked according their importance, 
the dataset is restricted to selected features and the process repeated until the list of 

















5.2.1 Prospective patient cohort 
Prospective patients undergoing CRS & HIPEC for metachronous CPM were recruited 
from the peritoneal malignancy clinic between the 1st of July 2017 and the 1st of April 
2018. Patients were eligible for inclusion if they had CPM (adenocarcinoma), no extra-
abdominal metastasis, a CC0 resection and a PCI of < 12. Twenty-one patients were 
recruited. 
Thirteen patients had a DFS of 14 months (13–14 range) following CRS & HIPEC and 
formed the ‘good prognosis’ cohort, eight patients had a DFS of 5 months (3-12 range) 
and formed the poor prognosis cohort (Figure 5.2). Whilst all patients were a minimum 
of 12 months post-CRS & HIPEC it is likely that the follow up for the prospective cohort 
is incomplete, sometimes it takes several months for data regarding recurrence or 
death to feedback to the tertiary CRS & HIPEC centre meaning patients classified as 
good prognosis may have recurred. The poor prognosis cohort had significantly more 
men 63% vs. 54% p=0.018, right-sided primary tumours 50% vs. 23% p0.018, fewer 
N2 tumours 38% vs. 46% p=0.042, a higher PCI score 9 vs. 5, p=0.04 and patients 













Age 61 +/-11.52 61 +/-11 0.85 
 
 












































DFI, mean +/- SD 22 +/-10 19 +/-12 0.95 
PCI, mean +/- SD 5 +/-4 9+/-4 0.04 










Follow up, months,                
median (range) 










DFS median (range) 14 (13-14) 5 (3-12) 0.000 
OS median (range) 15 (15-15) 10 (7-13) 0.68 
(DFI, disease-free interval, PCI, peritoneal carcinomatosis index, CC score, 







Kaplan-Meier curve showing disease free survival in patients in the prospective patient 
cohort with good and poor prognosis following CRS & HIPEC for CPM. Log-rank 













5.2.2 RNAseq classifier 
 
A differential gene expression prognostic signature was identified using the Biosigner 
method in the retrospective cohort. The dataset was split into a 60% training and 40% 
testing subset. The signature was unstable on repeat with the recommended 
bootstrapping of 50x. Bootstrapping was therefore increased in 50x increments and 
the procedure repeated until the classifier remained stable upon repeat at a level of 
400x (357). 
The significant features identified by the classifier included genes GNG12, FKB10 and 
PRRX1. The resulting classifier had an area under the curve of 0.997 on the training 
subset. The performance of the resulting classifier on the hold out test set resulted in 
a classifier accuracy of 0.607 (Table 5.2 and Figure 5.3). 
GNG12 is a G-protein with activity in the PI3K-AKT, MAPK and RAS pathways (261) 
suggesting increased tumour proliferation and growth in the poor prognosis cohort. 
FKBP10 is a PPIase responsible for the acceleration of protein folding during protein 
synthesis. Its function in CRC has not been described in the literature. Ge et al found 
increased expression of FKBP10 in Renal cell carcinoma, knockdown in vitro resulted 
in a cell-cycle arrest at G0/G1, reduced cell proliferation, invasion and migration 
suggesting a role in tumour proliferation and the process of metastasis (358). PRRX1 
encodes a transcription co-activator, required for the induction of genes by growth and 
differentiation factors (261). PRRX1 is capable of inducing EMT in CRC cells in vitro, 
the expression of PRRX1 in CRC is significantly associated with metastasis and poor 
prognosis (359). This supports the preceding RNAseq findings of an increased 
proportion of mesenchymal CMS4 tumours in poor prognosis CPM and may in part 






Table 5-2 RNAseq classifier confusion table and resulting sensitivity, 
specificity and error rate 
Gene ID PLSA-DA Random 
forest 
SVM 
GNG12 A S E 
FKBP10 A S E 
PRRX1 E S E 
Accuracy 
Full 0.463 0.726 0.469 
AS 0.901 0.996 NA 
S (final) NA 0.997 NA 
 Predicted negative Predicted positive Total 
Actual Negative TN= 8 FP = 0 8 
Actual Positive FN = 0 TP = 7 7 
Total 8 7 15 
Error rate (FP + FN / total) = 0+0 / 15 = 0% 
Sensitivity, (TP / actual yes) = 7/7 = 100% 
Specificity, (TN / actual no) = 8/0 = 100% 
Classifiers PLSA-DA, partial least square discriminant analysis, RF, random forest, 
SVM, support vector machines. Full is the initial classifier, AS the intermediate and S 
the final model containing features found to be significant in all selection steps. The 
selected classifiers are plotted as tiers from S – E by decreasing relevance. TN, true 
negative, FN false negative, FP false positive, TP, true positive. Figure produced by 








Differential gene expression of the features selected by the random forest 
classifier in the retrospective good and poor prognosis cohorts. Figure produced 
by the R Biosigner pipeline and taken from own results 
Figure 5-3 RNAseq classifier, differential expression of the features selected by the 




5.2.2.1 Analysis of significant classifier features in the prospective cohort 
The prospective cohort was analysed for differential gene expression for the significant 
features identified by the retrospective classifier in patients with good and poor 
prognosis. The median gene count of GNG12 was not significantly different between 
the good and poor prognosis cohorts at 35.96 (9.10-80.72) and 34.51 (12.2-63.28) 
respectively, P-value 0.772. The median gene count of FKBP10 and PRRX1 was 
higher in the poor prognosis cohort reflecting the retrospective classifier, however, the 
difference was not statistically significant. FKBP10 was 10.99 (1.99-35.64) in the good 
prognosis cohort and 20.69 (4.15-34.87) in the poor prognosis cohort P-value = 0.11. 
PRRX1 was 18.26 (3.24-75.94) in the good prognosis cohort and 33.75 (14.21-151.11) 







Differential gene expression of the features selected by the random forest classifier in 
the prospective good and poor prognosis patient cohorts. Figure produced in SPSS 
and taken from own results 
 
  
Figure 5-4 Individual boxplots for the features selected by the retrospective random 




5.2.3 Methylation classifier 
 
A differential methylation prognostic signature was identified using the Biosigner 
method in the retrospective cohort. The significant features identified by the classifier 
included CpG sites relating to the following genes TMEM100, RP11-22P4.1, POLR2M, 
GCOM1 and SOX2. The resulting classifier had an accuracy of 0.939 at the training 
stage (Table 5.4 and Figure 5.5). This will require training, testing and validation on a 
prospective cohort. 
TMEM100 encodes a gene essential for angiogenesis. Its function in CRC has not 
been described in the literature. TMEM100 has been described as a potential tumour 
suppressor in lung and hepatocellular carcinoma, overexpression inhibits invasion, 
migration and proliferation in vitro (360, 361), methylation of TMEM100 in poor 
prognosis CRC suggests a loss of its tumour suppressor role in this patient cohort. 
METTL15 encodes an S-adenosyl-L-methionine-dependent methyltransferase, a 
poorly described gene whose function in CRC has not been described  (261). POLR2M 
and GCOM1 are gene paralogs encoding an RNA polymerase which negatively 
regulates transcriptional activation (261), methylation in poor prognosis CRC suggests 
an increase in transcriptional activation. SOX2 encodes a transcription factor which 
induces a stem-cell state in CRC cells  (362) (363).  High expression of SOX2 is 
associated with reduced relapse-free survival in CRC, the induction of EMT and 
reduced Wnt activity (362-364). The silencing of SOX2 in vitro has been linked with the 
induction of EMT in CRC. This finding again supports the increased proportion of 
mesenchymal CMS4 tumours in poor prognosis CPM and may in part explain the 





























Table 5-3 Methylation classifier signature 







 TMEM100 cg01155092 S C C 
11 28373379  METTL15 
 
cg00196955 A S E 
15 57999170  POLR2M, 
GCOM1 
cg09876857 S E E 
3 181428046  SOX2 
 
cg24513480 S E E 
Accuracy 
 Full 0.659 0.726 0.469 
AS 0.979 0.996 NA 
S (final) 0.939 0.997 NA 
 
PLSA-DA, partial least square discriminant analysis, RF, random forest, SVM, support vector 
machines. Full is the initial classifier, AS the intermediate and S the final model containing 
features found to be significant in all selection steps. The selected classifiers are plotted as 
tiers from S – E by decreasing relevance. Figure produced by the R Biosigner pipeline and 





Figure 5-5 Methylation classifier, differential expression of the features 
selected by the RF and PLSA-DA classifier features in the good and poor 
prognosis cohorts 
Differential gene expression of the features selected by the partial least squares and 
random forest classifiers in the retrospective good and poor prognosis cohorts. Figure 










In the present study, a machine learning algorithm was applied to determine differential 
gene expression and methylation prognostic classifier for patients with CPM treated 
with CRS & HIPEC. 
The Biosigner pipeline combines three classifiers to extract and restrict meaningful 
signatures from complex NGS data sets. To ensure a robust classifier a high bootstrap 
number of 400x was used to increase feature stability. Bootstrap sampling increases 
the stability of the classifier and reduces the risk of overfitting. The RNAseq data was 
partitioned into a training and holdout testing subset. Due to the increased size and 
computational demands of the methylation dataset, it was not possible to do this for 
the methylation signature.  
The RNA signature identified three gene features capable of predicting prognosis in 
the Random forest classifier with an accuracy of 0.607. GNG12 a G-protein active in 
the PI3K-AKT, MAPK and RAS pathways, FKBP10 a PPIase controlling cell 
proliferation, invasion and migration and PRRX1 a transcription co-factor known to 
induce EMT. The expression of these genes was examined in a prospective cohort of 
patients. The expression of GG12 was equivalent between those with good and poor 
prognosis. The expression of FKBP10 and PRRX1 was increased in the poor 
prognosis cohort, this difference, however, was not statistically significant. This may 
be a true failure of the signature to validate, this may mean there is no true gene 
expression signature or, more likely that the sample size was too small to establish 
one. It may also reflect the incomplete follow up of the prospective cohort and the 
inability to confidently classify the good prognosis cohort as such. 
The methylation signature identified two classifiers, the random forest contained one 
CpG feature and the PLSDA three CpG features capable of predicting prognosis with 
an accuracy of 9.939 and 0.997 respectively at the model training stage. This will 
require validation on a second dataset. TMEM100 is a gene with a putative tumour 




POLR2M and GCOM1 encode RNA polymerases and SOX2 encodes a gene capable 
of inducing stemness and EMT as well as downregulating Wnt in CRC. 
mRNA classifiers such as Oncotype DX® and MammaPrint® are currently used 
clinically for prognostic classification and therapeutic stratification of adjuvant 
treatments in breast cancer (347, 348). Such classifiers have not yet been developed 
for patients with CPM. They do exist for primary CRC in the form of the CMS and CRIS 
classification systems though they are not in widespread clinical use as the results are 
not yet clinically actionable (59, 62). We know that genomic heterogeneity increases 
in metastatic disease, basing treatment decisions on the mutations of the primary CRC 
may lead to treatment failure due to tumour evolutionary adaptation. The analysis of a 
large cohort of patients with CPM is necessary therefore to determine the tumour 
heterogeneity and clonal events which occur during tumour progression and the 
development of CPM. 
To our knowledge, this is the first gene expression and methylation prognostic 
classifier in patients with CPM from CRC. This study, however, has several limitations. 
This a small cohort of patients, the results of the classifier vary from that in the 
prospective cohort if this a true observation confirmed by increased follow up it 
suggests a high level of variance in the learning algorithm which would be corrected 
by increasing the size of both the training and testing cohorts. Were the follow up 
complete in the prospective group it may have been possible to merge the 
retrospective and prospective cohorts, however with potentially incomplete prospective 
follow up there is a risk that patients have been classified incorrectly as good 
prognosis, this would result in incorrect training information for the classifier. Small 
sample size, however, reflects the limited numbers of patients suitable for and 
undergoing CRS & HIPEC in the UK, Good Hope Hospital performed an average of 37 
procedures per year over the 5 years the service has been established. The other UK 
commissioned centres include Manchester, Basingstoke and Dublin. Increasing 
sample size would benefit from collaboration between CRS & HIPEC centres which 
could be achieved as part of a clinical trial. As discussed above the follow up of the 
prospective cohort is not complete which limits the validation of the RNAseq classifier. 
Both will, therefore, require subsequent validation. This classifier captures gene 




the CPM tumour is inherently more complex. These features must be considered 
synergistically with the exome sequencing and clinical prognostic data. Other 
moderators of gene expression not captured here include post-transcriptional 
modifications from other species of RNA, histone modification and post-translational 
modifications of protein function such as phosphorylation and ubiquitination. 
Future directions for this study include increasing the duration of follow up to determine 
the true prognosis of this cohort. Both the gene expression and methylation classifiers 
require validation in a larger cohort of patients to increase its stability and robustness. 
RNA sequencing captures a snapshot of time within a tumour’s evolution, additionally, 
RNA expression levels vary by cell type, cell cycle and cell viability. The addition of a 
somatic variant classifier would increase the applicability of a prognostic classifier in 
CPM. This, however, is not a simple task. It can be difficult to predict the functional 
impact of variants at a molecular level. Cancer driver mutations co-exist with harmless 
passenger mutations and somatic variants are sparsely distributed in the coding 
regions of tumour samples (365). Somatic mutations can be used as binary data e.g. 
the presence or absence of a mutation, this is, however, an over-simplification as 
mutations and their outcomes are not identical. The development of a somatic classifier 




Chapter 6 Investigating use of circulating tumour 
DNA to predict tumour recurrence and determine the 
mutational burden in patients treated with curative 








CRS & HIPEC is a treatment used with curative intent in selected patients with CPM 
with limited resectable disease (366). A significant number of patients, however, 
develop tumour recurrence following treatment. In a European cohort of 274 patients 
who underwent complete CRS & HIPEC for CPM, 69.3% developed a recurrence 
within 5-years (367). Thirty-one per cent were isolated peritoneal recurrences, 35% 
distant. Iterative treatment with curative intent was performed in 39.5% of patients, in 
this group subsequent 5-year OS was 46% (367). Iterative treatment with CRS & 
HIPEC is, therefore, a viable option in selected patients with isolated intraperitoneal 
recurrences. This in addition to other locoregional treatments for isolated distant 
metastasis and systemic treatments for more extensive recurrence. It is imperative 
therefore to detect recurrences at an early, treatable stage.  
The follow up of patients following CRS & HIPEC for CPM is not currently standardised 
by national or international guidelines. Despite this, there is an international 
consensus. An international survey of nineteen surgeons performing CRS & HIPEC at 
the 2018 Peritoneal Surface Oncology Group International meeting found agreement 
in follow up schedules amongst the majority of surgeons surveyed (366).  Survey 
respondents recommended > 2 follow up visits in the first 2 years with a physical 
examination, CEA measurement and abdominal and thoracic CT at least once per year 
for the first five years following CRS & HIPEC (366).  
Contrast-enhanced CT is the imaging modality of choice in the follow up of patients 
post-CRS & HIPEC. The sensitivity for detecting peritoneal metastasis with CT varies 
widely from 25-100% with a specificity of 78-100% (368). Sensitivity is particularly 
reduced for deposits of less than 5 mm and those in certain anatomical locations 
including the root of the mesentery, lesser omentum, left hemidiaphragm and the small 
bowel serosa (368). Specialist radiologists in a limited number of centres can predict 
CPM tumour volume however there is low radiological sensitivity for patients with a low 
PCI score (234, 235). Recurrences, therefore, may not be detected by conventional 
imaging until they become widespread or of a large enough volume to preclude 




symptoms including nausea, diarrhoea, distension, abdominal pain or bowel 
obstruction are late signs associated with widespread, advanced disease. Patients are 
therefore unlikely to present with symptoms triggering additional imaging or further 
investigation as a result of tumour recurrence. 
One tumour marker is in clinical use for CRC follow-up following primary treatment, 
CEA. CEA is a cell surface glycoprotein, detectable in the serum at low concentrations 
in healthy adults and high concentrations in a large proportion of CRCs (281). CEA 
levels are elevated in numerous carcinomas including lung, breast, gastrointestinal and 
gynaecological (281). In the absences of systemic disease, levels normalise within 
weeks following primary resection (281). The sensitivity and specificity of CEA for the 
detection of distant metastasis can exceed 60% (281). Sensitivity, however, varies 
according to the site of recurrence with >70% for liver and <50% for peritoneal disease 
(281). There is a need, therefore, to identify an effective tumour marker for the 
monitoring of patients following treatment with CRS & HIPEC for CPM. 
 
Fragments of ctDNA circulate in the bloodstream. ctDNA is an attractive option as a 
tumour marker. As it is composed of tumour DNA it has potential as a non-invasive, 
liquid biopsy, which can determine genomic and epigenetic markers allowing the 
delivery of targeted personalised treatments without the need for surgical resection or 
biopsy. Although ctDNA fragments are short (150 – 250 bp), evidence suggests they 
provide a comprehensive view of the tumour genome as they are released from 
multiple tumour regions or foci, in some cases, they have been able to detect mutations 
missed in corresponding tumour samples (147). To be adopted as a tumour marker 
ctDNA must fill several criteria defined by the Evaluation of Genomic Applications in 
Practice and Prevention (EGAPP) Initiative before adoption into clinical practice (147). 
Analytical validity, (accurate and reproducible) clinical validity, (to be able to identify 
patients with distinct clinical outcomes) and clinical utility, (as a result of being tested 
patients have improved outcomes) (147). 
 
ctDNA levels vary according to tumour type, with higher levels in patients with CRC vs. 
glioma and with higher levels in metastatic than primary tumour (146). ctDNA has been 




adjuvant therapy and recurrent disease in CRC (160, 369).  This information can be 
used to guide closer surveillance or identify the need for additional further adjuvant 
therapy (160).  ctDNA has been used as a prognostic biomarker in CRC, patients with 
high ctDNA levels at diagnosis have significantly shorter OS (160). ctDNA can be used 
to detect both primary and acquired resistance to systemic therapies (160). Acquired 
resistance to anti-EGFR therapy occurs via the acquisition of KRAS mutations which 
can be detected as drug-resistant sub-clones up to 10 months earlier than radiographic 
disease progression (160). Stopping therapy can lead to a decline in mutant KRAS 
clones allowing potential re-challenge in the future (160). Primary resistance to anti-
EGFR therapy has been detected in KRAS wild type patients with ERBB2 amplification 
(160). 
 
Aim: To determine whether ctDNA mutations correlate with those found in CPM 

















6.2.1 Prospective patient cohort 
The prospective patient cohort is described in detail in chapter 5, section 5.2.1. The 
same patient cohort remains the focus of this chapter. In brief, twenty-three patients 
were recruited, patients P1 and P2 had a macroscopic complete pathological response 
to neoadjuvant chemotherapy and so have no tumour specimens. Patient P10 had a 
prior liver transplant and so had CRS & HIPEC at the hepatobiliary surgical unit, a 
tumour specimen was not possible in this case. All patients have a pre-operative ctDNA 
sample, nineteen patients have a post-operative ctDNA sample, sixteen patients have 
a 3-month ctDNA sample, thirteen a six- or nine-month sample and two a nine- or 
twelve-month sample. Difficulties in collecting follow up ctDNA samples were 
particularly noted in patients who were unwell with post-operative morbidity or early 
tumour recurrence. As patients come from a wide geographical area in these 
situations, they were either an inpatient at their local hospital or were too unwell to 
travel to the clinic for review. 
Following tumour resection with CRS & HIPEC ctDNA levels remained detectable for 
the majority of patients (90%). The absence of detectable ctDNA post CRS & HIPEC 
(4) was not predictive of improved DFS, median DFS 14 months (95% CI 9.84 – 18.16) 









Kaplan-Meier cure showing disease free survival for patients with ctDNA detected post 
CRS & HIPEC, (10.20 months (95% CI 13.15 – 13)), and not detected, (14 months 
(95% CI 9.84 – 18.16)), p-value 0.88. Figure produced in SPSS and taken from my 
own results. 
 




6.2.2 Hypermutant tumour 
One patient had significantly higher levels of mutation than others (P1). This patient 
had a metachronous CPM at the site of their previous sigmoid tumour, they had an 
apparent complete pathological response to neoadjuvant single-agent capecitabine 
chemotherapy with no tumour specimen at CRS & HIPEC. Despite complete 
pathological response baseline ctDNA levels at the time of CRS & HIPEC showed 
1964 non-synonymous variants, this may suggest high TMB (this would need to be 
confirmed on WES) and eligibility for PD-1 monoclonal antibody blockade. At CRS & 
HIPEC the anastomosis was resected with a pelvic peritonectomy and omentectomy. 
The complete pathological response was confirmed on histology. Following CRS & 
HIPEC the number of non-synonymous variants fell to 26 at 4 weeks, adjuvant 
chemotherapy was completed with 6x cycles of FOLFOX. Asymptomatic recurrence 
was detected 7 months post-CRS & HIPEC on CT and the chemotherapy changed to 
FOLFIRI. Preceding the radiological diagnosis of recurrence, the number of non-
synonymous variants increased to 245 at 6 months.  The high levels of non-
synonymous mutation despite apparent complete pathological response has not been 
described in the literature but may suggest a hypermutant subclone that expands. 
This patient has a hypermutated CRC. Hypermutation is highly correlated with MSI. 
Three per cent of MSI tumours are associated with Lynch syndrome and 12% result 
from sporadic mutations of the DNA mismatch repair system (370). MSI tumours 
express various immunological checkpoint inhibitors such as PD-1 and may respond 
well to immune checkpoint inhibitors such as pembrolizumab and nivolumab (370). In 
addition to MMR dysfunction, mutations in DNA polymerases POLD1 and POLE genes 
are known to result in hypermutation (370). Analysis of variant consequences for P1 
identified potentially damaging mutations of high functional consequence in ARID1A, 
MSH1, MSH2 and MSH6 suggesting dysfunction of the MMR pathway resulting in 
hypermutation (371). No germline variants were detected in any Lynch syndrome 
associated genes in this patient. 
6.2.3 ctDNA mutation number significantly higher than tumour 
There was a weak negative correlation between tumour and ctDNA mutation number, 




mutation number detected in baseline ctDNA was significantly higher than that 
detected in the tumour for each gene sequenced with a median for mutations across 
all genes of 47 (3-1963 range) vs. 10 (1-27 range) P-value = 0.0001 (Figure 6.4). The 
difference in mutation detection cannot be explained by the sufficiency of coverage. 
Tumour samples had a higher input of DNA at 40ng vs. 2ng for ctDNA and a resulting 
higher mean coverage at 1685x (293x-6941x) vs. 103x (10x-1206x). False-positive 
mutation calls increase with decreased sample input amounts, the input of DNA for the 
ctDNA samples was lower than matched tumour however several features of the 
technique used mitigate for this. DNA fragments are bound to unique molecular indices 
before PCR meaning only those which correctly bind to a UMI are amplified by PCR. 
In addition, during variant filtering, only alleles with a frequency above the background 







Figure 6-2 Sample ctDNA tape station electropherogram 
Electropherogram showing the expected ctDNA fragment size of 150 – 250 bp. 
Markers indicate lower marker, upper marker and the average size of the nucleic acid 








Figure 6-3 Correlation between mutation number in CPM tumour and baseline 
ctDNA samples 
Pearson’s correlation showing a weak negative correlation in mutation number 
between CPM tumour and matched ctDNA samples. Pearson’s correlation -.302, P-










Number of non-synonmymous mutations in CPM tumour sample (red) and paired 





















































































































































6.2.4 ctDNA remained detectable following complete CRS & HIPEC 
The half-life of ctDNA is less than 2 hours (372). ctDNA was collected following CRS 
& HIPEC at a minimum of 5 days post-resection, median 38 days (5-84). All patients 
had a complete cytoreduction, 90% CC0 meaning no residual disease following CRS 
and 10% CC1 meaning <2.5mm residual disease following CRS amenable to 
treatment with HIPEC. Despite this ctDNA levels remained detectable following CRS 
& HIPEC and were marginally higher than pre-CRS & HIPEC levels, 0.93 ng/ μL (0-
1.04) vs. 0.54ng/ μL (0.128-5.34), P-value 0.08. This trend was reflected in the 
mutation number 52 (0-107), vs. 47 (3 – 1963), P-value 0.39.  
6.2.5 The use of ctDNA as a biomarker of tumour recurrence 
Several limitations mean it was not possible to determine whether increased ctDNA 
levels or mutation number can be used to predict tumour recurrence. Firstly, there was 
a limited number of ctDNA samples per patient due to loss to follow up, this was 
particularly noted in patients with post-operative or adjuvant treatment morbidity or 
recurrence. Secondly, this was a small cohort of patients with a limited number of 
recurrences (3) during the period of ctDNA sampling. Finally, the follow up is 
incomplete, whilst for all patients, it is a minimum of 12 months following CRS & HIPEC, 
the median follow up with clinic contact is just 8 months (4-15). As CRS & HIPEC is 
performed at a tertiary referral centre it may take several months for data regarding 
recurrence or death captured by the patient’s local hospital to be fed back. Of the three 
patients with recurrences during the period of ctDNA sampling 2 (P1 and P10) showed 
increased levels of ctDNA preceding the diagnosis of tumour recurrence (Figure 6.5). 















































































































































Tumour Pre op Post op 3 month
P23
P23
Figure 6-5 Mutation number tracking from CRS & HIPEC to final follow up for 
individual patients 
Mutation number at each ctDNA timepoint sampled. All patients with two or more 
samples are shown, re-occurrences within the ctDNA sampling timeframe are indicated 





6.2.6 Mutations detected in ctDNA  
The QIAseqTM gene panel in use in our laboratory targets 30 genes of known 
significance in CRC. The mutations commonly detected in ctDNA the CPM cohort are 
discussed below (Table 6.1). The location and distribution of key CRC gene mutations 
(APC, RNF43, POLE, POLD, BRAF and KRAS) are displayed in lollipop plots, Figures 
6.6-6.8). 
High levels of mutations were found in key genes of the Wnt pathway. APC mutations 
were present in 96% of patients, Inactivation of the APC tumour suppressor gene 
results in inappropriate and consistent activation of the Wnt signalling pathway. APC 
is mutated in the majority of sporadic CRC (23). BCL9L and TCF7L2 mutations were 
present in 70% and 61% of patients. BCL9L and TCF7L2 are beta-catenin co-factors 
which form a transcriptional activation complex and Wnt activation. RNF43 mutations 
were present in 87% of patients, RNF43 is an upstream negative Wnt regulator which 
can be targeted by porcupine inhibitors (261). PTEN and PI3K mutations were present 
in 52% and 70% of patients respectively. PTEN is a negative regulator of PI3K, PI3K 
inhibits the activity of GSK-3B which results in B-catenin accumulation and Wnt 
activation. Mutations in PI3K are associated with resistance to anti EGFR therapies in 
the absence of EGFR mutation suggesting they may drive aberrant EGFR signalling 
(38). 
ARID1, ATM, MLH1, MSH2, MSH6 contained mutations in 87%, 87%, 70%, 83% and 
83% of patients respectively. MLH1, MSH2 and MSH6 are important DNA mismatch 
repair genes, ARID1 recruits MSH2 to chromatin during DNA replication promoting 
MMR (261). ATM coordinates DNA repair by activating enzymes to fix broken strands  
(261). Such high levels of mutations in the MMR pathway suggest MSI. POLE and 
POLD1 mutations were present in 87% and 70% of mutations respectively. POLE and 





Table 6-1 Gene panel mutation proportions detected in baseline ctDNA in all 
patients and by prognostic group 
 









Good vs. Poor 
P-value 
ACVR2A 30 6 (75)  5 (33) 0.006* 
APC 96 7 (88) 15 (100) 0.35 
ARID1A 87 6 (75) 14 (93) 0.29 
ATM 87 6 (75) 14 (93) 0.29 
B2M 13 1 (13) 4  (27) 1 
BCL9L 70 4 (50) 12 (80) 0.18 
BMPR2 61 3 (38) 12 (80) 0.07 
BRAF 57 4 (50) 10 (67) 0.40 
CTNNB1 48 4 (50) 8  (53) 1 
ELF3 35 2 (25) 7  (47) 0.40 
FBXW7 57 5 (63) 9  (60) 1 
GNAS 78 4 (50) 13 (87) 0.13 
KRAS 22 1 (13) 5  (33) 0.37 
MLH1 70 5 (63) 9  (60) 1 
MSH2 83 6 (75) 13 (87) 0.59 
MSH6 83 7 (88) 12 (80) 1 
NRAS 9 1 (13) 1  (7) 1 
PIK3CA 70 4 (50) 11 (73) 0.37 
POLD1 70 5 (63) 11 (73) 0.66 
POLE 87 8 (100) 13 (87) 0.53 
PTEN 52 5 (63) 7  (47) 0.67 
RNF43 87 7 (88) 13 (87) 1 
RPL22 13 2 (25) 2  (13) 0.59 
SMAD2 26 3 (38) 4  (27) 0.62 
SMAD4 30 3 (38) 5  (33) 0.62 
SOX9 30 3 (38) 5  (33) 1 
TCF7L2 61 4 (50) 11 (73) 1 
TGIF1 43 3 (38) 7  (47) 1 
TP53 87 8 (100) 12 (80) 0.53 
ZFP3 43 4 (500 6  (40) 0.67 









Variants relative to a schematic representation of the gene. Any position with a 
mutation obtains a circle, the length of the line depends on the number of mutations 
detected at that codon. The grey bar represents the entire protein with the different 
amino acid positions.  
Figure 6-6 Lollipop plots showing the location and distribution of mutations in  







Variants relative to a schematic representation of the gene. Any position with a 
mutation obtains a circle, the length of the line depends on the number of mutations 
detected at that codon. The grey bar represents the entire protein with the different 
amino acid positions.  
Figure 6-7 Lollipop plots showing the location and distribution of mutations in 






Variants relative to a schematic representation of the gene. Any position with a 
mutation obtains a circle, the length of the line depends on the number of mutations 
detected at that codon. The grey bar represents the entire protein with the different 
amino acid positions.  
 
Figure 6-8 Lollipop plots showing the location and distribution of mutations in  




BRAF mutations were present in 57% of patients, BRAF is a serine/threonine kinase 
downstream of KRAS in the MAPK signalling pathway (22). BRAF mutation is 
associated with hypermutation, CIMP and MSI (22). BMPR2 was mutated in 61% of 
CRC. BMPR2 mutation is thought to contribute to CRC development by the inactivation 
of BMP/ SMAD signalling (373). FBXW7 and p53 were mutated in 57% and 87% of 
patients. Both FBXW7 and p53 are important tumour suppressors in CRC. GNAS 
mutations were present in 78% of patients. GNAS can dysregulate several pathways 
of importance in CRC including Wnt, hedgehog and TGF-β  (261). 
The numbers of non-synonymous mutations in each gene were compared in the good 
and poor prognosis groups using the Fishers exact test. The proportion of patients with 
and without gene panel mutations was similar across the prognostic groups with 










Figure 6-9 The proportion of gene mutations detected in baseline ctDNA 
samples before CRS & HIPEC in patients with good and poor prognosis 
 
Number of non-synonymous mutations in good prognosis (blue) and poor 

























Gene mutations proportions detected in good and 
poor prognosis ctDNA samples






In this study, ctDNA samples had significantly higher mutational burden when 
compared with matched CPM tumour samples. This may reflect the origin of ctDNA 
fragments from multiple tumour sites which have not been fully captured by the tumour 
sample. Analysis of tumour samples gives a small sample of cells at a given time which 
gives a low temporal and spatial resolution of the tumour as a whole. ctDNA may, 
therefore, have several advantages over tumour sample or biopsy allowing the 
assessment of inter tumour heterogeneity and subclonal mutations which in the 
literature have been used to predict treatment response, the development of resistance 
to therapies necessitating a change in treatment and even allow re-treatment when 
resistant subclones decline (374-377).  
We were unable to draw any conclusion with regards to the utility of ctDNA as a 
biomarker of tumour recurrence. This may reflect the small volume of residual disease 
left following CRS & HIPEC. The literature, however, suggests ctDNA can be used as 
a marker of tumour recurrence following the treatment of both primary and metastatic 
CRC. Reinert et al examined the temporal presence of somatic structural variants, 
(SSV) in a cohort of patients post-primary CRC resection, they found SSV in ctDNA 
were capable of predicting relapse in 100% of patients at a mean of 10 months before 
the detection of metastatic recurrence with conventional follow up (369). Zhou et al 
compared the utility of ctDNA variant allele frequency to detect CRC disease relapse 
compared to CEA, cancer antigen 19-9 and imaging (378). They found ctDNA 
mutations decreased following resection or adjuvant treatment and increased 13-fold 
upon disease recurrence despite normal CEA and CA19-9 (378). Thierry et al 
examined the concordance between KRAS, NRAS and BRAF mutations between 
tumour and ctDNA samples in mCRC (379). They found ctDNA was able to detect a 
higher proportion of mutations than tumour biopsy and was quicker to process than 
tumour suggesting it could replace tissue biopsy to determine clinically actionable 
mutations in patients with mCRC (379). Kidess et al examined temporal ctDNA 
mutations in patients with CRC liver metastasis undergoing resection (380). They 




that ctDNA anticipated tumour recurrence earlier than CEA and imaging (380). Ng et 
al examined temporal ctDNA following the primary resection of CRC (381), they found 
ctDNA detection correlated with the early detection of metastasis (381). 
Following complete CRS & HIPEC levels of ctDNA increased marginally. The post-
CRS & HIPEC sample was taken in the clinic at between 4-8 weeks post-resection, at 
a median of 57 days (IQR 46-75). This rise in ctDNA occurred in patients with samples 
taken in the first 7 days post-resection as well as those taken later suggesting this is 
not a reflection of early disease recurrence. The impact of CRS & HIPEC on ctDNA 
has not been reported in the literature for patients with CPM. One hypothesis is that 
this represents a transient rise in novel mutations as a reaction to de novo treatment 
with Mitomycin which is not used in the systemic treatment of CRC (382). An alternative 
hypothesis is that ctDNA originates from multiple tumour sites and may be able to 
predict a more comprehensive picture of intra-tumour clonal heterogeneity than a 
single site tumour sample (147). Once apoptosis is induced fragmented cellular 
contents are packaged and efficiently cleared by macrophages, in the case of 
chemotherapy for cancer the high volume of apoptosis may engulf the capacity of local 
phagocytes resulting in the release of fragmented DNA into the circulation (383). No 
studies have analysed the effects of topical chemotherapy on ctDNA levels, it is likely 
that HIPEC results in tumour cell apoptosis and shedding over several days which may 
explain a peak in levels following CRS & HIPEC. A study by Tie et al found in cases of 
incomplete surgical resection or tumour debulking there followed a rise in ctDNA levels 
which may reflect surgically induced tissue injury, this is also a potential in cases of 
CRS where small areas of tumour are left behind (384). 
The absence of detectable ctDNA following resection was not predictive of improved 
DFS in this study. This is not in keeping with the literature and is likely a reflection of a 
small cohort of patients, of which 4 had undetectable ctDNA post-CRS & HIPEC and 
just one of these recurred within the timeframe of ctDNA collection. 
Within this targeted gene panel, patients with CPM had frequent mutations of Wnt 
pathway genes, APC, beta-catenin co-factors BCL9 and TCF7L2, upstream Wnt 
regulator RNF43,  PTEN and PI3K. Mismatch repair pathway genes including ARID1, 




instability. DNA polymerases POLE and POLD1 were commonly mutated which in 
addition to MMR defects can result in hypermutant CRCs. Other common mutations 
included BRAF, BMPR2, FBXW7, TOP53 and GNAS. 
There were significantly more frequent ACVR2A mutations in the poor prognosis 
cohort. The prognostic cohorts had otherwise similar mutation frequency across the 
gene panel. ACVR2A is part of the TGF-β signalling pathway. Zhou et al examined a 
cohort of 497 patients and found reduced ACVR2A expression correlated with 
advanced stage, metastasis, reduced survival and increased cell migration in vitro  
(385).  
This study is the first to our knowledge to examine the use of ctDNA as a biomarker of 
tumour recurrence in patients who have undergone CRS & HIPEC for CPM. This study 
has several limitations. This is a small patient cohort with significant loss to follow up 
in cases of tumour recurrence and post-operative morbidity limiting patient’s clinic 
attendance. This means we are unable to draw any conclusion with regards to the 
utility of ctDNA as a biomarker of tumour recurrence. The follow up of this cohort is 
incomplete, a number of patients likely have asymptomatic recurrence which will be 
reported at a later date meaning the distinction between good and poor prognosis 
cohorts is unclear.  Finally, the study contains no normal controls. The panel used 
looks for mutations of known importance in CRC that are unlikely to be found in 
circulating cell-free DNA of non-tumour origin. In extracting ctDNA the blood sample 
was centrifuged twice to separate the plasma from the serum within 24 hours of 
collection limiting the contamination of white blood cell cfDNA, we know however that 
there is a high correlation between background mutations found in white blood cells 
and those found in cfDNA meaning this can be a confounding factor (386).  
Future directions for this study include increasing the duration of follow up to determine 
the true prognosis of this cohort and capture any further patients with poor prognosis 
and recurrence occurring before 12 months post-CRS & HIPEC. To determine the 
utility of ctDNA as a biomarker of tumour recurrence for patients with CPM this study 
would need to be repeated on a larger cohort with a longer follow up period and a 
group of normal controls. A reduction in the loss to follow up may be achieved by local 




may prove logistically challenging unless part of a larger clinical trial with onsite 









7.1 Interpretation and implications 
7.1.1 Prognostic factors for patients with colorectal peritoneal metastasis 
undergoing Cytoreductive Surgery and Heated Intraperitoneal chemotherapy 
In this thesis, I firstly identified current prognostic factors for patients with CPM suitable 
for treatment with CRS & HIPEC using systematic review and meta-analysis. These 
factors were obstruction or perforation of the primary tumour (HR 2⋅91, 95 % CI 1⋅5 to 
5⋅65), the extent of peritoneal metastasis as described by the PCI (per increase of 1 
PCI point: (HR 1⋅07, 95 % CI 1⋅02 to 1⋅12) and the completeness of resection as 
described by the CC score (CC score above zero: HR 1⋅75, 95 % CI 1⋅18 to 2⋅59). 
These prognostic factors are commonly used in patient selection for CRS & HIPEC. 
Despite this survival still varies widely and can be difficult to predict.  
7.1.2 Describing the biology of colorectal peritoneal malignancy 
I therefore secondly sought to describe the biology of CPM, to identify the biological 
changes in gene expression, CNA, methylation and somatic mutation associated with 
the transition from primary CRC to isolated CPM and conferring a poor prognosis in 
response to the best available treatment CRS & HIPEC. Each CPM sample was 
matched to a germline normal and primary CRC sample to identify somatic variants 
and those changes unique to metachronous CPM. 
Biological changes identified in primary CRC were subtracted from matched CPM 
samples to identify changes unique to and associated with the progression from 
primary CRC to isolated CPM. A rapid rate of unchecked tumour growth was suggested 
by upregulation, hypermethylation, CNA or somatic mutation of genes promoting cell 
survival, the inhibition of apoptosis, regulating cell growth, proliferation, transcription 
and angiogenesis (CD53, TSC72D3, NF-Κb, IGF2, EDNRB, ZNF461, CDC16, NUP98, 
CCND2, TP53, VTRA2-1 and TRIM proteins). The MAPK and Wnt/β-catenin pathways 
were persistently activated in CPM with decreased expression and somatic mutation 
of Wnt regulators (OLFM4, DEAFA6, APC, RNF43 FAM123B, and TSC1) and 
hypermethylation of MAPK marker (RASFGFR1). Negative Wnt regulators such as 
RNF43 are an attractive therapeutic target for treatments such as the porcupine 
inhibitor LGK974 in the CPM cohort (338). The CPM cohort had a high proportion of 




were MSI-H, TMB-H, of these 25% were BRAF mutant. Of the patients with good 
prognosis 38% were MSI-H, TMB-H, of these 33% were BRAF mutant. High TMB is a 
surrogate marker for increased neoantigen expression, a biomarker for response to 
immune checkpoint inhibitors such as anti-PD-1/L1 therapy (339-341). 
The CPM cohort had downregulation or somatic mutations of regulators of innate 
immunity (DEFA6, DMBT1, MUC2, HLA-A antigen) suggesting an immune evasive 
phenotype. As expected for a metastasis CPM samples had downregulation of genes 
suppressing invasion, migration and EMT (MUC2, MMP26, ILK, FLNB, SPTB, PPL 
and SVEP1) and those triggering these were upregulated (CYR61, CXCL12, CTGF 
and CSTB). CPM tumour were more commonly of the mesenchymal subtype 
suggesting a potential response to TGFβ signalling inhibitors and targeted 
immunotherapies (61, 342). Methylation was dysregulated in CPM with somatic 
mutation of the TET2 enzyme and CDH7 chromatin regulator suggesting uncontrolled 
hyper-methylation and a theoretical benefit from methylation inhibitors (43, 49, 327). 
There was downregulation of CES2, a gene known to activate the prodrug irinotecan, 
a commonly used chemotherapy in the adjuvant treatment of primary CRC and CPM 
(CES2). Resistance to the treatment of primary CRC may in part explain the 
development of CPM in this cohort. 
Comparison of biological changes in good and poor prognosis cohorts identified 
changes exclusive to and potentially conferring poor prognosis in CPM. Oncogenes, 
genes regulating cell growth, cycle, angiogenesis, transcription and the inhibition of 
apoptosis were upregulated (RELB, HCKVEZF1, POLR3GL, FEM1C, KHDRBS3, 
BCYRN1 and DCAF12) or altered via hypermethylation or CNA (NKX6-2, GATA3, 
IRX5, ZKSCAN7, PAX5, DEAF1A, CHFR, PTPN21, VASH1, ,IGFBP7, SHB, PTPN21, 
FAM32 and MELK) suggesting a rapid rate of unchecked tumour growth. Increased 
expression of genes regulating immune invasion (CEACAM1) and hypermethylation of 
regulators of the immune response (RFTN1, SIT1) suggest an immune evasive 
phenotype in poor prognosis CPM. This is an interesting therapeutic target, CEA TCB 
IgG-based T-cell bispecific antibodies result in immune-mediated tumour lysis in 
tumour cells with high expression of CEA (282). MAPK, Wnt/β-catenin and TGF-β 
pathway regulators (AXIN1, FAM13A, RAB8A, RAB34, FGF5 and BMP3 were 




pathways in poor prognosis CPM. Poor prognosis CPM had hypermethylation and 
somatic mutation of regulators of invasion, migration and EMT (NR2F1-AS1, ZEB1, 
EPS8L2 and PIEZO). Poor prognosis CPM was more commonly of the mesenchymal 
subtype which can be targeted by several novel therapies including  TGF-β signalling 
inhibitors and targeted immunotherapies (61, 342). There was hypermethylation of a 
gene known to mediate resistance to oxaliplatin, a commonly used chemotherapy in 
the treatment of primary CRC and CPM (NR2F1-AS1). Resistance to the treatment 
may in part explain the poor prognosis CPM. 
7.1.3 Developing a bio-molecular classifier to predict prognosis for patients 
with CPM undergoing CRS & HIPEC 
I thirdly sought to identify from the biological changes discussed above a biomolecular 
classifier capable of predicting prognosis in response to the best currently available 
treatment for CPM, CRS & HIPEC. A machine-learning algorithm was applied to the 
RNA and methylation datasets to identify a prognostic classifier for patients with CPM. 
The RNA signature contained three genes capable of predicting prognosis with an 
accuracy of 99% at the training stage and 61% on the final hold outset, (GNG12, 
FKBP10 and PRRX1). The expression of these genes was examined in the 
prospective cohort, the expression of GNG12 was equivalent, FKBP10 and PRRX1 
expression were increased non-significantly in the poor prognosis cohort. This may be 
a true failure of the signature to validate, this may mean there is no true gene 
expression signature or that the sample size was too small to establish one. It may 
also reflect the incomplete follow up of the prospective cohort and the inability to 
confidently classify the good prognosis cohort as such. The methylation signature 
identified two classifiers, the random forest contained one CpG feature and the PLSDA 
three CpG features capable of predicting prognosis with an accuracy of 0.939 and 
0.997 respectively at the training stage, (TMEM100, METT-15, POLR2M, GCOM1 and 
SOX2). Due to the increased size of the methylation dataset, it was not possible to 
partition into a training and holdout subset and so this will need to be validated. 
Classifiers are in clinical use for prognostic classification and therapeutic stratification 
of adjuvant treatments in breast cancer (347, 348). Whilst we have not identified from 
this work a prognostic classifier for patients with CPM, we have identified a technique 




duration of follow up and validation set will result in a clinically relevant classifier for 
CPM.  
7.1.4 The use of circulating tumour DNA to predict tumour recurrence and 
determine mutational burden in patients with CPM 
Finally, I aimed to determine the use of ctDNA as a liquid biopsy before surgery and 
as a biomarker of residual disease and recurrence following CRS & HIPEC. Matched 
ctDNA samples had a significantly higher tumour mutational burden when compared 
with CPM tumour samples. This may reflect the ability of ctDNA to better capture the 
temporal and spatial resolution of the tumour. This improved assessment of tumour 
heterogeneity and subclonal mutations has been used in the literature to predict 
treatment response, resistance to therapies and to allow re-treatment when resistant 
sub-clones decline (374-377). Of those patients with recurrence during the period of 
ctDNA sampling, 75% showed increasing levels of ctDNA preceding tumour 
recurrence, these numbers are too small to draw any conclusions regarding the utility 
of ctDNA as a marker of tumour recurrence. Due to loss to follow up, there were a 
limited number of ctDNA samples per patient, this was particularly pronounced in 
patients with tumour recurrence. This was a small cohort of patients with just 3 
recurrences during the period of ctDNA sampling and limited duration of follow up. 
Following complete resection with CRS & HIPEC ctDNA levels increased marginally 
and remained detectable in 90% of cases. This may simply reflect lysis of microscopic 
tumour deposits in response to the chemotherapy and heat in the HIPEC treatment. 
One hypothesis is that it may represent a transient rise in novel mutations in response 
to de novo treatment with Mitomycin C which is not used in the treatment of CRC (382). 
The gene panel identified frequent mutations of Wnt pathways genes (APC, beta-
catenin cofactors BCL9 and TCF7L2, RNF43, PTEN and PI3K), mismatch repair 
pathway genes (ARID1, ATM, MLH1, MSH2 and MSH6) and DNA polymerases (POLE 
and POLD1). Comparison of mutations between the good and poor prognosis cohorts 
identified a mutation ACVR2A which was significantly more frequent in patients with 
poor prognosis and associated with advanced stage, metastasis and reduced survival 




7.2 Strengths and limitations 
This is the first study to comprehensively profile isolated colorectal peritoneal 
metastasis and to determine the biological changes associated with the development 
of peritoneal metastasis and associated with poor prognosis disease. 
I must acknowledge that this is a small cohort of patients. Whilst we identified 
significant biological changes associated with the development of CPM and associated 
with poor prognosis disease these must form a starting point in identifying the tumour 
biology of CPM. Increased sample size will reduce variance in the machine learning 
algorithm used to develop the classifier, increasing the confidence that the features 
identified reflect the population the cohort is taken from. Small sample size additionally 
meant there were few recurrences during the period of ctDNA sampling meaning we 
were unable to assess the utility of ctDNA as a marker of tumour recurrence. Small 
sample size reflects the limited number of patients with isolated CPM suitable for and 
undergoing CRS & HIPEC at the limited number of centres performing CRS & HIPEC 
in the UK. 
We were unable to validate the findings from chapter 4 as no suitable public dataset 
of isolated CPM exists in the literature or TCGA, GEO datasets to compare to. One 
dataset from Yaeger et al contains 52 patients with CPM, however in just 6 of these 
the sample sequenced was CPM (343-345). As we have demonstrated there is a 
significant change in tumour biology from primary CRC to CPM development which will 
not be captured in the analysis of the primary CRC or other sites of metastasis. We 
recruited a prospective cohort of patients to validate the retrospective findings. Whilst 
all patients in the prospective cohort had a minimum of 12 months follow up following 
CRS & HIPEC information regarding tumour recurrence and death was fed back from 
referring centres, this process is not immediate and means that it is likely that follow 
up is incomplete meaning patients classified as good prognosis may have recurred. 
This means we cannot be sure if the comparison between retrospective and 
prospective cohorts is accurate.  
In the prospective cohort, we had a significant loss to follow up. This was particularly 
apparent in patients with recurrence following either CRS & HIPEC or adjuvant 




HIPEC centre and are less likely to do so when unwell. This meant we were unable to 
accurately determine the use of ctDNA as a biomarker of tumour recurrence. 
The machine learning algorithms used in chapter 5 can develop classifiers for a set of 
features, in this case, we applied the methods to gene expression and methylation 
datasets. Tumour biology is more complex than this, genes connect by pathways and 
their expression and function are modulated via several mechanisms such as post-
transcriptional modification by methylation, other RNA species, histone modification 
and post-translational modifications of protein function such as phosphorylation and 
ubiquitination. A single classifier will capture only one dimension of tumour biology. 
These features must be considered synergistically with the other biological and clinical 
prognostic data. 
In chapter 6 we examined the use of ctDNA as a liquid biopsy and biomarker. In 
extracting ctDNA the blood sample was centrifuged twice to separate plasma from 
serum within 24 hours of collection to minimise sample contamination with white blood 
cell cfDNA. Additionally, we used a panel of mutations specific to CRC which should 
not be prevalent in germline samples. We know however that there is a high correlation 
between germline mutations in white blood cells and those found in cfDNA which can 
be a confounding factor (386). The use of normal control blood samples could be used 
as a comparator however clearly these would not be matched meaning germline 
mutations may not be comparable. 
7.3 Future directions 
7.3.1 Validation 
 
In NGS the biological changes identified are often orders of magnitude greater than 
the sample size, they, therefore, require validation in an additional cohort (387). This 
is a relatively small cohort and there would be a benefit in the validation of these 
findings in a larger cohort of patients with isolated CPM. This would be challenging as 
the numbers of patients suitable for CRS & HIPEC (having their tumours sampled) are 
small and the number of centres performing this procedure is limited. Collaboration 
between CRS & HIPEC centres would be required to recruit more patients. This would 




cohort. Experimental validation is then required using an additional technique. For RNA 
seq, real-time quantitative reverse transcription PCR, (qRT-PCR) can be used for 
absolute and relative qualification of gene expression. For methylation, the degree of 
methylation can be quantitatively measured and validated using pyrosequencing. 
Quantitative bisulfite pyrosequencing determines DNA methylation levels by analysing 
artificial C/T SNPs at CpG sites within specific pyrosequencing assays. Candidate 
driver mutations identified through exome sequencing can be validated using a gene 
panel targeted towards the mutations of interest, this would allow an additional benefit 
of increased read depth. 
 
Circulating tumour DNA has proven useful as a liquid biopsy and marker of tumour 
recurrence and treatment response in several cancers (374-377). Our results require 
validation in a larger cohort of patients. The loss to follow up was a problem in this 
study, strategies to improve this could include blood sample collection at the local 
hospital where patients attend for their imaging and adjuvant treatments or for this to 
form part of a clinical trial with a clearly defined follow up schedule. 
 
7.3.2 Future research 
 
Irinotecan is a chemotherapy agent used in the treatment of metastatic colorectal 
cancer. Carboxylesterase 2 (CES2) converts Irinotecan to its active metabolite SN-38. 
The expression of CES2 was reduced 3.2-fold in CPM, this is a mechanism of 
resistance in metastatic CRC (268). Oxaliplatin is a chemotherapy agent used in the 
treatment of metastatic colorectal cancer. ABC transporters export drugs into the 
extracellular space reducing their cytotoxic effect (388). LncRNA NR2F1-AS1 results 
in increased expression of ABC transporters and resistance to oxaliplatin 
chemotherapy in vitro (305). Resistance to such a commonly used chemotherapy in 
the CPM cohort may explain in part the poor prognosis in this group. The functional 
impact of differences in gene expression and methylation must be confirmed by 
analysis of CES2, NR2F1-AS1 and ABC protein expression. In a prospective cohort of 
patients treated with irinotecan or oxaliplatin the expression of these markers could be 




with low and high expression of these markers could then be compared to investigate 
whether high expression results in chemotherapy resistance in patients with CPM. The 
identification of a group of patients with resistance to individual chemotherapy drugs 
would allow alternative treatment strategies and outcomes in these patients. 
 
Novel therapeutic targets were identified in patients with CPM which have been 
targeted with good effect either alone or in combination with other treatments (Figure 
7.1). RNF43 a negative Wnt regulator was mutated in 23% of CPM patients. As an 
upstream Wnt regulator, this can be targeted by porcupine inhibitors which inhibit the 
Wnt pathway irrespective of the presence of downstream mutations (328, 338, 389). 
CPM had frequent mutations of mismatch repair proteins and high tumour mutational 
burden suggesting microsatellite instability, this suggests a good response to immune 
checkpoint inhibitors such as pembrolizumab (339). TET2 mutations were noted in 
23% of CPM samples suggesting a potential benefit from methylation inhibitors (43, 
49, 327). There appeared to be EMT and a mesenchymal subtype in CPM and 
particularly poor prognosis CPM, this can be targeted by several novel therapies 
including TGFβ signalling inhibitors and targeted immunotherapies (61, 342). The 
expression of genes regulating innate immunity was downregulated or altered by 
hypermethylation or CNA (DEFA6, DMBT1, MUC2, RTFN1, SIT1). Genes regulating 
immune evasion were upregulated (CEACAM1). Novel therapies in the form of immune 
checkpoint inhibitors or CEA TCB IgG-based T-cell bispecific antibodies may, 
therefore, be of benefit in this patient cohort, they result in immune-mediated tumour 
lysis in tumours overexpressing CEA (282). Before use in clinical studies, drugs are 
initially tested in-vitro. Traditionally this was in a two-dimensional cell culture model. 
Two-dimensional cell cultures, however, are not representative of the in vivo situation. 
Heterogeneity, three-dimensional organ structure, cell to cell relationships are lost and 
signalling networks altered. It is unsurprising then that the success of drugs tested in 
2D in vitro models commonly fails to translate into clinical trials (390). A type of three-
dimensional cell culture model provides an alternative. An organoid is a clonal 
derivative of primary epithelial stem cells grown without mesenchyme or epithelial-
mesenchymal co-culture (391). Organoids can be established in a short period and 




therefore, be used as in vitro models to test drugs targeted towards patients individual 
mutations (392, 393). We have successfully cultured two organoid lines from patient’s 
CPM samples. Expansion of this biobank and comparison with the tumours from which 
they are derived would be required prior to use of the model of in vitro drug testing. 
This would require histology to confirm tumour morphology, immunohistochemistry to 
confirm the expression of key CRC markers and a comparison of genetic mutation 







Figure 7-1 Novel therapeutic targets identified 
A) Microsatellite instability and increased tumour mutational burden was noted in CPM 
and particularly in poor prognosis CPM, this results in an increased neo-antigen burden 
and suggests response to PD1 checkpoint inhibitors. B) Increased CEACAM antigen 
related cell adhesion molecule expression was noted in poor prognosis CPM, this can 
be targeted by novel CEA-TCB bi-specific antibodies. C) RNF43 an upstream negative 
Wnt regulator was commonly mutated in CPM, this  results in persistent Wnt activation, 
this can be targeted by porcupine inhibitor LGK974. D) TET2 mutations were noted in 
CPM, this results in a low of active demethylation and hypermethylation and silencing 
of tumour suppressor genes, this is a potential target for methylation inhibitors such as 







Successful treatments at the in vitro stage could move forward into a clinical trial. CEA 
TCB antibodies, Methylation inhibitors and porcupine inhibitors are already being 
trialled in some phase 1 studies (394-397). Pembrolizumab and Nivolumab have been 
trialled with success in patients with MSI mismatch repair deficient metastatic CRC 
(339-341). No trials exist in patients with isolated peritoneal metastasis. 
Given the number of targetable mutations identified within patients with CPM an 
appropriate phase II trial design would be an umbrella trial with multiple treatment arms 
according to patients individual mutations. Patients with isolated metachronous CPM 
resected by CRS & HIPEC would undergo molecular profiling to determine their 
targetable mutations (RNF43, TET2, CEACAM, and MSI). Personalised targeted 
adjuvant treatments could then be given based on the individual tumours molecular 
features. Patients would be followed up clinically and with CT imaging for 24 months. 
Treatment response would be assessed according to the response evaluation criteria 
in solid tumours (RECIST) (398), in addition to a further analysis of long term survival 
outcomes at 5-years. 
A clinical trial could be combined with the repetition of the ctDNA experiment 
performed in chapter 6 which aimed to determine whether ctDNA can be used as a 
liquid biopsy before surgery and as a biomarker of residual disease and recurrence 
following CRS & HIPEC. The enhanced follow up demanded by a clinical trial is likely 
to reduce the loss to follow up we encountered. 
7.4 Conclusion 
 
Patients with CPM secondary to CRC have limited survival with the best available 
treatments. Despite selection for treatment using known prognostic factors survival 
varies widely and can be difficult to predict. This thesis has identified biological 
changes associated with the development of isolated CPM and conferring ‘poor 
prognosis’ in response to the best currently available treatment in a small cohort of 
patients. These results require validation. Further investigation in a larger cohort is 
needed to develop a prognostic biomolecular classifier and to determine whether 
ctDNA can be used as a marker of tumour recurrence. Therapeutically targetable 
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 Appendix 1 
 
Table S 1 Methylation bioinformatics R code 
library("ChAMP") 
read.idat(): 
bgxfile = dir(path = "/dummy_data/Image Data/Manifest/" ,pattern = ".bgx") 
myLoad <- champ.load(arraytype="EPIC") 
champ.QC() 




myDMP <- champ.DMP(adjPVal = 0.1) 
write.csv(myDMP,file="results.csv") 
myDMR <- champ.DMR() 
write.csv(myDMR,file="dmr.csv") 
myCNA <- champ.CNA() 
myCNA <- champ.CNA(intensity = myLoad$intensity, controlGroup = "T", 











pheno <- read.csv(file="latestpheno.csv",row.names=1,as.is=TRUE) 
 





pheno$Prognosis <- as.factor(pheno$Prognosis) 
 
crstranspose <- t(crsmatrix) 
 
training <- 1:floor(0.60 * nrow(crstranspose)) 
 
testing <- setdiff(1:nrow(crstranspose), training) 
 













plot(sigTrain, typeC = "boxplot") 
 
diaFitDF <- predict(sigTrain) 
 
lapply(diaFitDF, function(predFc) table(actual = pheno[training,"Prognosis"], 
predicted = predFc)) 
 
sapply(diaFitDF, function(predFc) { 
conf <- table(pheno[training, "Prognosis"], predFc) 




diaTestDF <- predict(sigTrain, newdata = crstranspose[testing, ]) 
 
sapply(diaTestDF, function(predFc) { 
conf <- table(pheno[testing, "Prognosis"], predFc) 












































Staining control - examines the efficiency of the staining in both red and green channels.  Ideal Green: 
Biotin High~ 20,000, Red: DNP~High 40,000 
 
Extension control - examines the efficiency of A, T, C and G nucleotide extension Ideal Green: 
C,G~30,000; A,T ~0, Red: A,T ~ 40,000; G,C ~ 0  
 
Hybridisation control – synthetic targets at thee concenrtations (high, medium, low) tests the overall 
performance of the assay. Only monitor green, Ideal Hyb (low) ~ 10,000, Hyb (medium) ~ 15,000, Hyb 




















































































































Target removal control –  highlight efficiency of the removal of probe sequences post extension. 
Target removals should exhibit a low signal compared to hybridisation controls. Only monitor green, 
Ideal low background ~ 10,000 
 
Bisulphite conversion control –  if sucesful the converted C probes match the converted sequence and 
are extended, unconverted DNA - U probes are extended Ideal Green: 1,2,3,4 ~ 0, Green: C1, C2, C3 























































































































































Specificity control –  check for non-specific signal against unmethylated background, Ideal Green 1,2,3 
perfect match ~ 10,000, mismatch ~ 0, Red 1,2,3 ~ 20,000 
Non-polymorphic control – query a base in a non-polymorphic region of genome, allows comparison of 





















GT Mismatch 1 (PM)
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Negative controls –  bisulfite converted sequences not containing CpG dinucleotides are targeted in 
600 negative controls on the array, defines the mean signal defines the system background <1000 
 
 
Table S 3 Significantly (FDR<0.1) downregulated genes in CPM samples 





FDR p value 
1 FABP6 -34.30 1.74 x 10-06 
2 DEFA6 -8.15 8.55 x 10-06 
3 DMBT1 -6.06 2.43 x 10-04 
4 TTC38 -4.56 5.80 x 10-05 
5 OLFM4 -3.77 1.01 x 10-04 
6 IGHA1 -3.66 4.23 x 10-05 
7 CES2 -3.20 6.84 x 10-05 
8 NDUFS6 -2.70 7.74 x 10-05 
9 P2RY11 -2.53 6.37 x 10-04 
10 MUC2 -2.34 7.22 x 10-04 
11 DES -2.32 4.68 x 10-04 
12 ECHS1 -2.25 9.80 x 10-04 
13 PIGR -2.16 1.04 x 10-03 
14 RXRA -2.06 5.13 x 10-04 
15 MTATP6P1 -1.78 1.10 x 10-03 






































Table S 4 Significantly (FDR<0.1) upregulated genes in CPM samples compared 
with primary CRC samples 
Rank Gene ID Fold 
change 
FDR p value 
1 CD53 7.29 5.87 x 10-05 
2 CYR61 4.24 3.12 x 10-04 
3 CXCL12 3.64 9.25 x 10-04 
4 NR2F1 3.53 7.09 x 10-04 
5 CTGF 3.49 1.55 x 10-04 
6 CSTB 3.41 6.13 x 10-04 
7 TSC22D3 3.36 3.94 x 10-04 
8 DCN 3.30 6.19 x 10-05 
9 PTEN 3.25 9.28 x 10-04 
10 NFKBIA 3.24 1.06 x 10-04 
11 PFKFB3 3.13 8.49 x 10-04 
12 SPARC 2.77 3.91 x 10-05 
13 AC120194.1 2.48 4.87 x 10-04 
14 TXNIP 2.43 6.33 x 10-04 
15 VIM 2.35 7.83 x 10-04 
16 MCL1 2.18 4.33 x 10-04 
17 EEF1A1 2.13 3.28 x 10-08 
18 RPS21 2.12 2.11 x 10-05 
19 RPS29 2.09 4.23 x 10-06 
20 PRPF8 2.08 6.48 x 10-04 
21 ITM2B 2.08 1.58 x 10-05 
22 MYL12A 2.02 9.83 x 10-04 
23 TMSB4X 1.99 2.21 x 10-05 
24 TOMM7 1.93 2.87 x 10-04 
25 RPL34 1.92 3.29 x 10-05 
26 RPL7A 1.88 6.17 x 10-05 
27 RHOA 1.85 1.05 x 10-04 
28 TPT1 1.84 3.81 x 10-06 
29 TMSB10 1.80 8.82 x 10-05 
30 FTH1 1.79 2.40 x 10-05 
31 SERF2 1.79 2.87 x 10-04 
32 RPL30 1.77 1.06 x 10-03 
33 RPL15 1.72 1.14 x 10-05 
34 RPLP1 1.71 1.06 x 10-05 
35 PFN1 1.69 6.59 x 10-04 
36 RPL39 1.69 1.64 x 10-04 
37 RPL23 1.65 1.22 x 10-04 
38 RPS3A 1.64 1.80 x 10-04 
39 CD63 1.63 1.79 x 10-04 




41 RPL41 1.62 3.65 x 10-04 
42 RPL31 1.61 5.26 x 10-04 
43 RPL32 1.60 5.04 x 10-05 
44 RPL11 1.59 4.69 x 10-04 
45 B2M 1.58 4.39 x 10-04 
46 RPS24 1.55 4.14 x 10-04 
47 RPS16 1.54 3.44 x 10-04 
48 RPLP0 1.54 7.90 x 10-04 





Table S 5 Significantly (FDR<0.1) upregulated genes in poor prognosis CRS 
samples compared with good prognosis CRS samples 
Rank Gene ID Fold 
change 
FDR p value 
1 VEZF1 -10.40 3.76x 10-05 
2 CEACAM1 -8.27 1.83x 10-03 
3 BCYRN1 -7.96 7.50x 10-05 
4 RP11-192H23.5 -6.22 2.38x 10-04 
5 RELB -6.17 9.50x 10-04 
6 DCAF12 -6.17 1.36x 10-05 
7 POLR3GL -6.05 1.48x 10-03 
8 FEM1C -5.69 1.87x 10-03 
9 AXIN1 -5.42 1.67x 10-04 
10 KHDRBS3 -5.01 1.23x 10-03 
11 TMEM167A -4.68 1.30x 10-04 
12 FHOD1 -4.60 4.54x 10-04 
13 ATG9A -4.59 1.28x 10-03 
14 DENND4B -4.43 2.50x 10-04 
15 PDCD5 -4.34 7.63x 10-04 
16 RAB22A -4.21 1.20x 10-03 
17 SNX3 -4.16 3.06x 10-03 
18 SEC61B -4.13 2.13x 10-03 
19 PAM -4.10 9.87x 10-05 
20 NKIRAS2 -4.10 2.77x 10-03 
21 PPP1R11 -4.10 1.95x 10-03 
22 IGSF8 -4.07 8.12x 10-04 
23 FOXK1 -3.95 2.90x 10-03 
24 SEPHS1 -3.76 1.87x 10-03 
25 NUBP2 -3.74 4.24x 10-04 




27 DCP1A -3.59 2.34x 10-03 
28 HSPBP1 -3.41 8.96x 10-04 
29 VPS26B -3.38 1.54x 10-03 
30 C14orf119 -3.38 1.34x 10-04 
31 IDH3A -3.37 2.57x 10-04 
32 KLHL12 -3.34 1.45x 10-03 
33 HSD3B7 -3.25 4.56x 10-04 
34 RNF216 -3.22 6.91x 10-04 
35 PES1 -3.20 8.67x 10-04 
36 TTC39B -3.17 1.90x 10-03 
37 FMNL2 -3.11 1.00x 10-03 
38 TMEM214 -3.09 9.61x 10-05 
39 CDH17 -3.08 1.72x 10-03 
40 POLR2H -3.06 1.27x 10-04 
41 CHMP4A -3.04 9.91x 10-04 
42 GGA1 -3.01 1.00x 10-03 
43 MKLN1 -3.00 1.30x 10-03 
44 VEGFB -2.99 1.56x 10-03 
45 NUDT3 -2.95 1.90x 10-04 
46 ATP6V0A1 -2.93 1.04x 10-03 
47 ANKH -2.93 1.95x 10-03 
48 CTNND1 -2.86 2.94x 10-03 
49 RP11-345J4.5 -2.84 7.67x 10-04 
50 SERTAD1 -2.82 4.57x 10-04 
51 HBEGF -2.82 5.48x 10-04 
52 COX20 -2.78 8.51x 10-04 
53 VKORC1 -2.77 2.29x 10-03 
54 APLP2 -2.70 1.42x 10-03 
55 SLC6A8 -2.69 1.54x 10-03 
56 MGMT -2.67 1.88x 10-03 
57 LTBP1 -2.66 1.27x 10-03 
58 WASL -2.66 7.97x 10-04 
59 TRAF7 -2.63 3.68x 10-04 
60 KLF10 -2.63 1.97x 10-03 
61 SHMT2 -2.63 9.78x 10-04 
62 EP300 -2.62 3.30x 10-05 
63 NQO1 -2.61 2.89x 10-03 
64 ACLY -2.58 3.07x 10-03 
65 MAP1A -2.58 1.23x 10-03 
66 IFNAR1 -2.57 1.73x 10-03 
67 PSMA1 -2.56 2.37x 10-03 
68 RAD1 -2.56 5.06x 10-04 
69 CD37 -2.55 1.21x 10-03 
70 MIEN1 -2.52 6.78x 10-04 
71 YARS -2.48 1.14x 10-03 




73 LDLR -2.43 1.42x 10-03 
74 C7orf73 -2.43 2.58x 10-03 
75 TARS -2.42 6.92x 10-04 
76 ARFIP1 -2.40 2.34x 10-03 
77 HNRNPH2 -2.39 6.49x 10-04 
78 CCDC90B -2.36 1.30x 10-03 
79 DERL1 -2.36 2.52x 10-04 
80 NUDT5 -2.35 1.27x 10-03 
81 KIAA0368 -2.32 2.52x 10-03 
82 TMEM165 -2.32 1.86x 10-03 
83 SLC2A8 -2.32 1.84x 10-03 
84 PRDX4 -2.30 1.73x 10-04 
85 ANKRD52 -2.25 1.01x 10-03 
86 ATP5C1 -2.21 1.13x 10-03 
87 RBBP6 -2.21 3.57x 10-04 
88 EHD2 -2.15 3.96x 10-04 
89 TRPC4AP -2.14 1.37x 10-03 
90 SOWAHC -2.11 1.62x 10-03 
91 NOP10 -2.10 1.24x 10-04 
92 PXN -2.05 2.99x 10-03 
93 PPAN -2.01 1.67x 10-03 
94 ALDH7A1 -1.99 1.79x 10-03 
95 RNF40 -1.98 1.57x 10-03 
96 EMP3 -1.98 2.73x 10-03 
97 NDST1 -1.95 1.49x 10-03 
98 NME7 -1.95 2.67x 10-03 
99 MARCH2 -1.94 1.80x 10-04 
100 PTPN14 -1.94 1.24x 10-03 
101 NSUN5 -1.93 2.69x 10-03 
102 CTA-363E6.7 -1.91 2.24x 10-03 
103 TRIAP1 -1.90 1.80x 10-03 
104 RNF149 -1.89 2.91x 10-03 
105 STOM -1.88 1.30x 10-03 
106 KDM2B -1.87 9.12x 10-04 
107 PRPS1 -1.86 1.11x 10-03 
108 MPLKIP -1.85 1.87x 10-04 
109 NCKAP1 -1.85 2.05x 10-03 
110 LSM14A -1.85 1.21x 10-04 
111 LEPREL4 -1.83 6.29x 10-04 
112 DGKA -1.82 1.60x 10-03 
113 CERCAM -1.82 1.12x 10-03 
114 RNASE6 -1.80 9.57x 10-04 
115 ZHX1 -1.77 6.17x 10-04 
116 PLRG1 -1.75 1.78x 10-03 
117 PRKAG1 -1.74 1.37x 10-04 




119 BRF2 -1.72 1.84x 10-03 
120 SIGMAR1 -1.72 4.24x 10-04 
121 AGPAT1 -1.69 1.95x 10-03 
122 JOSD1 -1.69 3.70x 10-04 
123 IFITM3 -1.67 1.58x 10-03 
124 ARL2 -1.66 2.59x 10-04 
125 TMEM230 -1.64 1.72x 10-03 
126 ADIRF -1.63 1.58x 10-03 
127 UBR4 -1.62 3.48x 10-04 
128 KCTD10 -1.60 1.00x 10-03 
129 WIPF1 -1.60 2.53x 10-03 
130 GSE1 -1.59 2.69x 10-03 
131 MRPL15 -1.58 2.60x 10-03 
132 TFRC -1.57 6.55x 10-04 
133 GBAS -1.56 2.00x 10-03 
134 PARVA -1.56 3.00x 10-03 
135 MXD1 -1.52 2.68x 10-04 
136 ZEB1 -1.50 2.94x 10-03 
137 SAFB2 -1.50 3.10x 10-03 
138 CYTH2 -1.46 3.14x 10-03 
139 CAPN2 -1.46 2.56x 10-03 
140 PLOD3 -1.46 1.68x 10-03 
141 TMEM164 -1.46 3.14x 10-03 
142 MRPL18 -1.46 1.21x 10-03 
143 PIK3R2 -1.45 1.26x 10-03 
144 RAPGEFL1 -1.40 2.33x 10-03 
145 NUDT22 -1.39 1.35x 10-03 
146 VPS37C -1.34 2.40x 10-03 
147 STX12 -1.32 3.15x 10-03 
148 ATP6V1B2 -1.32 2.76x 10-03 


















CRS1 202784980004 843445 97.29494 861852 99.41827 
CRS2 202784980004 830464 95.79753 860247 99.23313 




CRS4 202784980004 855345 98.66766 864308 99.70158 
CRS5 202784980004 861459 99.37293 864954 99.7761 
CSR6 202784980004 822886 94.92338 859315 99.12561 
CRS7 202784980004 861596 99.38874 865016 99.78325 
CRS8 202784980004 861981 99.43315 864697 99.74645 
CRS9 202784980045 804554 92.8087 854392 98.55773 
CRS10 202784980045 838711 96.74886 860838 99.3013 
CRS12 202784980045 794049 91.59691 854553 98.5763 
CRS13 202784980045 859991 99.20359 864680 99.74449 
CRS14 202784980045 849612 98.00633 862239 99.46291 
CRS15 202784980045 848152 97.83792 863304 99.58576 
CRS16 202784980045 767508 88.53529 845664 97.55091 
CRS17 202784980045 781328 90.12949 838259 96.69672 
CRS18 202784980029 833549 96.1534 861277 99.35194 
CRS20 202784980029 851528 98.22735 863489 99.6071 
CRS21 202784980029 834896 96.30878 860209 99.22874 
CRS22 202784980029 850487 98.10727 864086 99.67597 
CRS23 202784980029 852377 98.32529 864248 99.69466 
CRS24 202784980029 856861 98.84254 864473 99.72061 
CRS25 202784980029 822612 94.89177 857486 98.91463 
CRS26 202784980029 734406 84.71683 822035 94.82521 
P1 202784980001 843428 97.29298 862174 99.45541 
P2 202784980001 768280 88.62434 846622 97.66142 
P3 202784980001 826195 95.30508 857273 98.89006 
P4 202784980001 791419 91.29352 846301 97.6244 
P14 202784980001 818861 94.45908 854076 98.52127 
P15 202784980001 861106 99.33221 865045 99.78659 
P16 202784980001 773329 89.20677 844170 97.37858 






Table S 7 Differentially Methylated Regions (DMRs), in CPM samples compared 
with primary CRC samples 















DMR1 chr11 2160904 2161586 682 0.002 IGF2 302 
DMR2 chr19 37157318 37157945 627 0.003 ZNF461 39 
DMR3 chr15 79383167 79383980 813 0.003 RASGRF1 195 
DMR4 chr18 35145983 35147090 1107 0.003 CELF4 196 
DMR5 chr19 58609269 58609987 718 0.003 ZSCAN18 61 
DMR6 chr13 78493229 78493712 483 0.003 EDNRB 70 
DMR7 chr6 28602543 28603027 484 0.004 ZBED9 2 
DMR8 chr5 135415693 135416613 920 0.005 VTRNA2-1 24 
DMR9 chr19 58458572 58459358 786 0.005 ZNF256 52 
DMR10 chr5 38258007 38259243 1236 0.008 EGFLAM 108 




DMR12 chr18 5543271 5544237 966 0.010 EPB41L3 82 
DMR13 chr8 65492528 65492936 408 0.016 LOC401463 143 
DMR14 chr19 37328842 37329517 675 0.013 ZNF790 49 
DMR15 chr5 146257347 146258427 1080 0.013 PPP2R2B 97 
DMR16 chr19 38182773 38183418 645 0.016 ZNF781 47 
 
Table S 8 Copy number alterations, primary CRC and CPM, p value < x10-07 
Chr Start End Type Count Score P value 
chr11 Gain 3817692 3818253 22 0.91 2.78 X10-07 
chr11 Gain 3825449 4629195 22 0.91 2.78 X10-07 
chr11 Gain 4629529 5704417 22 0.91 2.78 X10-07 
chr11 Gain 5705995 5705995 22 0.91 2.78 X10-07 
chr11 Gain 5712109 6518263 22 0.91 2.78 X10-07 
chr11 Gain 6518907 6650480 22 0.91 2.78 X10-07 




chr16 Gain 57333722 57335017 22 0.91 2.78 X10-07 
chr16 Gain 57495650 57503371 22 0.91 2.78 X10-07 
chr16 Gain 71842906 71843647 22 0.91 2.78 X10-07 
chr16 Gain 71844102 72096368 22 0.91 2.78 X10-07 
chr16 Gain 72096449 72108059 22 0.91 2.78 X10-07 
chr16 Gain 77246048 77246057 22 0.91 2.78 X10-07 
chr16 Gain 77247012 77247012 22 0.91 2.78 X10-07 
chr16 Gain 88877767 88878414 22 0.91 2.78 X10-07 
chr5 Loss  32711355 32711431 21 0.87 6.73 X10-07 
chr5 Loss  32711517 32713290 21 0.87 6.73 X10-07 
chr5 Loss  32713464 32714010 21 0.87 6.73 X10-07 
chr5 Loss  33892083 33892429 21 0.87 6.73 X10-07 
chr5 Loss  33892457 33892457 21 0.87 6.73 X10-07 
chr5 Loss  33936232 33936322 21 0.87 6.73 X10-07 
chr5 Loss  33936402 33937673 21 0.87 6.73 X10-07 
chr5 Loss  33937876 33945086 21 0.87 6.73 X10-07 
chr5 Loss  38257541 38258007 21 0.87 6.73 X10-07 
chr5 Loss  38258028 38258670 21 0.87 6.73 X10-07 




Table S 9 Copy number alteration, poor and good prognosis CPM, p value < 
x10-10 
Chr Start End Type Count Score 
 
chr3 6902689 6905031 Loss 12 1 2.22 X10-16 
chr3 16554466 16554910 Loss 12 1 2.22 X10-16 
chr3 36985697 36986697 Loss 12 1 2.22 X10-16 
chr3 43020703 43022351 Loss 12 1 2.22 X10-16 
chr3 44596684 44596846 Loss 12 1 2.22 X10-16 




chr4 25657365 25657628 Loss 12 1 2.22 X10-16 
chr4 57975793 57976944 Loss 12 1 2.22 X10-16 
chr4 81187125 81188051 Loss 12 1 2.22 X10-16 
chr4 81951953 81952024 Loss 12 1 2.22 X10-16 
chr4 84206068 84206074 Loss 12 1 2.22 X10-16 
chr4 141489859 141490428 Loss 12 1 2.22 X10-16 
chr14 76839844 76843917 Loss 12 1 2.22 X10-16 
chr14 77227545 77228510 Loss 12 1 2.22 X10-16 
chr14 77228690 77228753 Loss 12 1 2.22 X10-16 
chr14 79744991 79745154 Loss 12 1 2.22 X10-16 
chr14 89017776 89018372 Loss 12 1 2.22 X10-16 
chr14 92788602 92790285 Loss 12 1 2.22 X10-16 
chr15 84115811 84116151 Loss 12 1 2.22 X10-16 
chr15 84116920 84116920 Loss 12 1 2.22 X10-16 
chr17 27044852 27045113 Loss 12 1 2.22 X10-16 
chr17 27045164 27046568 Loss 12 1 2.22 X10-16 
chr17 30681379 31617566 Loss 12 1 2.22 X10-16 
chr17 31618409 31620378 Loss 12 1 2.22 X10-16 
chr17 31620500 32255252 Loss 12 1 2.22 X10-16 
chr17 66596275 66597500 Loss 12 1 2.22 X10-16 
chr19 16151557 16163163 Loss 12 1 2.22 X10-16 
chr19 16223151 16235032 Loss 12 1 2.22 X10-16 
chr19 16294776 16294776 Loss 12 1 2.22 X10-16 
chr19 17378645 17392161 Loss 12 1 2.22 X10-16 
chr19 17392298 17392923 Loss 12 1 2.22 X10-16 
chr19 17393354 17415223 Loss 12 1 2.22 X10-16 
chr19 17580131 17580131 Loss 12 1 2.22 X10-16 
chr19 17581430 17581572 Loss 12 1 2.22 X10-16 
chr9 35658919 36400252 Gain 12 1 2.22 X10-16 
chr9 36401304 36598003 Gain 12 1 2.22 X10-16 




chr9 37033750 37800138 Gain 12 1 2.22 X10-16 
chr9 37800654 70971005 Gain 12 1 2.22 X10-16 
chr9 72435576 72436057 Gain 12 1 2.22 X10-16 
chr9 74061323 74061323 Gain 12 1 2.22 X10-16 
chr10 23461301 23489850 Gain 12 1 2.22 X10-16 
chr10 23492470 23978755 Gain 12 1 2.22 X10-16 
chr10 23982350 23984977 Gain 12 1 2.22 X10-16 
chr10 31435733 31531682 Gain 12 1 2.22 X10-16 
chr10 32240872 32266546 Gain 12 1 2.22 X10-16 
chr11 625894 625894 Gain 12 1 2.22 X10-16 
chr11 626307 636460 Gain 12 1 2.22 X10-16 
chr11 637885 693717 Gain 12 1 2.22 X10-16 
chr11 694295 703918 Gain 12 1 2.22 X10-16 
chr11 704672 804954 Gain 12 1 2.22 X10-16 
chr11 805666 809911 Gain 12 1 2.22 X10-16 
chr11 1968310 1968980 Gain 12 1 2.22 X10-16 
 
Chr, chromosomes, Type CNA, Start, start position of the CNA, End, end position of 
the CNA, count, number of samples carrying this type of event at this location, score, 
proportion of samples carrying this type of event at this location, GW_P, poisson-
binomial test for overlap of event across individuals at this location given proportion 

































N12 90.16 76.13 68.85 83.53 15.87 91.73 
p26 87.34 84.52 73.88 81.72 25.01 90.75 
N6 90.37 87.35 67.6 81.95 14.27 89.21 
P11 86.91 82.14 73.81 82.74 21.92 85.23 
C5 87.26 80.88 74.36 87.54 17.01 89.84 
C16 91.37 88.86 64.7 78.33 14.65 92.25 
N5 91.75 87.45 65.66 79.13 15.84 90.2 
N10 91.29 85.74 65.22 85.16 9.7 92.11 
P1 91.51 87.54 62.46 83.15 6.62 87.77 
P9 90.02 86.39 64.94 82.9 8.09 87.02 
C8 90.19 88.26 63.88 81.82 10.54 92.69 
p23 92.87 90.52 66.54 83.69 9.97 93.24 
N11 90.57 86.19 63.42 82.5 9.87 91.09 
p16 92.34 90.74 71.72 85.25 13.79 92.68 
C17 91.15 88.85 65.52 80.87 10.73 92.07 
N7 91.76 88.42 60.04 78.95 8.31 90.3 
C9 90.79 89.14 66.15 82.49 10.23 92 
C12 92.91 90.82 67.58 82.33 13.18 93.18 
P6 90.56 86.13 65.94 83.77 9.12 86.92 
N17 93.42 90.57 69.84 85.47 13.26 93.63 
CRS26 90.77 88.24 62.55 72.92 20.47 91.19 
CRS23 92.23 90.58 60.76 78.92 8.45 90.9 
p25 91.41 89.89 68.17 81.17 13.98 92.27 
p18 92.25 91.14 69.37 84.55 11.59 93.09 
P2 91.49 88.37 67.59 83.76 9.43 86.39 




C13 89.5 87.77 61.81 81.47 6.67 92.5 
N21 91.14 88.15 68.59 85.36 10.97 91.98 
C21 91.29 89.34 63.03 80.85 7.61 92.36 
p24 92.72 90.86 68.41 83.99 10.96 93.17 
p19 92.48 90.26 68.51 85.26 10.54 93.19 
N20 92.93 88.48 63.86 83.46 9.86 93.24 
C18 92.14 90.48 63.88 80.45 8.68 92.68 
CRS25 92.46 90.05 59.04 75.25 10.62 90.59 
p17 93.06 91.9 66.51 82.8 9.96 93.29 
N2 92.02 90.25 55.33 73.31 8.66 90.43 
C7 89.42 86.26 65.44 85.32 6.66 90.76 
C14 92.47 90.71 64.93 82.07 8.48 93.25 
C2 89.44 85.44 66.18 85.59 7.8 90.8 
C4 89.71 86.42 66.36 86.11 7.16 90.86 
N23 91.79 87.76 61.92 82.47 7.47 92.23 
C10 93.14 92.04 61.86 79.23 9.48 93.48 
N14 91.19 87.34 64.36 85.07 7.22 92.04 
P10 89.83 84.64 66.29 81.58 10.57 87.4 
p20 90.01 88.33 65.04 82.49 9.65 91.63 
P13 89.04 84.25 64.16 75.85 15.02 87.26 
CRS21 92.65 91.34 64.49 81.2 9.12 91.34 
P4 92.48 88.84 65.92 81.81 10.75 88.78 
N3 92.51 90.5 61.06 79.23 8.85 90.55 
N1 91.88 89.74 59.95 79.65 7.16 90.53 
P12 90.12 85.24 61.07 78.1 8.82 86.86 
P3 91.19 85.89 57.35 73.64 10.08 87.1 
CRS22 93.02 91.97 60.58 80.48 6.72 90.71 
N26 91.22 87.77 67.9 84.52 10.22 92.59 
p21 92.9 91.27 61.96 79.8 8.39 93.34 
N15 91.2 88.71 65.99 82.95 10.04 92.38 
p22 92.39 91.15 64.64 79.07 10.55 93.13 






Table S 11 Genes with a bias towards high functional levels of mutations in the 
primary CRC cohort, potential drivers 
 
P-value Q-value PPH2 P-
value 
MA P-value SIFT P-value 
KRAS 3.66E-15 
1.03E-11 
0.044 0.000 0.000 
TP53 3.90E-12 
5.46E-09 
0.000 0.000 0.002 
CAD 1.36E-11 
1.27E-08 
0.001 0.000 0.005 
NME1-NME2 1.35E-08 
9.47E-06 
0.081 0.000 0.054 
NMD3 1.46E-06 0.001 0.001 0.001 0.011 
RCN3 3.43E-05 0.014 0.010 0.002 0.011 
CDC42BPA 3.38E-05 0.014 0.004 0.007 0.011 
SDHA 5.17E-05 0.017 0.020 0.000 0.054 
AP1S1 5.71E-05 0.017 0.029 0.000 0.054 
ARHGEF12 6.22E-05 0.017 0.003 0.015 0.011 
EFEMP1 7.35E-05 0.019 0.003 0.018 0.011 
ZNF397 8.30E-05 0.019 0.006 0.002 0.054 
MCCC2 9.68E-05 0.021 0.023 0.001 0.054 
ATL2 0.000 0.021 0.006 0.003 0.054 
CDH1 0.000 0.026 0.017 0.002 0.054 
TTLL1 0.000 0.026 0.006 0.009 0.054 
C20 91.67 90.4 58.69 76.7 7.99 92.61 
C1 90.73 87.93 67.01 85.72 7.8 91.73 
N13 90.62 87.25 65.38 82.66 9.53 92.24 
C3 88.3 83.18 65.91 84.36 7.37 91.17 
p15 92.51 91.56 65.52 84.2 6.48 93.68 
P14 89.13 84.02 59.35 74.32 9.95 87.29 
C6 88.65 82.58 64.66 84.84 6.72 91.02 
CRS24 92.69 89.55 61.48 78.33 10.04 91.06 




CRNKL1 0.000 0.026 0.165 0.001 0.011 
ERICH1 0.000 0.026 0.006 0.009 0.054 
HIBADH 0.000 0.026 0.006 0.009 0.054 
GTPBP4 0.000 0.026 0.006 0.009 0.054 
MSH6 0.000 0.026 0.003 0.040 0.016 
ZNF410 0.000 0.026 0.006 0.009 0.054 
POLR1B 0.000 0.026 0.087 0.002 0.011 
OSER1 0.000 0.026 0.006 0.009 0.054 
CEP350 0.000 0.026 0.013 0.089 0.002 
EI24 0.000 0.026 0.006 0.009 0.054 
AHCYL1 0.000 0.026 0.059 0.001 0.054 
HLA-F 0.000 0.026 0.006 0.009 0.054 
MPV17L2 0.000 0.026 0.006 0.009 0.054 
EML2 0.000 0.028 0.006 0.011 0.054 
RICTOR 0.000 0.028 0.013 0.014 0.019 
PDE4DIP 0.000 0.028 0.017 0.010 0.021 
CDKAL1 0.000 0.029 0.157 0.000 0.079 
SPAG9 0.000 0.031 0.006 0.013 0.054 
CNTRL 0.000 0.032 0.027 0.019 0.009 
ZFYVE1 0.000 0.032 0.007 0.024 0.028 
ELP2 0.000 0.032 0.010 0.009 0.054 
ELP3 0.000 0.033 0.022 0.004 0.054 
SMARCAL1 0.000 0.035 0.018 0.006 0.053 
CHPF 0.001 0.036 0.006 0.018 0.054 
DCHS1 0.001 0.036 0.006 0.011 0.096 
APC 0.001 0.038 0.014 0.009 0.055 
NAA15 0.001 0.038 0.011 0.011 0.054 
SLC36A1 0.001 0.040 0.036 0.004 0.054 
WDR19 0.001 0.040 0.014 0.011 0.054 





Identified using OncodriveFM, Intogen, Q-value <0.05, (PPH2, Polyphen2, MA 
Mutation Assesor, SIFT Sorting Intolerant from Tolerant). 
 
 
Table S 12 The KEGG pathways with accumulated mutations of high functional 
impact in primary CRC 
Kegg ID Name Class Q-value 
hsa00280 Valine, leucine and 
isoleucine degradation 
Metabolism  7.54E-06 
hsa05217 Basal cell carcinoma Cancers: Specific types 2.13E-05 
hsa05210 Colorectal cancer Cancers: Specific types 0.000 
hsa04726 Serotonergic synapse Nervous system 0.000 
hsa03008 Ribosome biogenesis in 
eukaryotes 
Genetic; Translation 0.000 
hsa00240 Pyrimidine metabolism Metabolism 0.000 
hsa05216 Thyroid cancer Cancers: Specific types 0.000 
hsa04730 Long-term depression Nervous system 0.000 
hsa03430 Mismatch repair  Genetic Replication 
and repair 
0.001 
hsa01100 Metabolic pathways Metabolism 0.001 








hsa03030 DNA replication  Genetic Replication 
and repair 
0.001 
hsa03410 Base excision repair  Genetic Replication 
and repair 
0.002 
hsa05219 Bladder cancer  Cancers: Specific types 0.002 
hsa00900 Terpenoid backbone 
biosynthesis 
Metabolism 0.005 




hsa05222 Small cell lung cancer Cancers: Specific types 0.018 
hsa00410 beta-Alanine metabolism Metabolism 0.020 
hsa05220 Chronic myeloid leukemia Cancers: Specific types 0.020 
hsa05212 Pancreatic cancer Cancers: Specific types 0.020 
hsa05213 Endometrial cancer Cancers: Specific types 0.022 
hsa04920 Adipocytokine signaling 
pathway 
Endocrine system 0.024 
hsa05030 Cocaine addiction Human Diseases; 
Substance dependence 
0.026 
hsa00010 Glycolysis / 
Gluconeogenesis  
Metabolism 0.032 
hsa00640 Propanoate metabolism Metabolism 0.032 
hsa04340 Hedgehog signaling 
pathway 
Signal transduction 0.032 
hsa00071 Fatty acid degradation Metabolism 0.032 
hsa00340 Histidine metabolism Metabolism 0.040 
hsa00330 Arginine and proline 
metabolism 
Metabolism 0.041 




Table S 13 Genes with a bias towards high functional levels of mutations in the 
CPM CRC cohort, potential drivers 
 






FLNB 1.38E-13 7.53E-10 1.00E-08 0.0001 0.000 
TP53 1.10E-12 3.00E-09 0.000 1.00E-08 0.002 
RIOK2 2.33E-12 3.73E-09 0.000 1.00E-08 0.001 
PDE4DIP 3.42E-12 3.73E-09 0.001 1.00E-08 0.001 




SPTB 1.35E-11 1.22E-08 0.000 1.00E-08 0.009 
PPL 1.92E-10 1.49E-07 1.00E-08 0.007 0.007 
NUP98 2.49E-10 1.70E-07 1.00E-08 0.008 0.008 
SVEP1 2.16E-09 1.31E-06 0.000 0.000 0.000 
CDC16 1.75E-08 7.35E-06 0.000 0.000 0.003 
HIPK1 1.75E-08 7.35E-06 0.000 0.000 0.003 
TSC1 1.75E-08 7.35E-06 0.000 0.000 0.003 
THAP6 1.75E-08 7.35E-06 0.000 0.000 0.003 
CCHCR1 2.08E-08 8.12E-06 0.000 0.000 0.004 
MED14 2.54E-08 9.25E-06 0.000 0.000 0.003 
AHNAK2 8.26E-08 2.81E-05 0.001 0.000 0.005 
MUC4 2.67E-07 8.55E-05 1.00E-08 0.147 0.775 
ZNF462 5.26E-07 0.000 0.001 0.030 0.000 
SPG7 6.63E-07 0.000 0.001 0.001 0.003 
CENPJ 8.55E-07 0.000 0.001 0.002 0.002 
AIFM1 9.91E-07 0.000 0.002 0.001 0.003 
ZNF880 1.06E-06 0.000 0.000 0.004 0.004 
ZMYM6 2.07E-06 0.000 0.001 0.003 0.007 
TMEM2 2.17E-06 0.000 0.003 0.001 0.007 
HSPG2 4.03E-06 0.001 0.010 0.002 0.001 
FRG1BP 4.66E-06 0.001 0.000 
 
0.003 
KNL1 6.33E-06 0.001 0.001 0.006 0.011 
AMACR 6.20E-06 0.001 0.018 0.000 0.011 
POMT1 8.07E-06 0.002 0.008 0.004 0.002 
TTL 9.06E-06 0.002 0.002 0.005 0.006 
CNDP2 9.44E-06 0.002 0.012 0.000 0.050 
GGT6 1.01E-05 0.002 0.003 0.004 0.005 
NHS 9.84E-06 0.002 0.025 0.025 0.000 
ALMS1 1.31E-05 0.002 0.000 0.040 0.007 
BRWD1 1.31E-05 0.002 0.001 0.007 0.019 




SH3YL1 3.45E-05 0.002 0.003 0.004 0.023 
VCAN 2.04E-05 0.002 0.002 0.020 0.004 
NEDD4L 3.45E-05 0.002 0.003 0.004 0.023 
PIK3CB 3.45E-05 0.002 0.003 0.004 0.023 
SYNE2 2.12E-05 0.002 0.008 0.001 0.021 
GPATCH1 3.45E-05 0.002 0.003 0.004 0.023 
RAB10 3.45E-05 0.002 0.003 0.004 0.023 
DNMT3B 3.45E-05 0.002 0.003 0.004 0.023 
GRAMD1A 3.45E-05 0.002 0.003 0.004 0.023 
CRNKL1 3.45E-05 0.002 0.003 0.004 0.023 
USP14 3.45E-05 0.002 0.003 0.004 0.023 
ZNF419 3.45E-05 0.002 0.003 0.004 0.023 
NCAPG 3.45E-05 0.002 0.003 0.004 0.023 
SMAP1 2.19E-05 0.002 0.009 0.000 0.084 
ITGA4 3.45E-05 0.002 0.003 0.004 0.023 
DNAJC16 3.45E-05 0.002 0.003 0.004 0.023 
MPL 3.45E-05 0.002 0.003 0.004 0.023 
CCND2 3.45E-05 0.002 0.003 0.004 0.023 
TMEM214 3.14E-05 0.002 0.001 0.019 0.011 
EEF1E1 3.45E-05 0.002 0.003 0.004 0.023 
ERGIC3 3.45E-05 0.002 0.003 0.004 0.023 
LOXL1 2.42E-05 0.002 0.002 0.032 0.003 
XPO7 3.06E-05 0.002 0.014 0.001 0.013 
PTPRA 3.45E-05 0.002 0.003 0.004 0.023 
ELP3 3.45E-05 0.002 0.003 0.004 0.023 
CCNH 2.37E-05 0.002 0.016 0.004 0.003 
MRPS9 3.45E-05 0.002 0.003 0.004 0.023 
NDUFB5 3.45E-05 0.002 0.003 0.004 0.023 
NAAA 3.45E-05 0.002 0.003 0.004 0.023 
INTS7 3.45E-05 0.002 0.003 0.004 0.023 




ZKSCAN2 2.05E-05 0.002 0.001 0.010 0.011 
TSPAN7 3.45E-05 0.002 0.003 0.004 0.023 
ZNF276 2.72E-05 0.002 0.002 0.265 0.000 
EDIL3 3.45E-05 0.002 0.003 0.004 0.023 
CYB5A 3.45E-05 0.002 0.003 0.004 0.023 
TNXB 1.72E-05 0.002 0.096 0.000 0.012 
NPNT 3.29E-05 0.002 0.002 0.008 0.018 
ADAL 3.45E-05 0.002 0.003 0.004 0.023 
CSNK1G1 3.45E-05 0.002 0.003 0.004 0.023 
CHCHD7 3.45E-05 0.002 0.003 0.004 0.023 
SNCG 3.45E-05 0.002 0.003 0.004 0.023 
RNF213 2.90E-05 0.002 0.002 0.024 0.005 
LMLN 3.45E-05 0.002 0.003 0.004 0.023 
CLN3 1.94E-05 0.002 0.001 0.079 0.003 
FBF1 2.23E-05 0.002 0.020 0.020 0.000 
ZNF720 3.45E-05 0.002 0.003 0.004 0.023 
TSEN15 2.10E-05 0.002 0.001 0.037 0.003 
MOB3C 3.55E-05 0.002 0.024 0.004 0.003 
CUL7 3.70E-05 0.002 0.008 0.038 0.001 
EML2 3.91E-05 0.002 0.003 0.005 0.023 
LIG1 4.21E-05 0.003 0.007 0.005 0.011 
MKI67 4.61E-05 0.003 0.000 0.061 0.020 
HLA-DPB1 4.95E-05 0.003 0.277 0.001 0.002 
SLC26A6 4.93E-05 0.003 0.016 0.001 0.021 
WWC1 5.16E-05 0.003 0.001 0.019 0.027 
CRYBG1 5.70E-05 0.003 0.004 0.009 0.013 
ALDH3A2 5.94E-05 0.003 0.017 0.003 0.011 
LAMC2 6.02E-05 0.003 0.055 0.006 0.002 
PSPH 6.10E-05 0.003 0.022 0.001 0.023 
ITGA6 6.24E-05 0.004 0.008 0.006 0.011 




VRK2 7.19E-05 0.004 0.007 0.007 0.012 
FAT4 7.47E-05 0.004 0.001 0.014 0.032 
 
8.11E-05 0.004 0.026 0.010 0.003 
LIPE 9.58E-05 0.005 0.002 0.048 0.008 
BOD1 9.63E-05 0.005 0.016 0.019 0.003 
ATP6V0A2 9.66E-05 0.005 0.008 0.010 0.011 
FNIP1 9.71E-05 0.005 0.007 0.012 0.011 
TLR5 9.91E-05 0.005 0.009 0.004 0.026 
NUMBL 0.000 0.005 0.003 0.014 0.023 
MAP1A 0.000 0.006 0.000 0.010 1.000 
FRAS1 0.000 0.006 0.030 0.001 0.024 
CLEC2D 0.000 0.006 0.017 0.011 0.006 
EGFLAM 0.000 0.006 0.012 0.010 0.008 
FCHSD2 0.000 0.006 0.003 0.016 0.023 
TET2 0.000 0.006 0.003 0.133 0.003 
FKTN 0.000 0.006 0.003 0.025 0.016 
PLCE1 0.000 0.006 0.009 0.098 0.001 
PRUNE2 0.000 0.007 0.007 0.018 0.010 
DPYD 0.000 0.007 0.007 0.011 0.018 
GEMIN4 0.000 0.007 0.018 0.007 0.012 
TSEN54 0.000 0.007 0.015 0.029 0.003 
PTGES3L-
AARSD1 
0.000 0.007 0.004 0.133 0.003 
TMED5 0.000 0.007 0.023 0.004 0.018 
PPFIA1 0.000 0.007 0.004 0.038 0.009 
WDR19 0.000 0.007 0.043 0.001 0.031 
AKT1S1 0.000 0.007 0.004 0.074 0.006 
EPHX2 0.000 0.007 0.005 0.019 0.018 
TMEM63A 0.000 0.007 0.021 0.005 0.016 
LPL 0.000 0.007 0.140 0.003 0.004 




TCOF1 0.000 0.009 0.022 0.026 0.004 
TCP11L1 0.000 0.009 0.021 0.003 0.030 
CD320 0.000 0.009 0.003 0.219 0.003 
KNSTRN 0.000 0.009 0.006 
 
0.003 
ZNF511 0.000 0.010 0.005 0.161 0.003 
ASMTL 0.000 0.010 0.003 0.027 0.033 
CAPN12 0.000 0.010 0.006 0.019 0.023 
SMARCA1 0.000 0.010 0.009 0.008 0.036 
ARHGEF3 0.000 0.010 0.013 0.023 0.008 
SPG11 0.000 0.010 0.007 0.012 0.034 
PDE3B 0.000 0.010 0.026 0.005 0.023 
CLTCL1 0.000 0.010 0.010 0.011 0.025 
SELL 0.000 0.011 0.009 0.010 0.034 
TYK2 0.000 0.011 0.019 0.010 0.016 
C16orf70 0.000 0.011 0.008 0.018 0.023 
DDX49 0.000 0.012 0.014 0.010 0.023 
ZSCAN32 0.000 0.012 0.002 
 
0.013 
XRRA1 0.000 0.012 0.005 0.020 0.039 
APC 0.000 0.012 0.038 0.011 0.009 
ZHX3 0.000 0.012 0.007 0.035 0.015 
DNHD1 0.000 0.012 0.010 0.071 0.005 
ZNF415 0.000 0.012 0.004 0.284 0.004 
TBC1D5 0.000 0.012 0.005 0.083 0.008 
PGM1 0.000 0.012 0.002 0.028 0.072 
ACAP3 0.000 0.012 0.024 0.007 0.023 
HLA-DRB5 0.000 0.012 0.311 0.001 0.012 
UHRF1BP1 0.000 0.013 0.003 0.100 0.012 
C20orf96 0.000 0.014 0.005 0.026 0.039 
GGT1 0.000 0.014 0.015 0.019 0.016 
KDELR2 0.000 0.015 0.050 0.004 0.023 




KIF15 0.000 0.015 0.003 0.030 0.059 
CYB5D1 0.000 0.016 0.016 0.115 0.003 
CTTNBP2 0.000 0.016 0.006 0.024 0.039 
CEP120 0.000 0.016 0.021 0.010 0.027 
PALLD 0.001 0.017 0.033 0.013 0.013 
TXNDC17 0.001 0.017 0.009 0.029 0.023 
 
0.000 0.017 0.004 0.042 0.039 
ZNF626 0.001 0.017 0.003 0.026 0.078 
CALCOCO1 0.001 0.017 0.007 0.020 0.040 
HLA-DQB1 0.001 0.018 0.001 0.136 0.034 
VWF 0.001 0.018 0.048 0.003 0.044 
EPRS 0.001 0.018 0.098 0.005 0.016 
MOK 0.001 0.019 0.022 0.006 0.053 
FBRSL1 0.001 0.019 0.007 0.115 0.009 
PKN2 0.001 0.020 0.009 0.010 0.084 
INPP4B 0.001 0.020 0.009 0.010 0.084 
RASA2 0.001 0.020 0.009 0.010 0.084 
ACSF2 0.001 0.020 0.009 0.010 0.084 
VEGFB 0.001 0.020 0.009 0.010 0.084 
MAVS 0.001 0.020 0.006 0.054 0.025 
MTRR 0.001 0.020 0.017 0.016 0.029 
ABCB6 0.001 0.020 0.051 0.004 0.039 
IQCB1 0.001 0.021 0.012 0.040 0.018 
PTGR1 0.001 0.021 0.120 0.002 0.039 
GBP3 0.001 0.022 0.050 0.005 0.035 
SMYD4 0.001 0.022 0.017 0.025 0.023 
TMEM116 0.001 0.023 0.023 0.007 0.059 
ADAMTS5 0.001 0.023 0.004 0.025 0.090 
AK9 0.001 0.023 0.012 0.187 0.005 
TLR4 0.001 0.023 0.023 0.052 0.008 




SMARCAL1 0.001 0.023 0.010 0.026 0.039 
AMER1 0.001 0.023 0.007 0.063 0.023 
SH2D4A 0.001 0.023 0.048 0.011 0.020 
COPG1 0.001 0.024 0.279 0.003 0.013 
SLC39A4 0.001 0.024 0.037 0.012 0.025 
TP53BP1 0.001 0.024 0.008 0.139 0.010 
UIMC1 0.001 0.025 0.002 0.068 0.115 
TMEM176A 0.001 0.025 0.005 0.049 0.050 
FAM72B 0.001 0.025 0.005 0.050 0.050 
MAP1S 0.001 0.026 0.021 0.039 0.016 
SP100 0.001 0.028 0.056 0.018 0.014 
SALL2 0.001 0.028 0.004 0.148 0.023 
KIAA1549 0.001 0.028 0.008 0.065 0.028 
IDH3G 0.001 0.028 0.030 0.012 0.039 
CDK5RAP1 0.001 0.028 0.010 0.059 0.023 
RREB1 0.001 0.028 0.006 0.051 0.044 
RNF43 0.001 0.029 0.017 0.161 0.006 
RAPGEF3 0.001 0.029 0.006 0.144 0.018 
WDR72 0.001 0.029 0.092 0.035 0.005 
COX10 0.001 0.030 0.023 0.028 0.025 
NAV2 0.001 0.031 0.003 0.029 0.201 
WWOX 0.001 0.031 0.077 0.056 0.004 
LGALS8 0.001 0.031 0.025 0.013 0.050 
NARFL 0.001 0.031 0.028 0.026 0.023 
ZP3 0.001 0.031 0.047 0.018 0.020 
PACS1 0.001 0.031 0.014 0.021 0.058 
ESYT2 0.001 0.031 0.005 0.072 0.050 
SFI1 0.001 0.031 0.003 0.142 0.044 
ZNF17 0.001 0.031 0.002 0.317 0.025 
MTHFD1L 0.001 0.031 0.016 0.016 0.071 




NEK4 0.001 0.032 0.038 0.099 0.005 
MRPL9 0.001 0.032 0.355 0.007 0.008 
VAV3 0.001 0.033 0.121 0.006 0.025 
MTMR2 0.001 0.033 0.292 0.005 0.012 
ZNF777 0.001 0.033 0.012 0.052 0.032 
COG5 0.001 0.034 0.064 0.023 0.014 
MROH6 0.001 0.035 0.005 0.149 0.029 
AK1 0.001 0.036 0.061 0.004 0.082 
C1orf112 0.002 0.036 0.022 0.043 0.023 
CD2AP 0.002 0.036 0.013 0.071 0.023 
C3orf52 0.002 0.036 0.008 0.058 0.050 
MICB 0.002 0.037 0.022 0.012 0.087 
LAMA5 0.002 0.037 0.017 0.024 0.058 
FAM83H 0.002 0.037 0.015 0.132 0.012 
SZT2 0.002 0.038 0.019 0.154 0.008 
OLFM2 0.002 0.038 0.016 0.188 0.008 
MCAM 0.002 0.039 0.021 0.019 0.063 
ZNF28 0.002 0.039 0.040 0.014 0.046 
IGFBP3 0.002 0.039 0.017 0.025 0.059 
SIPA1 0.002 0.039 0.009 0.087 0.032 
MSH6 0.002 0.039 0.000 0.326 0.266 
AARS2 0.002 0.039 0.021 0.021 0.061 
UTP23 0.002 0.039 0.023 0.135 0.008 
RASAL1 0.002 0.040 0.008 0.070 0.050 
DOCK4 0.002 0.040 0.016 0.020 0.084 
STEAP4 0.002 0.040 0.086 0.014 0.023 
SUN1 0.002 0.040 0.037 0.133 0.006 
IFT88 0.002 0.041 0.140 0.036 0.006 
ZNF268 0.002 0.041 0.058 0.148 0.003 
TMEM63B 0.002 0.042 0.027 0.040 0.027 




KCNN4 0.002 0.043 0.051 0.025 0.023 
TIMM44 0.002 0.043 0.059 0.012 0.043 
MCPH1 0.002 0.043 0.010 0.041 0.074 
ERGIC1 0.002 0.043 0.034 0.039 0.023 
RPP40 0.002 0.043 0.804 0.003 0.012 
BDP1 0.002 0.043 0.062 0.040 0.012 
QSOX2 0.002 0.043 0.024 0.012 0.106 
LAMB3 0.002 0.043 0.113 0.005 0.053 
ZNF700 0.002 0.043 0.009 0.056 0.061 
E4F1 0.002 0.043 0.020 0.067 0.023 
VPS37A 0.002 0.043 0.098 0.004 0.084 
WDR90 0.002 0.044 0.090 0.041 0.009 
KLHL25 0.002 0.044 0.029 0.051 0.023 
 
Identified using OncodriveFM, Intogen, Q-value <0.05, (PPH2, Polyphen2, MA 
Mutation Assesor, SIFT Sorting Intolerant from Tolerant). 
 
Table S 14 The KEGG pathways with accumulated mutations of high functional 
impact in CPM CRC 
KEGG Name Class Q-value 
hsa04512 ECM-receptor 
interaction  
Signaling molecules and 
interaction 
1.90E-07 
hsa04940 Type I diabetes 
mellitus 
Endocrine and metabolic disease 1.90E-07 
hsa05330 Allograft rejection Immune diseases 2.09E-07 
hsa05332 Graft-versus-host 
disease 
Immune diseases 3.06E-07 
hsa05145 Toxoplasmosis Infectious diseases 6.45E-07 
hsa05310 Asthma Immune diseases 6.45E-07 
hsa05320 Autoimmune thyroid 
disease 




hsa04672 Intestinal immune 
network for IgA 
production 




hsa05217 Basal cell carcinoma Cancers: Specific types 0.000 
hsa05222 Small cell lung cancer Cancers: Specific types 0.000 
hsa05416 Viral myocarditis  Human Diseases; Cardiovascular 
diseases 
0.00 
hsa00053 Ascorbate and 
aldarate metabolism 
Metabolism 0.00 
hsa04514 Cell adhesion 
molecules  
Signaling molecules and 
interaction 
0.00 
hsa05168 Herpes simplex 
infection  
Infectious diseases 0.01 
hsa03008 Ribosome biogenesis 
in eukaryotes 
Genetic; Translation 0.01 
hsa00340 Histidine metabolism  Metabolism 0.01 
hsa00120 Primary bile acid 
biosynthesis  
Metabolism 0.02 
hsa00770 Pantothenate and 
CoA biosynthesis 
Metabolism 0.03 
hsa03430 Mismatch repair Genetic; Replication and repair 0.03 
hsa04612 Antigen processing 
and presentation 
Immune system 0.03 
hsa05150 Staphylococcus 
aureus infection 
Infectious diseases 0.03 
hsa05132 Influenza A  Infectious diseases 0.03 
hsa05146 Amoebiasis Infectious diseases 0.04 






hsa04620 Toll-like receptor 
signaling pathway 
Immune system 0.04 
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Background: Up to 15 per cent of colorectal cancers present with peritoneal metastases (CPM). Cyto-reductive 
surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) aims to achieve macroscopic tumour resection 
combined with HIPEC to destroy microscopic disease. CRS + HIPEC is a major operation with significant 
morbidity and effects on quality of life (QoL). Improving patient selection is crucial to maximize patient outcomes 
while minimizing morbidity and mortality. The aim of this study was to identify prognostic factors for patients 
with CPM undergoing CRS + HIPEC.  
Methods: A systematic search of MEDLINE, Embase and Cochrane Library electronic databases was performed 
using terms for colorectal cancer, peritoneal metastasis and CRS + HIPEC. Included studies focused on the 
impact of prognostic factors on overall survival following CRS + HIPEC in patients with CPM.  
Results: Twenty-four studies described 3128 patients. Obstruction or perforation of the primary tumour (hazard 
ratio (HR) 2⋅91, 95 per cent c.i. 1⋅5 to 5⋅65), extent of peritoneal metastasis as described by the Peritoneal 
Carcinomatosis Index (PCI) (per increase of 1 PCI point: HR 1⋅07, 1⋅02 to 1⋅12) and the completeness of 
cytoreduction (CC score above zero: HR 1⋅75, 1⋅18 to 2⋅59) were associated with reduced overall survival after 
CRS + HIPEC.  
Conclusion: Primary tumour obstruction or perforation, PCI score and CC score are valuable prognostic factors 
in the selection of patients with CPM for CRS + HIPEC. 
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Colorectal peritoneal metastasis (CPM) occurs in up to 15 per 
cent of patients with colorectal cancer1 
–
 3. The progno-sis of 
patients with CPM is poor: untreated median overall survival 
(OS) is just 6 months4. With systemic chemother-apy, median 
OS is improved to up to 20 months5 
–
 7. The standard for CPM 
is cytoreductive surgery and heated intraperitoneal 
chemotherapy (CRS + HIPEC), which may improve median 
OS by 20–63 months8 
–16.  
CRS + HIPEC is a long, high-cost operation associ-ated 
with a protracted inpatient and high-dependency or 
intensive care unit stay, and an associated mortality rate of 













crucial to maximize patient outcomes whilst minimizing 
morbidity and mortality.  
Variation in outcomes for CRS + HIPEC can be explained 
in part by patient selection, for example neces-sitating the 
ability to achieve complete cytoreduction at CRS, the 
exclusion of patients with extensive CPM as assessed by 
Sugarbaker’s Peritoneal Carcinomatosis Index (PCI), and 
selection of patients with minimal co-morbidity and good 
performance status.  
Several clinicopathological variables that impact on survival 
have been identified in the literature, includ-ing lymph node 
(LN) status, tumour differentiation and histological findings, 
the completeness of cytoreduction (CC score) and PCI. 
There is wide variation, however, in the variables reported 
by studies and selection criteria for 
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centres performing CRS + HIPEC worldwide, and in turn 
in their outcomes. 
Studies reporting prognostic factors for CRS + HIPEC are 
cohort in design with small samples, and each examines 
numerous and varying prognostic factors on differing scales of 
measurement. No consensus exists as to which prognos-tic 
factors contraindicate CRS + HIPEC, or predict a good 
outcome. A comprehensive evidence synthesis is therefore 
called for to determine relevant prognostic factors. 
The aim of this systematic review and meta-analysis 
was to analyse all prognostic factors affecting OS in 




A comprehensive literature search was conducted in 
accordance with the PRISMA guidelines
24
. MEDLINE, 
Embase and Cochrane Library electronic databases, reg-
isters of clinical trials (ClinicalTrials.gov and the WHO 
International Clinical Trials Registry) and the Conference 
Proceedings Citation Index, Zetoc, were searched from 
inception to the present. The search strategy captured 
terms for colorectal cancer, peritoneal metastasis and CRS 
+ HIPEC techniques, separated by the Boolean operator 
‘AND’. For an example search strategy, see Appendix S1 
(supporting information). Searches were sup-plemented by 
a hand search of selected journals and the reference lists 




English-language articles were eligible for inclusion if 
they reported on the impact of prognostic factors on OS 
in patients with CPM undergoing CRS + HIPEC. Where 
multiple studies described the same cohort of patients, 
the largest and most complete data set was included. 
Review articles, case reports and case series of fewer 
than ten patients were excluded. Additional exclusion 
cri-teria included studies involving patients with a 
primary tumour other than colorectal cancer and studies 
in which a proportion of the cohort did not receive 
combined CRS + HIPEC.  
After screening the titles and abstracts, articles ful-filling the 
eligibility criteria were identified and their full-text publications 
reviewed. Literature search and study selection were done 
independently by two researchers, and any disagreements 
were resolved by discussion with senior reviewers. After 
qualitative assessment, articles were screened to ensure they 
presented adequate statistical information to be included in the 
meta-analysis: hazard ratios (HRs) with confidence intervals or 





HRs, confidence intervals or P values were not provided 
directly, the methods of Tierney et al.
25
 were used to 
esti-mate them indirectly from Kaplan–Meier curves, 
when presented in adequate detail with the numbers of 




Assessment of risk of bias 
 
The quality and risk of bias of individual studies was 
assessed using the Quality in Prognosis Studies (QUIPS) 
tool
27
. This tool reviews each study according to six 
criteria: study participation, attrition, prognostic factor 
measurement, outcome measurement, confounding fac-
tors, and statistical analysis and reporting. Two authors 




Data were extracted independently by two reviewers 
using a dedicated and piloted data extraction form. The 
number of patients, study design, patient 
demographics, tumour characteristics, use of adjuvant 
and neoadjuvant regimens, CRS + HIPEC techniques, 
survival and prognostic factors were recorded.  
The unadjusted HR and its 95 per cent c.i. and P value 
were extracted. When adjusted HRs (with confidence 
intervals and P values) were reported, these were 
extracted along with the set of adjustment factors used. If 
HRs, con-fidence intervals or P values were not provided 
directly, the methods of Tierney and colleagues
25
 were 
used to esti-mate them indirectly from Kaplan–Meier 
curves, when presented in adequate detail with the 
numbers of events and patients at risk
26
.  
Prognostic factors reported on a continuous scale were 
extracted. If results were categorized into three or more 
categories, results for each comparison were extracted 
and, when clinically relevant, were grouped to form a 
binary comparison. 
 
Prognostic factor selection 
 
All prognostic factors described adequately and reported 




Owing to clinical and methodological heterogeneity, a random-
effects meta-analysis was used (on the log(HR) scale) using 
the method of DerSimonian and Laird28. The combined effect 
size was described by the pooled HR, its confidence interval 
and P value, with P < 0⋅050 considered significant. For 







tudies, a 95 per cent prediction interval (a 
measure of the variation in treatment effects) is 
presented
29





. All analyses were performed 
in STATA
®
 version 15 (StataCorp, Col-lege 
Station, Texas, USA). 
 
two s  
Results 
 
The final literature search was performed on 3 April 
2018. Literature searches (after removal of 
duplicates) identified 1052 records. Titles and 
abstract screening identified  158  full-text  articles  
for  review.  Of  these, 51  studies  met  the  inclusion  
criteria.  Twenty-four unique  studies11,18,20,31 –51  
reporting  on  3128  patients with CPM presented 
adequate data to be included in the  meta-analysis  
(Fig. 1).  Of  the  24  cohort  studies, were  prospective  
and  the  remaining 1811,20,31–33,35,36,38,39,41–
43,45,46,48–51 were retrospective (Table S1, supporting 
information). A number of studies presented both an 
unadjusted and adjusted HR. As adjustment factors 
varied widely between 
studies (Table S2, supporting information), meta-
analysis was stratified according to whether the 
HR was unadjusted or adjusted. 
 
 
Quality of research 
 
There was a low risk of bias from study participation. 
The moderate risk of bias due to study attrition 
reflects the poor reporting of loss to follow-up. There 
was a low risk of bias due to prognostic factor 
measurement. Prog-nostic factors were objective, 
clearly defined and clinically relevant.  
Reporting of all prognostic factors and treat-ment 
variations was incomplete in the majority of studies, 
resulting in a moderate risk of bias. The presentation 
of results and analytical strategy was sufficient in the 
majority of studies resulting in a low risk of bias 
(Table S3, supporting information).  
Pooled median OS across all studies was 32 (range 
12⋅2–51) months, with a pooled median follow-up of 
28⋅1 (13⋅3–62⋅4) months (Table S4, supporting 
information).



















Records identified through database searching of Ovid MEDLINE, Embase, Cochrane (CENTRAL, CDSR),  
registers of clinical trials (ClinicalTrials.gov and WHO International Clinical Trials Registry)  
and the Conference Proceedings Citation Index, Zetoc, and reference search of identified articles  






























Records screened after duplicates removed  






Full-text articles assessed for eligibility  





Studies included in qualitative synthesis n = 51  
Paper looked only at prognostic factors n = 4  
Conference abstract presenting inadequate data n = 11  
Paper presenting inadequate statistical data n = 12 
 
Records excluded after screening of title and abstract n = 
894 Incorrect topic n = 391  
Narrative review n = 186  
Foreign language n = 106  
Additional duplicates removed manually n = 76 Incorrect 
primary tumour type (none colorectal) n = 33 Mixed primary 
tumour types with no subgroup analysis for  
colorectal n = 42  
No analysis of prognostic factors n = 22 Systematic 
reviews and meta-analyses n = 17 
No peritoneal metastasis (preventive adjuvant HIPEC) n = 7  
Case reports, case series <10 n = 9  
Consensus statements n = 4  
No HIPEC given n = 1 
 
Records excluded after full-text review n = 107  
Duplicate data (data presented from same time period and institution  
or conference abstract later published as full paper) n = 32 
Mixed primary tumour n = 27  
No analysis of prognostic factors n = 20  
CRS+HIPEC not given to all patients n = 15  
Incorrect outcome measure (PFS/DFS) n = 10  
Repeat procedure for recurrence after CRS+HIPEC n = 2 








   
Studies included in  
quantitative synthesis  
(meta-analysis)  
n = 24  
 
 
CENTRAL, Cochrane Central Register of Controlled Trials; CDSR, Cochrane Database of Systematic Reviews; DARE, Database of Abstracts of Reviews of 












The pooled median age of patients included was 54 
(range 45⋅5 –69⋅3) years. Eleven 
studies18,20,33,34,37,40,42,48 –50,52 reported on 
age as a prognostic factor and ten presented 
adequate data to be included in the meta-analysis. 
Five studies categorized age into binary outcomes 
that could not be combined meaningfully. The pooled 
unadjusted HR was 1⋅00 (95 per cent c.i. 0⋅98 to 
1⋅03) (I2 = 38⋅5 per cent) and adjusted HR was 1⋅00 
(0⋅96 to 1⋅04) (I2 = 69⋅3 per cent), for an increase in 
age of 1 year (Fig. 2; Fig. S1, supporting information). 
These data provide no evidence that age is a useful 




Nine studies18,20,34,36,37,40,42,51,52 reported on 
the effect of sex on OS and eight presented adequate 
data to be included in the meta-analysis. The pooled 
unadjusted HR for male sex was 1⋅20 (95 per cent 
c.i. 0⋅83 to 1⋅71) (I2 = 33⋅8 per cent) and adjusted HR 
was 1⋅73 (1⋅20 to 2⋅48) (I2 = 11⋅6 per cent) (Fig. 2; 
Fig. S1, supporting information). It is therefore 
unclear whether sex is a useful predictor of OS. 
 
Eastern Cooperative Oncology Group 
performance status 
 
Five studies18,31,43,52,53 reported on the influence 
of East-ern Cooperative Oncology Group (ECOG) 
status on OS, and three presented adequate data to 
be included in the meta-analysis. The pooled 
unadjusted HR for an ECOG score of at least 2 was 
1⋅77 (95 per cent c.i. 0⋅85 to 3⋅67) (I2 = 0 per cent) 
(Fig. 2; Fig. S1, supporting information). These data 





Adverse primary tumour features 
 
Three studies18,33,52 reported on the influence of 
adverse features of the primary tumour (obstruction 
or perforation) on OS; two presented adequate data 
to be included in the meta-analysis. The pooled 
adjusted HR for adverse features of the primary 
tumour was 2⋅91 (95 per cent c.i. 1⋅5 to 5⋅64) (I2 = 0 
per cent) (Fig. 2; Fig. S1, supporting information). 
These data indicate that adverse primary features 
are a useful predictor of decreased OS (Table S5, 
supporting information). 
 
Rectal or colonic primary 
 
Eight studies20,34,36,40,43,47,53,54 reported on 
the influence of a rectal or colonic primary on OS and 
six presented ade-quate data to be included in the 




unadjusted HR for rectal primary (compared with 
colonic primary) was 1⋅48 (95 per cent c.i. 0⋅71 to 
3⋅09) (I2 = 73⋅8 per cent) (Fig. 2; Fig. S1, supporting 
information). These data provide no evidence that a 
rectal primary is a useful predictor of OS. 
 
Lymph node metastasis 
 
Eleven studies11,18,33 – 35,37,48 –50,53,54 
reported on the effect of LN status on OS; nine 
presented adequate data to be included in the meta-
analysis. The pooled unadjusted HR for positive LNs 
(compared with negative LNs) was 1⋅42 (95 per cent 
c.i. 1⋅06 to 1⋅92) (I2 = 0 per cent) and adjusted HR 
was 1⋅08 (0⋅60 to 1⋅95) (I2 = 68⋅6 per cent) (Fig. 2; 
Fig. S1, supporting information). It is therefore 





Two studies34,40 reported on the effect of primary 
tumour differentiation on OS. The pooled unadjusted 
HR for well differentiated tumours was 0⋅90 (95 per 
cent c.i. 0⋅18 to 4⋅40) (I2 = 72⋅4 per cent) (Fig. 2; Fig. 
S1, supporting information). These data provide no 
evidence that primary tumour differentiation is a 
useful predictor of OS. 
 
Timing of colorectal peritoneal metastasis 
(synchronous or metachronous) 
 
Three studies11,40,54 reported on the effect of the 
tim-ing of CPM (synchronous or metachronous) on 
OS. Two presented adequate data to be included in 
the meta-analysis. The pooled unadjusted HR for 
synchronous CPM was 1⋅13 (95 per cent c.i. 0⋅56 to 
2⋅28) (I2 = 57⋅1 per cent) (Fig. 2; Fig. S1, supporting 
information), indicating that the timing of CPM is not 






Two studies18,40 reported on the effect of malignant 
ascites on OS. One paper40 presented an 
unadjusted HR (1⋅50, 95 per cent c.i. 0⋅70 to 3⋅21) 
and one18 an adjusted HR (3⋅23, 1⋅56 to 6⋅69) (Fig. 
2; Fig. S1, supporting information), so it was not 




Eleven studies18,31,34 –38,43,44,47,50 reported 
on the effect of surgically treated hepatic metastasis 
on OS. Seven pre-sented adequate data to be 
included in the meta-analysis. The pooled 
unadjusted HR for surgically treated hepatic 
metastasis was 1⋅36 (95 per cent c.i. 0⋅85 to 2⋅16) 
(I2 = 43⋅6 per cent) and the adjusted HR was 2⋅49 
(0⋅74 to 8⋅41) (I2 = 85⋅3 per cent) (Fig. 2; Fig. S1, 
supporting informa-tion). These data provide no 
evidence that the presence of surgically treated 




Previous surgical score 
 
Three studies11,34,42 reported on the influence of the 
pre-vious surgical score (PSS) on OS. The pooled 
unadjusted 
HR for a PSS of at least 2 was 1⋅23 (95 per cent c.i. 
0⋅78 to 1⋅95) (I2 = 0 per cent) (Fig. 2; Fig. S1, 
supporting informa-tion). These data provide no 




Three studies40,43,50 reported on the association 
between postoperative morbidity and OS. The 
pooled unadjusted HR for a Clavien–Dindo 
complication of grade III or above was 1⋅56 (95 per 
cent c.i. 0⋅74 to 3⋅31) (I2 = 48⋅7 per cent) (Fig. 2; Fig. 
S1, supporting information). These data provide no 
evidence that postoperative morbidity is a useful 
predictor of OS. 
 
Neoadjuvant and adjuvant chemotherapy 
 
Neoadjuvant and adjuvant treatment of the primary 
tumour was reported poorly (Table S6, supporting 
infor-mation). No study reported response to 
treatment, or whether it was completed as planned. 
 
Two studies11,43 reported on the effect of 
neoadjuvant chemotherapy before CRS + HIPEC on 
OS. The pooled unadjusted HR for the use of 
neoadjuvant chemotherapy was 1⋅00 (95 per cent c.i. 
0⋅63 to 1⋅58) (I2 = 0 per cent) (Fig. 2; Fig. S1, 
supporting information). These data pro-vide no 
evidence that neoadjuvant chemotherapy is a useful 
predictor of OS. 
Adjuvant chemotherapy 
 
Four studies11,35,43,50 reported on the effect of 
adjuvant chemotherapy after CRS + HIPEC on OS. 
The pooled unadjusted HR for adjuvant 
chemotherapy was 0⋅60 (95 per cent c.i. 0⋅29 to 1⋅21) 
(I2 = 68⋅1 per cent) (Fig. 2; Fig. S1, supporting 
information), which suggests there is no evidence 
that use of adjuvant chemotherapy is predictive of 
OS. 
 
Completeness of cytoreduction 
 
Eight studies11,32,35,40,42,43,51,55 reported on the effect 
of the completeness of cytoreduction on OS; seven 
presented adequate data to be included in the meta-
analysis. A CC score above zero was predictive of a 
reduction in OS (un-adjusted HR 1⋅75, 95 per cent 
c.i. 1⋅18 to 2⋅59) (I2 = 79⋅5 per cent), as was a CC 
score of 2 or more (HR 1⋅61, 1⋅31 to 1⋅97) (I2 = 0 per 




This systematic review and meta-analysis examined 
the effect of prognostic factors on OS following CRS 
+ HIPEC for CPM. Emergency presentation with 
obstruc-tion or perforation of the primary tumour as 
well as the extent of CPM and the completeness of 
resection, as described by the PCI and the CC score 





























































Hazard ratios are shown with 95 per cent confidence intervals. Values in parentheses after each factor indicate the numbers of studies 
providing unadjusted and adjusted hazard ratios respectively. ECOG, Eastern Cooperative Oncology Group; PM, peritoneal metastasis; 
GI, gastrointestinal; PCI, Peritoneal Carcinomatosis Index; CC, completeness of cytoreduction. 
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Fig. 2 Effect of prognostic factors on overall survival 
 
 
Patient factors   
Age (2) (3) 
 
Sex (5) (4) 
 




Adverse feature (obstruction or perforation) (0) (2) 
 
Rectal or colonic primary (4) (2) 
 
Lymph node metastasis (4) (5) 
 
Tumour differentiation (2) (0) 
 
Synchronous or metachronous PM (2) (0) 
 
Ascites (1) (1) 
 
Hepatic metastasis (4) (3) 
 
Signet ring histology (1) (2) 
 
Mucinous histology (3) (0) 
 
Presence of GI anastamosis (1) (1) 
 
PCI score (13) (11)  
Unadjusted > 20  
Unadjusted > 15  
Unadjusted > 12  
Unadjusted > 10  
Unadjusted > 6  
Unadjusted per point increase  
Adjusted > 20  
Adjusted > 15  
Adjusted > 10  
Adjusted > 6  
Adjusted per point increase 
 
Treatment factors  
Previous surgical score (2) (1) 
 
Postoperative morbidity (2) (1) 
 
Adjuvant chemotherapy (1) (1) 
 
Neoadjuvant chemotherapy (2) (0) 
 
CC score (3) (5)  
Unadjusted CC0 versus ≥ CC1  
Unadjusted CC0/1 versus ≥ CC2  
Adjusted CC0 versus ≥ CC1  
Adjusted CC0/1 versus ≥ CC2  





1·00 (0·95, 1·03)  
1·00 (0·96, 1·04)  
1·20 (0·83, 1·71)  
1·73 (1·20, 2·48)  
1·77 (0·85, 3·67)  
2·38 (1·17, 4·82) 
 
2·91 (1·50, 5·65) 
 
1·48 (0·71, 3·09)  
0·79 (0·43, 1·44)  
1·42 (1·06, 1·92) 
1·08 (0·60, 1·95)  
0·90 (0·18, 4·4) 
 
1·13 (0·56, 2·28) 
 
1·50 (0·70, 3·21)  
3·23 (1·56, 6·69) 
 
1·36 (0·85, 2·16)  
2·49 (0·74, 8·41)  
2·51 (1·03, 6·10)  
1·66 (0·68, 4·03) 
 
1·10 (0·70, 1·72) 
 
1·21 (1·06, 1·38)  
0·90 (0·43, 1·89) 
 
2·90 (1·95, 4·31)  
3·12 (2·02, 4·80)  
2·09 (1·04, 4·21)  
2·57 (0·68, 9·67)  
5·80 (2·80, 12·01)  
1·07 (1·02, 1·12)  
5·04 (2·74, 9·29)  
2·09 (1·39, 3·15)  
1·76 (0·61, 5·11)  
3·28 (0·77, 13·94)  
1·07 (1·04, 1·11) 
 
 
1·23 (0·78, 1·95)  
1·95 (0·33, 11·54)  
1·56 (0·74, 3·31)  
0·65 (0·39, 1·09)  
1·00 (0·63, 1·58)  
1·75 (1·18, 2·59)  
0·59 (0·41, 0·82) 
 
1·75 (1·18, 2·59)  
1·56 (1·14, 2·15)  
1·44 (0·58, 3·62)  
1·61 (1·31, 1·97)  































An emergency presentation of the primary tumour 
with obstruction or perforation was predictive of 
reduced OS (for both synchronous and 
metachronous CPM). A num-ber of factors may 
contribute to this. In the primary setting, colorectal 
cancers presenting with obstruction or perfor-ation 
are associated with decreased cancer-specific sur-
vival and increased postoperative mortality56. 
Obstructed or perforated colorectal cancer is, by 
definition, advanced in stage and increases the risk 
of metastasis; additionally, emergency presentation 
limits the possibility of neoadju-vant treatment and 
may delay adjuvant treatment owing to postoperative 
morbidity. The extent of peritoneal metas-tasis as 
described by the PCI was predictive of reduced OS 
as a continuous variable and when the PCI score was 
12 or above. A complete cytoreduction (CC0) was 
pre-dictive of improved OS. Improving patient 
selection is therefore reliant on the ability to predict 
accurately the extent of peritoneal metastasis and 
the ability to resect it completely. Specialist 
radiologists have demonstrated good concordance 
between radiological and surgical PCI esti-mations, 
particularly when combining modalities; however, 
these tend to be most accurate in patients with high 
PCI scores57,58. In some centres this is used in 
combination with diagnostic laparoscopy before CRS 
+ HIPEC. This is feas-ible in the majority of patients 
and may help to reduce the laparotomy rate in 
patients for whom CRS + HIPEC may not be 
possible59. 
 
Included patients were relatively young at 54 (range 
45–69) years compared with the incident age of 
colorectal cancer (80–90 years)60 In addition, 
performance status was not reported by the majority 
of studies in the review, and limited to an ECOG 
score of less than 2 by a further nine. Within these 
limits, no other patient or tumour factor was 
predictive of OS. 
 
Details of neoadjuvant and adjuvant treatments were 
reported poorly in the included studies. Within these 
limits, the use of neoadjuvant or adjuvant chemother-
apy was not predictive of OS after CRS + HIPEC. 
One meta-analysis, by Kwakman and colleagues61 
from 2016, examined the effect of clinicopathological 
variables only on OS following CRS + HIPEC. 
Significant prognostic factors identified in the present 
review (adverse features of the primary tumour, PCI, 
CC score) were not comparable with those from 
Kwakman et al.61 as they were not exam-ined. In 
contrast to the present study, Kwakman and co-
workers61 found performance status, the presence of 
lymph node or hepatic metastasis, tumour 
differentiation, signet ring histology, a rectal primary 
and the use of neoadjuvant chemotherapy to be 
predictive prognostic factors. A number of 
differences may explain this vari-ation in findings: the 
exclusion of 73 papers described as unavailable in 
full text may introduce a potential selec-tion bias61. In 
addition, a number of studies included by Kwakman 
and colleagues were excluded in the present study 
for the following reasons: presentation of inadequate 
data to estimate the HR accurately13,52,54,62 the 
inclusion of mixed primary tumours48,63,64, and the 
inclusion of patients having repeat CRS + HIPEC 
procedures. Finally, the meta-analysis61 combined all 
studies regardless of the presentation of unadjusted 
or adjusted HR. 
The strengths of the present study include the 
compre-hensive and systematic literature search 
including 3128 patients with CPM undergoing CRS + 
HIPEC, all poten-tial prognostic factors were 
included, and a consistent asso-ciation was found 
between predictive prognostic factors across 
different studies. The low heterogeneity associated 
with these factors adds to the strength and 
generalizabil-ity of the findings. The application of 
strict inclusion cri-teria limits the potential impact of 
factors such as mixed primary tumour origin. The 
present analysis takes into account the adjustment 
factors used in primary studies to ensure meta-
analysis of time to event data was performed only 
when data were comparable. 
 
A number of limitations must, however, be acknow-
ledged. This review is limited by the quality of primary 
studies and the heterogeneity of the population. 
Prognos-tic factor systematic reviews, by their 
nature, represent one of the most difficult categories 
due to their retrospective and observational nature. 
As CRS + HIPEC is performed at tertiary centres, 
data concerning the primary tumour and its treatment 
may not have been captured or reported fully. 
Additionally, the statistical analysis and presentation 
of data necessary for accurate meta-analysis varied 
widely across primary studies, which may introduce 
a degree of inclusion bias. 
 
There was a lack of molecular and genetic data 
concern-ing patients with CPM undergoing CRS + 
HIPEC in com-parison with studies of primary 
colorectal cancer, and this is an area for future 
research. Discordance between primary genetic 
mutations and those in peritoneal metastases may 
identify novel therapeutic targets and prognostic 
markers in this metastatic group. Recent research by 
Schneider and colleagues65 found that RAS/RAF 
mutations impair sur-vival after CRS/HIPEC, 
although this is the only study that has considered 
this prognostic factor and validation is required. 
Further large-scale research is needed to account for 
these factors; this would require collaboration 
between CRS + HIPEC centres, standardization of 
the analysis and presentation of prognostic factor 
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OPEN The transition from primary 
colorectal cancer to isolated peritoneal 
malignancy is associated with an 
increased tumour mutational burden 
Sally Hallam, Joanne Stockton, Claire Bryer, Celina Whalley, Valerie Pestinger, Haney Youssef & Andrew 
D. Beggs 
Colorectal Peritoneal metastases (CPM) develop in 15% of colorectal cancers. Cytoreductive surgery and heated 
intraperitoneal chemotherapy (CRS & HIPEC) is the current standard of care in selected patients with limited 
resectable CPM. Despite selection using known prognostic factors survival is varied and morbidity and mortality are 
relatively high. There is a need to improve patient selection and a paucity of research concerning the biology of 
isolated CPM. We aimed to determine the biology associated with transition from primary CRC to CPM and of 
patients with CPM not responding to treatment with CRS & HIPEC, to identify those suitable for treatment with CRS 
& HIPEC and to identify targets for existing repurposed or novel treatment strategies. A cohort of patients with CPM 
treated with CRS & HIPEC was recruited and divided according to prognosis. Molecular profiling of the transcriptome 
(n = 25), epigenome (n = 24) and genome (n = 21) of CPM and matched primary CRC was performed. CPM were 
characterised by frequent Wnt/ β catenin negative regulator mutations, TET2 mutations, mismatch repair mutations 
and high tumour mutational burden. Here we show the molecular features associated with CPM development and 
associated with not responding to CRS & HIPEC. Potential applications include improving patient selection for 
treatment with CRS & HIPEC and in future research into novel and personalised treatments targeting the molecular 
features identified here. 
Abbreviations 
 CRC   Colorectal cancer 
 CPM  C olorectal peritoneal metastasis 
 CRS & HIPEC   Cytoreductive surgery and heated intraperitoneal chemotherapy 
 DFS   Disease free survival 
 DMR  D ifferentially methylated regions 
 OS   Overall survival 
 FFPE   Formalin fixed paraffin embedded 
Background 
Little is known about the biology of isolated colorectal peritoneal metastasis (CPM), which although a relatively rare 
phenomenon is one with a high mortality  rate1. Understanding tumour biology may identify which patients with primary 
colorectal cancer (CRC) are at risk of developing CPM, and which are suitable for treatment with cytoreductive surgery and 
heated intra-peritoneal chemotherapy (CRS & HIPEC). CRS & HIPEC (usually using an agent such as mitomycin C or more 
recently, oxaliplatin) aims to achieve macroscopic tumour resection with multiple visceral and peritoneal resections and 
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widely, and morbidity and mortality are relatively h igh2. There is a need therefore to improve patient selection, allowing 
alternative existing or novel treatment strategies to be used for patients unlikely to respond. 
Primary CRC research has identified markers of response to specific treatments, for example KRAS mutation in selection for 
anti-EGFR mAb t herapy3. Gene expression signatures have been developed and are in clinical use for prognostication and 
therapeutic stratification in breast c ancer4–7. Gene expression profiling in primary CRC has identified signatures associated 
with the development of m etastasis6. One small study combining a small number of CPM with a larger cohort of appendix 
adenocarcinoma identified a signature predictive of reduced overall survival (OS) following CRS & HIPEC; these are however 
two biologically distinct tumours, appendix having significantly improved p rognosis7. 
The dysregulation of methylation is a key step in tumorigenesis CpG island promoter methylation (CIMP) appears to be stable 
between matched primary CRC and hepatic metastasis suggesting an epigenetic methylation programme is established prior to 
the development of m etastasis8–10. Hypermethylation of KRAS, Wnt modulators, tumour suppressor genes, CIMP and 
hypomethylation of oncogenes are associated with an unfavourable response to chemotherapy and anti-EGFR antibodies as 
well as tumour recurrence and reduced OS in primary and metastatic CRC 11–16. Chromosomal instability is ubiquitous in 
cancer, increased copy number alteration, indicative of chromosomal instability is found in metastatic CRC 17,18. Lopez-Garcia 
et al.19 demonstrated that the evolution of chromosomal instability is depending on cellular tolerance, either via dysregulation 
of TP53 or via alternate escape mechanisms such as dysfunction of BCL9L regulated caspase signalling. 
CRC metastatic drivers are less clearly defined, apart from TP53 which is well characterised as being present in metastatic c 
ancer20. Some studies have found mutations exclusive to metastatic s ites21,22, whereas others found similar patterns of mutation 
between primary and  metastasis23. Studies have examined the somatic mutations in CPM and their prognostic implications. 
These studies are limited to individual or small panels of mutations routinely tested for in clinical practice with limited evidence 
to suggest which genes should be included in panel sequencing in CPM. Schneider et al. examined the KRAS and BRAF 
mutation status of patients with CPM who underwent CRS & H IPEC24. They found mutations of RAS/RAF were associated 
with reduced OS independent of the use of targeted anti-EGFR  treatment24. Sasaki et al. examined the KRAS, BRAF and 
PIK3CA mutation status of patients with metastatic CRC, with or without C PM25. They found the incidence of BRAF mutation 
was significantly associated with the presence of CPM but not with  prognosis25. 
The landscape of metastatic colorectal cancer was studied by the MSK-IMPACT 20 group which undertook panel based 
sequencing of 1134 metastatic colorectal cancers. Of these 39 patients were defined as “peritoneal” malignancy, it is unclear 
whether these were isolated peritoneal metastasis. Only 14 of these patients had metasectomy. 7 of these had peritonectomy 
suggesting isolated disease suitable for resection. These tumours were also not studied with matched primary tumour of origin. 
There is a need to improve the outcomes for patients with CPM and significant variation in survival despite patient selection 
for treatment using known prognostic factors. There is a paucity of knowledge concerning CPM tumour biology. Understanding 
tumour biology will identify patients with primary CRC at risk of developing CPM, those suitable for treatment with CRS & 
HIPEC or alternative existing and novel treatment strategies. This study aims to determine the landscape of gene expression, 
methylation, and somatic mutation profile associated with the transition from primary CRC to isolated CPM and determine the 
association between these and prognosis following CRS & HIPEC in order to identify therapeutic targets. 
Methods 
Patient cohorts. This study obtained ethical approval from the North West Haydock Research Ethics Committee, 
(15/NW/0079), project ID (17/283). Participants gave informed consent. All experiments were performed in accordance with 
relevant guidelines and regulations Consecutive retrospective patients were recruited from an internally held database of all 
patients undergoing CRS & HIPEC at Good Hope hospital from 2011 to 2017. Patients with CPM (adenocarcinoma), no extra-
abdominal metastasis, a complete resection (CC0) and a peritoneal carcinomatosis index (PCI) of < 12 were eligible for 
inclusion. The completeness of cytoreduction score describes the degree of macroscopic tumour remaining after CRS and the 
likelihood of benefit from intraperitoneal  chemotherapy26. Patients with no residual tumour score CC0, residual tumour < 0.25 
cm, CC1, residual tumour 0.25–2.5 cm CC2. The extent of peritoneal metastasis is described by the PCI score. A PCI of ≥ 12 
is poor prognostic factor for patients undergoing CRS &  HIPEC27. Patients were divided into two groups. CRS & HIPEC is a 
long operation associated with a protracted inpatient and high dependency (HDU) or intensive care (ITU) stay an associated 
mortality of 1–12% and morbidity of 7–63% and a prolonged post-operative  recovery28–37.With palliative chemotherapy DFS 




defined as “non-responders”38. Patients undergoing therapy with DFS > 12 months were defined as “responders”. Patients were 
imaged with CT which was reported by an experienced CPM radiologist, diagnostic laparoscopy was not used, not all patients 
with recurrence are suitable for iterative CRS & HIPEC and so this is not a standard procedure in their follow up. Adhesions 
following primary excision and CRS & HIPEC may also preclude accurate assessment of peritoneal recurrence in all areas with 
laparoscopy. Disease recurrence was determined when confirmed by CT and MDT review. 
Demographic, tumour and treatment details were compared between the prognostic cohorts. For continuous variables, the 
students T-test was applied to normally distributed data and Mann Whitney-U to non-normally distributed data. Categorical 
variables were compared with the Chi-squared test or Fishers exact test. A p value of < 0.05 was considered statistically 
significant. DFS survival between the responders and non-responders was compared using the Kaplan Meier method. Statistical 
analysis was performed in IBM SPSS Statistics for Windows, Version 24.039. 
Nucleic acid extraction. DNA and RNA were extracted from histologically confirmed Formalin fixed, paraffin embedded 
(FFPE) scrolls using the Covaris E220 evolution focused-ultrasonicator and the truTRAC FFPE total NA Kit. All peritoneal 
metastases samples were taken at the commencement of surgery. Nucleic acid concentration was quantified using the Qubit 
3.0 Fluorometer and Qubit RNA / DNA HS (high sensitivity) assay kit. Nucleic acid quality was measured by electrophoresis 
using the Agilent 2200 TapeStation Nucleic Acid System, Agilent 2200 TapeStation Software A.01.05 and the Agilent High 
Sensitivity RNA / DNA ScreenTape and reagents. 
RNA library preparation, sequencing and bioinformatics. RNA library preparation was performed using the Lexogen 
Quant Seq 3′ mRNA-Seq Library Prep kit. RNA libraries were denatured, diluted, loaded onto a 75-cycle High output flow 
cell and sequenced using the NextSeq500 at 2.5–5 million r eads40. 
Quality control, trimming and alignment to the reference genome, (NCBI build 37, hg19) was performed with the Partek Flow 
genomics suite software package (Partek, St Louis, MI, USA). The gene expression profiles of primary and CPM and 
responders and non-responders were compared using gene Specific Analysis (GSA) Modelling using Partek flow with a false 
discovery rate (FDR) of < 0.1. Gene specific enrichment analysis (GSEA) and gene expression pathway analysis was performed 
using Partek flow, a p value of ≤ 0.05 was considered statistically significant. 
CMS and CRIS classifications were performed using ‘CMScaller’ (v0.99.1) in the R package, version 2.10.238,41,42. Fishers 
exact test was used to compare contingency between primary and CPM and responders and non-responders in IBM SPSS 
Statistics for Windows, Version 24.039. A p value of < 0.05 was considered significant. 
Methylation array and bioinformatics. DNA was treated with sodium bisulphite using the Zymo EZDNA methylation 
kit, according to manufacturer’s instructions. Degraded FFPE DNA was restored prior to methylation array with the Infinium 
HD FFPE restore kit, according to manufacturer’s instructions. Methylation array was performed according to the Infinium 
MethylationEPIC BeadChip Kit manufacturer’s instructions. BeadChips were imaged using the Illumina iScan system. Initial 
data quality was checked using GenomeStudio Methylation Module Software. 
Raw data was loaded into the RStudio version 3.5.0 software using the minifi package. Bioinformatics analysis was performed 
using the Chip Analysis Methylation Pipeline (ChAMP) R package, version 2.10.243,44. Probes with signals from less than three 
functional beads, low confidence with a detection p value > 0.01, covering SNPs, non-CpG and those located on the X and Y 
chromosome where filtered. Beta-mixture quantile normalization (BMIQ) was applied and a singular value decomposition 
(SVD) performed to identify batch effects. The association between methylation and prognosis was determined using the 
Bioconductor R package limma and bumphunter functions. Copy number alteration calling was performed using the CHAMP 
CNA function with a significance threshold of, p value < p < × 10–10. 
Exome capture, high‐throughput sequencing and bioinformatics. DNA was sheared using the Covaris E220 
evolution focused-ultrasonicator to produce a uniform 150 bp fragment size. Libraries were prepared using the TruSeq Exome 
Kit then denatured, diluted, loaded onto a 150-cycle High output flow cell and sequenced using the NextSeq500. 
Sequencing reads were assessed using FastQC. Sequences with a Phred score of < 30 were removed giving a base call accuracy 
of 99.9%. Sequence reads were aligned to the human reference genome, (hg19) using the Burrows–Wheeler Aligner (BWA) p 
ackage45. SAMTools was used to generate chromosomal coordinate-sorted BAM files and Picard was used to remove PCR  
duplicates46. Somatic variants were called from matched tumournormal samples using Strelka2 in tumour/normal  mode47. 
Somatic variants were viewed, filtered and annotated in genomics  workbench48. Mutations with a MAF of > 1% in known 
variant databases, (dbSNP and 100,000 genomes) were filtered. Mutations were annotated with information from known variant 
databases, (dbSNP and 100,000 genomes), PhastCons score and functional consequences. The prognostic groups were 
compared using Fischer exact test to identify potential candidate driver mutations for non-responders. Somatic mutations were 
entered into the IntOGen platform for further  analysis49. The IntOGen-mutation platform incorporates a number of pipelines 
to identify cancer driver mutations and activated p athways49. The OncodriveFM pipeline identifies mutations with a high 




Assessor scores)49,52, and assesses the likelihood that such mutations are cancer drivers. The OncodriveCLUST pipeline 
assesses the clustering of mutations to identify relevant activated p athways49. MSI assessment was carried out using 
MSI_classifier_v3 (https ://rpubs .com/sigve n/msi_class ifica tion_v3). 
Ethics approval and consent to participate. North West Haydock Research Ethics Committee, (15/ NW/0079), project 
ID (17/283). 
Results 
Patient cohort.  From 2011 to 2017 a total of n = 161 patients underwent CRS & HIPEC at University Hospitals 
Birmingham, n = 88 patients for metachronous CPM. 
Patients were excluded for the following reasons: other primary tumour (appendix, pseudomyxoma peritonei, ovarian) n = 49, 
synchronous colorectal cancer n = 26, no primary tumour available n = 53 CC2 resection n = 826, PCI of ≥ 12 n = 20, follow 
up period of ≤ 12 months n = 27, leaving n = 28 patients. Complete information regarding the primary CRC pathology and 
treatment was available for n = 26 patients who form the basis of this study.  
Each patient had matched normal, primary CRC and CPM samples. 
  Responders Non-responders p Value 
Age, mean + /−SD  58 ± 13 58 ± 9 0.97 
Gender, male  n = 7 (54) n = 7 (54) 0.68 
Tumour location 
Right n = 9 (69) n = 6 (46)  
Transverse n = 1 (8) n = 0 (0)  
Left n = 3 (23) n = 7 (54) 0.33 
T stage primary 
3 n = 3 (23) n = 3 (23)  
4a n = 5 (38.5) n = 7 (54  
4b n = 5 (38.5) n = 3 (23) 0.66 
N stage primary 
0 n = 4 (31) n = 1 (8)  
1 n = 7 (54) n = 5 (38)  
2 n = 2 (15) n = 7 (54) 0.86 
DFI months  25 ± 9 24 ± 12 0.83 
PCI score, median (range)  5 (3–12) 8 (2–12) 0.019 
CC score 
CC0 n = 13 (100) n = 13 (100) 1 
CC1 n = 0 (0) n = 0 (0)  
CC2 n = 0 (0) n = 0 (0)  
Follow up, months, median (range)  29 (19–72) 16 (5–55) 0.11 
Adjuvant treatment 
Yes n = 11 (85) n = 12 (92) 0.38 
No n = 2 (15) n = 1 (8)  
DFS, median (range)  24 (15–72) 6 (2–11)  < 
0.0001 
OS, median (range)  29 (19–72) 16 (5–55) 0.12 
Table 1.  Comparison of responders and non-responders to CRS & HIPEC. N number value in parenthesis, percentage, DFI 
disease free interval, time from primary CRC to metachronous CPM, PCI peritoneal carcinomatosis index, CC score 
completeness of cytoreduction, DFS disease free survival, OS overall survival. Log rank p < 0.0001. 
 
Thirteen patients had a DFS of 24 months (15–72 range) following CRS & HIPEC and formed the ‘responders cohort, thirteen 
patients had a DFS of 6 months (2–11 range) and formed the ‘non-responders’. There were no significant differences between 
cohorts in demographics, primary CRC or CPM tumour, treatment or follow up (Table 1). No patients had neoadjuvant therapy 
for their primary tumour. Three patients (all in the responders group) had poorly differentiated, mucinous adenocarcinoma, one 
had signet ring adenocarcinoma (in the nonresponders group) and all the others had moderately differentiated adenocarcinoma. 
Following nucleic acid extraction all patients had adequate CPM RNA for RNAseq (n = 13 responders, n = 13 non-responders), 
n = 25 had matched primary CRC samples. For methylation array n = 24 patients (n = 12 responders, n = 12 non-responders) 
had adequate DNA. As the Infinium methylation array comprises a 32-prep kit, n = 4 responders and n = 4 non-responders 




adequate DNA from both the primary and CPM samples, extraction of DNA from normal tissue resulted in n = 21 samples (n 
= 9 responders, n = 12 non-responders). 
Exome sequencing. Across all six sequencing runs, we obtained a median of 60X coverage (42–166) with a median 
uniformity of 88% (71–89). 
Somatic mutations identified in the primary and matched CPM cohort. In the matched CPM cohort, a total of n = 
244,531 somatic SNV’s were identified (CPM-primary subtraction) significantly more than found in the matched primary 
cohort (n = 112,420). 
Nine CPM samples, 9/24 (56%) had a high tumour mutational burden TMB ≥ 10 mut/Mb53 compared with 7/24 (30%) samples 
in the matched primary cohort. Mutations were identified in n = 69 of n = 95 known CRC driver genes, n = 51 were shared 
between the primary and CPM, n = 13 were novel (supplementary table S1)54. Of the somatic variants identified in CPM, n = 
58,958 (29%) were present in the primary CRC, n = 205,552 variants occurred exclusively in the CPM suggesting a significant 
accumulation of mutations in the transition to CPM (Fig. 1). OncodriveFM identified n = 265 potential driver genes with high 
levels of functional mutation (Q-value < 0.05) in the CPM cohort: FLNB, SPTB, PPL, TP53, PDE4DIP, RIOK2, CDC16, 
NUP98, CDC16 and SVEP1 (supplementary table S2), however these results must be treated with caution due to the bias of 
the hypermutator phenotype. KEGG pathway analysis of mutations demonstrated enrichment in pathways concerning the 
immune system, signalling, metabolism and cancer (supplementary table S1). In the CPM group KRAS or BRAF status was 
not significantly associated with prognosis (chi2 p = 1.00). 
Clonality analysis with SuperFreq showed significant (Wilcoxon rank p = 0.007) differences between the responders and non-
responders groups, with a median of 2 clones in the responders group of primary tumours (range 1–4) and 3 clones in the non-
responders group (range 2–7). In the peritoneal metastases there were a  
 
Figure 1.  Venn diagrams depicting the frequency of mutations exclusive to and shared between primary CRC and matched 
CPM and responders and non-responders. 
 
Chr Position Reference Allele p 
Value 





4 93,084,410 C G 0.007 0.53 62.5 0 FAM13A 
18 11,552,313 G C 0.023 0.53 50 0 PIEZO2 
Table 2.  Potential candidate variants, non-responders to CRS & HIPEC. CPM identified through Fisher exact test, genomics 
workbench (Chr, chromosome, FDR, false discovery rate). 
 
median of 3 clones in both the responders (range 1–4) and non-responders (range 2–5) groups. Of note, in the non-responders 
group during clonal expansion, the dominant clone in the peritoneal metastasis group arose de-novo rather than being a prior 
clone that existed in the primary tumour (Supplementary Fig. 1, S1e primary tumours, 9/21 were MSI (47.4%) and 10/21 were 
MSS (52.6%) whereas in the isolated peritoneal metastasis group, 4/21 (19.0%) were MSS and 17/21 MSI (81.0%) 





variants occurred exclusively in non-responders, suggesting a high tumour mutational burden was associated with non-response 
to CRS & HIPEC (Fig. 1). Mutational signature analysis of the MSI tumours demonstrated a predominance of signature 5 
(associated with mutational “clock” effects), signature 26 (associated with defective mismatch repair) and signature 20 
(associated with defective mismatch repair). 
Comparison of somatic mutations in responders and non-responders identified two potential candidate genes to identify non-
responders, FAM13A and PIEZO2 (Fishers exact p < 0.05, FDR = 0.53) (Table 2). 
Differentialene expression. Differential gene expression between primary CRC and matched CPM. Primary CRC and 
matched CPM showed differential expression of n = 65 genes with an FDR < 0.1. (Fig. 2) Sixteen genes showed significantly 
decreased expression in CPM compared with primary CRC (Table 3). Forty-nine genes showed significantly increased 
expression in CPM compared with primary CRC (Table 3). A KEGG pathway analysis was performed to identify the enriched 
biological functions among the differentially expressed genes (Supplementary Table 1). The expression of FABP6, an 
intercellular bile acid transporter, was decreased 34.30-fold in CPM. OLFM4 is a target of the Wnt/β-catenin pathway, its 
expression was reduced 3.77-fold in CPM. DCN and PTEN are able to initiate a number of signalling pathways including ERK 
and EGFR leading to growth suppression, their expression was increased 3.3-fold and 3.25 fold in CPM, this was unexpected 
and in contrast to the  literature55. NF-κBIA expression was increased 3.24-fold in CPM, its upregulation may reflect increased 
NF-κB activity in the development of  CPM56. 
Gene specific enrichment analysis (GSEA) results are presented in supplementary table 5 We identified 848 upregulated gene 
ontology categories in CPM and 14 upregulated gene pathways. which may contribute to the pathogenesis of CPM: the mTOR 
pathway as well as immune pathways including the intestinal immune network for IgA production, Leukocyte transendothelial 
migration and the actin cytoskeleton pathway. 
Differential gene expression between non-responders and responders to CRS & HIPEC. One hundred and fortynine genes 
showed increased expression in non-responders (Fig. 3). Five genes showed decreased expression in non-responders, however 
none had a fold change ≥ 1.5 suggesting minimal difference in expression between the responders and non-responders 
(Supplementary Table 2). KEGG pathway analysis demonstrated enrichment in endocytosis, metabolism, phagocytosis, cell 
movement and architecture, bacterial and viral cell infection, tran- scription and the expression of genes controlling apoptosis, 
cell cycle, oxidative stress resistance and longevity (Table 3). The expression of CEACAM1, a member of the carcinoembryonic 
antigen (CEA) immunoglobulin family, was increased 8.27-fold in non-responders57. 
AXIN1 encodes a cytoplasmic protein which forms the ß-Catenin destruction complex, a negative regulator of the WNT 
signalling p athway58. AXIN1 expression was increased 5.42-fold in non-responders59. 
Gene specific enrichment analysis (GSEA) results are presented in supplementary table 6. We identified 591 upregulated gene 
ontology categories in CPM and 15 upregulated gene pathways. which may contribute to the pathogenesis of CPM: 
Endocytosis, the adherens junction pathway and immune pathways such as those regulating the bacterial invasion of epithelial 
cells. 
Amongst the n = 51 primary CRC and CPM samples n = 29 were representative of each CMS subtype, the remaining n = 22 
samples did not have a consistent pattern (Fig. 4). Comparison of the CMS subtypes in primary and CPM and prognostic groups 
revealed an apparent transition from primary CRC to CPM. No primary CRC samples were classified as CMS4 (mesenchymal 
subtype characterized by prominent transforming growth factor activation, stromal invasion and angiogenesis) compared to 
31% of CPM (p = 0.085). Secondly, non-responders were more commonly CMS4, 46% vs. 15% (p = 0.005, Table 4). 
Methylation. Differential methylation between primary CRC and matched CPM. Thirty-two samples in total were hybridised 
successfully to the Illumina HumanMethylation EPIC microarrays. DMPs were called between the primary CRC and CPM. 
The top ranked differentially methylated probe was cg04146982, BF 34.5, adjusted p value 5.67 × 10–16 (chr8:144,943,810–
144,943,810, hg19 coordinates), which tags a CpG dinucleotide 3651 bp upstream of the transcription start site of gene 
Epiplakin 1, (EPPK1)60. EPPK1 is part of the Plakin family an important component of the cell  cytoskeleton61. The other DMP 
was cg12209861, BF 7.1, adjusted p value 0.059 (chr4:37,459,078–37,459,078, hg19 coordinates), 3526 bp upstream of the 
transcription start site of gene Chromosome 4 Open Reading Frame 19, (C4orf19). DMRs were called between primary CRC 
and CPM via the dmrLasso function of the CHAMP pipeline (Supplementary Table 3). The top 10 most DMRs were in the 
region of IGF2, ZNF461, RASGFR1, CELF4, ZSCAN18, EDNRB, ZBED9, VTRNA2-1, ZNF256 and EGFLAM. KEGG 
pathway analysis did not reveal any significantly enriched pathways. 
Comparison of CNA between primary and CPM via methylation arrays did not identify and significant differences in CNA 




threshold, p = 2.78 × 10–07 (Supplementary Table 4).Genes showing CNA gains of known significance in patients with CPM 















Reduced expression CPM samples vs. primary CRC  
1 FABP6 Intracellular bile acid transporter − 34.30 1.74 × 10–06 
2 DEFA6 Cytotoxic peptide involved in host intestine defence − 8.15 8.55 × 10–06 
3 DMBT1 Tumour suppressor − 6.06 2.43 × 10–04 
4 TTC38 Protein coding gene − 4.56 5.80 × 10–05 
5 OLFM4 Wnt/β-catenin pathway target − 3.77 1.01 × 10–04 
6 IGHA1 Immune receptor − 3.66 4.23 × 10–05 
7 CES2 Intestinal enzyme controlling drug clearance − 3.20 6.84 × 10–05 
8 NDUFS6 Enzyme in electron transport chain of mitochondria − 2.70 7.74 × 10–05 
9 P2RY11 G-protein coupled receptor − 2.53 6.37 × 10–04 
10 MUC2 Encodes a mucinous intestinal coating − 2.34 7.22 × 10–04 
Increased expression CPM samples vs. primary CRC  
1 CD53 Tetraspanin 7.29 5.87 × 10–05 
2 CYR61 Extracellular signalling protein 4.24 3.12 × 10–04 
3 CXCL12 G-protein coupled receptor 3.64 9.25 × 10–04 
4 NR2F1 Nuclear hormone receptor and transcriptional regulator 3.53 7.09 × 10–04 
5 CTGF Connective tissue growth factor 3.49 1.55 × 10–04 
6 CSTB Cystatin 3.41 6.13 × 10–04 
7 TSC22D3 Anti-inflammatory protein glucocorticoid (GC)-induced leucine zipper 3.36 3.94 × 10–04 
8 DCN Tumour suppressor gene 3.30 6.19 × 10–05 
9 PTEN Tumour suppressor gene 3.25 9.28 × 10–04 
10 NF-κBIA Inhibits the NF-κB transcription factor 3.24 1.06 × 10–04 











Figure 4.  Sankey diagram depicting the transition in consensus molecular subtypes (CMS) from primary to CPM. CMS 
classifications were performed using ‘CMScaller’ (v0.99.1) in the R /Bioconductor statistics package. Classifications include 
CMS1 to CMS4, non-consensus samples do not have a consistent pattern of subtype label association. Primary CRC samples, 
classification and number are shown to the left of the diagram with CPM samples, classification and number to the right of 
the diagram. Fishers exact p value 0.085, values in parenthesis percentages. 
 
 Non-consensus CMS1 CMS2 CMS3 CMS4  Total 
Responders 10 (77) 0 (0) 0 (0) 1 (8) 2 (15)  13 
Non-responders 2 (15) 1 (8) 3 (23) 1 (8) 6 (46)  13 
Table 4.  CMS classification responders vs. non-responders to CRS & HIPEC. CMS Fishers exact p value 0.005, CRIS 
Fischer’s exact p value 0.148, values in parenthesis percentages. 
 
Differential methylation between non-responders and responders to CRS & HIPEC. The top ranked differentially methylated 




BF 4 adjusted p value 0.47 (chr11:120,081,487–120,082,345) which tags an intron of gene OAF and cg12977942, BF 4 adjusted 
p value 0.47 (chr5:92,839,309–92,839,309) which tags an intron of gene NR2F1-AS160. Six significant DMRs (Supplementary 
Table 3) were identified in the regions of NKX6-2, CHFR, GATA3, IRX5, HCK and BC019904. KEGG pathway analysis did 
not reveal any significantly enriched pathways. 
Comparison of CNA between the CPM prognostic groups identified recurrent gene losses at chromosomes 3, 4, 14, 15, 17 and 
19 (Supplementary Table 4). CNA losses clustered in the RAS-MAPK-ERK signalling pathway suggesting dysregulation in 
non-responders. 
Comparison of CNA between the CPM prognostic groups identified n = 19 gene gains at chromosomes 9, 10 and 11. Genes 
showing CNA gains in non-responders included: SIT1, RNF38, MELK, PAX5, SHB, ZEB1, DEAF1, ANTXR, EPS8L2 and 
PIDD1. 
Discussion 
This study determined the gene expression, CNA, methylation and somatic mutation profile of primary CRC and matched 
isolated CPM to determine whether there were changes associated with the development of CPM or predicting prognosis for 
patients with CPM. To our knowledge, this is the first such analysis in a cohort of patients with isolated CPM suitable for 
treatment with CRS & HIPEC. The MSKCC cohort of metastatic c ancer20 had a diverse range of metastatic cancer, none of 
whom overlapped with the type we have studied, which is isolated colorectal peritoneal metastasis, with matched primary 
samples, suitable for cytoreduction. 
Within this study responders and non-responders to CRS & HIPEC were well matched by demographics, tumour stage, 
treatment and follow up. PCI varied between groups with responders having a median PCI of 5 (3–12) and non-responders a 
median PCI of 8 (2–12). A PCI of greater than 12 is associated with reduced survival following CRS & HIPEC, no significant 
difference is consistently found at PCI levels below t his27. 
Comparison of patients with primary CRC and metachronous CPM identified biological changes associated with the transition 
from primary CRC to CPM. Hypermethylation, CNA and hypermutation resulted in the inactivation of tumour suppressors and 
oncogene activation in CPM, (TP53, VTRA2-1, TRIM proteins). These changes suggest a rapid rate of tumour growth 
unchecked by tumour suppressor or apoptotic mechanisms. 
Increased MAPK and Wnt/β-catenin pathway activation was noted in CPM. Gene expression of negative regulators of the Wnt 
pathway was reduced, (OLFM4, DEAFA6), negative Wnt regulators contained somatic mutations, (APC, RNF43, FAM123B 
and TSC1), and the MAPK marker, RASFGFR1 was hypermethylated suggesting persistent activation of MAPK and Wnt 
pathways. Multiple mutations of negative Wnt signalling regulators make this an attractive therapeutic target. Porcupine 
inhibitors mediate the palmitoylation of Wnt ligands, blocking Wnt signalling. The porcupine inhibitor LGK974 inhibits the 
upstream negative Wnt regulator mutant RNF43 and is a potential therapeutic target in C PM62. 
CPM contained a high proportion of MSH6 somatic mutations suggesting deficiency in the mismatch repair pathway and MSI. 
MSH6 mutations are commonly found in isolated peritoneal m etastasis59. As expected for tumours with mismatch repair 
deficiency both the primary CRC and CPM cohort had a high tumour mutational burden, crucially this suggests they may have 
a good response to treatment with immune checkpoint inhibitors such as p embrolizumab63, a new therapeutic avenue for these 
difficult to treat patients. The frequency of hypermutation seen in our study (48%) was considerably higher than that observed 
for both the MSKCC metastatic disease cohort (5%) and the TCGA  Colorectal64 cohort (10%). The expression of genes 
regulating innate immunity however was downregulated, (DEFA6, DMBT1, MUC2) or altered via somatic mutations, (HLA-
A antigen) suggesting immune evasion in the transition to CPM which may reduce the likelihood of successful PD-1 therapy. 
The expression of genes supressing invasion, migration and EMT was downregulated or hypermethylated, (MUC2, MMP26, 
ILK, FLNB, SPTB, PPL, and SVEP1) and those triggering these processes upregulated, (CYR61, CXCL12, CTGF, and CSTB). 
These changes suggest a mechanism by which CPM cells metastasise from the primary CRC. In keeping with changes in EMT 
regulators there appeared to be a transition in CMS subtypes towards CMS4 from primary CRC to CPM. The CMS4 subtype 
is an interesting therapeutic target, TGFβ signalling inhibitors and targeted immunotherapies have been trialled with success in 
pre-clinical models to block cross talk between the tumour microenvironment and halt disease progression of stromal rich 
CMS4 CRC 65,66. 
Methylation appeared to be dysregulated in CPM with a bias towards a hypermethylator phenotype caused by somatic mutation 
of the TET2 tumour suppressor and CDH7 chromatin regulator. Active DNA demethylation by TET enzymes is an important 
tumour suppressor mechanism in a variety of  cancers67–69. Downregulation of CES2, a gene known to activate the prodrug 
irinotecan, a chemotherapy used as part of the FOLFIRI regimen in the UK in the adjuvant treatment of primary CRC and CPM 




CEACAM1 expression correlates with metastasis and reduced survival in CRC and was upregulated in this cohort of  patients70. 
Novel therapies in the form or CEA TCB IgG-based T-cell bispecific antibodies (Cibisatamab) may therefore be of b enefit71. 
Additionally there was a downregulation of gene expression of negative regulators of the Wnt pathway, (AXIN1) and somatic 
mutations of key Wnt regulators, (FAM13A) and hypermethylation of MAPK and TGF-β pathway markers, (RAB8A, RAB34, 
FGF5 and BMP3) suggesting persistent activation of MAPK, TGF-β and Wnt in non-responders to CRS & HIPEC. 
A recent randomised controlled trial has called into question the use of HIPEC in CPM, PRODIGE-7 treated patients with 
CPM with CRS & HIPEC or CRS alone in addition to systemic chemotherapy. PRODIGE-7 suggests no added benefit from 
HIPEC however this study was not powered to stratify the impact of HIPEC according to PCI score, on subgroup analysis 
patients with a PCI of 11–15 had significantly improved median survival with the addition of HIPEC 41.6 months vs. 32.7 
months p value 0.020972. 
A relative weakness of this study is the small cohort of patients, the biological changes identified here form a starting point in 
identifying the tumour biology associated with the development of CPM and predicting nonresponders to CRS & HIPEC. 
However, we have identified multiple potential targets for therapy, along with the important finding that CPM appears to be a 
hypermutated, hypermethylated, immune evasive cancer which allows it to be potentially targeted by emerging novel 
therapeutics. Our study findings have implications for the recent addition of oxaliplatin to HIPEC, as the FOXTROT study of 
neoadjuvant therapy in colorectal cancer showed that oxaliplatin has no effect in dMMR tumours. 
Conclusions 
Patients with colorectal peritoneal metastasis (CPM) secondary to colorectal cancer have limited survival with the best available 
treatments. Despite selection for treatment using known prognostic factors survival varies widely and can be difficult to predict. 
There is a paucity of knowledge concerning the biology of CPM, it is likely that there are additional biological markers of 
response to currently available as well as novel or re-purposed alternative treatments. Here we have comprehensively profiled 
a cohort of patients with isolated CPM and identified a number of therapeutically targetable alterations including mutations in 
Wnt/β catenin regulators (via Porcupine inhibitors), the mismatch repair pathway (via PD-1/CTLA-4 immunotherapy) and 
methylation regulators. We suggest that these are urgently investigated in a larger cohort with the development of pre-clinical 
models as, in particular, the finding that these patients may be sensitive to immunotherapy may radically change the therapy 
options available for this difficult to treat group of patients. 
Data availability 
The data that support the findings of this study are available from the corresponding author upon reasonable request. 
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